{"3f01210d0e8b9571f26c941186e447a2b4a8b628": [["IntroductionThe order Nidovirales includes several families of large RNA viruses, arranged from longest to shortest genome as the Coronaviridae, Roniviridae, Mesoniviridae and Arteriviridae.", [["large RNA viruses", "PROBLEM", 63, 80], ["the Coronaviridae", "TREATMENT", 126, 143], ["Roniviridae", "TREATMENT", 145, 156], ["Mesoniviridae", "TREATMENT", 158, 171], ["Arteriviridae", "TREATMENT", 176, 189], ["large", "OBSERVATION_MODIFIER", 63, 68], ["RNA viruses", "OBSERVATION", 69, 80]]], ["The Coronaviridae currently contains the Torovirinae and Coronavirinae lineages, though analysis of recently reported divergent toro-like viruses suggests that the Torovirinae may be better represented as an independent family in the Nidovirales (Stenglein et al., 2014) .", [["Torovirinae", "GENE_OR_GENE_PRODUCT", 41, 52], ["toro-like viruses", "ORGANISM", 128, 145], ["Torovirinae", "GENE_OR_GENE_PRODUCT", 164, 175], ["The Coronaviridae", "TREATMENT", 0, 17], ["the Torovirinae and Coronavirinae lineages", "TREATMENT", 37, 79], ["divergent toro-like viruses", "PROBLEM", 118, 145]]], ["The Coronavirinae currently contains four genera e Alpha-and Betacoronavirus that infect mammals, and Gamma-and Deltacoronavirus that infect birds and mammals.IntroductionMembers of the Nidovirales infect metazoan hosts, have several replicative genes in common (Lauber et al., 2013) , express their structural genes via subgenomic mRNAs which usually join sequences from both genomic termini (Sawicki et al., 2007) , express their replicases as polyproteins via a ribosomal frameshift, and replicate in association with viral transmembrane proteins on intracellular paired membranes (reviewed in (V'Kovski et al., 2015) ).", [["ribosomal", "ANATOMY", 465, 474], ["transmembrane", "ANATOMY", 527, 540], ["intracellular", "ANATOMY", 553, 566], ["membranes", "ANATOMY", 574, 583], ["Coronavirinae", "CHEMICAL", 4, 17], ["Alpha-", "GENE_OR_GENE_PRODUCT", 51, 57], ["Betacoronavirus", "GENE_OR_GENE_PRODUCT", 61, 76], ["Gamma-", "GENE_OR_GENE_PRODUCT", 102, 108], ["Deltacoronavirus", "GENE_OR_GENE_PRODUCT", 112, 128], ["birds", "ORGANISM", 141, 146], ["ribosomal", "CELLULAR_COMPONENT", 465, 474], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 553, 566], ["membranes", "CELLULAR_COMPONENT", 574, 583], ["replicative genes", "DNA", 234, 251], ["structural genes", "DNA", 300, 316], ["subgenomic mRNAs", "RNA", 321, 337], ["ribosomal frameshift", "DNA", 465, 485], ["viral transmembrane proteins", "PROTEIN", 521, 549], ["The Coronavirinae", "TREATMENT", 0, 17], ["four genera e Alpha-", "TREATMENT", 37, 57], ["Betacoronavirus", "TREATMENT", 61, 76], ["Gamma-and Deltacoronavirus", "TREATMENT", 102, 128], ["the Nidovirales infect metazoan hosts", "TREATMENT", 182, 219], ["subgenomic mRNAs", "PROBLEM", 321, 337], ["a ribosomal frameshift", "PROBLEM", 463, 485], ["viral transmembrane proteins on intracellular paired membranes", "PROBLEM", 521, 583], ["subgenomic mRNAs", "OBSERVATION", 321, 337], ["ribosomal frameshift", "OBSERVATION", 465, 485]]], ["Coronavirus growth is accompanied by a variety of intracellular membrane rearrangements, as illustrated for the corona- 2014; Maier et al., 2016) suggest that there may be considerable plasticity and overlap among coronavirus paired membrane replicative structures.", [["intracellular membrane", "ANATOMY", 50, 72], ["membrane", "ANATOMY", 233, 241], ["intracellular membrane", "CELLULAR_COMPONENT", 50, 72], ["membrane", "CELLULAR_COMPONENT", 233, 241], ["Coronavirus growth", "PROBLEM", 0, 18], ["intracellular membrane rearrangements", "PROBLEM", 50, 87], ["considerable plasticity", "PROBLEM", 172, 195], ["overlap among coronavirus paired membrane replicative structures", "PROBLEM", 200, 264], ["intracellular membrane rearrangements", "OBSERVATION", 50, 87], ["may be", "UNCERTAINTY", 165, 171], ["considerable", "OBSERVATION_MODIFIER", 172, 184], ["plasticity", "OBSERVATION", 185, 195], ["membrane replicative", "OBSERVATION", 233, 253]]], ["For this reason, it seems preferable to break with past practice of focussing on double-membrane vesicles in particular, to consider the double-membrane organelle (DMO) as a whole.", [["membrane vesicles", "ANATOMY", 88, 105], ["double-membrane organelle", "ANATOMY", 137, 162], ["membrane vesicles", "CELLULAR_COMPONENT", 88, 105], ["membrane organelle", "CELLULAR_COMPONENT", 144, 162], ["DMO", "SIMPLE_CHEMICAL", 164, 167], ["double-membrane vesicles", "TREATMENT", 81, 105]]], ["The term DMO encompasses DMVs as well as all of the other associated paired-membrane structures like convoluted membranes and spherules that make up the viral replicative organelle.", [["membrane structures", "ANATOMY", 76, 95], ["convoluted membranes", "ANATOMY", 101, 121], ["spherules", "ANATOMY", 126, 135], ["organelle", "ANATOMY", 171, 180], ["DMO", "CHEMICAL", 9, 12], ["DMO", "CHEMICAL", 9, 12], ["DMO", "SIMPLE_CHEMICAL", 9, 12], ["convoluted membranes", "CELLULAR_COMPONENT", 101, 121], ["spherules", "CELLULAR_COMPONENT", 126, 135], ["organelle", "CELLULAR_COMPONENT", 171, 180], ["The term DMO encompasses DMVs", "PROBLEM", 0, 29], ["convoluted membranes and spherules", "PROBLEM", 101, 135], ["term DMO", "OBSERVATION", 4, 12], ["membrane", "ANATOMY_MODIFIER", 76, 84], ["convoluted membranes", "OBSERVATION", 101, 121], ["viral replicative organelle", "OBSERVATION", 153, 180]]], ["The term DMO will be used throughout this review except when specifically referring to the DMV component of the replicative organelle.", [["organelle", "ANATOMY", 124, 133], ["DMO", "CHEMICAL", 9, 12], ["DMO", "CHEMICAL", 9, 12], ["DMO", "SIMPLE_CHEMICAL", 9, 12], ["organelle", "CELLULAR_COMPONENT", 124, 133], ["The term DMO", "TREATMENT", 0, 12], ["replicative organelle", "OBSERVATION", 112, 133]]], ["This review summarizes what we know about coronavirus DMOs, and what bioinformatics can tell us about DMOmaking proteins.Origin of DMO membranesMembrane-bound replicative organelles are a widespread but not universal intracellular feature associated with positive-strand RNA virus replication (Neuman et al., 2014a) .", [["DMO membranes", "ANATOMY", 131, 144], ["organelles", "ANATOMY", 171, 181], ["intracellular", "ANATOMY", 217, 230], ["DMO", "CHEMICAL", 131, 134], ["coronavirus", "ORGANISM", 42, 53], ["DMOmaking", "GENE_OR_GENE_PRODUCT", 102, 111], ["DMO membranes", "CELLULAR_COMPONENT", 131, 144], ["Membrane", "CELLULAR_COMPONENT", 144, 152], ["replicative organelles", "CELLULAR_COMPONENT", 159, 181], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 217, 230], ["DMOmaking proteins", "PROTEIN", 102, 120], ["coronavirus", "SPECIES", 42, 53], ["DMOmaking proteins", "PROBLEM", 102, 120], ["DMO membranesMembrane", "PROBLEM", 131, 152], ["bound replicative organelles", "PROBLEM", 153, 181], ["universal intracellular feature", "PROBLEM", 207, 238], ["positive-strand RNA virus replication", "PROBLEM", 255, 292], ["DMO membranes", "OBSERVATION", 131, 144], ["bound", "OBSERVATION_MODIFIER", 153, 158], ["replicative organelles", "OBSERVATION", 159, 181]]], ["Coronaviruses form a double-membrane organelle (DMO) derived from the endoplasmic reticulum (ER) that contains viral RNA and replicase proteins (Deming et al., 2007; Hagemeijer et al., 2010; Oostra et al., 2007; Shi et al., 1999; van der Meer et al., 1999) .", [["double-membrane organelle", "ANATOMY", 21, 46], ["endoplasmic reticulum", "ANATOMY", 70, 91], ["ER", "ANATOMY", 93, 95], ["Coronaviruses", "GENE_OR_GENE_PRODUCT", 0, 13], ["membrane organelle", "CELLULAR_COMPONENT", 28, 46], ["DMO", "SIMPLE_CHEMICAL", 48, 51], ["endoplasmic reticulum", "CELLULAR_COMPONENT", 70, 91], ["ER", "GENE_OR_GENE_PRODUCT", 93, 95], ["Coronaviruses", "PROTEIN", 0, 13], ["ER", "PROTEIN", 93, 95], ["viral RNA", "RNA", 111, 120], ["replicase proteins", "PROTEIN", 125, 143], ["Coronaviruses", "PROBLEM", 0, 13], ["viral RNA", "PROBLEM", 111, 120], ["endoplasmic reticulum", "ANATOMY", 70, 91], ["viral RNA", "OBSERVATION", 111, 120]]], ["In the DMO, two lipid bilayers are held at a constant distance of about 20 nm (Angelini et al., 2013) .", [["DMO", "CHEMICAL", 7, 10], ["DMO", "CHEMICAL", 7, 10], ["DMO", "SIMPLE_CHEMICAL", 7, 10], ["two lipid bilayers", "TREATMENT", 12, 30], ["lipid bilayers", "OBSERVATION", 16, 30]]], ["Electron microscopy and tomography studies have revealed that the replicative organelles of coronaviruses and the related arteriviruses are drawn from a repertoire of paired-membranes, including open-ended spherules, closed double-membrane vesicles, and both planar and convoluted paired membranes (Knoops et al., 2008 (Knoops et al., , 2012 Maier et al., 2013) .", [["organelles", "ANATOMY", 78, 88], ["membranes", "ANATOMY", 174, 183], ["spherules", "ANATOMY", 206, 215], ["membrane vesicles", "ANATOMY", 231, 248], ["membranes", "ANATOMY", 288, 297], ["organelles", "CELLULAR_COMPONENT", 78, 88], ["coronaviruses", "ORGANISM", 92, 105], ["arteriviruses", "GENE_OR_GENE_PRODUCT", 122, 135], ["membranes", "CELLULAR_COMPONENT", 174, 183], ["spherules", "CELLULAR_COMPONENT", 206, 215], ["membrane vesicles", "CELLULAR_COMPONENT", 231, 248], ["membranes", "CELLULAR_COMPONENT", 288, 297], ["Electron microscopy", "TEST", 0, 19], ["tomography studies", "TEST", 24, 42], ["the replicative organelles of coronaviruses", "PROBLEM", 62, 105], ["the related arteriviruses", "PROBLEM", 110, 135], ["closed double-membrane vesicles", "TREATMENT", 217, 248], ["replicative organelles", "OBSERVATION", 66, 88], ["coronaviruses", "OBSERVATION", 92, 105], ["closed", "OBSERVATION_MODIFIER", 217, 223], ["double", "OBSERVATION", 224, 230], ["membrane vesicles", "OBSERVATION", 231, 248], ["both", "ANATOMY_MODIFIER", 254, 258], ["planar", "ANATOMY_MODIFIER", 259, 265]]], ["Nonstructural proteins nsp3, nsp4 and nsp6 are required to form structures similar to the DMOs observed in SARS coronavirus (SARS-CoV) infected cells (Angelini et al., 2013) .", [["cells", "ANATOMY", 144, 149], ["SARS coronavirus (SARS-CoV) infected", "DISEASE", 107, 143], ["nsp3", "GENE_OR_GENE_PRODUCT", 23, 27], ["nsp4", "GENE_OR_GENE_PRODUCT", 29, 33], ["nsp6", "GENE_OR_GENE_PRODUCT", 38, 42], ["DMOs", "GENE_OR_GENE_PRODUCT", 90, 94], ["SARS coronavirus", "ORGANISM", 107, 123], ["SARS-CoV", "ORGANISM", 125, 133], ["cells", "CELL", 144, 149], ["Nonstructural proteins", "PROTEIN", 0, 22], ["nsp3", "PROTEIN", 23, 27], ["nsp4", "PROTEIN", 29, 33], ["nsp6", "PROTEIN", 38, 42], ["DMOs", "PROTEIN", 90, 94], ["SARS coronavirus (SARS-CoV) infected cells", "CELL_LINE", 107, 149], ["SARS coronavirus", "SPECIES", 107, 123], ["SARS-CoV", "SPECIES", 125, 133], ["Nonstructural proteins nsp3", "TEST", 0, 27], ["nsp4", "PROBLEM", 29, 33], ["nsp6", "PROBLEM", 38, 42], ["the DMOs", "PROBLEM", 86, 94], ["SARS coronavirus", "PROBLEM", 107, 123], ["infected cells", "PROBLEM", 135, 149], ["proteins nsp3", "OBSERVATION", 14, 27]]], ["And since protease domains of nsp5 are required to release nsp4 and nsp6 from the polyprotein precursor, the region from nsp3 to nsp6 can collectively be thought of as the DMO-forming apparatus of coronaviruses.", [["DMO", "CHEMICAL", 172, 175], ["DMO", "CHEMICAL", 172, 175], ["nsp5", "GENE_OR_GENE_PRODUCT", 30, 34], ["nsp4", "GENE_OR_GENE_PRODUCT", 59, 63], ["nsp6", "GENE_OR_GENE_PRODUCT", 68, 72], ["nsp3", "GENE_OR_GENE_PRODUCT", 121, 125], ["nsp6", "GENE_OR_GENE_PRODUCT", 129, 133], ["DMO", "SIMPLE_CHEMICAL", 172, 175], ["coronaviruses", "ORGANISM", 197, 210], ["protease domains", "PROTEIN", 10, 26], ["nsp5", "PROTEIN", 30, 34], ["nsp4", "PROTEIN", 59, 63], ["nsp6", "PROTEIN", 68, 72], ["nsp3", "PROTEIN", 121, 125], ["nsp6", "PROTEIN", 129, 133], ["protease domains of nsp5", "TREATMENT", 10, 34], ["nsp4", "PROBLEM", 59, 63], ["nsp6", "PROBLEM", 68, 72], ["the polyprotein precursor", "PROBLEM", 78, 103], ["nsp3", "PROBLEM", 121, 125], ["the DMO", "PROBLEM", 168, 175], ["coronaviruses", "PROBLEM", 197, 210], ["polyprotein precursor", "OBSERVATION", 82, 103], ["coronaviruses", "OBSERVATION", 197, 210]]], ["Phylogenetic analysis and comparison of domain architecture can be taken as evidence of homology of the coronavirus DMO-making proteins across the Nidovirales (Fig. 2) .Origin of DMO membranesThe formation of paired membranes probably involves interactions on both sides of the membrane, and perhaps within the membrane, and a few of these interactions have been confirmed biochemically.", [["DMO membranes", "ANATOMY", 179, 192], ["membranes", "ANATOMY", 216, 225], ["membrane", "ANATOMY", 278, 286], ["membrane", "ANATOMY", 311, 319], ["DMO", "CHEMICAL", 179, 182], ["coronavirus", "ORGANISM", 104, 115], ["DMO", "SIMPLE_CHEMICAL", 116, 119], ["DMO membranes", "CELLULAR_COMPONENT", 179, 192], ["membranes", "CELLULAR_COMPONENT", 216, 225], ["membrane", "CELLULAR_COMPONENT", 278, 286], ["membrane", "CELLULAR_COMPONENT", 311, 319], ["coronavirus DMO-making proteins", "PROTEIN", 104, 135], ["Phylogenetic analysis", "TEST", 0, 21], ["domain architecture", "TEST", 40, 59], ["the coronavirus DMO", "PROBLEM", 100, 119], ["DMO membranes", "PROBLEM", 179, 192], ["paired membranes", "PROBLEM", 209, 225], ["DMO membranes", "OBSERVATION", 179, 192], ["paired membranes", "OBSERVATION", 209, 225], ["membrane", "ANATOMY_MODIFIER", 278, 286], ["membrane", "ANATOMY_MODIFIER", 311, 319]]], ["SARS-CoV nsp3-nsp3 interactions have been detected in cells by yeast two-hybridization (Pan et al., 2008) and GST pulldown (Imbert et al., 2008) , and in purified protein by perfluorooctanoic acid polyacrylamide gel electrophoresis (Neuman et al., 2008) .", [["cells", "ANATOMY", 54, 59], ["SARS", "DISEASE", 0, 4], ["perfluorooctanoic acid", "CHEMICAL", 174, 196], ["perfluorooctanoic acid polyacrylamide", "CHEMICAL", 174, 211], ["SARS-CoV", "ORGANISM", 0, 8], ["nsp3", "GENE_OR_GENE_PRODUCT", 9, 13], ["nsp3", "GENE_OR_GENE_PRODUCT", 14, 18], ["cells", "CELL", 54, 59], ["GST", "GENE_OR_GENE_PRODUCT", 110, 113], ["perfluorooctanoic acid", "SIMPLE_CHEMICAL", 174, 196], ["nsp3", "PROTEIN", 9, 13], ["nsp3", "PROTEIN", 14, 18], ["GST", "PROTEIN", 110, 113], ["purified protein", "PROTEIN", 154, 170], ["yeast", "SPECIES", 63, 68], ["SARS-CoV", "SPECIES", 0, 8], ["yeast", "SPECIES", 63, 68], ["SARS", "PROBLEM", 0, 4], ["CoV nsp3-nsp3 interactions", "PROBLEM", 5, 31], ["GST pulldown", "TEST", 110, 122], ["perfluorooctanoic acid polyacrylamide gel electrophoresis", "TREATMENT", 174, 231], ["CoV nsp3", "OBSERVATION", 5, 13]]], ["While SARS-CoV nsp4-nsp4 interactions were not found in yeast-two hybrid or mammalian two-hybrid screens (Pan et al., 2008; von Brunn et al., 2007) studies with MHV did detect nsp4-nsp4 interactions by Venus reporter fluorescence (Hagemeijer et al., 2011) .", [["SARS-CoV", "ORGANISM", 6, 14], ["nsp4", "GENE_OR_GENE_PRODUCT", 15, 19], ["nsp4", "GENE_OR_GENE_PRODUCT", 20, 24], ["MHV", "ORGANISM", 161, 164], ["nsp4", "GENE_OR_GENE_PRODUCT", 176, 180], ["nsp4", "GENE_OR_GENE_PRODUCT", 181, 185], ["nsp4", "PROTEIN", 20, 24], ["nsp4", "PROTEIN", 176, 180], ["nsp4", "PROTEIN", 181, 185], ["yeast", "SPECIES", 56, 61], ["SARS-CoV", "SPECIES", 6, 14], ["yeast", "SPECIES", 56, 61], ["MHV", "SPECIES", 161, 164], ["SARS", "PROBLEM", 6, 10], ["CoV nsp4-nsp4 interactions", "PROBLEM", 11, 37], ["nsp4", "PROBLEM", 176, 180]]], ["To date, homotypic interactions have not been demonstrated for nsp6 despite several attempts (Imbert et al., 2008; Pan et al., 2008; von Brunn et al., 2007) .", [["nsp6", "GENE_OR_GENE_PRODUCT", 63, 67], ["nsp6", "PROTEIN", 63, 67]]], ["Heterotypic interactions between coronavirus nsp3 and nsp4 have been observed by mammalian two-hybridization (Pan et al., 2008) and Venus reporter fluorescence (Hagemeijer et al., 2011) , although because of differences in the parts of nsp3 that were used, these may actually represent two distinct modes of interaction between nsp3 and nsp4.", [["coronavirus", "ORGANISM", 33, 44], ["nsp3", "GENE_OR_GENE_PRODUCT", 45, 49], ["nsp4", "GENE_OR_GENE_PRODUCT", 54, 58], ["nsp3", "GENE_OR_GENE_PRODUCT", 236, 240], ["nsp3", "GENE_OR_GENE_PRODUCT", 328, 332], ["nsp4", "GENE_OR_GENE_PRODUCT", 337, 341], ["coronavirus nsp3", "PROTEIN", 33, 49], ["nsp4", "DNA", 54, 58], ["nsp3", "PROTEIN", 236, 240], ["nsp3", "PROTEIN", 328, 332], ["nsp4", "PROTEIN", 337, 341], ["coronavirus", "SPECIES", 33, 44], ["Heterotypic interactions", "PROBLEM", 0, 24], ["coronavirus nsp3", "PROBLEM", 33, 49], ["nsp4", "PROBLEM", 54, 58], ["nsp3", "TREATMENT", 236, 240], ["nsp3", "PROBLEM", 328, 332], ["nsp4", "PROBLEM", 337, 341], ["coronavirus nsp3", "OBSERVATION", 33, 49]]], ["Nsp4-nsp6 interaction has been demonstrated by Venus reporter fluorescence (Hagemeijer et al., 2011) and indirectly because co-expression of nsp4 abrogates vesicle accumulation due to expression of nsp6 (Angelini et al., 2013) .", [["vesicle", "ANATOMY", 156, 163], ["Nsp4", "GENE_OR_GENE_PRODUCT", 0, 4], ["nsp6", "GENE_OR_GENE_PRODUCT", 5, 9], ["nsp4", "GENE_OR_GENE_PRODUCT", 141, 145], ["vesicle", "CELLULAR_COMPONENT", 156, 163], ["nsp6", "GENE_OR_GENE_PRODUCT", 198, 202], ["Nsp4", "PROTEIN", 0, 4], ["nsp6", "PROTEIN", 5, 9], ["nsp4", "PROTEIN", 141, 145], ["nsp6", "PROTEIN", 198, 202], ["Nsp4", "PROBLEM", 0, 4], ["nsp4", "PROBLEM", 141, 145], ["vesicle accumulation", "PROBLEM", 156, 176]]], ["Each of these proteins also potentially interacts with host proteins, which may have a downstream effect on pathogenesis (Pfefferle et al., 2011) .Origin of DMO membranesCoexpression of nsp3 and nsp4 produces large areas of paired membranes, apparently arranged in parallel tubes (Angelini et al., 2013; Hagemeijer et al., 2014) .", [["DMO membranes", "ANATOMY", 157, 170], ["membranes", "ANATOMY", 231, 240], ["DMO", "CHEMICAL", 157, 160], ["DMO membranes", "CELLULAR_COMPONENT", 157, 170], ["nsp3", "GENE_OR_GENE_PRODUCT", 186, 190], ["nsp4", "GENE_OR_GENE_PRODUCT", 195, 199], ["membranes", "CELLULAR_COMPONENT", 231, 240], ["host proteins", "PROTEIN", 55, 68], ["nsp3", "PROTEIN", 186, 190], ["nsp4", "PROTEIN", 195, 199], ["host proteins", "PROBLEM", 55, 68], ["pathogenesis", "PROBLEM", 108, 120], ["DMO membranes", "PROBLEM", 157, 170], ["nsp3", "PROBLEM", 186, 190], ["nsp4", "PROBLEM", 195, 199], ["large areas of paired membranes", "PROBLEM", 209, 240], ["downstream", "OBSERVATION_MODIFIER", 87, 97], ["DMO membranes", "OBSERVATION", 157, 170], ["nsp3", "OBSERVATION", 186, 190], ["large", "OBSERVATION_MODIFIER", 209, 214], ["areas", "OBSERVATION_MODIFIER", 215, 220], ["paired membranes", "OBSERVATION", 224, 240]]], ["In terms of topology, nsp3-4 membrane pairing involves linking opposite sides of the ER across the ER lumen, so it is likely that the luminal domains of both proteins are involved in this interaction.", [["nsp3-4 membrane", "ANATOMY", 22, 37], ["ER", "ANATOMY", 85, 87], ["ER lumen", "ANATOMY", 99, 107], ["luminal", "ANATOMY", 134, 141], ["luminal", "CHEMICAL", 134, 141], ["nsp3-4", "GENE_OR_GENE_PRODUCT", 22, 28], ["ER", "GENE_OR_GENE_PRODUCT", 85, 87], ["ER", "GENE_OR_GENE_PRODUCT", 99, 101], ["nsp3", "PROTEIN", 22, 26], ["ER", "PROTEIN", 85, 87], ["luminal domains", "PROTEIN", 134, 149], ["nsp3-4 membrane pairing", "TREATMENT", 22, 45], ["lumen", "ANATOMY_MODIFIER", 102, 107], ["is likely", "UNCERTAINTY", 115, 124], ["luminal", "ANATOMY_MODIFIER", 134, 141]]], ["Membrane pairing would not necessarily need to involve high-affinity interactions, as demonstrated by a study where paired membranes were induced by low-affinity interactions between membrane-linked green fluorescent protein (Snapp et al., 2003) .", [["Membrane", "ANATOMY", 0, 8], ["membranes", "ANATOMY", 123, 132], ["membrane", "ANATOMY", 183, 191], ["Membrane", "CELLULAR_COMPONENT", 0, 8], ["membranes", "CELLULAR_COMPONENT", 123, 132], ["membrane", "CELLULAR_COMPONENT", 183, 191], ["green fluorescent protein", "GENE_OR_GENE_PRODUCT", 199, 224], ["membrane-linked green fluorescent protein", "PROTEIN", 183, 224], ["Membrane pairing", "PROBLEM", 0, 16], ["a study", "TEST", 102, 109], ["paired membranes", "PROBLEM", 116, 132]]], ["The minimal requirements for DMO-like membrane pairing appear to be the C-terminal region of nsp3 that contains both transmembrane regions and the luminal ectodomain (Hagemeijer et al., 2014) , and at least the N-terminal region of nsp4 including the first three transmembrane regions of nsp4 (Sparks et al., 2007) .", [["membrane", "ANATOMY", 38, 46], ["transmembrane", "ANATOMY", 117, 130], ["luminal", "ANATOMY", 147, 154], ["transmembrane", "ANATOMY", 263, 276], ["DMO", "CHEMICAL", 29, 32], ["luminal", "CHEMICAL", 147, 154], ["DMO", "CHEMICAL", 29, 32], ["C", "CHEMICAL", 72, 73], ["N", "CHEMICAL", 211, 212], ["DMO", "SIMPLE_CHEMICAL", 29, 32], ["membrane", "CELLULAR_COMPONENT", 38, 46], ["nsp3", "GENE_OR_GENE_PRODUCT", 93, 97], ["transmembrane", "CELLULAR_COMPONENT", 117, 130], ["nsp4", "GENE_OR_GENE_PRODUCT", 232, 236], ["nsp4", "GENE_OR_GENE_PRODUCT", 288, 292], ["C-terminal region", "PROTEIN", 72, 89], ["nsp3", "PROTEIN", 93, 97], ["transmembrane regions", "PROTEIN", 117, 138], ["luminal ectodomain", "PROTEIN", 147, 165], ["N-terminal region", "PROTEIN", 211, 228], ["nsp4", "PROTEIN", 232, 236], ["transmembrane regions", "PROTEIN", 263, 284], ["nsp4", "PROTEIN", 288, 292], ["DMO-like membrane pairing", "PROBLEM", 29, 54], ["nsp3", "PROBLEM", 93, 97], ["nsp4", "PROBLEM", 232, 236], ["nsp4", "PROBLEM", 288, 292], ["minimal", "OBSERVATION_MODIFIER", 4, 11], ["terminal", "ANATOMY_MODIFIER", 74, 82], ["nsp3", "OBSERVATION", 93, 97], ["both", "ANATOMY_MODIFIER", 112, 116], ["transmembrane", "ANATOMY_MODIFIER", 117, 130], ["regions", "ANATOMY_MODIFIER", 131, 138], ["luminal ectodomain", "ANATOMY", 147, 165], ["terminal", "ANATOMY_MODIFIER", 213, 221], ["nsp4", "OBSERVATION", 232, 236], ["nsp4", "OBSERVATION", 288, 292]]], ["Mutations in the glycosylated luminal domain of nsp4 result in either non-recoverable virus or less consistent membrane pairing (Gadlage et al., 2010) .", [["membrane", "ANATOMY", 111, 119], ["luminal", "CHEMICAL", 30, 37], ["nsp4", "GENE_OR_GENE_PRODUCT", 48, 52], ["membrane", "CELLULAR_COMPONENT", 111, 119], ["glycosylated luminal domain", "PROTEIN", 17, 44], ["nsp4", "PROTEIN", 48, 52], ["Mutations in the glycosylated luminal domain of nsp4", "PROBLEM", 0, 52], ["non-recoverable virus", "PROBLEM", 70, 91]]], ["While the final transmembrane C-terminal cytosolic domain of nsp4 is dispensible for coronavirus replication (Sparks et al., 2007) , it is not clear whether partial deletion of nsp4 affects DMO structure.", [["transmembrane", "ANATOMY", 16, 29], ["DMO", "CHEMICAL", 190, 193], ["C", "CHEMICAL", 30, 31], ["DMO", "CHEMICAL", 190, 193], ["transmembrane", "CELLULAR_COMPONENT", 16, 29], ["nsp4", "GENE_OR_GENE_PRODUCT", 61, 65], ["nsp4", "GENE_OR_GENE_PRODUCT", 177, 181], ["DMO", "SIMPLE_CHEMICAL", 190, 193], ["transmembrane C-terminal cytosolic domain", "PROTEIN", 16, 57], ["nsp4", "PROTEIN", 61, 65], ["nsp4", "PROTEIN", 177, 181], ["nsp4", "PROBLEM", 61, 65], ["coronavirus replication", "PROBLEM", 85, 108], ["nsp4 affects DMO structure", "PROBLEM", 177, 203], ["nsp4 affects", "OBSERVATION", 177, 189]]], ["These observations together suggest that coronavirus membranes most likely pair through heterotypic interactions involving the luminal domains of nsp3 and nsp4, though interactions between cytosolic domains that lead to nsp3 and nsp4 clustering may also be important for membrane pairing.Origin of DMO membranesThe ER is the likely source of coronavirus DMO membranes, which may be obtained by co-opting the ER-associated degradation (ERAD) tuning pathway, a cellular degradation pathway that is responsible for the turnover of misfolded proteins in the ER .", [["membranes", "ANATOMY", 53, 62], ["luminal domains", "ANATOMY", 127, 142], ["cytosolic", "ANATOMY", 189, 198], ["membrane", "ANATOMY", 271, 279], ["DMO membranes", "ANATOMY", 298, 311], ["membranes", "ANATOMY", 358, 367], ["cellular", "ANATOMY", 459, 467], ["ER", "ANATOMY", 554, 556], ["luminal", "CHEMICAL", 127, 134], ["DMO", "CHEMICAL", 298, 301], ["DMO", "CHEMICAL", 354, 357], ["coronavirus", "ORGANISM", 41, 52], ["nsp3", "GENE_OR_GENE_PRODUCT", 146, 150], ["nsp4", "GENE_OR_GENE_PRODUCT", 155, 159], ["nsp3", "GENE_OR_GENE_PRODUCT", 220, 224], ["nsp4", "GENE_OR_GENE_PRODUCT", 229, 233], ["membrane", "CELLULAR_COMPONENT", 271, 279], ["DMO membranes", "CELLULAR_COMPONENT", 298, 311], ["ER", "GENE_OR_GENE_PRODUCT", 315, 317], ["coronavirus", "ORGANISM", 342, 353], ["DMO membranes", "CELLULAR_COMPONENT", 354, 367], ["ER", "GENE_OR_GENE_PRODUCT", 408, 410], ["cellular", "CELL", 459, 467], ["ER", "GENE_OR_GENE_PRODUCT", 554, 556], ["luminal domains", "PROTEIN", 127, 142], ["nsp3", "PROTEIN", 146, 150], ["nsp4", "PROTEIN", 155, 159], ["cytosolic domains", "PROTEIN", 189, 206], ["nsp3", "PROTEIN", 220, 224], ["nsp4", "PROTEIN", 229, 233], ["ER", "PROTEIN", 315, 317], ["ER", "PROTEIN", 408, 410], ["ERAD", "PROTEIN", 435, 439], ["misfolded proteins", "PROTEIN", 528, 546], ["ER", "PROTEIN", 554, 556], ["These observations", "TEST", 0, 18], ["coronavirus membranes", "PROBLEM", 41, 62], ["nsp3", "PROBLEM", 146, 150], ["nsp4", "PROBLEM", 155, 159], ["interactions between cytosolic domains", "PROBLEM", 168, 206], ["nsp3", "PROBLEM", 220, 224], ["nsp4 clustering", "PROBLEM", 229, 244], ["DMO membranes", "PROBLEM", 298, 311], ["coronavirus DMO membranes", "PROBLEM", 342, 367], ["a cellular degradation pathway", "PROBLEM", 457, 487], ["coronavirus membranes", "OBSERVATION", 41, 62], ["DMO membranes", "OBSERVATION", 298, 311], ["likely source of", "UNCERTAINTY", 325, 341], ["coronavirus DMO", "OBSERVATION", 342, 357]]], ["The ERAD tuning pathway is modulated by stress-inducible positive regulators of protein disposal such as EDEM1 (ER degradation-enhancing alpha mannosidase-like 1) and OS-9 (osteosarcoma amplified 9), which assist in transporting misfolded proteins into the cytosol for proteasomal degradation.", [["cytosol", "ANATOMY", 257, 264], ["proteasomal", "ANATOMY", 269, 280], ["EDEM1", "GENE_OR_GENE_PRODUCT", 105, 110], ["ER degradation-enhancing alpha mannosidase-like 1", "GENE_OR_GENE_PRODUCT", 112, 161], ["OS-9", "GENE_OR_GENE_PRODUCT", 167, 171], ["osteosarcoma", "CANCER", 173, 185], ["cytosol", "CELLULAR_COMPONENT", 257, 264], ["ERAD", "PROTEIN", 4, 8], ["EDEM1", "PROTEIN", 105, 110], ["ER", "PROTEIN", 112, 114], ["alpha mannosidase-like 1", "PROTEIN", 137, 161], ["OS-9", "DNA", 167, 171], ["osteosarcoma amplified 9", "DNA", 173, 197], ["misfolded proteins", "PROTEIN", 229, 247], ["stress-inducible positive regulators of protein disposal", "PROBLEM", 40, 96], ["EDEM1", "PROBLEM", 105, 110], ["ER degradation", "TEST", 112, 126], ["enhancing alpha mannosidase", "TEST", 127, 154], ["OS", "TEST", 167, 169], ["osteosarcoma", "PROBLEM", 173, 185], ["proteasomal degradation", "PROBLEM", 269, 292], ["ERAD tuning", "OBSERVATION", 4, 15], ["proteasomal degradation", "OBSERVATION", 269, 292]]], ["Under physiological conditions, low concentrations of EDEM1 and OS-9 are maintained in the ER lumen in order to avoid premature degradation of proteins that are in the process of folding (Cal\u00ec et al., 2008) .", [["ER lumen", "ANATOMY", 91, 99], ["OS-9", "CHEMICAL", 64, 68], ["EDEM1", "GENE_OR_GENE_PRODUCT", 54, 59], ["OS-9", "GENE_OR_GENE_PRODUCT", 64, 68], ["ER", "GENE_OR_GENE_PRODUCT", 91, 93], ["lumen", "IMMATERIAL_ANATOMICAL_ENTITY", 94, 99], ["EDEM1", "PROTEIN", 54, 59], ["low concentrations of EDEM1", "PROBLEM", 32, 59], ["OS", "TEST", 64, 66], ["the ER lumen", "TREATMENT", 87, 99], ["premature degradation of proteins", "PROBLEM", 118, 151], ["low concentrations", "OBSERVATION_MODIFIER", 32, 50], ["lumen", "ANATOMY_MODIFIER", 94, 99]]], ["In this case, EDEM1 and OS-9 are selectively confined by interacting with the transmembrane-anchored cargo receptor SEL1L (suppressor of lin-12-like) and later released from the ER lumen in small short-lived vesicles, called EDEMosomes, which rapidly fuse with the endolysosomal compartments (Bernasconi et al., 2012) .", [["transmembrane", "ANATOMY", 78, 91], ["ER lumen", "ANATOMY", 178, 186], ["vesicles", "ANATOMY", 208, 216], ["endolysosomal compartments", "ANATOMY", 265, 291], ["OS-9", "CHEMICAL", 24, 28], ["EDEM1", "GENE_OR_GENE_PRODUCT", 14, 19], ["OS-9", "GENE_OR_GENE_PRODUCT", 24, 28], ["transmembrane", "CELLULAR_COMPONENT", 78, 91], ["SEL1L", "GENE_OR_GENE_PRODUCT", 116, 121], ["lin-12", "GENE_OR_GENE_PRODUCT", 137, 143], ["ER", "GENE_OR_GENE_PRODUCT", 178, 180], ["vesicles", "CELLULAR_COMPONENT", 208, 216], ["EDEMosomes", "GENE_OR_GENE_PRODUCT", 225, 235], ["EDEM1 and OS-9", "DNA", 14, 28], ["transmembrane-anchored cargo receptor", "PROTEIN", 78, 115], ["SEL1L", "PROTEIN", 116, 121], ["suppressor of lin-12", "PROTEIN", 123, 143], ["EDEMosomes", "PROTEIN", 225, 235], ["EDEM1", "TEST", 14, 19], ["OS", "TEST", 24, 26], ["small short-lived vesicles", "PROBLEM", 190, 216], ["lumen", "ANATOMY_MODIFIER", 181, 186], ["small", "OBSERVATION_MODIFIER", 190, 195], ["short", "OBSERVATION_MODIFIER", 196, 201]]], ["In infected cells, viral double-stranded RNA colocalizes with EDEM1, OS-9, SEL1L and LC3-I, which is recruited to autophagosomes.", [["cells", "ANATOMY", 12, 17], ["autophagosomes", "ANATOMY", 114, 128], ["cells", "CELL", 12, 17], ["EDEM1", "GENE_OR_GENE_PRODUCT", 62, 67], ["OS-9", "GENE_OR_GENE_PRODUCT", 69, 73], ["SEL1L", "GENE_OR_GENE_PRODUCT", 75, 80], ["LC3-I", "GENE_OR_GENE_PRODUCT", 85, 90], ["autophagosomes", "CELLULAR_COMPONENT", 114, 128], ["viral double-stranded RNA", "RNA", 19, 44], ["EDEM1", "PROTEIN", 62, 67], ["OS", "PROTEIN", 69, 71], ["SEL1L", "PROTEIN", 75, 80], ["LC3-I", "PROTEIN", 85, 90], ["infected cells", "PROBLEM", 3, 17], ["viral double", "TEST", 19, 31], ["EDEM1", "TEST", 62, 67], ["OS", "TEST", 69, 71], ["SEL1L", "TEST", 75, 80], ["infected cells", "OBSERVATION", 3, 17], ["viral double", "OBSERVATION", 19, 31], ["stranded RNA", "OBSERVATION_MODIFIER", 32, 44]]], ["Moreover, replication of MHV, which does not require an intact autophagy pathway, is impaired upon knockdown of LC3 or SEL1L (Bernasconi et al., 2012) .", [["MHV", "ORGANISM", 25, 28], ["LC3", "GENE_OR_GENE_PRODUCT", 112, 115], ["SEL1L", "GENE_OR_GENE_PRODUCT", 119, 124], ["LC3", "PROTEIN", 112, 115], ["SEL1L", "PROTEIN", 119, 124], ["MHV", "SPECIES", 25, 28], ["MHV", "PROBLEM", 25, 28], ["MHV", "OBSERVATION_MODIFIER", 25, 28], ["autophagy", "OBSERVATION", 63, 72], ["impaired", "OBSERVATION_MODIFIER", 85, 93]]], ["Taken together, this is evidence that MHV exploits the ERAD-tuning machinery to establish DMOs for replication.", [["MHV", "ORGANISM", 38, 41], ["DMOs", "GENE_OR_GENE_PRODUCT", 90, 94], ["ERAD", "PROTEIN", 55, 59], ["DMOs", "PROTEIN", 90, 94], ["MHV", "SPECIES", 38, 41], ["MHV", "OBSERVATION", 38, 41]]], ["A summary of nsp3-6 interactions and induced membrane rearrangements is shown in Fig. 3 .Nsp3Coronavirus nsp3 is a large multidomain protein ranging from around 1450 amino acid residues in Deltacoronavirus (Woo et al., 2012) to nearly 2100 amino acid residues in the unpublished Hipposideros pratti betacoronavirus-Zhejiang2013 (GenBank accession NC_025217).", [["membrane", "ANATOMY", 45, 53], ["amino acid", "CHEMICAL", 166, 176], ["amino acid", "CHEMICAL", 240, 250], ["amino acid", "CHEMICAL", 166, 176], ["amino acid", "CHEMICAL", 240, 250], ["nsp3-6", "GENE_OR_GENE_PRODUCT", 13, 19], ["membrane", "CELLULAR_COMPONENT", 45, 53], ["Nsp3Coronavirus", "GENE_OR_GENE_PRODUCT", 89, 104], ["nsp3", "GENE_OR_GENE_PRODUCT", 105, 109], ["amino acid", "AMINO_ACID", 166, 176], ["amino acid", "AMINO_ACID", 240, 250], ["nsp3", "PROTEIN", 13, 17], ["Nsp3Coronavirus nsp3", "PROTEIN", 89, 109], ["multidomain protein", "PROTEIN", 121, 140], ["Hipposideros pratti betacoronavirus", "SPECIES", 279, 314], ["Hipposideros pratti betacoronavirus-Zhejiang2013 (GenBank accession NC_025217", "SPECIES", 279, 356], ["nsp3", "TEST", 13, 17], ["induced membrane rearrangements", "PROBLEM", 37, 68], ["Nsp3Coronavirus nsp3", "PROBLEM", 89, 109], ["a large multidomain protein", "PROBLEM", 113, 140], ["amino acid residues", "PROBLEM", 166, 185], ["amino acid residues", "TEST", 240, 259], ["large", "OBSERVATION_MODIFIER", 115, 120]]], ["Most nsp3s are predicted to be~200 kDa, and are cleaved from the polyprotein 1a or 1ab papain-like proteases (PL pro ) that are encoded within nsp3.Nsp3To make it easier to discuss specific parts of such a large protein in terms of both structure and function, we previously published a domain-level annotation of nsp3 (Neuman et al., 2008) , which we have updated for this review (Fig. 4) .Nsp3Based on phylogenetic analysis of nidovirus nsp3 homologues, results from previously published studies (Gorbalenya et al., 2006; Ratia et al., 2006; Saikatendu et al., 2005; Serrano et al., 2007b; Thiel et al., 2003; Ziebuhr et al., 2001) and de novo domain prediction software (Jaroszewski et al., 2005) , we estimate that the full repertoire of sequenced coronavirus nsp3 genes encodes 18 domains, with individual viruses having 10e16 domains each.", [["nsp3s", "GENE_OR_GENE_PRODUCT", 5, 10], ["PL pro", "GENE_OR_GENE_PRODUCT", 110, 116], ["nsp3", "GENE_OR_GENE_PRODUCT", 143, 147], ["Nsp3To", "GENE_OR_GENE_PRODUCT", 148, 154], ["nsp3", "GENE_OR_GENE_PRODUCT", 314, 318], ["nidovirus nsp3", "GENE_OR_GENE_PRODUCT", 429, 443], ["coronavirus", "ORGANISM", 752, 763], ["nsp3", "GENE_OR_GENE_PRODUCT", 764, 768], ["nsp3s", "PROTEIN", 5, 10], ["polyprotein 1a or 1ab papain-like proteases", "PROTEIN", 65, 108], ["PL pro", "PROTEIN", 110, 116], ["nsp3", "PROTEIN", 143, 147], ["Nsp3To", "PROTEIN", 148, 154], ["nsp3", "PROTEIN", 314, 318], ["Nsp3Based", "PROTEIN", 391, 400], ["nidovirus nsp3 homologues", "DNA", 429, 454], ["coronavirus nsp3 genes", "DNA", 752, 774], ["10e16 domains", "DNA", 826, 839], ["1ab papain", "TREATMENT", 83, 93], ["proteases (PL pro", "TREATMENT", 99, 116], ["a large protein", "PROBLEM", 204, 219], ["phylogenetic analysis", "TEST", 404, 425], ["sequenced coronavirus nsp3 genes encodes 18 domains", "PROBLEM", 742, 793], ["individual viruses", "PROBLEM", 800, 818], ["large", "OBSERVATION_MODIFIER", 206, 211], ["protein", "OBSERVATION", 212, 219]]], ["Several of these domains are duplicated, including two ubiquitin-like domains Ub1 and Ub2, two PL pro , and three macrodomains (Mac1, Mac2 and Mac3).", [["Ub1", "GENE_OR_GENE_PRODUCT", 78, 81], ["Ub2", "GENE_OR_GENE_PRODUCT", 86, 89], ["Mac1", "GENE_OR_GENE_PRODUCT", 128, 132], ["Mac2", "GENE_OR_GENE_PRODUCT", 134, 138], ["Mac3", "GENE_OR_GENE_PRODUCT", 143, 147], ["ubiquitin-like domains", "PROTEIN", 55, 77], ["Ub1", "PROTEIN", 78, 81], ["Ub2", "PROTEIN", 86, 89], ["PL pro", "PROTEIN", 95, 101], ["macrodomains", "PROTEIN", 114, 126], ["Mac1", "PROTEIN", 128, 132], ["Mac2", "PROTEIN", 134, 138], ["Mac3", "PROTEIN", 143, 147], ["Ub2", "TEST", 86, 89], ["duplicated", "OBSERVATION", 29, 39], ["ubiquitin", "OBSERVATION_MODIFIER", 55, 64]]], ["Ten of these domains form the core of coronavirus nsp3, and are found in every currently known coronavirus, including both ubiquitin-like domains, the second PL pro , the first macrodomain Mac1, a hypervariable region consisting of mostly acidic residues, and a region including the transmembrane regions TM1 and TM2, nsp3 ectodomain (3Ecto), a nidovirus-conserved domain of unknown function (Y) and a region predicted to contain two structural domains which are only found in coronaviruses (CoVeY).", [["transmembrane", "ANATOMY", 283, 296], ["coronavirus", "ORGANISM", 38, 49], ["nsp3", "GENE_OR_GENE_PRODUCT", 50, 54], ["coronavirus", "ORGANISM", 95, 106], ["ubiquitin", "GENE_OR_GENE_PRODUCT", 123, 132], ["Mac1", "GENE_OR_GENE_PRODUCT", 189, 193], ["transmembrane", "CELLULAR_COMPONENT", 283, 296], ["TM2", "AMINO_ACID", 313, 316], ["nsp3", "GENE_OR_GENE_PRODUCT", 318, 322], ["3Ecto", "GENE_OR_GENE_PRODUCT", 335, 340], ["coronaviruses", "ORGANISM", 477, 490], ["CoVeY", "GENE_OR_GENE_PRODUCT", 492, 497], ["coronavirus nsp3", "PROTEIN", 38, 54], ["ubiquitin-like domains", "PROTEIN", 123, 145], ["PL pro", "PROTEIN", 158, 164], ["Mac1", "PROTEIN", 189, 193], ["hypervariable region", "PROTEIN", 197, 217], ["acidic residues", "PROTEIN", 239, 254], ["transmembrane regions", "PROTEIN", 283, 304], ["TM1", "PROTEIN", 305, 308], ["TM2", "PROTEIN", 313, 316], ["nsp3 ectodomain", "PROTEIN", 318, 333], ["3Ecto", "PROTEIN", 335, 340], ["nidovirus-conserved domain", "PROTEIN", 345, 371], ["structural domains", "PROTEIN", 434, 452], ["coronavirus nsp3", "PROBLEM", 38, 54], ["coronavirus", "PROBLEM", 95, 106], ["a hypervariable region", "PROBLEM", 195, 217], ["mostly acidic residues", "PROBLEM", 232, 254], ["TM2", "TEST", 313, 316], ["nsp3 ectodomain", "TEST", 318, 333], ["a nidovirus", "TEST", 343, 354], ["two structural domains", "PROBLEM", 430, 452], ["coronavirus nsp3", "OBSERVATION", 38, 54], ["coronavirus", "OBSERVATION", 95, 106], ["mostly", "OBSERVATION_MODIFIER", 232, 238], ["acidic residues", "OBSERVATION", 239, 254], ["transmembrane", "ANATOMY_MODIFIER", 283, 296], ["regions", "ANATOMY_MODIFIER", 297, 304], ["TM1", "ANATOMY_MODIFIER", 305, 308], ["TM2", "ANATOMY_MODIFIER", 313, 316], ["nsp3 ectodomain", "OBSERVATION", 318, 333], ["two", "OBSERVATION_MODIFIER", 430, 433], ["structural domains", "OBSERVATION", 434, 452]]], ["Six of the ten domains conserved in all coronaviruses are also found in other members of the Nidovirales, with evidence that the region from TM1 to Y is present in all nidoviruses except the two families that infect arthropods, namely the Roniviridae and Mesoniviridae (V' Kovski et al., 2015) .Nsp3The ectodomain of nsp3, 3Ecto, is glycosylated in SARS-CoV at positions 1431 and 1434 (Harcourt et al., 2004) and the corresponding region of MHV (Kanjanahaluethai et al., 2007) , and is predicted to be located on the luminal side of the membrane.", [["luminal", "ANATOMY", 517, 524], ["membrane", "ANATOMY", 537, 545], ["coronaviruses", "ORGANISM", 40, 53], ["Nidovirales", "GENE_OR_GENE_PRODUCT", 93, 104], ["TM1", "GENE_OR_GENE_PRODUCT", 141, 144], ["Y", "GENE_OR_GENE_PRODUCT", 148, 149], ["nidoviruses", "CANCER", 168, 179], ["Nsp3", "GENE_OR_GENE_PRODUCT", 295, 299], ["nsp3", "GENE_OR_GENE_PRODUCT", 317, 321], ["3Ecto", "GENE_OR_GENE_PRODUCT", 323, 328], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 349, 357], ["membrane", "CELLULAR_COMPONENT", 537, 545], ["Y", "DNA", 148, 149], ["Nsp3", "PROTEIN", 295, 299], ["ectodomain", "PROTEIN", 303, 313], ["nsp3", "PROTEIN", 317, 321], ["3Ecto", "PROTEIN", 323, 328], ["SARS-CoV", "SPECIES", 349, 357], ["MHV", "SPECIES", 441, 444], ["all coronaviruses", "PROBLEM", 36, 53], ["the Roniviridae", "TREATMENT", 235, 250], ["Mesoniviridae", "TREATMENT", 255, 268], ["nsp3", "TEST", 317, 321], ["all coronaviruses", "ANATOMY", 36, 53], ["ectodomain", "OBSERVATION_MODIFIER", 303, 313], ["nsp3", "OBSERVATION", 317, 321], ["MHV", "ANATOMY", 441, 444], ["luminal", "ANATOMY_MODIFIER", 517, 524], ["membrane", "ANATOMY_MODIFIER", 537, 545]]], ["Each copy of nsp3 is predicted span the membrane twice, placing the first 1395 residues of SARS-CoV nsp3 and the last 377 residues (Y and CoVeY) on the cytosolic face of the membrane.", [["membrane", "ANATOMY", 40, 48], ["cytosolic face", "ANATOMY", 152, 166], ["membrane", "ANATOMY", 174, 182], ["nsp3", "GENE_OR_GENE_PRODUCT", 13, 17], ["membrane", "CELLULAR_COMPONENT", 40, 48], ["SARS-CoV nsp3", "GENE_OR_GENE_PRODUCT", 91, 104], ["membrane", "CELLULAR_COMPONENT", 174, 182], ["nsp3", "DNA", 13, 17], ["SARS-CoV nsp3", "PROTEIN", 91, 104], ["last 377 residues", "PROTEIN", 113, 130], ["CoVeY", "PROTEIN", 138, 143], ["SARS-CoV", "SPECIES", 91, 99], ["SARS", "PROBLEM", 91, 95], ["CoV nsp3", "PROBLEM", 96, 104], ["cytosolic", "ANATOMY_MODIFIER", 152, 161], ["face", "ANATOMY_MODIFIER", 162, 166], ["membrane", "ANATOMY", 174, 182]]], ["Notably, the regions immediately before TM1 and after TM2, which would both have a cytosolic membrane topology are highly hydrophobic, and Organization of the proteins most likely to be involved in formation of replicative organelles across the order Nidovirales.", [["cytosolic membrane", "ANATOMY", 83, 101], ["organelles", "ANATOMY", 223, 233], ["TM2", "GENE_OR_GENE_PRODUCT", 54, 57], ["membrane", "CELLULAR_COMPONENT", 93, 101], ["organelles", "CELLULAR_COMPONENT", 223, 233], ["TM1", "PROTEIN", 40, 43], ["TM2", "PROTEIN", 54, 57], ["TM2", "TEST", 54, 57], ["a cytosolic membrane topology", "PROBLEM", 81, 110], ["the proteins", "PROBLEM", 155, 167], ["replicative organelles", "PROBLEM", 211, 233], ["regions", "ANATOMY_MODIFIER", 13, 20], ["cytosolic membrane", "OBSERVATION", 83, 101], ["highly", "OBSERVATION_MODIFIER", 115, 121], ["hydrophobic", "OBSERVATION_MODIFIER", 122, 133], ["most likely", "UNCERTAINTY", 168, 179], ["replicative organelles", "OBSERVATION", 211, 233]]], ["Conserved domains were identified by amino acid alignment, or by comparison of predicted protein secondary structure.", [["amino acid", "CHEMICAL", 37, 47], ["amino acid", "CHEMICAL", 37, 47], ["amino acid", "AMINO_ACID", 37, 47], ["protein secondary structure", "PROTEIN", 89, 116], ["Conserved domains", "PROBLEM", 0, 17], ["amino acid alignment", "TEST", 37, 57], ["amino acid alignment", "OBSERVATION", 37, 57], ["secondary structure", "OBSERVATION", 97, 116]]], ["Domain function was predicted by hhpred (Soding et al., 2005) .", [["Domain function", "TEST", 0, 15]]], ["Potential cleavage sites were annotated by analogy to known cleavage sites and proximity to conserved domains.", [["cleavage sites", "DNA", 60, 74], ["conserved domains", "DNA", 92, 109], ["Potential cleavage sites", "PROBLEM", 0, 24], ["known cleavage sites", "PROBLEM", 54, 74]]], ["Clusters with 4 histidine or cysteine residues within 25 amino acid residues that may bind metal ions are indicated.", [["histidine", "CHEMICAL", 16, 25], ["amino acid", "CHEMICAL", 57, 67], ["histidine", "CHEMICAL", 16, 25], ["cysteine", "CHEMICAL", 29, 37], ["amino acid", "CHEMICAL", 57, 67], ["histidine", "AMINO_ACID", 16, 25], ["cysteine", "AMINO_ACID", 29, 37], ["amino acid", "AMINO_ACID", 57, 67], ["metal ions", "SIMPLE_CHEMICAL", 91, 101], ["4 histidine or cysteine residues", "TREATMENT", 14, 46], ["25 amino acid residues", "TREATMENT", 54, 76], ["bind metal ions", "TREATMENT", 86, 101]]], ["Conserved transmembrane regions (black) and regions predicted as transmembrane helices by TMHMM 2.0 (Sonnhammer et al., 1998 ) but shown experimentally not to be transmembrane are zebra striped. may serve to link the pre-and post-transmembrane regions of nsp3.Nsp3 (Ub1 to PL1 pro )The N-terminal domain of all coronavirus nsp3 proteins containing Ub1, a hypervariable region (HVR) and PL1 pro appears poorly conserved at first glance, showing less than 20% average amino acid identity between members of different coronavirus genera (Fig. 5 ), but secondary structure prediction (JPred; (Drozdetskiy et al., 2015) ) suggests that the Ub1 and PL1 pro domains adopt a conserved fold in all coronaviruses (data not shown).", [["transmembrane", "ANATOMY", 10, 23], ["transmembrane", "ANATOMY", 65, 78], ["transmembrane", "ANATOMY", 162, 175], ["amino acid", "CHEMICAL", 466, 476], ["amino acid", "CHEMICAL", 466, 476], ["transmembrane", "CELLULAR_COMPONENT", 10, 23], ["transmembrane", "CELLULAR_COMPONENT", 162, 175], ["zebra", "ORGANISM_SUBDIVISION", 180, 185], ["nsp3", "GENE_OR_GENE_PRODUCT", 255, 259], ["Nsp3", "GENE_OR_GENE_PRODUCT", 260, 264], ["Ub1 to PL1 pro", "GENE_OR_GENE_PRODUCT", 266, 280], ["nsp3", "GENE_OR_GENE_PRODUCT", 323, 327], ["Ub1", "GENE_OR_GENE_PRODUCT", 348, 351], ["PL1 pro", "GENE_OR_GENE_PRODUCT", 386, 393], ["amino acid", "AMINO_ACID", 466, 476], ["Ub1", "GENE_OR_GENE_PRODUCT", 635, 638], ["PL1", "GENE_OR_GENE_PRODUCT", 643, 646], ["Conserved transmembrane regions", "PROTEIN", 0, 31], ["transmembrane helices", "PROTEIN", 65, 86], ["pre-and post-transmembrane regions", "PROTEIN", 217, 251], ["nsp3", "PROTEIN", 255, 259], ["Nsp3 (Ub1 to PL1 pro", "PROTEIN", 260, 280], ["N-terminal domain", "PROTEIN", 286, 303], ["coronavirus nsp3 proteins", "PROTEIN", 311, 336], ["Ub1", "PROTEIN", 348, 351], ["hypervariable region", "PROTEIN", 355, 375], ["HVR", "DNA", 377, 380], ["PL1 pro", "DNA", 386, 393], ["Ub1", "PROTEIN", 635, 638], ["PL1", "PROTEIN", 643, 646], ["zebra striped", "SPECIES", 180, 193], ["Conserved transmembrane regions (black) and regions", "PROBLEM", 0, 51], ["nsp3", "PROBLEM", 255, 259], ["Nsp3", "TEST", 260, 264], ["PL1 pro", "TEST", 273, 280], ["The N-terminal domain", "PROBLEM", 282, 303], ["all coronavirus nsp3 proteins", "TEST", 307, 336], ["a hypervariable region", "PROBLEM", 353, 375], ["PL1 pro", "TEST", 386, 393], ["different coronavirus genera", "TREATMENT", 505, 533], ["secondary structure prediction", "PROBLEM", 549, 579], ["the Ub1 and PL1 pro domains", "PROBLEM", 631, 658], ["a conserved fold in all coronaviruses", "PROBLEM", 665, 702], ["transmembrane", "ANATOMY_MODIFIER", 10, 23], ["black", "OBSERVATION_MODIFIER", 33, 38], ["zebra striped", "OBSERVATION", 180, 193], ["nsp3", "OBSERVATION", 255, 259], ["coronavirus nsp3", "OBSERVATION", 311, 327]]], ["The NMR structure of the residues 1e112 of SARS-CoV nsp3 exhibits a globular ubiquitin-like fold with two additional helices which make the overall structure of the Ub1 domain somewhat more elongated than other ubiquitin-like proteins (Serrano et al., 2007b) .", [["SARS-CoV nsp3", "GENE_OR_GENE_PRODUCT", 43, 56], ["Ub1", "GENE_OR_GENE_PRODUCT", 165, 168], ["SARS-CoV nsp3", "PROTEIN", 43, 56], ["globular ubiquitin-like fold", "PROTEIN", 68, 96], ["Ub1 domain", "PROTEIN", 165, 175], ["ubiquitin-like proteins", "PROTEIN", 211, 234], ["SARS-CoV", "SPECIES", 43, 51], ["SARS", "PROBLEM", 43, 47], ["CoV nsp3", "PROBLEM", 48, 56], ["a globular ubiquitin-like fold", "PROBLEM", 66, 96], ["two additional helices", "TREATMENT", 102, 124], ["globular ubiquitin", "OBSERVATION", 68, 86], ["like fold", "OBSERVATION_MODIFIER", 87, 96], ["overall", "OBSERVATION_MODIFIER", 140, 147], ["structure", "OBSERVATION", 148, 157], ["elongated", "OBSERVATION_MODIFIER", 190, 199]]], ["In contrast, the following HVR was shown to be structurally disordered for SARS-CoV (Serrano et al., 2007b) and is dispensable for replication in MHV (Hurst et al., 2013) .Nsp3 (Ub1 to PL1 pro )While the function of Ub1 has only been investigated in MHV, this domain has been found to play an essential role in initiating viral RNA synthesis, where it interacts with the viral nucleoprotein (N; (Hurst et al., 2013; Hurst-Hess et al., 2015) ).", [["SARS", "DISEASE", 75, 79], ["Ub1", "CHEMICAL", 216, 219], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 75, 83], ["MHV", "ORGANISM", 146, 149], ["Nsp3", "GENE_OR_GENE_PRODUCT", 172, 176], ["Ub1", "GENE_OR_GENE_PRODUCT", 178, 181], ["Ub1", "GENE_OR_GENE_PRODUCT", 216, 219], ["MHV", "ORGANISM", 250, 253], ["Nsp3", "PROTEIN", 172, 176], ["Ub1", "PROTEIN", 178, 181], ["PL1 pro", "PROTEIN", 185, 192], ["Ub1", "PROTEIN", 216, 219], ["SARS-CoV", "SPECIES", 75, 83], ["MHV", "SPECIES", 146, 149], ["MHV", "SPECIES", 250, 253], ["structurally disordered", "PROBLEM", 47, 70], ["SARS", "PROBLEM", 75, 79], ["Nsp3", "TEST", 172, 176], ["viral RNA synthesis", "TREATMENT", 322, 341]]], ["This was demonstrated in experiments that attempted to delete nsp3 domains, or substitute with the corresponding domains from other coronaviruses.", [["nsp3", "GENE_OR_GENE_PRODUCT", 62, 66], ["nsp3 domains", "PROTEIN", 62, 74], ["delete nsp3 domains", "PROBLEM", 55, 74], ["the corresponding domains from other coronaviruses", "PROBLEM", 95, 145], ["coronaviruses", "OBSERVATION", 132, 145]]], ["The interaction of Ub1 with N could effectively tether nsp3 to viral RNA during the replication process, but further experimentation is needed to better understand how the nsp3-N interaction leads to more efficient viral RNA synthesis.Nsp3 (Ub1 to PL1 pro )Additionally, Ub1 has an extra alpha helix and a 3 10 helix that is unusual for ubiquitin folds in general (Serrano et al., 2007a) .", [["Ub1", "CHEMICAL", 19, 22], ["Ub1", "GENE_OR_GENE_PRODUCT", 19, 22], ["nsp3", "GENE_OR_GENE_PRODUCT", 55, 59], ["nsp3", "GENE_OR_GENE_PRODUCT", 172, 176], ["Nsp3", "GENE_OR_GENE_PRODUCT", 235, 239], ["Ub1 to PL1 pro", "GENE_OR_GENE_PRODUCT", 241, 255], ["Ub1", "GENE_OR_GENE_PRODUCT", 271, 274], ["ubiquitin", "GENE_OR_GENE_PRODUCT", 337, 346], ["Ub1", "PROTEIN", 19, 22], ["N", "PROTEIN", 28, 29], ["nsp3", "PROTEIN", 55, 59], ["viral RNA", "RNA", 63, 72], ["nsp3", "PROTEIN", 172, 176], ["viral RNA", "RNA", 215, 224], ["Nsp3", "PROTEIN", 235, 239], ["Ub1", "PROTEIN", 241, 244], ["PL1 pro", "PROTEIN", 248, 255], ["Ub1", "PROTEIN", 271, 274], ["alpha helix", "PROTEIN", 288, 299], ["ubiquitin folds", "PROTEIN", 337, 352], ["viral RNA", "PROBLEM", 63, 72], ["Nsp3", "TEST", 235, 239], ["an extra alpha helix", "PROBLEM", 279, 299], ["ubiquitin folds", "PROBLEM", 337, 352], ["viral RNA", "OBSERVATION", 63, 72], ["viral RNA synthesis", "OBSERVATION", 215, 234], ["unusual for", "UNCERTAINTY", 325, 336], ["ubiquitin folds", "OBSERVATION", 337, 352]]], ["Among the closest structural matches to SARS-CoV Ub1 is one of the ubiquitin-like domains of ISG15, an interferon-induced protein constitutively present in higher eukaryotes.", [["SARS", "DISEASE", 40, 44], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 40, 48], ["ISG15", "GENE_OR_GENE_PRODUCT", 93, 98], ["SARS-CoV Ub1", "DNA", 40, 52], ["ubiquitin-like domains", "PROTEIN", 67, 89], ["ISG15", "PROTEIN", 93, 98], ["interferon-induced protein", "PROTEIN", 103, 129], ["SARS-CoV", "SPECIES", 40, 48], ["the ubiquitin", "TEST", 63, 76], ["ISG15", "TREATMENT", 93, 98], ["an interferon", "TREATMENT", 100, 113], ["protein constitutively", "OBSERVATION", 122, 144], ["higher eukaryotes", "OBSERVATION", 156, 173]]], ["This has led to speculation that Ub1 may be involved in modulating the effects of intracellular immunity in a manner analogous to the immunomodulatory decoys of poxviruses (Johnston and McFadden, 2003) .", [["intracellular", "ANATOMY", 82, 95], ["Ub1", "CHEMICAL", 33, 36], ["Ub1", "GENE_OR_GENE_PRODUCT", 33, 36], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 82, 95], ["poxviruses", "ORGANISM", 161, 171], ["Ub1", "PROTEIN", 33, 36], ["intracellular immunity", "TREATMENT", 82, 104], ["may be", "UNCERTAINTY", 37, 43]]], ["Some viruses have developed a mechanism to avoid the expression of ISG15.", [["ISG15", "GENE_OR_GENE_PRODUCT", 67, 72], ["ISG15", "PROTEIN", 67, 72], ["Some viruses", "PROBLEM", 0, 12], ["ISG15", "TREATMENT", 67, 72], ["viruses", "OBSERVATION", 5, 12]]], ["For example, Influenza B virus blocks its expression by means of NS1 protein in order to overcome the immune response.", [["Influenza B virus", "ORGANISM", 13, 30], ["NS1", "GENE_OR_GENE_PRODUCT", 65, 68], ["NS1 protein", "PROTEIN", 65, 76], ["Influenza B virus", "SPECIES", 13, 30], ["Influenza B virus", "SPECIES", 13, 30], ["Influenza B virus blocks", "TREATMENT", 13, 37], ["NS1 protein", "TREATMENT", 65, 76]]], ["The PL2 pro domain of SARS-CoV nsp3 also recognizes and cleaves ISG15 (Lindner et al., 2007) , which could potentially modulate the intracellular response to infection (Morales et al., 2015) .", [["intracellular", "ANATOMY", 132, 145], ["infection", "DISEASE", 158, 167], ["SARS-CoV nsp3", "GENE_OR_GENE_PRODUCT", 22, 35], ["ISG15", "GENE_OR_GENE_PRODUCT", 64, 69], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 132, 145], ["PL2 pro domain", "PROTEIN", 4, 18], ["SARS-CoV nsp3", "PROTEIN", 22, 35], ["ISG15", "PROTEIN", 64, 69], ["SARS-CoV", "SPECIES", 22, 30], ["The PL2 pro domain", "TEST", 0, 18], ["SARS", "PROBLEM", 22, 26], ["CoV nsp3", "PROBLEM", 27, 35], ["infection", "PROBLEM", 158, 167], ["intracellular response", "OBSERVATION", 132, 154], ["infection", "OBSERVATION", 158, 167]]], ["However, the comparison with ISG15 remains speculative because an immunomodulatory function for Ub1 has not yet been demonstrated experimentally.", [["ISG15", "GENE_OR_GENE_PRODUCT", 29, 34], ["Ub1", "GENE_OR_GENE_PRODUCT", 96, 99], ["ISG15", "PROTEIN", 29, 34], ["Ub1", "PROTEIN", 96, 99]]], ["It is known that ISG15 is able to inhibit virus replication by abrogating nuclear processing of unspliced viral RNA precursors.", [["nuclear", "ANATOMY", 74, 81], ["ISG15", "GENE_OR_GENE_PRODUCT", 17, 22], ["nuclear", "CELLULAR_COMPONENT", 74, 81], ["ISG15", "PROTEIN", 17, 22], ["unspliced viral RNA precursors", "RNA", 96, 126], ["ISG15", "PROBLEM", 17, 22], ["virus replication", "TREATMENT", 42, 59], ["unspliced viral RNA precursors", "PROBLEM", 96, 126], ["viral RNA precursors", "OBSERVATION", 106, 126]]], ["However, some viruses have developed a mechanism to avoid the expression of ISG15.", [["ISG15", "GENE_OR_GENE_PRODUCT", 76, 81], ["ISG15", "PROTEIN", 76, 81], ["some viruses", "PROBLEM", 9, 21], ["ISG15", "PROBLEM", 76, 81], ["viruses", "OBSERVATION", 14, 21]]], ["For example, influenza B virus blocks its expression by means of NS1 protein in order to overcome the immune response.", [["influenza B virus", "ORGANISM", 13, 30], ["NS1", "GENE_OR_GENE_PRODUCT", 65, 68], ["NS1 protein", "PROTEIN", 65, 76], ["influenza B virus", "SPECIES", 13, 30], ["influenza B virus", "SPECIES", 13, 30], ["influenza B virus blocks", "TREATMENT", 13, 37], ["NS1 protein", "TREATMENT", 65, 76]]], ["It is possible that the PL2 pro domain of nsp3 may also bind ISG15 and modulate the intracellular response to infection (Morales et al., 2015) .", [["intracellular", "ANATOMY", 84, 97], ["infection", "DISEASE", 110, 119], ["PL2", "GENE_OR_GENE_PRODUCT", 24, 27], ["nsp3", "GENE_OR_GENE_PRODUCT", 42, 46], ["ISG15", "GENE_OR_GENE_PRODUCT", 61, 66], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 84, 97], ["PL2 pro domain", "PROTEIN", 24, 38], ["nsp3", "PROTEIN", 42, 46], ["ISG15", "PROTEIN", 61, 66], ["the PL2 pro domain of nsp3", "PROBLEM", 20, 46], ["infection", "PROBLEM", 110, 119], ["intracellular response", "OBSERVATION", 84, 106], ["infection", "OBSERVATION", 110, 119]]], ["However, the comparison with ISG15 remains speculative because an immunomodulatory function for Ub1 has not yet been demonstrated experimentally.Nsp3 (Ub1 to PL1 pro )When SARS-CoV Ub1 was expressed in E. coli, it was found to bind tightly to a small RNA fragment that mass spectrometry analysis revealed to be consistent with the sequence GAUA or GUAA (Serrano et al., 2007a) .", [["ISG15", "GENE_OR_GENE_PRODUCT", 29, 34], ["Ub1", "GENE_OR_GENE_PRODUCT", 96, 99], ["Nsp3", "GENE_OR_GENE_PRODUCT", 145, 149], ["Ub1 to PL1 pro", "GENE_OR_GENE_PRODUCT", 151, 165], ["SARS-CoV Ub1", "GENE_OR_GENE_PRODUCT", 172, 184], ["E. coli", "ORGANISM", 202, 209], ["ISG15", "PROTEIN", 29, 34], ["Ub1", "PROTEIN", 96, 99], ["Nsp3", "PROTEIN", 145, 149], ["Ub1", "PROTEIN", 151, 154], ["PL1 pro", "PROTEIN", 158, 165], ["SARS-CoV Ub1", "DNA", 172, 184], ["small RNA fragment", "DNA", 245, 263], ["E. coli", "SPECIES", 202, 209], ["SARS-CoV", "SPECIES", 172, 180], ["E. coli", "SPECIES", 202, 209], ["Nsp3", "TEST", 145, 149], ["SARS", "PROBLEM", 172, 176], ["CoV Ub1", "PROBLEM", 177, 184], ["E. coli", "PROBLEM", 202, 209], ["a small RNA fragment", "PROBLEM", 243, 263], ["mass spectrometry analysis", "TEST", 269, 295], ["E. coli", "OBSERVATION", 202, 209], ["small", "OBSERVATION_MODIFIER", 245, 250]]], ["While matching sequences can be found throughout the SARS-CoV, none are prominently located in regions of the 5 0 -UTR or 3 0 -UTR that are known to contain sequences essential for recognition of viral RNA by components of the replicase.", [["SARS", "DISEASE", 53, 57], ["SARS-CoV", "ORGANISM", 53, 61], ["5 0 -UTR or 3 0 -UTR", "DNA", 110, 130], ["viral RNA", "RNA", 196, 205], ["replicase", "PROTEIN", 227, 236], ["SARS-CoV", "SPECIES", 53, 61], ["viral RNA", "PROBLEM", 196, 205], ["the replicase", "PROBLEM", 223, 236], ["viral RNA", "OBSERVATION", 196, 205], ["replicase", "OBSERVATION_MODIFIER", 227, 236]]], ["The functional significance of RNA-binding by Ub1 therefore remains unknown, but may complement the Ub1-N interaction.Nsp3 (Ub1 to PL1 pro )A papain-like protease domain (PL1 pro ) follows the HVR domain in some coronaviruses, but is absent in SARS-CoV and Middle east respiratory syndrome coronavirus (MERS-CoV).", [["SARS-CoV", "DISEASE", 244, 252], ["Middle east respiratory syndrome coronavirus", "DISEASE", 257, 301], ["Ub1-N", "CHEMICAL", 100, 105], ["Ub1", "GENE_OR_GENE_PRODUCT", 46, 49], ["Ub1", "GENE_OR_GENE_PRODUCT", 100, 103], ["Nsp3", "GENE_OR_GENE_PRODUCT", 118, 122], ["Ub1 to PL1 pro )A papain-like protease", "GENE_OR_GENE_PRODUCT", 124, 162], ["PL1 pro", "GENE_OR_GENE_PRODUCT", 171, 178], ["SARS-CoV", "ORGANISM", 244, 252], ["Middle east respiratory syndrome coronavirus", "ORGANISM", 257, 301], ["MERS-CoV", "ORGANISM", 303, 311], ["Ub1", "PROTEIN", 46, 49], ["Ub1", "PROTEIN", 100, 103], ["Nsp3 (Ub1 to PL1 pro )A papain-like protease domain", "PROTEIN", 118, 169], ["PL1 pro", "PROTEIN", 171, 178], ["HVR domain", "PROTEIN", 193, 203], ["SARS-CoV", "SPECIES", 244, 252], ["Middle east respiratory syndrome coronavirus", "SPECIES", 257, 301], ["MERS-CoV", "SPECIES", 303, 311], ["Nsp3", "TEST", 118, 122], ["A papain", "TREATMENT", 140, 148], ["protease domain (PL1 pro", "TREATMENT", 154, 178], ["the HVR domain", "PROBLEM", 189, 203], ["some coronaviruses", "PROBLEM", 207, 225], ["SARS", "PROBLEM", 244, 248], ["CoV", "PROBLEM", 249, 252], ["Middle east respiratory syndrome coronavirus", "PROBLEM", 257, 301], ["coronaviruses", "OBSERVATION", 212, 225], ["SARS", "OBSERVATION", 244, 248], ["Middle", "ANATOMY_MODIFIER", 257, 263], ["respiratory syndrome", "OBSERVATION", 269, 289]]], ["Where present, PL1 pro generally cleaves at the N-terminal boundary of nsp3, but in viruses that have only one PL pro , this cleavage is carried out by PL2 pro (Hilgenfeld, 2014) .", [["N", "CHEMICAL", 48, 49], ["PL1", "GENE_OR_GENE_PRODUCT", 15, 18], ["nsp3", "GENE_OR_GENE_PRODUCT", 71, 75], ["PL1 pro", "PROTEIN", 15, 22], ["N-terminal boundary", "PROTEIN", 48, 67], ["nsp3", "PROTEIN", 71, 75], ["PL pro", "PROTEIN", 111, 117], ["nsp3", "PROBLEM", 71, 75], ["this cleavage", "PROBLEM", 120, 133]]], ["A transcription factor-like zinc finger is conserved in all complete coronavirus PL pro domains (Culver et al., 1993) , which was taken as an early indication that nsp3 might be involved in coronavirus RNA synthesis.", [["zinc", "CHEMICAL", 28, 32], ["nsp3", "GENE_OR_GENE_PRODUCT", 164, 168], ["coronavirus", "ORGANISM", 190, 201], ["transcription factor", "PROTEIN", 2, 22], ["zinc finger", "PROTEIN", 28, 39], ["coronavirus PL pro domains", "PROTEIN", 69, 95], ["nsp3", "PROTEIN", 164, 168], ["coronavirus RNA", "RNA", 190, 205], ["coronavirus", "SPECIES", 190, 201], ["A transcription factor", "TEST", 0, 22], ["zinc finger", "PROBLEM", 28, 39], ["nsp3", "PROBLEM", 164, 168], ["coronavirus RNA synthesis", "PROBLEM", 190, 215]]], ["This hypothesis is supported by a report in which the Equine arteritis virus nonstructural protein 1, which is structurally and enzymatically similar to coronavirus PL1 pro (Sun et al., 2009) , was shown to be indispensable for viral subgenomic mRNA synthesis (Phizicky and Greer, 1993) .Nsp3 (Ub1 to PL1 pro )Some strains of Infectious bronchitis virus and Hipposideros pratti betacoronavirus-Zhejiang2013 contain only partial papain-like protease domains that are lacking one of the two catalytic domains (Fig. 2) .", [["Equine arteritis", "DISEASE", 54, 70], ["Infectious bronchitis virus", "DISEASE", 326, 353], ["Equine arteritis virus", "ORGANISM", 54, 76], ["nonstructural protein 1", "GENE_OR_GENE_PRODUCT", 77, 100], ["coronavirus PL1", "ORGANISM", 153, 168], ["Nsp3", "GENE_OR_GENE_PRODUCT", 288, 292], ["Ub1", "GENE_OR_GENE_PRODUCT", 294, 297], ["Infectious bronchitis virus", "ORGANISM", 326, 353], ["Hipposideros pratti betacoronavirus", "ORGANISM", 358, 393], ["Equine arteritis virus nonstructural protein 1", "PROTEIN", 54, 100], ["coronavirus PL1 pro", "PROTEIN", 153, 172], ["viral subgenomic mRNA", "RNA", 228, 249], ["Ub1", "PROTEIN", 294, 297], ["papain-like protease domains", "PROTEIN", 428, 456], ["catalytic domains", "PROTEIN", 489, 506], ["Equine arteritis virus", "SPECIES", 54, 76], ["Infectious bronchitis virus", "SPECIES", 326, 353], ["Hipposideros pratti betacoronavirus", "SPECIES", 358, 393], ["Equine arteritis virus", "SPECIES", 54, 76], ["Infectious bronchitis virus", "SPECIES", 326, 353], ["Hipposideros pratti betacoronavirus-Zhejiang2013", "SPECIES", 358, 406], ["the Equine arteritis virus nonstructural protein", "PROBLEM", 50, 98], ["viral subgenomic mRNA synthesis", "PROBLEM", 228, 259], ["Nsp3", "TEST", 288, 292], ["PL1 pro", "TEST", 301, 308], ["Some strains", "PROBLEM", 310, 322], ["Infectious bronchitis virus", "PROBLEM", 326, 353], ["Hipposideros pratti betacoronavirus", "TREATMENT", 358, 393], ["partial papain", "TREATMENT", 420, 434], ["protease domains", "TREATMENT", 440, 456], ["arteritis", "OBSERVATION", 61, 70], ["subgenomic mRNA", "OBSERVATION", 234, 249], ["Infectious", "OBSERVATION_MODIFIER", 326, 336], ["bronchitis", "OBSERVATION", 337, 347]]], ["It is not clear whether these domains are able to interact with the missing domains from PL2 pro and remain functional, or whether these are inactive relict domains derived from an ancestral genome that are no longer necessary for viral growth and are in the process of being deleted.Nsp3 (Mac1 to DPUP)The next conserved domain is the first of up to three domains that adopt macrodomain folds similar to the histone H2A in SARS-CoV (Saikatendu et al., 2005) .", [["macrodomain folds", "ANATOMY", 376, 393], ["PL2 pro", "GENE_OR_GENE_PRODUCT", 89, 96], ["Nsp3", "GENE_OR_GENE_PRODUCT", 284, 288], ["Mac1 to DPUP", "GENE_OR_GENE_PRODUCT", 290, 302], ["histone H2A", "GENE_OR_GENE_PRODUCT", 409, 420], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 424, 432], ["PL2 pro", "PROTEIN", 89, 96], ["Nsp3", "PROTEIN", 284, 288], ["Mac1", "PROTEIN", 290, 294], ["DPUP", "PROTEIN", 298, 302], ["macrodomain folds", "PROTEIN", 376, 393], ["histone H2A", "PROTEIN", 409, 420], ["SARS-CoV", "SPECIES", 424, 432], ["inactive relict domains", "PROBLEM", 141, 164], ["an ancestral genome", "PROBLEM", 178, 197], ["viral growth", "PROBLEM", 231, 243], ["Nsp3", "PROBLEM", 284, 288], ["macrodomain folds", "PROBLEM", 376, 393], ["the histone H2A", "PROBLEM", 405, 420], ["SARS", "PROBLEM", 424, 428], ["not", "UNCERTAINTY", 6, 9], ["clear", "OBSERVATION", 10, 15], ["ancestral genome", "OBSERVATION", 181, 197], ["no longer", "UNCERTAINTY", 207, 216], ["histone H2A", "OBSERVATION", 409, 420]]], ["This domain was originally called an X-domain (Gorbalenya et al., 1991) , an alternate name that is still used in some publications.", [["X-domain", "DNA", 37, 45]]], ["The structure of Mac1 has been solved for several coronaviruses Saikatendu et al., 2005; Tan et al., 2009; Wojdyla et al., 2009; Xu et al., 2009) .", [["Mac1", "GENE_OR_GENE_PRODUCT", 17, 21], ["Mac1", "PROTEIN", 17, 21], ["Mac1", "ANATOMY", 17, 21]]], ["Purified SARS-CoV Mac1 was shown to have relatively weak ADP ribose 1 00 phosphatase (ADRP) activity (Saikatendu et al., 2005) .", [["ADP", "CHEMICAL", 57, 60], ["ADP", "CHEMICAL", 57, 60], ["ribose", "CHEMICAL", 61, 67], ["SARS-CoV Mac1", "GENE_OR_GENE_PRODUCT", 9, 22], ["ADP ribose 1 00 phosphatase", "GENE_OR_GENE_PRODUCT", 57, 84], ["ADRP", "GENE_OR_GENE_PRODUCT", 86, 90], ["SARS-CoV Mac1", "PROTEIN", 9, 22], ["ADP ribose 1 00 phosphatase", "PROTEIN", 57, 84], ["ADRP", "PROTEIN", 86, 90], ["SARS-CoV", "SPECIES", 9, 17], ["CoV Mac1", "TEST", 14, 22], ["relatively weak ADP ribose", "PROBLEM", 41, 67], ["SARS", "OBSERVATION", 9, 13]]], ["Structures that were solved at the time of domain assignment are shown in red, and domain assignments based on amino acid alignments are shown in grey.", [["amino acid", "CHEMICAL", 111, 121], ["amino acid", "CHEMICAL", 111, 121], ["amino acid", "AMINO_ACID", 111, 121], ["amino acid alignments", "TEST", 111, 132]]], ["Panel B is based on a multiple sequence alignment of nsp3 amino acid sequences from the genera Alphacoronavirus (aCoV), Betacoronavirus (bCoV), Gammacoronavirus (gCoV) and Deltacoronavirus (dCoV).", [["amino acid", "CHEMICAL", 58, 68], ["amino acid", "CHEMICAL", 58, 68], ["nsp3", "SIMPLE_CHEMICAL", 53, 57], ["amino acid", "AMINO_ACID", 58, 68], ["Alphacoronavirus", "GENE_OR_GENE_PRODUCT", 95, 111], ["aCoV", "GENE_OR_GENE_PRODUCT", 113, 117], ["Betacoronavirus", "GENE_OR_GENE_PRODUCT", 120, 135], ["bCoV", "GENE_OR_GENE_PRODUCT", 137, 141], ["Gammacoronavirus", "GENE_OR_GENE_PRODUCT", 144, 160], ["gCoV", "GENE_OR_GENE_PRODUCT", 162, 166], ["Deltacoronavirus", "GENE_OR_GENE_PRODUCT", 172, 188], ["nsp3 amino acid sequences", "PROTEIN", 53, 78], ["bCoV", "PROTEIN", 137, 141], ["gCoV", "PROTEIN", 162, 166], ["dCoV", "PROTEIN", 190, 194], ["bCoV", "SPECIES", 137, 141], ["gCoV", "SPECIES", 162, 166], ["a multiple sequence alignment", "TEST", 20, 49], ["nsp3 amino acid sequences", "TEST", 53, 78], ["the genera Alphacoronavirus", "TEST", 84, 111], ["Betacoronavirus (bCoV)", "TREATMENT", 120, 142], ["Gammacoronavirus (gCoV)", "TREATMENT", 144, 167], ["Deltacoronavirus (dCoV)", "TREATMENT", 172, 195]]], ["Four to fifteen amino nsp3 protein sequences are shown per genus, organized into phylogenetic clusters.", [["amino", "CHEMICAL", 16, 21], ["amino nsp3 protein sequences", "DNA", 16, 44], ["fifteen amino nsp3 protein sequences", "TEST", 8, 44], ["phylogenetic clusters", "OBSERVATION", 81, 102]]], ["Amino acid residues in the alignment have been converted to colored blocks to show domain-level conservation and highlight areas with clusters of well-conserved hydrophobic (grey), polar (light blue), acidic (red) and cysteine/histidine (black) residues.", [["Amino acid", "CHEMICAL", 0, 10], ["cysteine", "CHEMICAL", 218, 226], ["histidine", "CHEMICAL", 227, 236], ["Amino acid", "CHEMICAL", 0, 10], ["cysteine", "CHEMICAL", 218, 226], ["histidine", "CHEMICAL", 227, 236], ["Amino acid", "AMINO_ACID", 0, 10], ["cysteine", "AMINO_ACID", 218, 226], ["histidine", "AMINO_ACID", 227, 236], ["red", "PROTEIN", 209, 212], ["Amino acid residues", "PROBLEM", 0, 19], ["colored blocks", "PROBLEM", 60, 74], ["domain-level conservation", "TREATMENT", 83, 108], ["polar (light blue", "TEST", 181, 198], ["cysteine/histidine (black) residues", "TREATMENT", 218, 253], ["acid residues", "OBSERVATION", 6, 19]]], ["Domain designations include ubiquitin-like (Ub1, Ub2), hypervariable region (HVR) previously described as acidic (Ac), full (PL1 pro , PL2 pro ) or partial (PL1 x ) papain-like protease that is missing at least one domain and one catalytically important amino acid, macro domains Mac1 (previously X or ADP-ribose 1 00 phosphatase), Mac2 (previously SARS-CoV unique domain N-terminal or metal-binding domain MBD), Mac3 (previously SARS-CoV unique domain middle), domain preceding Ub2 and PL2 pro (DPUP), nucleic acid binding (NAB), group specific markers (GSM), Betacoronavirus specific marker (bSM, previously group 2 specific marker G2M), Gammacoronavirus specific marker (gSM), large Gammacoronavirus marker (LgM), transmembrane region (TM1, TM2), nsp3 ectodomain (3Ecto, formerly zinc finger ZF), Y domain regions Y1 and coronavirus-specific Y domain (CoVeY).", [["amino acid", "CHEMICAL", 254, 264], ["ADP", "CHEMICAL", 302, 305], ["nucleic acid", "CHEMICAL", 503, 515], ["amino acid", "CHEMICAL", 254, 264], ["ADP", "CHEMICAL", 302, 305], ["ribose", "CHEMICAL", 306, 312], ["N", "CHEMICAL", 372, 373], ["zinc", "CHEMICAL", 783, 787], ["ubiquitin", "GENE_OR_GENE_PRODUCT", 28, 37], ["Ub1", "GENE_OR_GENE_PRODUCT", 44, 47], ["Ub2", "GENE_OR_GENE_PRODUCT", 49, 52], ["amino acid", "AMINO_ACID", 254, 264], ["Mac1", "GENE_OR_GENE_PRODUCT", 280, 284], ["ADP-ribose 1 00 phosphatase", "GENE_OR_GENE_PRODUCT", 302, 329], ["Mac2", "GENE_OR_GENE_PRODUCT", 332, 336], ["metal-binding domain MBD", "GENE_OR_GENE_PRODUCT", 386, 410], ["Mac3", "GENE_OR_GENE_PRODUCT", 413, 417], ["Ub2", "GENE_OR_GENE_PRODUCT", 479, 482], ["PL2 pro", "GENE_OR_GENE_PRODUCT", 487, 494], ["DPUP", "GENE_OR_GENE_PRODUCT", 496, 500], ["G2M", "GENE_OR_GENE_PRODUCT", 634, 637], ["Gammacoronavirus specific marker", "GENE_OR_GENE_PRODUCT", 640, 672], ["gSM", "GENE_OR_GENE_PRODUCT", 674, 677], ["large Gammacoronavirus marker", "GENE_OR_GENE_PRODUCT", 680, 709], ["LgM", "GENE_OR_GENE_PRODUCT", 711, 714], ["transmembrane", "CELLULAR_COMPONENT", 717, 730], ["nsp3 ectodomain", "GENE_OR_GENE_PRODUCT", 750, 765], ["zinc finger ZF", "GENE_OR_GENE_PRODUCT", 783, 797], ["coronavirus-specific Y domain", "GENE_OR_GENE_PRODUCT", 824, 853], ["ubiquitin", "PROTEIN", 28, 37], ["Ub1", "PROTEIN", 44, 47], ["Ub2", "PROTEIN", 49, 52], ["hypervariable region", "PROTEIN", 55, 75], ["HVR", "DNA", 77, 80], ["acidic (Ac)", "PROTEIN", 106, 117], ["PL1 pro", "PROTEIN", 125, 132], ["PL2 pro", "PROTEIN", 135, 142], ["papain", "PROTEIN", 165, 171], ["protease", "PROTEIN", 177, 185], ["macro domains", "PROTEIN", 266, 279], ["Mac1", "PROTEIN", 280, 284], ["X or ADP-ribose 1 00 phosphatase", "PROTEIN", 297, 329], ["Mac2", "PROTEIN", 332, 336], ["SARS-CoV unique domain N-terminal or metal-binding domain", "PROTEIN", 349, 406], ["MBD", "PROTEIN", 407, 410], ["Mac3", "PROTEIN", 413, 417], ["SARS-CoV unique domain middle", "PROTEIN", 430, 459], ["domain", "PROTEIN", 462, 468], ["Ub2", "PROTEIN", 479, 482], ["PL2 pro", "PROTEIN", 487, 494], ["DPUP", "PROTEIN", 496, 500], ["nucleic acid binding", "PROTEIN", 503, 523], ["NAB", "PROTEIN", 525, 528], ["group specific markers", "PROTEIN", 531, 553], ["GSM", "PROTEIN", 555, 558], ["Betacoronavirus specific marker", "PROTEIN", 561, 592], ["bSM", "PROTEIN", 594, 597], ["G2M", "PROTEIN", 634, 637], ["Gammacoronavirus specific marker", "PROTEIN", 640, 672], ["gSM", "PROTEIN", 674, 677], ["Gammacoronavirus marker", "PROTEIN", 686, 709], ["LgM", "PROTEIN", 711, 714], ["transmembrane region", "PROTEIN", 717, 737], ["TM1", "PROTEIN", 739, 742], ["TM2", "PROTEIN", 744, 747], ["nsp3 ectodomain", "PROTEIN", 750, 765], ["3Ecto", "PROTEIN", 767, 772], ["formerly zinc finger ZF", "PROTEIN", 774, 797], ["Y domain regions", "PROTEIN", 800, 816], ["Y1", "PROTEIN", 817, 819], ["coronavirus-specific Y domain", "PROTEIN", 824, 853], ["CoVeY", "PROTEIN", 855, 860], ["Domain designations", "TEST", 0, 19], ["ubiquitin", "TEST", 28, 37], ["hypervariable region (HVR)", "PROBLEM", 55, 81], ["partial (PL1 x ) papain", "PROBLEM", 148, 171], ["protease", "TREATMENT", 177, 185], ["amino acid", "TEST", 254, 264], ["macro domains Mac1", "TEST", 266, 284], ["ADP", "TEST", 302, 305], ["ribose", "TEST", 306, 312], ["Mac2", "TEST", 332, 336], ["terminal or metal-binding domain MBD", "TREATMENT", 374, 410], ["Mac3", "TEST", 413, 417], ["domain preceding Ub2", "TEST", 462, 482], ["PL2 pro (DPUP)", "TREATMENT", 487, 501], ["nucleic acid binding", "PROBLEM", 503, 523], ["large Gammacoronavirus marker", "TEST", 680, 709], ["transmembrane region", "TEST", 717, 737], ["TM2", "TEST", 744, 747], ["nsp3 ectodomain (3Ecto, formerly zinc finger ZF)", "PROBLEM", 750, 798], ["Y domain regions Y1", "PROBLEM", 800, 819], ["coronavirus", "PROBLEM", 824, 835], ["large", "OBSERVATION_MODIFIER", 680, 685]]], ["In panel C, grey boxes show regions of apparent homology between coronavirus nsp3 and the equivalent proteins of Arteriviridae (Arteri), Mesoniviridae (Mesoni), Torovirinae including Bafinivirus (Toro), Ball python nidovirus (BPNV) and Bovine nidovirus-TCH5, and present in Arteriviridae but processed into separate polypeptides (Arteri*).", [["coronavirus", "ORGANISM", 65, 76], ["nsp3", "GENE_OR_GENE_PRODUCT", 77, 81], ["Arteriviridae", "GENE_OR_GENE_PRODUCT", 113, 126], ["Arteri", "GENE_OR_GENE_PRODUCT", 128, 134], ["Mesoniviridae", "GENE_OR_GENE_PRODUCT", 137, 150], ["Mesoni", "GENE_OR_GENE_PRODUCT", 152, 158], ["Torovirinae", "GENE_OR_GENE_PRODUCT", 161, 172], ["Bafinivirus", "GENE_OR_GENE_PRODUCT", 183, 194], ["Ball python nidovirus", "ORGANISM", 203, 224], ["BPNV", "GENE_OR_GENE_PRODUCT", 226, 230], ["Bovine", "ORGANISM", 236, 242], ["nidovirus", "GENE_OR_GENE_PRODUCT", 243, 252], ["TCH5", "GENE_OR_GENE_PRODUCT", 253, 257], ["Arteriviridae", "CANCER", 274, 287], ["coronavirus nsp3", "PROTEIN", 65, 81], ["BPNV", "PROTEIN", 226, 230], ["TCH5", "PROTEIN", 253, 257], ["Ball python nidovirus", "SPECIES", 203, 224], ["Bovine", "SPECIES", 236, 242], ["Ball python nidovirus", "SPECIES", 203, 224], ["BPNV", "SPECIES", 226, 230], ["Bovine nidovirus-TCH5", "SPECIES", 236, 257], ["grey boxes", "TEST", 12, 22], ["apparent homology between coronavirus nsp3", "PROBLEM", 39, 81], ["Arteriviridae (Arteri)", "TREATMENT", 113, 135], ["Mesoniviridae (Mesoni)", "TREATMENT", 137, 159], ["Torovirinae", "TREATMENT", 161, 172], ["Bafinivirus (Toro)", "TREATMENT", 183, 201], ["Ball python nidovirus", "TREATMENT", 203, 224], ["Bovine nidovirus", "TREATMENT", 236, 252], ["TCH5", "TREATMENT", 253, 257], ["Arteriviridae", "TREATMENT", 274, 287], ["coronavirus nsp3", "OBSERVATION", 65, 81]]], ["Percentage amino acid identity (%ID) was calculated between viruses in the same genus or in different genera.", [["amino acid", "CHEMICAL", 11, 21], ["amino acid", "CHEMICAL", 11, 21], ["amino acid", "AMINO_ACID", 11, 21], ["Percentage amino acid identity", "TEST", 0, 30], ["viruses", "PROBLEM", 60, 67]]], ["Average percent amino acid identity was calculated from 528 unique comparisons and plotted plus or minus standard deviation. activity of Mac1 was predicted to be due to His45 based on comparison with the homologous protein from yeast Ymx7, Archaeoglobus fulgidus AF1521 and Er58 from E. coli.", [["amino acid", "CHEMICAL", 16, 26], ["amino acid", "CHEMICAL", 16, 26], ["amino acid", "AMINO_ACID", 16, 26], ["Mac1", "GENE_OR_GENE_PRODUCT", 137, 141], ["His45", "GENE_OR_GENE_PRODUCT", 169, 174], ["Ymx7", "GENE_OR_GENE_PRODUCT", 234, 238], ["Archaeoglobus fulgidus AF1521", "ORGANISM", 240, 269], ["Er58", "GENE_OR_GENE_PRODUCT", 274, 278], ["E. coli", "ORGANISM", 284, 291], ["Mac1", "PROTEIN", 137, 141], ["His45", "PROTEIN", 169, 174], ["homologous protein", "PROTEIN", 204, 222], ["yeast Ymx7", "PROTEIN", 228, 238], ["AF1521", "PROTEIN", 263, 269], ["Er58", "PROTEIN", 274, 278], ["yeast", "SPECIES", 228, 233], ["Archaeoglobus fulgidus", "SPECIES", 240, 262], ["E. coli", "SPECIES", 284, 291], ["yeast", "SPECIES", 228, 233], ["Archaeoglobus fulgidus", "SPECIES", 240, 262], ["E. coli", "SPECIES", 284, 291], ["Average percent amino acid identity", "TEST", 0, 35], ["the homologous protein", "TEST", 200, 222], ["Archaeoglobus fulgidus", "PROBLEM", 240, 262], ["E. coli", "PROBLEM", 284, 291], ["amino acid", "OBSERVATION", 16, 26], ["standard deviation", "OBSERVATION", 105, 123], ["Archaeoglobus fulgidus", "OBSERVATION", 240, 262], ["E. coli", "OBSERVATION", 284, 291]]], ["The active site was verified by site directed mutagenesis data in the Human coronavirus 229E (HCoV-229E) Mac1, which suggested that the corresponding residues Asn37, Asn40, His45, Gly44 and Gly48 of SARS-CoV Mac1 are part of the active site (Putics et al., 2005) .", [["Asn37", "CHEMICAL", 159, 164], ["Asn40", "CHEMICAL", 166, 171], ["His45", "CHEMICAL", 173, 178], ["Gly44", "CHEMICAL", 180, 185], ["Gly48", "CHEMICAL", 190, 195], ["Human", "ORGANISM", 70, 75], ["coronavirus 229E", "ORGANISM", 76, 92], ["HCoV-229E) Mac1", "GENE_OR_GENE_PRODUCT", 94, 109], ["Asn37", "GENE_OR_GENE_PRODUCT", 159, 164], ["Asn40", "GENE_OR_GENE_PRODUCT", 166, 171], ["His45", "GENE_OR_GENE_PRODUCT", 173, 178], ["Gly44", "GENE_OR_GENE_PRODUCT", 180, 185], ["Gly48", "GENE_OR_GENE_PRODUCT", 190, 195], ["SARS-CoV Mac1", "GENE_OR_GENE_PRODUCT", 199, 212], ["Human coronavirus 229E (HCoV-229E) Mac1", "DNA", 70, 109], ["Asn37, Asn40, His45, Gly44 and Gly48 of SARS-CoV Mac1", "DNA", 159, 212], ["active site", "DNA", 229, 240], ["Human", "SPECIES", 70, 75], ["coronavirus", "SPECIES", 76, 87], ["Human coronavirus 229E (HCoV-229E)", "SPECIES", 70, 104], ["SARS-CoV", "SPECIES", 199, 207], ["the Human coronavirus", "TEST", 66, 87], ["HCoV", "TEST", 94, 98], ["Asn40", "TEST", 166, 171], ["His45", "TEST", 173, 178], ["Gly44", "TEST", 180, 185], ["SARS", "PROBLEM", 199, 203], ["CoV Mac1", "TREATMENT", 204, 212], ["active", "OBSERVATION_MODIFIER", 4, 10], ["active", "OBSERVATION_MODIFIER", 229, 235]]], ["Both the SARS-CoV ADRP and the HCoV-229E counterpart dephosphorylate ADP ribose 1'' phosphate to ADP-ribose in a highly specific manner, the enzyme having no detectable activity on several other nucleoside phosphates (Putics et al., 2005) .", [["SARS", "DISEASE", 9, 13], ["ADP ribose 1'' phosphate", "CHEMICAL", 69, 93], ["ADP-ribose", "CHEMICAL", 97, 107], ["nucleoside phosphates", "CHEMICAL", 195, 216], ["ADP ribose 1'' phosphate", "CHEMICAL", 69, 93], ["ADP", "CHEMICAL", 97, 100], ["ribose", "CHEMICAL", 101, 107], ["nucleoside phosphates", "CHEMICAL", 195, 216], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 9, 17], ["ADP ribose 1'' phosphate", "SIMPLE_CHEMICAL", 69, 93], ["ADP-ribose", "SIMPLE_CHEMICAL", 97, 107], ["nucleoside phosphates", "SIMPLE_CHEMICAL", 195, 216], ["SARS-CoV ADRP", "PROTEIN", 9, 22], ["HCoV-229E counterpart", "DNA", 31, 52], ["SARS-CoV", "SPECIES", 9, 17], ["the SARS", "TEST", 5, 13], ["CoV ADRP", "TEST", 14, 22], ["the HCoV", "TEST", 27, 35], ["dephosphorylate ADP ribose", "TREATMENT", 53, 79], ["phosphate to ADP", "TREATMENT", 84, 100], ["ribose", "TREATMENT", 101, 107], ["the enzyme", "TEST", 137, 147], ["nucleoside phosphates", "TREATMENT", 195, 216], ["SARS", "OBSERVATION", 9, 13], ["CoV ADRP", "OBSERVATION", 14, 22]]], ["Characterization of an ADP ribose 1 00 phosphatase-deficient HCoV-229E mutant revealed no significant effects on viral RNA synthesis and virus titer (Putics et al., 2005) , but mutation of the Mac1 active site altered MHV pathogenicity, suggesting that this domain may play an immunomodulatory role by interacting with unknown host factors .Nsp3 (Mac1 to DPUP)The existence of an ADRP-like domain in all CoV nsp3s (as well as in several other RNA viruses) suggests that ADP ribose phosphatase activity confers some sort of advantage to coronaviruses.", [["ADP", "CHEMICAL", 23, 26], ["ADP", "CHEMICAL", 470, 473], ["ribose", "CHEMICAL", 474, 480], ["ADP", "CHEMICAL", 23, 26], ["ribose", "CHEMICAL", 27, 33], ["ADP", "CHEMICAL", 470, 473], ["ribose", "CHEMICAL", 474, 480], ["ADP ribose 1 00", "GENE_OR_GENE_PRODUCT", 23, 38], ["HCoV", "GENE_OR_GENE_PRODUCT", 61, 65], ["Mac1", "GENE_OR_GENE_PRODUCT", 193, 197], ["MHV", "CANCER", 218, 221], ["Nsp3", "GENE_OR_GENE_PRODUCT", 341, 345], ["Mac1", "GENE_OR_GENE_PRODUCT", 347, 351], ["DPUP", "GENE_OR_GENE_PRODUCT", 355, 359], ["ADRP", "GENE_OR_GENE_PRODUCT", 380, 384], ["CoV nsp3s", "ORGANISM", 404, 413], ["ADP ribose phosphatase", "GENE_OR_GENE_PRODUCT", 470, 492], ["coronaviruses", "ORGANISM", 536, 549], ["ADP ribose 1 00 phosphatase", "PROTEIN", 23, 50], ["HCoV", "PROTEIN", 61, 65], ["229E mutant", "PROTEIN", 66, 77], ["viral RNA", "RNA", 113, 122], ["Mac1 active site", "DNA", 193, 209], ["host factors", "PROTEIN", 327, 339], ["Nsp3", "PROTEIN", 341, 345], ["Mac1", "PROTEIN", 347, 351], ["DPUP", "PROTEIN", 355, 359], ["ADRP-like domain", "PROTEIN", 380, 396], ["CoV nsp3s", "PROTEIN", 404, 413], ["ADP ribose phosphatase", "PROTEIN", 470, 492], ["MHV", "SPECIES", 218, 221], ["an ADP ribose", "TEST", 20, 33], ["phosphatase-deficient HCoV", "TEST", 39, 65], ["significant effects", "PROBLEM", 90, 109], ["viral RNA synthesis", "PROBLEM", 113, 132], ["virus titer", "TEST", 137, 148], ["altered MHV pathogenicity", "PROBLEM", 210, 235], ["Nsp3", "TEST", 341, 345], ["an ADRP-like domain", "PROBLEM", 377, 396], ["all CoV nsp3s", "TEST", 400, 413], ["several other RNA viruses", "PROBLEM", 429, 454], ["ADP ribose phosphatase activity", "PROBLEM", 470, 501], ["coronaviruses", "PROBLEM", 536, 549], ["no", "UNCERTAINTY", 87, 89], ["significant", "OBSERVATION_MODIFIER", 90, 101], ["viral RNA", "OBSERVATION", 113, 122], ["MHV pathogenicity", "OBSERVATION", 218, 235], ["ADRP", "OBSERVATION", 380, 384], ["ribose phosphatase", "OBSERVATION", 474, 492]]], ["Egloff et al. suggested that Mac1 may primarily be a poly-ADPribose binding (PAR-binding) module, rather than an ADP-ribose cleaving enzyme (Egloff et al., 2006) .", [["Mac1", "CHEMICAL", 29, 33], ["poly-ADPribose", "CHEMICAL", 53, 67], ["ADP", "CHEMICAL", 113, 116], ["poly-ADPribose", "CHEMICAL", 53, 67], ["ADP", "CHEMICAL", 113, 116], ["ribose", "CHEMICAL", 117, 123], ["Mac1", "GENE_OR_GENE_PRODUCT", 29, 33], ["poly-ADPribose", "SIMPLE_CHEMICAL", 53, 67], ["PAR", "GENE_OR_GENE_PRODUCT", 77, 80], ["ADP", "SIMPLE_CHEMICAL", 113, 116], ["Mac1", "PROTEIN", 29, 33], ["PAR", "PROTEIN", 77, 80], ["ADP-ribose cleaving enzyme", "PROTEIN", 113, 139], ["a poly-ADPribose binding (PAR-binding) module", "PROBLEM", 51, 96], ["an ADP", "TEST", 110, 116], ["ribose cleaving enzyme", "TEST", 117, 139]]], ["PARylation occurs when PAR polymerases are activated, often in compromised cells, to trigger apoptosis or DNA repair.", [["cells", "ANATOMY", 75, 80], ["PAR polymerases", "GENE_OR_GENE_PRODUCT", 23, 38], ["cells", "CELL", 75, 80], ["DNA", "CELLULAR_COMPONENT", 106, 109], ["PAR polymerases", "PROTEIN", 23, 38], ["PARylation", "TREATMENT", 0, 10], ["PAR polymerases", "PROBLEM", 23, 38], ["compromised cells", "PROBLEM", 63, 80], ["apoptosis", "PROBLEM", 93, 102], ["DNA repair", "TREATMENT", 106, 116], ["DNA repair", "OBSERVATION", 106, 116]]], ["Perhaps more relevant to coronavirus infection, the formation of cytoplasmic stress granules, which are aggregates of cellular stalled translation complexes, appears to be regulated by PARylation (Leung, 2014) .", [["cytoplasmic stress granules", "ANATOMY", 65, 92], ["cellular", "ANATOMY", 118, 126], ["coronavirus infection", "DISEASE", 25, 46], ["coronavirus", "ORGANISM", 25, 36], ["cytoplasmic", "ORGANISM_SUBSTANCE", 65, 76], ["stress granules", "CELLULAR_COMPONENT", 77, 92], ["cellular", "CELL", 118, 126], ["cellular stalled translation complexes", "PROTEIN", 118, 156], ["coronavirus", "SPECIES", 25, 36], ["coronavirus infection", "PROBLEM", 25, 46], ["cytoplasmic stress granules", "PROBLEM", 65, 92], ["coronavirus", "OBSERVATION_MODIFIER", 25, 36], ["infection", "OBSERVATION", 37, 46], ["cytoplasmic stress granules", "OBSERVATION", 65, 92], ["aggregates", "OBSERVATION_MODIFIER", 104, 114], ["cellular", "OBSERVATION_MODIFIER", 118, 126], ["stalled", "OBSERVATION_MODIFIER", 127, 134], ["translation complexes", "OBSERVATION", 135, 156], ["appears to be", "UNCERTAINTY", 158, 171]]], ["Further research is needed to determine whether coronavirus ADRP expression affects RNA granule formation or stability.", [["granule", "ANATOMY", 88, 95], ["coronavirus", "ORGANISM", 48, 59], ["ADRP", "GENE_OR_GENE_PRODUCT", 60, 64], ["ADRP", "PROTEIN", 60, 64], ["coronavirus", "SPECIES", 48, 59], ["coronavirus ADRP expression", "PROBLEM", 48, 75], ["RNA granule formation", "PROBLEM", 84, 105], ["stability", "OBSERVATION_MODIFIER", 109, 118]]], ["However, the Infectious bronchitis virus Mac1 does not have detectable ADP-ribose binding activity suggesting that Mac1 domains may have other important functions that are unrelated to ADP-ribose .Nsp3 (Mac1 to DPUP)In SARS-CoV Mac1 is followed by two more macrodomains (Chatterjee et al., 2009; Tan et al., 2009 ) that form part of the region that was originally called the SARS-CoV Unique Domain (SUD).", [["Infectious bronchitis virus", "DISEASE", 13, 40], ["ADP", "CHEMICAL", 71, 74], ["ribose", "CHEMICAL", 75, 81], ["ADP-ribose", "CHEMICAL", 185, 195], ["SARS", "DISEASE", 375, 379], ["SUD", "DISEASE", 399, 402], ["ADP", "CHEMICAL", 71, 74], ["ribose", "CHEMICAL", 75, 81], ["ADP", "CHEMICAL", 185, 188], ["ribose", "CHEMICAL", 189, 195], ["Infectious bronchitis virus", "ORGANISM", 13, 40], ["ADP", "SIMPLE_CHEMICAL", 71, 74], ["ribose", "SIMPLE_CHEMICAL", 75, 81], ["Mac1", "GENE_OR_GENE_PRODUCT", 115, 119], ["ADP-ribose", "SIMPLE_CHEMICAL", 185, 195], ["Nsp3", "GENE_OR_GENE_PRODUCT", 197, 201], ["Mac1 to DPUP)", "GENE_OR_GENE_PRODUCT", 203, 216], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 219, 227], ["Mac1 domains", "PROTEIN", 115, 127], ["Nsp3 (Mac1 to DPUP", "PROTEIN", 197, 215], ["SARS-CoV Mac1", "DNA", 219, 232], ["Infectious bronchitis virus", "SPECIES", 13, 40], ["SARS-CoV", "SPECIES", 219, 227], ["SARS-CoV", "SPECIES", 375, 383], ["the Infectious bronchitis virus Mac1", "PROBLEM", 9, 45], ["ribose binding activity", "PROBLEM", 75, 98], ["Mac1 domains", "PROBLEM", 115, 127], ["ADP-ribose", "TREATMENT", 185, 195], ["Nsp3", "TEST", 197, 201], ["SARS", "PROBLEM", 219, 223], ["CoV Mac1", "TEST", 224, 232], ["Infectious", "OBSERVATION_MODIFIER", 13, 23], ["bronchitis", "OBSERVATION", 24, 34], ["ribose binding activity", "OBSERVATION", 75, 98]]], ["However, in light of more recent structural evidence that the SUD contains not one but three distinct structural domains, and phylogenetic evidence that some SUD domains are not unique to SARS-CoV, a revision to the name of this region is necessary .", [["SUD", "DISEASE", 62, 65], ["SUD", "DISEASE", 158, 161], ["SARS", "DISEASE", 188, 192], ["SARS-CoV", "ORGANISM", 188, 196], ["structural domains", "PROTEIN", 102, 120], ["SUD domains", "DNA", 158, 169], ["SARS-CoV", "SPECIES", 188, 196], ["the SUD", "PROBLEM", 58, 65], ["some SUD domains", "PROBLEM", 153, 169], ["a revision", "TREATMENT", 198, 208]]], ["This region was originally divided into N-terminal and middle domains, which appear in the literature as SUD-N, SUD-M, but are here renamed as Mac2 and Mac3 to reflect their conservation outside SARS-CoV, followed by a small C-terminal domain known as DPUP for its position as the Domain Preceding Ub2 and PL2 pro .", [["SUD", "DISEASE", 105, 108], ["N", "CHEMICAL", 40, 41], ["C", "CHEMICAL", 225, 226], ["Mac2", "GENE_OR_GENE_PRODUCT", 143, 147], ["Mac3", "GENE_OR_GENE_PRODUCT", 152, 156], ["DPUP", "GENE_OR_GENE_PRODUCT", 252, 256], ["PL2 pro", "GENE_OR_GENE_PRODUCT", 306, 313], ["N-terminal and middle domains", "PROTEIN", 40, 69], ["Mac2", "PROTEIN", 143, 147], ["Mac3", "PROTEIN", 152, 156], ["small C-terminal domain", "PROTEIN", 219, 242], ["DPUP", "PROTEIN", 252, 256], ["Domain Preceding Ub2 and PL2 pro", "PROTEIN", 281, 313], ["SARS-CoV", "SPECIES", 195, 203], ["SUD", "TEST", 105, 108], ["a small C-terminal domain", "PROBLEM", 217, 242], ["PL2 pro", "TREATMENT", 306, 313], ["terminal", "ANATOMY_MODIFIER", 42, 50], ["middle domains", "ANATOMY_MODIFIER", 55, 69]]], ["The structure of both Mac2 and Mac3 is a close structural match for the SARS-CoV Mac1 domain despite a lack of detectable amino acid homology between these proteins (Tan et al., 2009) .", [["SARS", "DISEASE", 72, 76], ["amino acid", "CHEMICAL", 122, 132], ["amino acid", "CHEMICAL", 122, 132], ["Mac2", "GENE_OR_GENE_PRODUCT", 22, 26], ["Mac3", "GENE_OR_GENE_PRODUCT", 31, 35], ["amino acid", "AMINO_ACID", 122, 132], ["Mac2", "PROTEIN", 22, 26], ["Mac3", "PROTEIN", 31, 35], ["SARS-CoV Mac1 domain", "PROTEIN", 72, 92], ["SARS-CoV", "SPECIES", 72, 80], ["the SARS", "TEST", 68, 76], ["detectable amino acid homology", "PROBLEM", 111, 141], ["both", "ANATOMY_MODIFIER", 17, 21], ["Mac2", "ANATOMY", 22, 26]]], ["The presence of these additional macrodomain folds has also been confirmed by the NMR structure of the complete Mac2-Mac3-DPUP (Johnson et al., 2010) and the NMR structure of SUD-M (Chatterjee et al., 2009 ).", [["Mac2", "GENE_OR_GENE_PRODUCT", 112, 116], ["macrodomain folds", "PROTEIN", 33, 50], ["Mac2", "PROTEIN", 112, 116], ["Mac3", "PROTEIN", 117, 121], ["these additional macrodomain folds", "PROBLEM", 16, 50], ["macrodomain folds", "OBSERVATION", 33, 50]]], ["The SARS-CoV DPUP domain contains a novel fold that consists of an antiparallel beta sheet (Johnson et al., 2010) that was surprisingly also found in the corresponding region of MHV despite negligible evidence of homology based on alignment of amino acid sequences .Nsp3 (Mac1 to DPUP)All three of the domains that make up the SUD have been demonstrated to interact with nucleic acid in some way.", [["SARS", "DISEASE", 4, 8], ["amino acid", "CHEMICAL", 244, 254], ["SUD", "DISEASE", 327, 330], ["nucleic acid", "CHEMICAL", 371, 383], ["amino acid", "CHEMICAL", 244, 254], ["amino acid", "AMINO_ACID", 244, 254], ["Nsp3", "GENE_OR_GENE_PRODUCT", 266, 270], ["Mac1 to DPUP)", "GENE_OR_GENE_PRODUCT", 272, 285], ["SARS-CoV DPUP domain", "PROTEIN", 4, 24], ["antiparallel beta sheet", "PROTEIN", 67, 90], ["amino acid sequences", "PROTEIN", 244, 264], ["Nsp3", "PROTEIN", 266, 270], ["Mac1 to DPUP)", "PROTEIN", 272, 285], ["SARS-CoV", "SPECIES", 4, 12], ["MHV", "SPECIES", 178, 181], ["The SARS-CoV DPUP domain", "PROBLEM", 0, 24], ["a novel fold", "PROBLEM", 34, 46], ["alignment of amino acid sequences", "TEST", 231, 264], ["Nsp3", "TEST", 266, 270], ["nucleic acid", "TREATMENT", 371, 383], ["SARS", "OBSERVATION", 4, 8], ["MHV", "ANATOMY", 178, 181]]], ["Expressed Mac2-Mac3 has a high affinity for G-rich sequences and G-quadruplexes (Tan et al., 2009) , while the Mac3-DPUP showed a general preference for purine nucleotides (Johnson et al., 2010) .", [["purine", "CHEMICAL", 153, 159], ["purine nucleotides", "CHEMICAL", 153, 171], ["Mac2-Mac3", "GENE_OR_GENE_PRODUCT", 10, 19], ["G-quadruplexes", "SIMPLE_CHEMICAL", 65, 79], ["Mac3-DPUP", "GENE_OR_GENE_PRODUCT", 111, 120], ["purine nucleotides", "SIMPLE_CHEMICAL", 153, 171], ["Mac2", "PROTEIN", 10, 14], ["Mac3", "PROTEIN", 15, 19], ["G-rich sequences", "DNA", 44, 60], ["Mac3", "PROTEIN", 111, 115], ["DPUP", "PROTEIN", 116, 120], ["a high affinity", "PROBLEM", 24, 39], ["G-rich sequences", "TREATMENT", 44, 60], ["the Mac3", "TEST", 107, 115], ["purine nucleotides", "TREATMENT", 153, 171]]], ["Notably, while Mac2 and Mac3 domains bear a close structural resemblance to the SARS-CoV Mac1 ADRP domain, neither domain has any demonstrable affinity for ADP-ribose (Tan et al., 2009 ).", [["SARS", "DISEASE", 80, 84], ["ADP-ribose", "CHEMICAL", 156, 166], ["ADP", "CHEMICAL", 156, 159], ["ribose", "CHEMICAL", 160, 166], ["Mac2", "GENE_OR_GENE_PRODUCT", 15, 19], ["Mac3", "GENE_OR_GENE_PRODUCT", 24, 28], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 80, 88], ["ADP-ribose", "SIMPLE_CHEMICAL", 156, 166], ["Mac2", "PROTEIN", 15, 19], ["Mac3 domains", "PROTEIN", 24, 36], ["SARS-CoV Mac1 ADRP domain", "PROTEIN", 80, 105], ["SARS-CoV", "SPECIES", 80, 88], ["the SARS", "TEST", 76, 84], ["ADP", "TEST", 156, 159]]], ["The amino acid residues responsible for Mac3 and DPUP RNA binding have been mapped, and appear to fall near the region of Mac3 that corresponds to the active site in the structurally similar Mac1 domain (Chatterjee et al., 2009) .", [["amino acid", "CHEMICAL", 4, 14], ["amino acid", "CHEMICAL", 4, 14], ["amino acid", "AMINO_ACID", 4, 14], ["Mac3", "GENE_OR_GENE_PRODUCT", 40, 44], ["DPUP", "GENE_OR_GENE_PRODUCT", 49, 53], ["Mac3", "GENE_OR_GENE_PRODUCT", 122, 126], ["Mac3", "PROTEIN", 40, 44], ["Mac3", "PROTEIN", 122, 126], ["Mac1 domain", "PROTEIN", 191, 202], ["The amino acid residues", "TREATMENT", 0, 23], ["Mac3 and DPUP RNA binding", "PROBLEM", 40, 65], ["amino", "OBSERVATION", 4, 9], ["acid residues", "OBSERVATION", 10, 23], ["region", "ANATOMY_MODIFIER", 112, 118], ["active", "OBSERVATION_MODIFIER", 151, 157], ["site", "OBSERVATION_MODIFIER", 158, 162]]], ["Together this suggests that the cluster of three macrodomains in SARS-CoV nsp3 arose through gene duplication and that additional macrodomains may contribute to the function of nsp3 as an accessory to the viral replication process (Neuman et al., 2008) .", [["SARS", "DISEASE", 65, 69], ["SARS-CoV", "ORGANISM", 65, 73], ["nsp3", "GENE_OR_GENE_PRODUCT", 74, 78], ["nsp3", "GENE_OR_GENE_PRODUCT", 177, 181], ["SARS-CoV nsp3", "DNA", 65, 78], ["nsp3", "PROTEIN", 177, 181], ["SARS-CoV", "SPECIES", 65, 73], ["three macrodomains in SARS", "PROBLEM", 43, 69], ["CoV nsp3", "PROBLEM", 70, 78], ["gene duplication", "PROBLEM", 93, 109], ["additional macrodomains", "PROBLEM", 119, 142], ["nsp3", "PROBLEM", 177, 181], ["cluster", "OBSERVATION_MODIFIER", 32, 39], ["gene duplication", "OBSERVATION", 93, 109], ["viral replication", "OBSERVATION", 205, 222]]], ["Interestingly, in the context of a SARS-CoV infectious cDNA clone, Mac1 and Mac2 were dispensable but Mac3 was essential for RNA replication (Kusov et al., 2015) .Nsp3 (UB2 and PL2 pro )Unlike many coronaviruses that encode two papain-like proteases, SARS-CoV has a single copy of papain-like cysteine protease (PL2 pro ) that cleaves polyprotein 1a at three sites at the N-terminus to release nsp1, nsp2, and nsp3, respectively (Harcourt et al., 2004; Thiel et al., 2003) .", [["SARS", "DISEASE", 35, 39], ["cysteine", "CHEMICAL", 293, 301], ["N", "CHEMICAL", 372, 373], ["SARS-CoV", "ORGANISM", 35, 43], ["Mac1", "GENE_OR_GENE_PRODUCT", 67, 71], ["Mac2", "GENE_OR_GENE_PRODUCT", 76, 80], ["Mac3", "GENE_OR_GENE_PRODUCT", 102, 106], ["Nsp3", "GENE_OR_GENE_PRODUCT", 163, 167], ["UB2", "GENE_OR_GENE_PRODUCT", 169, 172], ["PL2", "GENE_OR_GENE_PRODUCT", 177, 180], ["papain", "GENE_OR_GENE_PRODUCT", 228, 234], ["SARS-CoV", "ORGANISM", 251, 259], ["papain-like cysteine protease", "GENE_OR_GENE_PRODUCT", 281, 310], ["PL2 pro", "GENE_OR_GENE_PRODUCT", 312, 319], ["polyprotein 1a", "GENE_OR_GENE_PRODUCT", 335, 349], ["nsp1", "GENE_OR_GENE_PRODUCT", 394, 398], ["nsp2", "GENE_OR_GENE_PRODUCT", 400, 404], ["nsp3", "GENE_OR_GENE_PRODUCT", 410, 414], ["SARS-CoV infectious cDNA clone", "DNA", 35, 65], ["Mac1", "PROTEIN", 67, 71], ["Mac2", "PROTEIN", 76, 80], ["Mac3", "PROTEIN", 102, 106], ["Nsp3", "PROTEIN", 163, 167], ["UB2", "PROTEIN", 169, 172], ["PL2 pro", "PROTEIN", 177, 184], ["papain-like proteases", "PROTEIN", 228, 249], ["SARS-CoV", "PROTEIN", 251, 259], ["papain", "PROTEIN", 281, 287], ["cysteine protease", "PROTEIN", 293, 310], ["PL2 pro", "PROTEIN", 312, 319], ["polyprotein 1a", "PROTEIN", 335, 349], ["N-terminus", "PROTEIN", 372, 382], ["nsp1", "PROTEIN", 394, 398], ["nsp2", "PROTEIN", 400, 404], ["nsp3", "PROTEIN", 410, 414], ["SARS-CoV", "SPECIES", 35, 43], ["SARS-CoV", "SPECIES", 251, 259], ["a SARS-CoV infectious cDNA clone", "PROBLEM", 33, 65], ["Mac1 and Mac2", "TREATMENT", 67, 80], ["RNA replication", "TREATMENT", 125, 140], ["Nsp3", "TEST", 163, 167], ["many coronaviruses", "PROBLEM", 193, 211], ["two papain", "TREATMENT", 224, 234], ["SARS", "PROBLEM", 251, 255], ["papain", "TREATMENT", 281, 287], ["cysteine protease (PL2 pro", "TREATMENT", 293, 319], ["coronaviruses", "OBSERVATION", 198, 211]]], ["However, another important role for SARS-CoV PL2 pro may be linked to its deubiquitinating activity; it efficiently disassembles diubiquitin and branched polyubiquitin chains, cleaves 7-amino-4-methylcoumarin-conjugated ubiquitin substrates, and has de-ISGylating activity Lindner et al., 2005) .", [["SARS", "DISEASE", 36, 40], ["7-amino-4-methylcoumarin", "CHEMICAL", 184, 208], ["7-amino-4-methylcoumarin", "CHEMICAL", 184, 208], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 36, 44], ["diubiquitin", "SIMPLE_CHEMICAL", 129, 140], ["7-amino-4-methylcoumarin", "SIMPLE_CHEMICAL", 184, 208], ["SARS-CoV PL2 pro", "PROTEIN", 36, 52], ["diubiquitin", "PROTEIN", 129, 140], ["branched polyubiquitin chains", "PROTEIN", 145, 174], ["SARS-CoV", "SPECIES", 36, 44], ["SARS", "PROBLEM", 36, 40], ["CoV PL2 pro", "TREATMENT", 41, 52], ["branched polyubiquitin chains", "TREATMENT", 145, 174], ["methylcoumarin-conjugated ubiquitin substrates", "TREATMENT", 194, 240]]], ["Thus, PL2 pro may have critical roles not only in proteolytic processing of the replicase complex but also in subverting cellular ubiquitination machinery to facilitate viral replication (Bailey-Elkin et al., 2014; Mielech et al., 2014 , as demonstrated for the arterivirus Equine arteritis virus (van Kasteren et al., 2013) .", [["cellular", "ANATOMY", 121, 129], ["Equine arteritis", "DISEASE", 274, 290], ["PL2 pro", "GENE_OR_GENE_PRODUCT", 6, 13], ["cellular", "CELL", 121, 129], ["arterivirus Equine arteritis virus", "ORGANISM", 262, 296], ["PL2 pro", "PROTEIN", 6, 13], ["replicase complex", "PROTEIN", 80, 97], ["Equine arteritis virus", "SPECIES", 274, 296], ["Equine arteritis virus", "SPECIES", 274, 296], ["the arterivirus Equine arteritis virus", "PROBLEM", 258, 296], ["viral replication", "OBSERVATION", 169, 186]]], ["PL2 pro is preceded by a second ubiquitin-like domain .", [["PL2", "GENE_OR_GENE_PRODUCT", 0, 3], ["PL2 pro", "PROTEIN", 0, 7], ["ubiquitin-like domain", "PROTEIN", 32, 53]]], ["The protease catalytic domain adopts the canonical \"thumb, palm and fingers\" domain architecture.", [["thumb", "ANATOMY", 52, 57], ["thumb", "ORGANISM_SUBDIVISION", 52, 57], ["palm", "ORGANISM_SUBDIVISION", 59, 63], ["protease catalytic domain", "PROTEIN", 4, 29], ["canonical \"thumb, palm and fingers\" domain", "PROTEIN", 41, 83], ["The protease catalytic domain", "TREATMENT", 0, 29], ["thumb", "ANATOMY", 52, 57], ["palm", "ANATOMY", 59, 63], ["fingers", "ANATOMY", 68, 75]]], ["Two beta-hairpins at the fingertips region contain four cysteine residues, which coordinate a zinc ion.", [["zinc", "CHEMICAL", 94, 98], ["cysteine", "CHEMICAL", 56, 64], ["zinc", "CHEMICAL", 94, 98], ["beta-hairpins", "GENE_OR_GENE_PRODUCT", 4, 17], ["cysteine", "AMINO_ACID", 56, 64], ["zinc ion", "SIMPLE_CHEMICAL", 94, 102], ["fingertips region", "DNA", 25, 42], ["Two beta-hairpins at the fingertips region", "PROBLEM", 0, 42], ["four cysteine residues", "PROBLEM", 51, 73], ["a zinc ion", "TREATMENT", 92, 102], ["fingertips", "ANATOMY", 25, 35], ["region", "ANATOMY_MODIFIER", 36, 42], ["four", "OBSERVATION_MODIFIER", 51, 55], ["cysteine residues", "OBSERVATION", 56, 73]]], ["Mutational analysis of the zinc-coordinating cysteines of SARS-CoV PL pro showed that zinc-binding ability is essential for structural integrity and protease activity (Barretto et al., 2005) .", [["zinc", "CHEMICAL", 27, 31], ["zinc", "CHEMICAL", 86, 90], ["zinc", "CHEMICAL", 27, 31], ["cysteines", "CHEMICAL", 45, 54], ["zinc", "CHEMICAL", 86, 90], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 58, 66], ["zinc", "SIMPLE_CHEMICAL", 86, 90], ["zinc-coordinating cysteines", "PROTEIN", 27, 54], ["SARS-CoV PL pro", "PROTEIN", 58, 73], ["protease", "PROTEIN", 149, 157], ["SARS-CoV", "SPECIES", 58, 66], ["Mutational analysis", "TEST", 0, 19], ["the zinc", "TEST", 23, 31], ["SARS", "PROBLEM", 58, 62], ["CoV PL pro", "TEST", 63, 73], ["zinc-binding ability", "PROBLEM", 86, 106]]], ["PL2 pro has several structural homologues from the cysteine protease superfamily that are cellular deubiquitinating enzymes.", [["cellular", "ANATOMY", 90, 98], ["cysteine", "CHEMICAL", 51, 59], ["PL2", "GENE_OR_GENE_PRODUCT", 0, 3], ["cellular", "CELL", 90, 98], ["PL2 pro", "PROTEIN", 0, 7], ["cysteine protease superfamily", "PROTEIN", 51, 80], ["cellular deubiquitinating enzymes", "PROTEIN", 90, 123], ["the cysteine protease superfamily", "TREATMENT", 47, 80], ["cellular deubiquitinating enzymes", "TEST", 90, 123]]], ["The active site of PL pro consists of a catalytic triad of cysteine, histidine, and aspartic acid residues, consistent with catalytic triads found in many PL pro domains.", [["cysteine", "CHEMICAL", 59, 67], ["histidine", "CHEMICAL", 69, 78], ["aspartic acid", "CHEMICAL", 84, 97], ["cysteine", "CHEMICAL", 59, 67], ["histidine", "CHEMICAL", 69, 78], ["aspartic acid", "CHEMICAL", 84, 97], ["cysteine", "AMINO_ACID", 59, 67], ["histidine", "AMINO_ACID", 69, 78], ["aspartic acid", "AMINO_ACID", 84, 97], ["PL pro", "PROTEIN", 19, 25], ["PL pro domains", "PROTEIN", 155, 169], ["a catalytic triad of cysteine", "TREATMENT", 38, 67], ["histidine", "TREATMENT", 69, 78], ["aspartic acid residues", "PROBLEM", 84, 106], ["catalytic triads", "PROBLEM", 124, 140], ["active", "OBSERVATION_MODIFIER", 4, 10], ["acid residues", "OBSERVATION", 93, 106], ["consistent with", "UNCERTAINTY", 108, 123], ["catalytic triads", "OBSERVATION", 124, 140]]], ["Comparison of the SARS-CoV PL2 pro structure with the structure of TGEV PL1 pro demonstrates that the coronavirus-like PL pro folds have a common architecture (Wojdyla et al., 2010) , and likely arose through gene duplication.Nsp3 (UB2 and PL2 pro )It has been demonstrated that an L/I X G G motif at the (precleavage) P4eP1 positions of the substrate is essential for recognition and cleavage by Betacoronavirus PL2 pro (Barretto et al., 2005; Han et al., 2005) .", [["SARS", "DISEASE", 18, 22], ["TGEV", "ORGANISM", 67, 71], ["coronavirus", "ORGANISM", 102, 113], ["Nsp3", "GENE_OR_GENE_PRODUCT", 226, 230], ["UB2", "GENE_OR_GENE_PRODUCT", 232, 235], ["G G", "GENE_OR_GENE_PRODUCT", 288, 291], ["TGEV PL1 pro", "PROTEIN", 67, 79], ["Nsp3", "PROTEIN", 226, 230], ["UB2", "PROTEIN", 232, 235], ["PL2 pro", "PROTEIN", 240, 247], ["L/I X G G motif", "DNA", 282, 297], ["SARS-CoV", "SPECIES", 18, 26], ["TGEV", "SPECIES", 67, 71], ["the SARS", "TEST", 14, 22], ["TGEV PL1 pro", "TEST", 67, 79], ["the coronavirus", "PROBLEM", 98, 113], ["Nsp3", "TEST", 226, 230], ["an L/I X G G motif at the (precleavage)", "TREATMENT", 279, 318], ["coronavirus", "OBSERVATION", 102, 113], ["gene duplication", "OBSERVATION", 209, 225]]], ["There appear to be no preferences for the postcleavage positions or for residues before P4.", [["appear to be", "UNCERTAINTY", 6, 18]]], ["It is not surprising then that SARS-CoV PL pro is able to cleave after the four C-terminal residues of ubiquitin, LRGG.", [["SARS", "DISEASE", 31, 35], ["C", "CHEMICAL", 80, 81], ["SARS-CoV", "ORGANISM", 31, 39], ["ubiquitin", "GENE_OR_GENE_PRODUCT", 103, 112], ["LRGG", "GENE_OR_GENE_PRODUCT", 114, 118], ["C-terminal residues", "PROTEIN", 80, 99], ["ubiquitin", "PROTEIN", 103, 112], ["LRGG", "PROTEIN", 114, 118], ["SARS-CoV", "SPECIES", 31, 39], ["SARS", "PROBLEM", 31, 35], ["the four C-terminal residues of ubiquitin", "PROBLEM", 71, 112], ["not surprising", "UNCERTAINTY", 6, 20]]], ["As predicted , SARS-CoV PL2 pro possesses de-ubiquitinating activity Lindner et al., 2005) in addition to cysteine protease activity involved in viral polyprotein processing.", [["SARS", "DISEASE", 15, 19], ["cysteine", "CHEMICAL", 106, 114], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 15, 23], ["cysteine protease", "GENE_OR_GENE_PRODUCT", 106, 123], ["SARS-CoV PL2 pro", "PROTEIN", 15, 31], ["cysteine protease", "PROTEIN", 106, 123], ["SARS-CoV", "SPECIES", 15, 23], ["SARS", "PROBLEM", 15, 19], ["cysteine protease activity", "TREATMENT", 106, 132], ["viral polyprotein processing", "TREATMENT", 145, 173], ["viral polyprotein", "OBSERVATION", 145, 162]]], ["The specific deubiquitinating enzyme inhibitor, ubiquitin aldehyde, inhibited its activity at a K i of 210 nM .Nsp3 (UB2 and PL2 pro )Interestingly, a number of cellular deubiquitinases, including full-length USP14 and Ubp6, possess an N-terminal ubiquitin-like domain.", [["cellular", "ANATOMY", 161, 169], ["ubiquitin aldehyde", "CHEMICAL", 48, 66], ["K", "CHEMICAL", 96, 97], ["aldehyde", "CHEMICAL", 58, 66], ["N", "CHEMICAL", 236, 237], ["ubiquitin aldehyde", "SIMPLE_CHEMICAL", 48, 66], ["Nsp3", "GENE_OR_GENE_PRODUCT", 111, 115], ["UB2", "GENE_OR_GENE_PRODUCT", 117, 120], ["PL2 pro", "GENE_OR_GENE_PRODUCT", 125, 132], ["cellular", "CELL", 161, 169], ["USP14", "GENE_OR_GENE_PRODUCT", 209, 214], ["Ubp6", "GENE_OR_GENE_PRODUCT", 219, 223], ["Nsp3", "PROTEIN", 111, 115], ["UB2", "PROTEIN", 117, 120], ["PL2 pro", "PROTEIN", 125, 132], ["cellular deubiquitinases", "PROTEIN", 161, 185], ["USP14", "PROTEIN", 209, 214], ["Ubp6", "PROTEIN", 219, 223], ["N-terminal ubiquitin-like domain", "PROTEIN", 236, 268], ["The specific deubiquitinating enzyme inhibitor", "TREATMENT", 0, 46], ["ubiquitin aldehyde", "TREATMENT", 48, 66], ["Nsp3", "TEST", 111, 115], ["cellular deubiquitinases", "TEST", 161, 185], ["Ubp6", "TEST", 219, 223], ["ubiquitin aldehyde", "OBSERVATION", 48, 66], ["cellular deubiquitinases", "OBSERVATION", 161, 185], ["terminal ubiquitin", "OBSERVATION", 238, 256]]], ["Although the significance of this domain in these proteins is not well established, it has been demonstrated that the presence of the ubiquitin-like domain in USP14 and Ubp6 serves a regulatory function by mediating interactions between these deubiquitinases and specific components of the proteasome (Hu et al., 2005; Leggett et al., 2002) .", [["USP14", "GENE_OR_GENE_PRODUCT", 159, 164], ["Ubp6", "GENE_OR_GENE_PRODUCT", 169, 173], ["deubiquitinases", "GENE_OR_GENE_PRODUCT", 243, 258], ["ubiquitin-like domain", "PROTEIN", 134, 155], ["USP14", "PROTEIN", 159, 164], ["Ubp6", "PROTEIN", 169, 173], ["deubiquitinases", "PROTEIN", 243, 258], ["proteasome", "PROTEIN", 290, 300], ["this domain in these proteins", "PROBLEM", 29, 58], ["the ubiquitin-like domain in USP14", "PROBLEM", 130, 164], ["the proteasome", "TREATMENT", 286, 300]]], ["Comparisons of deubiquitinase activities between wild-type and mutant Ubp6 lacking the ubiquitin-like domain reveal that these associations are responsible for a 300-fold increase in catalytic rate and serve to activate the enzyme (Leggett et al., 2002) .", [["deubiquitinase", "GENE_OR_GENE_PRODUCT", 15, 29], ["Ubp6", "GENE_OR_GENE_PRODUCT", 70, 74], ["ubiquitin", "GENE_OR_GENE_PRODUCT", 87, 96], ["deubiquitinase", "PROTEIN", 15, 29], ["mutant Ubp6", "PROTEIN", 63, 74], ["ubiquitin-like domain", "PROTEIN", 87, 108], ["deubiquitinase activities", "TEST", 15, 40], ["a 300-fold increase in catalytic rate", "TREATMENT", 160, 197], ["the enzyme", "TEST", 220, 230]]], ["It is intriguing to consider whether the ubiquitin-like domain of PL pro may have a similar function.Nsp3 (UB2 and PL2 pro )While the role of PL2 pro in polyprotein processing is well understood, the physiological significance of its deubiquitinating activity in the viral replication cycle is still not completely clear.", [["PL pro", "GENE_OR_GENE_PRODUCT", 66, 72], ["Nsp3", "GENE_OR_GENE_PRODUCT", 101, 105], ["UB2", "GENE_OR_GENE_PRODUCT", 107, 110], ["PL2", "GENE_OR_GENE_PRODUCT", 142, 145], ["ubiquitin-like domain", "PROTEIN", 41, 62], ["PL pro", "PROTEIN", 66, 72], ["Nsp3", "PROTEIN", 101, 105], ["UB2", "PROTEIN", 107, 110], ["PL2 pro", "PROTEIN", 115, 122], ["PL2 pro", "PROTEIN", 142, 149], ["the ubiquitin-like domain of PL pro", "PROBLEM", 37, 72], ["Nsp3", "TEST", 101, 105], ["PL2 pro in polyprotein processing", "TREATMENT", 142, 175], ["the viral replication cycle", "TEST", 263, 290], ["deubiquitinating activity", "OBSERVATION", 234, 259], ["viral replication", "OBSERVATION", 267, 284], ["clear", "OBSERVATION", 315, 320]]], ["However the conserved structural protein E is readily ubiquitinated in infected cells, suggesting that control of ubiquitination may be important for SARS-CoV assembly (Alvarez et al., 2010) .", [["cells", "ANATOMY", 80, 85], ["E", "GENE_OR_GENE_PRODUCT", 41, 42], ["cells", "CELL", 80, 85], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 150, 158], ["conserved structural protein E", "PROTEIN", 12, 42], ["infected cells", "CELL_TYPE", 71, 85], ["SARS-CoV", "SPECIES", 150, 158], ["infected cells", "PROBLEM", 71, 85], ["SARS", "PROBLEM", 150, 154], ["protein E", "OBSERVATION", 33, 42], ["ubiquitinated", "OBSERVATION_MODIFIER", 54, 67], ["infected cells", "OBSERVATION", 71, 85]]], ["Mounting evidence suggests that PL2 pro interferes with interferon transcriptional activation pathways by inactivating TBK1, blocking NF-kappaB signaling and preventing translocation of IRF3 to the nucleus (Frieman et al., 2009; Wang et al., 2011; Zheng et al., 2008) .", [["nucleus", "ANATOMY", 198, 205], ["PL2 pro", "GENE_OR_GENE_PRODUCT", 32, 39], ["interferon", "GENE_OR_GENE_PRODUCT", 56, 66], ["TBK1", "GENE_OR_GENE_PRODUCT", 119, 123], ["NF-kappaB", "GENE_OR_GENE_PRODUCT", 134, 143], ["IRF3", "GENE_OR_GENE_PRODUCT", 186, 190], ["nucleus", "CELLULAR_COMPONENT", 198, 205], ["PL2 pro", "PROTEIN", 32, 39], ["interferon", "PROTEIN", 56, 66], ["TBK1", "PROTEIN", 119, 123], ["NF-kappaB", "PROTEIN", 134, 143], ["IRF3", "PROTEIN", 186, 190], ["PL2 pro", "PROBLEM", 32, 39], ["interferon transcriptional activation pathways", "TREATMENT", 56, 102], ["blocking NF", "TREATMENT", 125, 136], ["IRF3", "OBSERVATION", 186, 190], ["nucleus", "ANATOMY", 198, 205]]], ["In agreement with this proposed function, an arterivirus PL2 pro was shown to play an important role in immune evasion (van Kasteren et al., 2013) .Nsp3 (NAB to CoVeY)The region between the PL2 pro domain and the transmembrane region of nsp3 does not show obvious sequence similarity to any known domain that would give a clue to its function.", [["transmembrane region", "ANATOMY", 213, 233], ["PL2", "GENE_OR_GENE_PRODUCT", 57, 60], ["Nsp3", "GENE_OR_GENE_PRODUCT", 148, 152], ["NAB to CoVeY", "GENE_OR_GENE_PRODUCT", 154, 166], ["transmembrane", "CELLULAR_COMPONENT", 213, 226], ["nsp3", "GENE_OR_GENE_PRODUCT", 237, 241], ["arterivirus PL2 pro", "PROTEIN", 45, 64], ["Nsp3", "PROTEIN", 148, 152], ["CoVeY", "PROTEIN", 161, 166], ["PL2 pro domain", "PROTEIN", 190, 204], ["transmembrane region", "PROTEIN", 213, 233], ["nsp3", "PROTEIN", 237, 241], ["an arterivirus PL2 pro", "TREATMENT", 42, 64], ["Nsp3", "PROBLEM", 148, 152], ["the PL2 pro domain", "TREATMENT", 186, 204], ["nsp3", "PROBLEM", 237, 241]]], ["However, a NMR structural study revealed that the nucleic acid binding (NAB) domain is an independently folded unit capable of binding RNA with relatively high affinity, and with duplex-unwinding activity reminiscent of an RNA chaperone (Neuman et al., 2008) .", [["nucleic acid", "CHEMICAL", 50, 62], ["nucleic acid binding (NAB) domain", "PROTEIN", 50, 83], ["binding RNA", "RNA", 127, 138], ["RNA chaperone", "PROTEIN", 223, 236], ["a NMR structural study", "TEST", 9, 31], ["the nucleic acid binding", "PROBLEM", 46, 70], ["binding RNA", "PROBLEM", 127, 138], ["relatively high affinity", "PROBLEM", 144, 168], ["duplex", "TEST", 179, 185], ["binding RNA", "OBSERVATION", 127, 138], ["high affinity", "OBSERVATION", 155, 168]]], ["The NAB, along with several other domains of nsp3 has been demonstrated to form homodimers upon incubation at 37 C (Neuman et al., 2008) by perfluorooctanoic acid polyacrylamide gel electrophoresis.", [["nsp3", "CHEMICAL", 45, 49], ["perfluorooctanoic acid", "CHEMICAL", 140, 162], ["perfluorooctanoic acid polyacrylamide", "CHEMICAL", 140, 177], ["NAB", "GENE_OR_GENE_PRODUCT", 4, 7], ["nsp3", "GENE_OR_GENE_PRODUCT", 45, 49], ["perfluorooctanoic acid", "SIMPLE_CHEMICAL", 140, 162], ["NAB", "PROTEIN", 4, 7], ["nsp3", "PROTEIN", 45, 49], ["homodimers", "PROTEIN", 80, 90], ["The NAB", "TREATMENT", 0, 7], ["nsp3", "PROBLEM", 45, 49], ["perfluorooctanoic acid polyacrylamide gel electrophoresis", "TREATMENT", 140, 197], ["nsp3", "OBSERVATION", 45, 49]]], ["Little else is known about the function of NAB in the viral replication cycle, or about the structure and function of the betacoronavirus-specific marker (bSM) domain that follows or the conserved hydrophobic, non-transmembrane region that immediately precedes the first transmembrane region of nsp3.Nsp3 (NAB to CoVeY)The region from the first transmembrane helix to the carboxyl terminus of nsp3 was originally annotated as the Y-domain (Gorbalenya et al., 1991) , in the sense that it followed the X-domain that we now refer to as Mac1.", [["transmembrane", "ANATOMY", 271, 284], ["transmembrane", "ANATOMY", 345, 358], ["CoVeY", "CHEMICAL", 313, 318], ["carboxyl", "CHEMICAL", 372, 380], ["NAB", "GENE_OR_GENE_PRODUCT", 43, 46], ["transmembrane", "CELLULAR_COMPONENT", 271, 284], ["nsp3", "GENE_OR_GENE_PRODUCT", 295, 299], ["Nsp3", "GENE_OR_GENE_PRODUCT", 300, 304], ["NAB to CoVeY", "GENE_OR_GENE_PRODUCT", 306, 318], ["nsp3", "GENE_OR_GENE_PRODUCT", 393, 397], ["Mac1", "GENE_OR_GENE_PRODUCT", 534, 538], ["NAB", "PROTEIN", 43, 46], ["betacoronavirus-specific marker (bSM) domain", "PROTEIN", 122, 166], ["non-transmembrane region", "PROTEIN", 210, 234], ["transmembrane region", "PROTEIN", 271, 291], ["nsp3", "PROTEIN", 295, 299], ["Nsp3", "PROTEIN", 300, 304], ["CoVeY", "PROTEIN", 313, 318], ["carboxyl terminus", "PROTEIN", 372, 389], ["nsp3", "PROTEIN", 393, 397], ["X-domain", "DNA", 501, 509], ["Mac1", "PROTEIN", 534, 538], ["the betacoronavirus", "TEST", 118, 137], ["the conserved hydrophobic, non-transmembrane region", "PROBLEM", 183, 234], ["nsp3", "PROBLEM", 295, 299], ["Nsp3", "PROBLEM", 300, 304], ["nsp3", "PROBLEM", 393, 397], ["viral replication", "OBSERVATION", 54, 71], ["hydrophobic", "OBSERVATION_MODIFIER", 197, 208], ["nsp3", "OBSERVATION", 295, 299]]], ["We have subdivided this region into two transmembrane regions, an ectodomain (3Ecto), a widelyconserved initial domain (Y1), and an apparently coronavirusspecific carboxyl-terminal domain (CoVeY).", [["transmembrane", "ANATOMY", 40, 53], ["carboxyl", "CHEMICAL", 163, 171], ["transmembrane regions", "PROTEIN", 40, 61], ["ectodomain", "PROTEIN", 66, 76], ["3Ecto", "PROTEIN", 78, 83], ["widelyconserved initial domain", "PROTEIN", 88, 118], ["Y1", "PROTEIN", 120, 122], ["coronavirusspecific carboxyl-terminal domain", "PROTEIN", 143, 187], ["CoVeY", "PROTEIN", 189, 194], ["an apparently coronavirusspecific carboxyl", "TREATMENT", 129, 171], ["transmembrane", "ANATOMY_MODIFIER", 40, 53], ["regions", "ANATOMY_MODIFIER", 54, 61]]], ["No protein structures are available at this time for any part of the Y-domain, and the domain assignment in this region may change as new structures appear.", [["protein structures", "PROBLEM", 3, 21], ["protein structures", "OBSERVATION", 3, 21]]], ["A Fold and Function Annotation System search (FFAS; (Jaroszewski et al., 2005) ) using the sequence from the SARS-CoV NAB to the end of nsp3 reveals three of seven significant hits (with expect values of \u00c08 or better) to viral RNA-dependent RNA polymerase proteins, which may hint at the evolutionary origin of nsp3, which comprises nearly one fifth of most coronavirus genomes.", [["SARS", "DISEASE", 109, 113], ["nsp3", "GENE_OR_GENE_PRODUCT", 136, 140], ["nsp3", "GENE_OR_GENE_PRODUCT", 311, 315], ["coronavirus", "ORGANISM", 358, 369], ["SARS-CoV NAB", "DNA", 109, 121], ["nsp3", "DNA", 136, 140], ["viral RNA", "RNA", 221, 230], ["RNA polymerase proteins", "PROTEIN", 241, 264], ["nsp3", "DNA", 311, 315], ["coronavirus genomes", "DNA", 358, 377], ["SARS-CoV", "SPECIES", 109, 117], ["the sequence", "TEST", 87, 99], ["the SARS", "TEST", 105, 113], ["CoV NAB", "TEST", 114, 121], ["seven significant hits", "PROBLEM", 158, 180], ["viral RNA", "TEST", 221, 230], ["dependent RNA polymerase proteins", "PROBLEM", 231, 264], ["nsp3", "PROBLEM", 311, 315], ["significant", "OBSERVATION_MODIFIER", 164, 175], ["hits", "OBSERVATION", 176, 180], ["nsp3", "OBSERVATION", 311, 315], ["coronavirus genomes", "OBSERVATION", 358, 377]]], ["The level of conservation in the Y1 domain in particular approaches levels consistent with the other enzymatic domains of nsp3, and exceeds the conservation of other domains that are believed to be non-enzymatic (Neuman et al., 2008) , but the function and structure of this region remain to be explored (Fig. 5) .", [["nsp3", "GENE_OR_GENE_PRODUCT", 122, 126], ["Y1 domain", "PROTEIN", 33, 42], ["enzymatic domains", "PROTEIN", 101, 118], ["nsp3", "PROTEIN", 122, 126], ["the other enzymatic domains of nsp3", "PROBLEM", 91, 126], ["consistent with", "UNCERTAINTY", 75, 90], ["nsp3", "OBSERVATION", 122, 126], ["believed to be", "UNCERTAINTY", 183, 197]]], ["The 3Ecto, Y1 and CoVeY domains are highly conserved in all CoVs, but this region has not been structurally characterized yet.", [["3Ecto", "GENE_OR_GENE_PRODUCT", 4, 9], ["Y1", "GENE_OR_GENE_PRODUCT", 11, 13], ["CoVeY", "GENE_OR_GENE_PRODUCT", 18, 23], ["CoVs", "GENE_OR_GENE_PRODUCT", 60, 64], ["3Ecto, Y1 and CoVeY domains", "DNA", 4, 31], ["CoVs", "DNA", 60, 64], ["all CoVs", "OBSERVATION", 56, 64]]], ["An Fold and Function Annotation System search (FFAS; (Jaroszewski et al., 2005) ) using the sequence from the SARS-CoV NAB to the end of nsp3 reveals three of seven significant hits (with expect values of \u00c08 or better) to viral RdRp proteins, which may hint at the evolutionary origin of nsp3, which comprises nearly one fifth of most coronavirus genomes.", [["SARS", "DISEASE", 110, 114], ["nsp3", "GENE_OR_GENE_PRODUCT", 137, 141], ["nsp3", "GENE_OR_GENE_PRODUCT", 288, 292], ["coronavirus", "ORGANISM", 335, 346], ["SARS-CoV NAB", "DNA", 110, 122], ["nsp3", "DNA", 137, 141], ["viral RdRp proteins", "PROTEIN", 222, 241], ["nsp3", "DNA", 288, 292], ["coronavirus genomes", "DNA", 335, 354], ["SARS-CoV", "SPECIES", 110, 118], ["the sequence", "TEST", 88, 100], ["the SARS", "TEST", 106, 114], ["CoV NAB", "TEST", 115, 122], ["seven significant hits", "PROBLEM", 159, 181], ["viral RdRp proteins", "PROBLEM", 222, 241], ["nsp3", "PROBLEM", 288, 292], ["significant", "OBSERVATION_MODIFIER", 165, 176], ["hits", "OBSERVATION", 177, 181], ["viral RdRp", "OBSERVATION", 222, 232], ["nsp3", "OBSERVATION", 288, 292], ["coronavirus genomes", "OBSERVATION", 335, 354]]], ["The level of conservation in the Y1 domain in particular approaches levels consistent with the other enzymatic domains of nsp3, and exceeds the conservation of other domains that are believed to be non-enzymatic (Neuman et al., 2008) , but the function and structure of this region remain to be explored (Fig. 3 ).Nsp3 (NAB to CoVeY)It appears that domains from PL2 pro to the CoVeY domain have not undergone significant deletion or rearrangement during coronavirus evolution, while other nsps like nsp1, nsp2, and the Nterminal regions of nsp3 clearly have evolved by duplication and deletion of domains (Neuman et al., 2008 (Neuman et al., , 2014b .", [["nsp3", "GENE_OR_GENE_PRODUCT", 122, 126], ["Nsp3", "GENE_OR_GENE_PRODUCT", 314, 318], ["NAB to CoVeY", "GENE_OR_GENE_PRODUCT", 320, 332], ["PL2 pro", "GENE_OR_GENE_PRODUCT", 362, 369], ["CoVeY", "GENE_OR_GENE_PRODUCT", 377, 382], ["nsps", "GENE_OR_GENE_PRODUCT", 489, 493], ["nsp1", "GENE_OR_GENE_PRODUCT", 499, 503], ["nsp2", "GENE_OR_GENE_PRODUCT", 505, 509], ["Nterminal", "GENE_OR_GENE_PRODUCT", 519, 528], ["nsp3", "GENE_OR_GENE_PRODUCT", 540, 544], ["Y1 domain", "PROTEIN", 33, 42], ["enzymatic domains", "PROTEIN", 101, 118], ["nsp3", "PROTEIN", 122, 126], ["Nsp3", "PROTEIN", 314, 318], ["CoVeY", "PROTEIN", 327, 332], ["PL2 pro", "PROTEIN", 362, 369], ["CoVeY domain", "DNA", 377, 389], ["nsps", "DNA", 489, 493], ["nsp1", "DNA", 499, 503], ["nsp2", "DNA", 505, 509], ["Nterminal regions", "DNA", 519, 536], ["nsp3", "DNA", 540, 544], ["the other enzymatic domains of nsp3", "PROBLEM", 91, 126], ["Nsp3", "PROBLEM", 314, 318], ["PL2 pro", "TREATMENT", 362, 369], ["significant deletion", "PROBLEM", 409, 429], ["coronavirus evolution", "PROBLEM", 454, 475], ["nsp1", "PROBLEM", 499, 503], ["nsp2", "PROBLEM", 505, 509], ["the Nterminal regions of nsp3", "PROBLEM", 515, 544], ["duplication and deletion of domains", "PROBLEM", 569, 604], ["consistent with", "UNCERTAINTY", 75, 90], ["nsp3", "OBSERVATION", 122, 126], ["believed to be", "UNCERTAINTY", 183, 197], ["significant", "OBSERVATION_MODIFIER", 409, 420], ["deletion", "OBSERVATION", 421, 429], ["nsp1", "OBSERVATION", 499, 503], ["nsp2", "OBSERVATION", 505, 509], ["nsp3", "OBSERVATION", 540, 544], ["duplication", "OBSERVATION", 569, 580]]], ["The C-terminal portion of nsp3 has been shown to change the localization of nsp4 (Hagemeijer et al., 2011) , and cause a membrane proliferation phenotype in transfected cells (Angelini et al., 2013) .", [["membrane", "ANATOMY", 121, 129], ["cells", "ANATOMY", 169, 174], ["nsp3", "CHEMICAL", 26, 30], ["nsp3", "GENE_OR_GENE_PRODUCT", 26, 30], ["nsp4", "GENE_OR_GENE_PRODUCT", 76, 80], ["membrane", "CELLULAR_COMPONENT", 121, 129], ["cells", "CELL", 169, 174], ["C-terminal portion", "PROTEIN", 4, 22], ["nsp3", "PROTEIN", 26, 30], ["nsp4", "PROTEIN", 76, 80], ["transfected cells", "CELL_LINE", 157, 174], ["The C-terminal portion of nsp3", "PROBLEM", 0, 30], ["nsp4", "PROBLEM", 76, 80], ["a membrane proliferation phenotype in transfected cells", "PROBLEM", 119, 174], ["nsp3", "OBSERVATION", 26, 30], ["membrane proliferation", "OBSERVATION", 121, 143], ["transfected cells", "OBSERVATION", 157, 174]]], ["The topology of nsp3 leaves only one domain, annotated here as the ectodomain of nsp3, or 3Ecto, on the luminal side of the membrane.", [["luminal", "ANATOMY", 104, 111], ["membrane", "ANATOMY", 124, 132], ["luminal", "CHEMICAL", 104, 111], ["nsp3", "GENE_OR_GENE_PRODUCT", 16, 20], ["nsp3", "GENE_OR_GENE_PRODUCT", 81, 85], ["3Ecto", "GENE_OR_GENE_PRODUCT", 90, 95], ["membrane", "CELLULAR_COMPONENT", 124, 132], ["nsp3", "PROTEIN", 16, 20], ["ectodomain", "PROTEIN", 67, 77], ["nsp3", "PROTEIN", 81, 85], ["3Ecto", "PROTEIN", 90, 95], ["nsp3", "PROBLEM", 16, 20], ["nsp3", "PROBLEM", 81, 85], ["nsp3", "OBSERVATION", 81, 85], ["luminal", "ANATOMY_MODIFIER", 104, 111], ["membrane", "ANATOMY_MODIFIER", 124, 132]]], ["If nsp3 participates directly in the membrane pairing exhibited in cells transfected with SARS-CoV nsp3 and nsp4 (Angelini et al., 2013) , then the 3Ecto domain likely helps mediate membrane pairing directly.", [["membrane", "ANATOMY", 37, 45], ["cells", "ANATOMY", 67, 72], ["membrane", "ANATOMY", 182, 190], ["nsp3", "GENE_OR_GENE_PRODUCT", 3, 7], ["membrane", "CELLULAR_COMPONENT", 37, 45], ["cells", "CELL", 67, 72], ["SARS-CoV nsp3", "GENE_OR_GENE_PRODUCT", 90, 103], ["nsp4", "GENE_OR_GENE_PRODUCT", 108, 112], ["membrane", "CELLULAR_COMPONENT", 182, 190], ["nsp3", "PROTEIN", 3, 7], ["SARS-CoV nsp3", "PROTEIN", 90, 103], ["3Ecto domain", "DNA", 148, 160], ["SARS-CoV", "SPECIES", 90, 98], ["nsp3", "PROBLEM", 3, 7], ["SARS", "PROBLEM", 90, 94], ["nsp4", "PROBLEM", 108, 112], ["the 3Ecto domain", "TREATMENT", 144, 160]]], ["We previously noted that a cluster of cysteine and histidine residues in 3Ecto may coordinate a metal ion, but analysis of newly sequenced viruses shows that the Cys-His cluster is not conserved in all coronaviruses, hence this domain has been renamed in the annotation presented here.Nsp4Nsp4 is a transmembrane protein with four transmembrane helices and a cytosolic C-terminal domain (Oostra et al., 2007) .", [["transmembrane", "ANATOMY", 299, 312], ["transmembrane", "ANATOMY", 331, 344], ["cytosolic", "ANATOMY", 359, 368], ["cysteine", "CHEMICAL", 38, 46], ["histidine", "CHEMICAL", 51, 60], ["cysteine", "CHEMICAL", 38, 46], ["histidine", "CHEMICAL", 51, 60], ["Cys", "CHEMICAL", 162, 165], ["His", "CHEMICAL", 166, 169], ["C", "CHEMICAL", 369, 370], ["cysteine", "AMINO_ACID", 38, 46], ["histidine", "AMINO_ACID", 51, 60], ["3Ecto", "AMINO_ACID", 73, 78], ["Nsp4Nsp4", "GENE_OR_GENE_PRODUCT", 285, 293], ["transmembrane", "CELLULAR_COMPONENT", 299, 312], ["Cys-His cluster", "PROTEIN", 162, 177], ["Nsp4Nsp4", "PROTEIN", 285, 293], ["transmembrane protein", "PROTEIN", 299, 320], ["transmembrane helices", "PROTEIN", 331, 352], ["cytosolic C-terminal domain", "PROTEIN", 359, 386], ["cysteine and histidine residues", "TREATMENT", 38, 69], ["a metal ion", "PROBLEM", 94, 105], ["newly sequenced viruses", "PROBLEM", 123, 146], ["the Cys", "TEST", 158, 165], ["all coronaviruses", "PROBLEM", 198, 215], ["a transmembrane protein", "TEST", 297, 320], ["four transmembrane helices", "TREATMENT", 326, 352], ["histidine residues", "OBSERVATION", 51, 69]]], ["Coronavirus nsp4 is approximately 500 amino acid residues in length, and is the only part of the viral polyprotein that is released after processing by both the PL pro and M pro .", [["amino acid", "CHEMICAL", 38, 48], ["amino acid", "CHEMICAL", 38, 48], ["nsp4", "GENE_OR_GENE_PRODUCT", 12, 16], ["amino acid", "AMINO_ACID", 38, 48], ["Coronavirus nsp4", "PROTEIN", 0, 16], ["viral polyprotein", "PROTEIN", 97, 114], ["PL pro and M pro", "PROTEIN", 161, 177], ["Coronavirus nsp4", "PROBLEM", 0, 16], ["amino acid residues in length", "PROBLEM", 38, 67], ["the viral polyprotein", "PROBLEM", 93, 114], ["viral polyprotein", "OBSERVATION", 97, 114]]], ["The location and topology of the four transmembrane regions has been mapped (Oostra et al., 2007) , but only the C-terminal portion of nsp4 appears to be conserved throughout the Nidovirales (Fig. 6) .Nsp4The C-terminal domain of nsp4 is conserved in all known coronaviruses, but deletion of this domain including the fourth transmembrane helix from a MHV infectious clone resulted in only slightly attenuated growth, consistent with a non-essential function (Sparks et al., 2007) .", [["transmembrane", "ANATOMY", 38, 51], ["C", "CHEMICAL", 113, 114], ["nsp4", "GENE_OR_GENE_PRODUCT", 135, 139], ["Nsp4", "GENE_OR_GENE_PRODUCT", 201, 205], ["nsp4", "GENE_OR_GENE_PRODUCT", 230, 234], ["coronaviruses", "ORGANISM", 261, 274], ["transmembrane regions", "PROTEIN", 38, 59], ["C-terminal portion", "PROTEIN", 113, 131], ["nsp4", "PROTEIN", 135, 139], ["Nidovirales", "PROTEIN", 179, 190], ["Nsp4", "PROTEIN", 201, 205], ["C-terminal domain", "PROTEIN", 209, 226], ["nsp4", "PROTEIN", 230, 234], ["fourth transmembrane helix", "PROTEIN", 318, 344], ["MHV", "SPECIES", 352, 355], ["nsp4", "PROBLEM", 135, 139], ["The C-terminal domain of nsp4", "PROBLEM", 205, 234], ["all known coronaviruses", "PROBLEM", 251, 274], ["deletion of this domain", "PROBLEM", 280, 303], ["the fourth transmembrane helix", "PROBLEM", 314, 344], ["a MHV infectious clone", "PROBLEM", 350, 372], ["slightly attenuated growth", "PROBLEM", 390, 416], ["nsp4", "OBSERVATION", 135, 139], ["appears to be", "UNCERTAINTY", 140, 153], ["nsp4", "OBSERVATION", 230, 234], ["coronaviruses", "OBSERVATION", 261, 274], ["MHV", "OBSERVATION_MODIFIER", 352, 355], ["infectious", "OBSERVATION", 356, 366], ["slightly", "OBSERVATION_MODIFIER", 390, 398], ["attenuated", "OBSERVATION_MODIFIER", 399, 409], ["growth", "OBSERVATION_MODIFIER", 410, 416], ["consistent with", "UNCERTAINTY", 418, 433], ["non-essential function", "OBSERVATION", 436, 458]]], ["It is somewhat surprising that the C-terminal domain of nsp4 is dispensible for replication since other nidoviruses with the exception of the Mesoniviridae contain a domain at this position with a similar predicted structure (V' Kovski et al., 2015) .", [["C", "CHEMICAL", 35, 36], ["nsp4", "GENE_OR_GENE_PRODUCT", 56, 60], ["nidoviruses", "CANCER", 104, 115], ["Mesoniviridae", "GENE_OR_GENE_PRODUCT", 142, 155], ["C-terminal domain", "PROTEIN", 35, 52], ["nsp4", "PROTEIN", 56, 60], ["Mesoniviridae", "DNA", 142, 155], ["the C-terminal domain of nsp4", "PROBLEM", 31, 60], ["the Mesoniviridae", "TREATMENT", 138, 155], ["nsp4", "OBSERVATION", 56, 60]]], ["Mutation of the two glycosylation sites in nsp4, however, led to defective DMV formation and attenuation (Gadlage et al., 2010) .", [["nsp4", "GENE_OR_GENE_PRODUCT", 43, 47], ["DMV", "SIMPLE_CHEMICAL", 75, 78], ["glycosylation sites", "PROTEIN", 20, 39], ["nsp4", "PROTEIN", 43, 47], ["Mutation of the two glycosylation sites", "PROBLEM", 0, 39], ["nsp4", "PROBLEM", 43, 47], ["defective DMV formation", "PROBLEM", 65, 88], ["glycosylation sites", "OBSERVATION", 20, 39], ["nsp4", "OBSERVATION", 43, 47], ["defective DMV", "OBSERVATION", 65, 78], ["attenuation", "OBSERVATION_MODIFIER", 93, 104]]], ["The structure of the C-terminal 4Endo domain of Feline coronavirus has been reported.", [["Feline coronavirus", "DISEASE", 48, 66], ["Feline coronavirus", "ORGANISM", 48, 66], ["C-terminal 4Endo domain", "PROTEIN", 21, 44], ["Feline coronavirus", "SPECIES", 48, 66], ["Feline coronavirus", "SPECIES", 48, 66], ["Feline coronavirus", "PROBLEM", 48, 66], ["Feline coronavirus", "OBSERVATION", 48, 66]]], ["4Endo consists of two small antiparallel beta-sheets and four alpha-helices , and is highly conserved among coronaviruses at the amino acid level (Fig. 6) .Nsp4SARS-CoV Nsp4 is an essential component for the formation of viral double-membrane vesicles (Angelini et al., 2013) .", [["double-membrane vesicles", "ANATOMY", 227, 251], ["amino acid", "CHEMICAL", 129, 139], ["amino acid", "CHEMICAL", 129, 139], ["coronaviruses", "ORGANISM", 108, 121], ["amino acid", "AMINO_ACID", 129, 139], ["Nsp4SARS-CoV", "GENE_OR_GENE_PRODUCT", 156, 168], ["membrane vesicles", "CELLULAR_COMPONENT", 234, 251], ["4Endo", "PROTEIN", 0, 5], ["antiparallel beta-sheets", "PROTEIN", 28, 52], ["alpha-helices", "PROTEIN", 62, 75], ["Nsp4SARS", "PROTEIN", 156, 164], ["CoV Nsp4", "PROTEIN", 165, 173], ["two small antiparallel beta-sheets", "TREATMENT", 18, 52], ["the amino acid level", "TEST", 125, 145], ["Nsp4SARS", "TEST", 156, 164], ["CoV Nsp4", "PROBLEM", 165, 173], ["viral double-membrane vesicles", "PROBLEM", 221, 251], ["two", "OBSERVATION_MODIFIER", 18, 21], ["small", "OBSERVATION_MODIFIER", 22, 27], ["antiparallel", "OBSERVATION_MODIFIER", 28, 40], ["CoV Nsp4", "OBSERVATION", 165, 173], ["essential", "OBSERVATION_MODIFIER", 180, 189], ["component", "OBSERVATION_MODIFIER", 190, 199], ["viral double", "OBSERVATION", 221, 233], ["membrane vesicles", "OBSERVATION", 234, 251]]], ["Intracellular expression studies have demonstrated a biological interaction between the carboxyl-terminal region of MHV nsp3 and nsp4 (Hagemeijer et al., 2011) , and co-expression of full-length SARS-CoV nsp3 and nsp4 results in extensive membrane pairing, in which the paired membranes are held at the same distance as observed in authentic DMVs (Angelini et al., 2013) .", [["Intracellular", "ANATOMY", 0, 13], ["membrane", "ANATOMY", 239, 247], ["membranes", "ANATOMY", 277, 286], ["carboxyl", "CHEMICAL", 88, 96], ["Intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 0, 13], ["MHV", "ORGANISM", 116, 119], ["nsp3", "GENE_OR_GENE_PRODUCT", 120, 124], ["nsp4", "GENE_OR_GENE_PRODUCT", 129, 133], ["SARS-CoV nsp3", "GENE_OR_GENE_PRODUCT", 195, 208], ["nsp4", "GENE_OR_GENE_PRODUCT", 213, 217], ["membrane", "CELLULAR_COMPONENT", 239, 247], ["membranes", "CELLULAR_COMPONENT", 277, 286], ["carboxyl-terminal region", "PROTEIN", 88, 112], ["MHV nsp3", "PROTEIN", 116, 124], ["nsp4", "PROTEIN", 129, 133], ["full-length SARS-CoV nsp3", "PROTEIN", 183, 208], ["nsp4", "PROTEIN", 213, 217], ["Intracellular expression studies", "TEST", 0, 32], ["nsp4", "PROBLEM", 129, 133], ["full-length SARS", "PROBLEM", 183, 199], ["CoV nsp3", "TEST", 200, 208], ["nsp4", "PROBLEM", 213, 217], ["extensive membrane pairing", "TREATMENT", 229, 255], ["MHV nsp3", "OBSERVATION", 116, 124], ["extensive", "OBSERVATION_MODIFIER", 229, 238], ["membrane pairing", "OBSERVATION", 239, 255]]], ["Nsp4 has also been shown to interact with nsp2 in a yeast two-hybrid screen (von Brunn et al., 2007) , and to interact with other nsp4 molecules in cells (Hagemeijer et al., 2011) .", [["cells", "ANATOMY", 148, 153], ["Nsp4", "CHEMICAL", 0, 4], ["Nsp4", "GENE_OR_GENE_PRODUCT", 0, 4], ["nsp2", "GENE_OR_GENE_PRODUCT", 42, 46], ["nsp4", "GENE_OR_GENE_PRODUCT", 130, 134], ["cells", "CELL", 148, 153], ["Nsp4", "PROTEIN", 0, 4], ["nsp2", "PROTEIN", 42, 46], ["nsp4 molecules", "PROTEIN", 130, 144], ["yeast", "SPECIES", 52, 57], ["yeast", "SPECIES", 52, 57], ["Nsp4", "PROBLEM", 0, 4], ["nsp2", "PROBLEM", 42, 46]]], ["Mutagenesis of the 4Ecto domain of nsp4 has been shown to cause aberrant DMV formation upon mutation, leading to a loss of nsp4 glycosylation (Gadlage et al., 2010; Sparks et al., 2007) .Nsp5Coronavirus nsp5 is also known as the main protease (M pro ), a chymotrypsin-like protease related to the enteroviral 3C protease.", [["nsp4", "CHEMICAL", 35, 39], ["nsp4", "GENE_OR_GENE_PRODUCT", 35, 39], ["DMV", "SIMPLE_CHEMICAL", 73, 76], ["nsp4", "GENE_OR_GENE_PRODUCT", 123, 127], ["Nsp5Coronavirus", "GENE_OR_GENE_PRODUCT", 187, 202], ["nsp5", "GENE_OR_GENE_PRODUCT", 203, 207], ["M pro", "GENE_OR_GENE_PRODUCT", 244, 249], ["chymotrypsin", "GENE_OR_GENE_PRODUCT", 255, 267], ["enteroviral 3C protease", "GENE_OR_GENE_PRODUCT", 297, 320], ["4Ecto domain", "PROTEIN", 19, 31], ["nsp4", "PROTEIN", 35, 39], ["nsp4", "PROTEIN", 123, 127], ["Nsp5Coronavirus nsp5", "PROTEIN", 187, 207], ["protease", "PROTEIN", 234, 242], ["M pro", "PROTEIN", 244, 249], ["chymotrypsin-like protease", "PROTEIN", 255, 281], ["enteroviral 3C protease", "PROTEIN", 297, 320], ["nsp4", "PROBLEM", 35, 39], ["aberrant DMV formation upon mutation", "PROBLEM", 64, 100], ["a loss of nsp4 glycosylation", "PROBLEM", 113, 141], ["Nsp5Coronavirus nsp5", "PROBLEM", 187, 207], ["a chymotrypsin-like protease", "PROBLEM", 253, 281], ["the enteroviral 3C protease", "TREATMENT", 293, 320], ["shown to cause", "UNCERTAINTY", 49, 63], ["aberrant", "OBSERVATION_MODIFIER", 64, 72], ["DMV", "OBSERVATION", 73, 76]]], ["It belongs to the C30 family of endopeptidases and is responsible for cleavage at 11 sequence specific sites within polyprotein 1a/1ab.", [["endopeptidases", "GENE_OR_GENE_PRODUCT", 32, 46], ["C30 family", "PROTEIN", 18, 28], ["endopeptidases", "PROTEIN", 32, 46], ["polyprotein 1a/1ab", "DNA", 116, 134], ["endopeptidases", "PROBLEM", 32, 46], ["cleavage", "PROBLEM", 70, 78]]], ["The resultant \"mature\" protein products (nsp4 to nsp16) assemble into components of the replication complexes (reviewed in (Hilgenfeld et al., 2006; Ziebuhr et al., 2000) ).", [["nsp4", "GENE_OR_GENE_PRODUCT", 41, 45], ["nsp16", "GENE_OR_GENE_PRODUCT", 49, 54], ["protein products", "PROTEIN", 23, 39], ["nsp4", "PROTEIN", 41, 45], ["nsp16", "PROTEIN", 49, 54], ["replication complexes", "PROTEIN", 88, 109], ["The resultant \"mature\" protein products", "TREATMENT", 0, 39]]], ["M pro is one of only three parts of the coronavirus replicase, along with the nsp12 polymerase and nsp13 helicase regions, that is conserved throughout the Nidovirales (Lauber et al., 2013) .Nsp5Based on both structure and sequence characteristics, nsp5 can be divided into three domains: a two-domain active region (Dom I and II) and a third domain that plays a role in nsp5 dimerization (Dom III; (Yang et al., 2003) ).", [["M pro", "GENE_OR_GENE_PRODUCT", 0, 5], ["coronavirus", "ORGANISM", 40, 51], ["nsp12 polymerase", "GENE_OR_GENE_PRODUCT", 78, 94], ["nsp13", "GENE_OR_GENE_PRODUCT", 99, 104], ["Nsp5Based", "GENE_OR_GENE_PRODUCT", 191, 200], ["nsp5", "GENE_OR_GENE_PRODUCT", 249, 253], ["nsp5", "GENE_OR_GENE_PRODUCT", 371, 375], ["M pro", "PROTEIN", 0, 5], ["coronavirus replicase", "PROTEIN", 40, 61], ["nsp12 polymerase", "PROTEIN", 78, 94], ["nsp13 helicase regions", "PROTEIN", 99, 121], ["Nsp5Based", "PROTEIN", 191, 200], ["nsp5", "PROTEIN", 249, 253], ["two-domain active region", "PROTEIN", 291, 315], ["Dom I and II", "PROTEIN", 317, 329], ["third domain", "PROTEIN", 337, 349], ["nsp5", "PROTEIN", 371, 375], ["Dom III", "PROTEIN", 390, 397], ["the coronavirus replicase", "PROBLEM", 36, 61], ["the nsp12 polymerase", "PROBLEM", 74, 94], ["nsp13 helicase regions", "PROBLEM", 99, 121], ["a two-domain active region", "PROBLEM", 289, 315], ["a third domain", "PROBLEM", 335, 349], ["coronavirus replicase", "OBSERVATION", 40, 61]]], ["The three-domain architecture is conserved in all coronaviruses, all nidoviral groups and several other RNA viruses that share a common polyprotein processing scheme (Ziebuhr et al., 2000) .", [["several other RNA viruses", "PROBLEM", 90, 115], ["all coronaviruses", "ANATOMY", 46, 63], ["RNA viruses", "OBSERVATION", 104, 115]]], ["The sequence is related to chymotrypsin-like protease superfamily of endopeptidases (Murzin et al., 1995) .", [["chymotrypsin-like protease", "GENE_OR_GENE_PRODUCT", 27, 53], ["chymotrypsin-like protease superfamily", "PROTEIN", 27, 65], ["endopeptidases", "PROTEIN", 69, 83], ["chymotrypsin", "TREATMENT", 27, 39]]], ["The three-domain architecture is conserved in all coronaviruses, all nidoviral groups and several other RNA viruses that share a common polyprotein processing scheme (Ziebuhr et al., 2000) .", [["several other RNA viruses", "PROBLEM", 90, 115], ["all coronaviruses", "ANATOMY", 46, 63], ["RNA viruses", "OBSERVATION", 104, 115]]], ["The sequence is related to chymotrypsin-like protease superfamily of endopeptidases.Nsp5The critical role of the first seven residues at the N terminus in dimerization and its close proximity to the active site results in this enzyme to be an obligate dimer (Anand et al., 2002) , although modification of the termini appears to modulate higher order oligomerization (Zhang et al., 2010) .", [["N", "CHEMICAL", 141, 142], ["chymotrypsin-like protease", "GENE_OR_GENE_PRODUCT", 27, 53], ["Nsp5", "GENE_OR_GENE_PRODUCT", 84, 88], ["chymotrypsin-like protease superfamily", "PROTEIN", 27, 65], ["endopeptidases", "PROTEIN", 69, 83], ["Nsp5", "PROTEIN", 84, 88], ["N terminus", "PROTEIN", 141, 151], ["enzyme", "PROTEIN", 227, 233], ["chymotrypsin", "PROBLEM", 27, 39], ["endopeptidases", "PROBLEM", 69, 83], ["this enzyme", "TEST", 222, 233], ["an obligate dimer", "PROBLEM", 240, 257], ["modification of the termini", "PROBLEM", 290, 317], ["active", "OBSERVATION_MODIFIER", 199, 205]]], ["Deletion of the first five amino acid residues results in complete inactivation of this enzyme.", [["amino acid", "CHEMICAL", 27, 37], ["amino acid", "CHEMICAL", 27, 37], ["amino acid", "AMINO_ACID", 27, 37], ["enzyme", "PROTEIN", 88, 94], ["Deletion of the first five amino acid residues", "PROBLEM", 0, 46], ["this enzyme", "TEST", 83, 94]]], ["The helical C-terminal domain III mediates homodimerization of coronaviral M pro proteases.", [["C", "CHEMICAL", 12, 13], ["helical C-terminal domain III", "PROTEIN", 4, 33], ["coronaviral M pro proteases", "PROTEIN", 63, 90], ["The helical C-terminal domain III mediates", "TREATMENT", 0, 42], ["coronaviral M pro proteases", "TREATMENT", 63, 90]]], ["This interaction is believed to be important for its trans-proteolytic activity.", [["believed to be", "UNCERTAINTY", 20, 34]]], ["The active site is located at the interface of the two beta-barrels with the catalytic residues H51 and C145 being contributed by domains 1 and 2 respectively in the SARS-CoV M pro .Nsp5As part of its proteolytic activity, M pro is destined to interact with all the non-structural proteins from nsp4 to nsp16, presumably near its catalytic site.", [["SARS", "DISEASE", 166, 170], ["C145", "AMINO_ACID", 104, 108], ["M pro", "GENE_OR_GENE_PRODUCT", 223, 228], ["nsp4", "GENE_OR_GENE_PRODUCT", 295, 299], ["nsp16", "GENE_OR_GENE_PRODUCT", 303, 308], ["beta-barrels", "PROTEIN", 55, 67], ["catalytic residues", "PROTEIN", 77, 95], ["C145", "PROTEIN", 104, 108], ["domains 1 and 2", "PROTEIN", 130, 145], ["SARS-CoV M pro", "PROTEIN", 166, 180], ["Nsp5As part", "PROTEIN", 182, 193], ["non-structural proteins", "PROTEIN", 266, 289], ["nsp4", "PROTEIN", 295, 299], ["nsp16", "PROTEIN", 303, 308], ["catalytic site", "PROTEIN", 330, 344], ["SARS-CoV", "SPECIES", 166, 174], ["The active site", "PROBLEM", 0, 15], ["the catalytic residues H51", "PROBLEM", 73, 99], ["the SARS", "PROBLEM", 162, 170], ["active", "OBSERVATION_MODIFIER", 4, 10], ["site", "OBSERVATION_MODIFIER", 11, 15], ["catalytic residues", "OBSERVATION", 77, 95]]], ["Interestingly, comparison of all the known sites where mutation can lead to a temperature-sensitive, RNA-negative phenotype suggests a close connection to M pro (Fig. 7) .", [["M pro", "PROTEIN", 155, 160], ["mutation", "PROBLEM", 55, 63], ["a temperature", "TEST", 76, 89], ["RNA", "TEST", 101, 104]]], ["To date, the only proteins where temperature-sensitive mutations have been discovered are nsp3, nsp5, nsp10, nsp12, nsp14 and nsp16 (Al-Mulla et al., 2014; Sawicki et al., 2005; Stokes et al., 2010) , all of which make fewer or smaller DMVs compared to wild-type virus (Al-Mulla et al., 2014) .", [["nsp3", "GENE_OR_GENE_PRODUCT", 90, 94], ["nsp5", "GENE_OR_GENE_PRODUCT", 96, 100], ["nsp10", "GENE_OR_GENE_PRODUCT", 102, 107], ["nsp12", "GENE_OR_GENE_PRODUCT", 109, 114], ["nsp14", "GENE_OR_GENE_PRODUCT", 116, 121], ["nsp16", "GENE_OR_GENE_PRODUCT", 126, 131], ["DMVs", "GENE_OR_GENE_PRODUCT", 236, 240], ["wild-type virus", "ORGANISM", 253, 268], ["nsp3", "PROTEIN", 90, 94], ["nsp5", "PROTEIN", 96, 100], ["nsp10", "PROTEIN", 102, 107], ["nsp12", "PROTEIN", 109, 114], ["nsp14", "PROTEIN", 116, 121], ["nsp16", "PROTEIN", 126, 131], ["temperature", "TEST", 33, 44], ["sensitive mutations", "PROBLEM", 45, 64], ["nsp3", "TEST", 90, 94], ["nsp5", "TEST", 96, 100], ["nsp10", "TEST", 102, 107], ["nsp12", "TEST", 109, 114], ["nsp14", "TEST", 116, 121], ["nsp16", "TEST", 126, 131], ["smaller DMVs", "PROBLEM", 228, 240], ["type virus", "PROBLEM", 258, 268], ["smaller", "OBSERVATION_MODIFIER", 228, 235]]], ["Nsp10 interacts with nsp5 directly (Imbert et al., 2008) , and both nsp10 and nsp3 mutations paradoxically inhibit M pro activity (Donaldson et al., 2007; Stokes et al., 2010) .", [["Nsp10", "GENE_OR_GENE_PRODUCT", 0, 5], ["nsp5", "GENE_OR_GENE_PRODUCT", 21, 25], ["nsp10", "GENE_OR_GENE_PRODUCT", 68, 73], ["nsp3", "GENE_OR_GENE_PRODUCT", 78, 82], ["M pro", "GENE_OR_GENE_PRODUCT", 115, 120], ["Nsp10", "PROTEIN", 0, 5], ["nsp5", "PROTEIN", 21, 25], ["nsp10", "PROTEIN", 68, 73]]], ["One interactome study showed that nsp12 and nsp14 also directly interact with nsp5 (Pan et al., 2008) , and nsp14 and 16 would also indirectly interact with nsp5 as part of the nsp10-14-16 complex (Bouvet et al., 2010; Decroly et al., 2011; Imbert et al., 2008; Pan et al., 2008) .", [["nsp12", "GENE_OR_GENE_PRODUCT", 34, 39], ["nsp14", "GENE_OR_GENE_PRODUCT", 44, 49], ["nsp5", "GENE_OR_GENE_PRODUCT", 78, 82], ["nsp14", "GENE_OR_GENE_PRODUCT", 108, 113], ["16", "GENE_OR_GENE_PRODUCT", 118, 120], ["nsp5", "GENE_OR_GENE_PRODUCT", 157, 161], ["nsp10", "GENE_OR_GENE_PRODUCT", 177, 182], ["nsp12", "PROTEIN", 34, 39], ["nsp14", "PROTEIN", 44, 49], ["nsp5", "PROTEIN", 78, 82], ["nsp14", "PROTEIN", 108, 113], ["16", "PROTEIN", 118, 120], ["nsp5", "PROTEIN", 157, 161], ["nsp10-14-16 complex", "PROTEIN", 177, 196], ["One interactome study", "TEST", 0, 21], ["nsp12", "TEST", 34, 39], ["the nsp10", "TEST", 173, 182]]], ["Together this suggests that nsp5 plays a critical role in both RNA replication and DMV formation, likely by proteolytically releasing nsp4 and nsp6.Nsp6Nsp6 has six transmembrane regions, with both termini located on the cytosolic side of the membrane .", [["transmembrane", "ANATOMY", 165, 178], ["cytosolic", "ANATOMY", 221, 230], ["membrane", "ANATOMY", 243, 251], ["nsp5", "CHEMICAL", 28, 32], ["nsp5", "GENE_OR_GENE_PRODUCT", 28, 32], ["DMV", "SIMPLE_CHEMICAL", 83, 86], ["nsp4", "GENE_OR_GENE_PRODUCT", 134, 138], ["nsp6", "GENE_OR_GENE_PRODUCT", 143, 147], ["Nsp6Nsp6", "GENE_OR_GENE_PRODUCT", 148, 156], ["membrane", "CELLULAR_COMPONENT", 243, 251], ["nsp5", "PROTEIN", 28, 32], ["nsp4", "PROTEIN", 134, 138], ["nsp6", "PROTEIN", 143, 147], ["Nsp6Nsp6", "PROTEIN", 148, 156], ["transmembrane regions", "PROTEIN", 165, 186], ["both RNA replication", "TREATMENT", 58, 78], ["DMV formation", "PROBLEM", 83, 96], ["RNA replication", "OBSERVATION", 63, 78], ["six", "OBSERVATION_MODIFIER", 161, 164], ["transmembrane", "OBSERVATION_MODIFIER", 165, 178], ["regions", "ANATOMY_MODIFIER", 179, 186], ["both", "ANATOMY_MODIFIER", 193, 197], ["termini", "ANATOMY_MODIFIER", 198, 205], ["cytosolic side", "ANATOMY_MODIFIER", 221, 235], ["membrane", "ANATOMY_MODIFIER", 243, 251]]], ["Although most coronavirus nsp6 proteins are predicted by TMHMM2.0 (Krogh et al., 2001) to contain seven transmembrane regions, only six of these function as membrane-spanning helices.", [["transmembrane", "ANATOMY", 104, 117], ["membrane", "ANATOMY", 157, 165], ["coronavirus", "ORGANISM", 14, 25], ["nsp6", "GENE_OR_GENE_PRODUCT", 26, 30], ["membrane", "CELLULAR_COMPONENT", 157, 165], ["coronavirus nsp6 proteins", "PROTEIN", 14, 39], ["transmembrane regions", "PROTEIN", 104, 125], ["membrane-spanning helices", "PROTEIN", 157, 182], ["coronavirus", "SPECIES", 14, 25], ["most coronavirus nsp6 proteins", "TEST", 9, 39]]], ["The presence of additional non-transmembrane hydrophobic domains near authentic transmembrane domains is a common theme running through the DMO making proteins.", [["transmembrane", "ANATOMY", 80, 93], ["DMO", "CHEMICAL", 140, 143], ["DMO", "SIMPLE_CHEMICAL", 140, 143], ["non-transmembrane hydrophobic domains", "PROTEIN", 27, 64], ["transmembrane domains", "PROTEIN", 80, 101], ["DMO making proteins", "PROTEIN", 140, 159], ["additional non-transmembrane hydrophobic domains near authentic transmembrane domains", "PROBLEM", 16, 101], ["hydrophobic domains", "OBSERVATION", 45, 64], ["transmembrane domains", "OBSERVATION", 80, 101]]], ["IBV and SARS-CoV nsp6 have been shown to activate autophagy, inducing vesicles containing Atg5 and LC3-II (Cottam et al., 2011) .", [["vesicles", "ANATOMY", 70, 78], ["IBV", "ORGANISM", 0, 3], ["SARS-CoV nsp6", "GENE_OR_GENE_PRODUCT", 8, 21], ["vesicles", "CELLULAR_COMPONENT", 70, 78], ["Atg5", "GENE_OR_GENE_PRODUCT", 90, 94], ["LC3-II", "GENE_OR_GENE_PRODUCT", 99, 105], ["SARS-CoV nsp6", "PROTEIN", 8, 21], ["Atg5", "PROTEIN", 90, 94], ["LC3", "PROTEIN", 99, 102], ["IBV", "SPECIES", 0, 3], ["SARS-CoV", "SPECIES", 8, 16], ["IBV", "PROBLEM", 0, 3], ["SARS", "PROBLEM", 8, 12], ["CoV nsp6", "PROBLEM", 13, 21], ["Atg5", "TEST", 90, 94]]], ["MHV Nsp6 colocalizes with nsp4 when co-expressed (Hagemeijer et al., 2012) , suggesting that the two proteins may interact.", [["MHV", "ORGANISM", 0, 3], ["Nsp6", "GENE_OR_GENE_PRODUCT", 4, 8], ["nsp4", "GENE_OR_GENE_PRODUCT", 26, 30], ["MHV Nsp6", "PROTEIN", 0, 8], ["nsp4", "PROTEIN", 26, 30], ["MHV", "SPECIES", 0, 3], ["nsp4", "PROBLEM", 26, 30]]], ["SARS-CoV nsp6 has also been shown to interact with nsp2, nsp8, nsp9 and accessory protein 9b via yeast two-hybrid assays (von Brunn et al., 2007) .", [["SARS", "DISEASE", 0, 4], ["SARS-CoV nsp6", "GENE_OR_GENE_PRODUCT", 0, 13], ["nsp2", "GENE_OR_GENE_PRODUCT", 51, 55], ["nsp8", "GENE_OR_GENE_PRODUCT", 57, 61], ["nsp9", "GENE_OR_GENE_PRODUCT", 63, 67], ["accessory protein 9b", "GENE_OR_GENE_PRODUCT", 72, 92], ["SARS-CoV nsp6", "PROTEIN", 0, 13], ["nsp2", "PROTEIN", 51, 55], ["nsp8", "PROTEIN", 57, 61], ["nsp9", "PROTEIN", 63, 67], ["accessory protein 9b", "PROTEIN", 72, 92], ["yeast", "SPECIES", 97, 102], ["SARS-CoV", "SPECIES", 0, 8], ["nsp2", "TEST", 51, 55], ["nsp8", "TEST", 57, 61], ["accessory protein", "TEST", 72, 89]]], ["It is notable that both the 4Endo and 6Endo domains are nearly as well conserved in coronaviruses as the catalytic domain of M pro (Fig. 5) .Nsp6Overexpression of nsp6 disturbs intracellular membrane trafficking (Cottam et al., 2011) , resulting in an accumulation of singlemembrane vesicles around the microtubule organization complex (Angelini et al., 2013) .", [["intracellular membrane", "ANATOMY", 177, 199], ["singlemembrane vesicles", "ANATOMY", 268, 291], ["microtubule", "ANATOMY", 303, 314], ["4Endo", "GENE_OR_GENE_PRODUCT", 28, 33], ["6Endo", "GENE_OR_GENE_PRODUCT", 38, 43], ["nsp6", "GENE_OR_GENE_PRODUCT", 163, 167], ["intracellular membrane", "CELLULAR_COMPONENT", 177, 199], ["singlemembrane vesicles", "CELLULAR_COMPONENT", 268, 291], ["microtubule", "CELLULAR_COMPONENT", 303, 314], ["4Endo and 6Endo domains", "PROTEIN", 28, 51], ["catalytic domain", "PROTEIN", 105, 121], ["M pro", "PROTEIN", 125, 130], ["nsp6", "PROTEIN", 163, 167], ["microtubule organization complex", "PROTEIN", 303, 335], ["nsp6", "PROBLEM", 163, 167], ["an accumulation of singlemembrane vesicles", "PROBLEM", 249, 291], ["intracellular membrane", "OBSERVATION", 177, 199], ["accumulation", "OBSERVATION_MODIFIER", 252, 264], ["singlemembrane vesicles", "OBSERVATION", 268, 291], ["microtubule organization", "OBSERVATION", 303, 327], ["complex", "OBSERVATION_MODIFIER", 328, 335]]], ["However, coexpression with nsp4 prevents vesicle accumulation due to nsp6 expression, suggesting that nsp4 and 6 interact.", [["vesicle", "ANATOMY", 41, 48], ["nsp4", "GENE_OR_GENE_PRODUCT", 27, 31], ["vesicle", "CELLULAR_COMPONENT", 41, 48], ["nsp6", "GENE_OR_GENE_PRODUCT", 69, 73], ["nsp4", "GENE_OR_GENE_PRODUCT", 102, 106], ["nsp4", "PROTEIN", 27, 31], ["nsp6", "PROTEIN", 69, 73], ["nsp4 and 6", "PROTEIN", 102, 112], ["nsp4", "PROBLEM", 27, 31], ["vesicle accumulation", "PROBLEM", 41, 61], ["nsp6 expression", "PROBLEM", 69, 84], ["nsp4", "PROBLEM", 102, 106], ["vesicle accumulation", "OBSERVATION", 41, 61], ["nsp4", "OBSERVATION", 102, 106]]], ["While nsp6 was not necessary for membrane pairing, it was essential for forming the DMVs that are characteristic of coronavirus replicative organelles.Nsp6After serial passage of Human coronavirus 229E virus in the presence of the experimental antiviral K22, resistant viruses carrying mutations in nsp6 were selected (Lundin et al., 2014) .", [["membrane", "ANATOMY", 33, 41], ["organelles", "ANATOMY", 140, 150], ["K22", "CHEMICAL", 254, 257], ["nsp6", "GENE_OR_GENE_PRODUCT", 6, 10], ["membrane", "CELLULAR_COMPONENT", 33, 41], ["DMVs", "GENE_OR_GENE_PRODUCT", 84, 88], ["coronavirus", "ORGANISM", 116, 127], ["organelles", "CELLULAR_COMPONENT", 140, 150], ["Nsp6After", "GENE_OR_GENE_PRODUCT", 151, 160], ["Human coronavirus 229E virus", "ORGANISM", 179, 207], ["nsp6", "GENE_OR_GENE_PRODUCT", 299, 303], ["nsp6", "PROTEIN", 6, 10], ["DMVs", "PROTEIN", 84, 88], ["nsp6", "DNA", 299, 303], ["Human", "SPECIES", 179, 184], ["coronavirus 229E virus", "SPECIES", 185, 207], ["Human coronavirus 229E virus", "SPECIES", 179, 207], ["membrane pairing", "PROBLEM", 33, 49], ["the DMVs", "PROBLEM", 80, 88], ["coronavirus replicative organelles", "PROBLEM", 116, 150], ["Human coronavirus 229E virus", "PROBLEM", 179, 207], ["the experimental antiviral K22", "TREATMENT", 227, 257], ["resistant viruses carrying mutations in nsp6", "PROBLEM", 259, 303], ["characteristic of", "UNCERTAINTY", 98, 115], ["coronavirus", "OBSERVATION", 116, 127], ["replicative organelles", "OBSERVATION", 128, 150]]], ["K22 showed antiviral effects in the high nanomolar to low micromolar range, requiring higher amounts to achieve an antiviral effect than would normally be considered practical for wider clinical use.", [["K22", "CHEMICAL", 0, 3], ["K22", "SIMPLE_CHEMICAL", 0, 3], ["K22", "TEST", 0, 3], ["antiviral effects", "PROBLEM", 11, 28], ["an antiviral effect", "TREATMENT", 112, 131], ["antiviral effects", "OBSERVATION", 11, 28], ["low micromolar", "OBSERVATION_MODIFIER", 54, 68]]], ["Time of addition and removal studies showed that K22 was most effective early in infection, after entry, consistent with effects on establishment of viral replication complexes or direct interference with the process of RNA replication (Lundin et al., 2014) .", [["K22", "CHEMICAL", 49, 52], ["infection", "DISEASE", 81, 90], ["K22", "SIMPLE_CHEMICAL", 49, 52], ["viral replication complexes", "PROTEIN", 149, 176], ["removal studies", "TEST", 21, 36], ["K22", "TEST", 49, 52], ["infection", "PROBLEM", 81, 90], ["viral replication complexes", "TREATMENT", 149, 176], ["RNA replication", "TREATMENT", 220, 235], ["infection", "OBSERVATION", 81, 90], ["consistent with", "UNCERTAINTY", 105, 120], ["viral replication", "OBSERVATION", 149, 166]]], ["Surprisingly, two independently isolated resistance mutations mapped to opposite ends of transmembrane helices in nsp6 at positions H121L and M159V.", [["transmembrane", "ANATOMY", 89, 102], ["nsp6", "GENE_OR_GENE_PRODUCT", 114, 118], ["transmembrane helices", "PROTEIN", 89, 110], ["nsp6", "PROTEIN", 114, 118], ["two independently isolated resistance mutations", "PROBLEM", 14, 61], ["transmembrane helices", "PROBLEM", 89, 110], ["resistance mutations", "OBSERVATION", 41, 61]]], ["The resistant viruses released similar amounts of new progeny compared to wt, but produced only about half as many DMVs per infected cell, confirming the importance of nsp6 for authentic DMV formation.", [["cell", "ANATOMY", 133, 137], ["DMVs", "GENE_OR_GENE_PRODUCT", 115, 119], ["cell", "CELL", 133, 137], ["nsp6", "GENE_OR_GENE_PRODUCT", 168, 172], ["DMV", "SIMPLE_CHEMICAL", 187, 190], ["nsp6", "PROTEIN", 168, 172], ["The resistant viruses", "PROBLEM", 0, 21], ["nsp6", "TREATMENT", 168, 172], ["authentic DMV formation", "PROBLEM", 177, 200], ["resistant", "OBSERVATION_MODIFIER", 4, 13], ["viruses", "OBSERVATION", 14, 21], ["similar", "OBSERVATION_MODIFIER", 31, 38], ["amounts", "OBSERVATION_MODIFIER", 39, 46], ["new", "OBSERVATION_MODIFIER", 50, 53], ["progeny", "OBSERVATION_MODIFIER", 54, 61], ["infected cell", "OBSERVATION", 124, 137]]], ["In addition, the DMVs induced by resistance mutants appeared structurally impaired.", [["DMVs", "GENE_OR_GENE_PRODUCT", 17, 21], ["DMVs", "PROTEIN", 17, 21], ["resistance mutants", "PROBLEM", 33, 51], ["structurally impaired", "PROBLEM", 61, 82], ["structurally", "OBSERVATION_MODIFIER", 61, 73], ["impaired", "OBSERVATION", 74, 82]]], ["Similarly to MHV nsp4 mutants (Beachboard et al., 2015; Gadlage et al., 2010) , K22 escape mutants induced DMV with partially collapsed inner membranes, even when K22 was not present.", [["inner membranes", "ANATOMY", 136, 151], ["MHV", "ORGANISM", 13, 16], ["nsp4", "GENE_OR_GENE_PRODUCT", 17, 21], ["K22", "GENE_OR_GENE_PRODUCT", 80, 83], ["DMV", "SIMPLE_CHEMICAL", 107, 110], ["inner membranes", "CELLULAR_COMPONENT", 136, 151], ["MHV nsp4 mutants", "PROTEIN", 13, 29], ["K22", "PROTEIN", 163, 166], ["MHV", "SPECIES", 13, 16], ["K22 escape mutants induced DMV", "PROBLEM", 80, 110], ["partially collapsed inner membranes", "PROBLEM", 116, 151], ["MHV", "OBSERVATION_MODIFIER", 13, 16], ["nsp4 mutants", "OBSERVATION", 17, 29], ["partially", "OBSERVATION_MODIFIER", 116, 125], ["collapsed", "OBSERVATION", 126, 135], ["inner membranes", "OBSERVATION", 136, 151]]], ["Moreover, the specific infectivity of those newly released virions was about ten-fold lower for nsp6 mutants than for wt.", [["virions", "ANATOMY", 59, 66], ["nsp6", "GENE_OR_GENE_PRODUCT", 96, 100], ["nsp6 mutants", "PROTEIN", 96, 108]]], ["This suggested that the mutations in nsp6 conferred resistance to K22 at a cost of impairing an early intracellular step in the establishment of infection.DMOs and viral replication fitnessWhile the structure of coronavirus DMOs has become increasingly clear, their purpose remains somewhat mysterious.", [["intracellular", "ANATOMY", 102, 115], ["nsp6", "CHEMICAL", 37, 41], ["K22", "CHEMICAL", 66, 69], ["infection", "DISEASE", 145, 154], ["DMOs", "CHEMICAL", 224, 228], ["nsp6", "GENE_OR_GENE_PRODUCT", 37, 41], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 102, 115], ["coronavirus DMOs", "ORGANISM", 212, 228], ["nsp6", "DNA", 37, 41], ["coronavirus", "SPECIES", 212, 223], ["the mutations", "PROBLEM", 20, 33], ["K22", "TREATMENT", 66, 69], ["an early intracellular step", "PROBLEM", 93, 120], ["infection", "PROBLEM", 145, 154], ["DMOs", "PROBLEM", 155, 159], ["viral replication fitness", "PROBLEM", 164, 189], ["coronavirus DMOs", "PROBLEM", 212, 228], ["infection", "OBSERVATION", 145, 154], ["viral", "OBSERVATION", 164, 169], ["replication fitness", "OBSERVATION", 170, 189], ["coronavirus DMOs", "OBSERVATION", 212, 228], ["increasingly", "OBSERVATION_MODIFIER", 240, 252], ["clear", "OBSERVATION", 253, 258]]], ["Mutations in nsp4 of MHV resulted in decreased replication and competitive fitness (Beachboard et al., 2015) .", [["nsp4", "GENE_OR_GENE_PRODUCT", 13, 17], ["MHV", "ORGANISM", 21, 24], ["nsp4", "PROTEIN", 13, 17], ["MHV", "PROTEIN", 21, 24], ["MHV", "SPECIES", 21, 24], ["Mutations in nsp4 of MHV", "PROBLEM", 0, 24], ["decreased replication", "PROBLEM", 37, 58], ["decreased replication", "OBSERVATION", 37, 58]]], ["MHV mutants that produced fewer DMVs, but equal or greater amounts of genomic and subgenomic viral RNA have been described (Al-Mulla et al., 2014) , suggesting that coronavirus replication is not strictly dependent on high numbers of DMVs or the size of the DMV interior.", [["MHV", "ORGANISM", 0, 3], ["DMVs", "GENE_OR_GENE_PRODUCT", 32, 36], ["coronavirus", "ORGANISM", 165, 176], ["DMVs", "GENE_OR_GENE_PRODUCT", 234, 238], ["subgenomic viral RNA", "RNA", 82, 102], ["DMVs", "PROTEIN", 234, 238], ["MHV", "SPECIES", 0, 3], ["coronavirus", "SPECIES", 165, 176], ["MHV mutants", "PROBLEM", 0, 11], ["fewer DMVs", "PROBLEM", 26, 36], ["genomic and subgenomic viral RNA", "PROBLEM", 70, 102], ["coronavirus replication", "PROBLEM", 165, 188], ["DMVs", "PROBLEM", 234, 238], ["fewer", "OBSERVATION_MODIFIER", 26, 31], ["DMVs", "OBSERVATION", 32, 36], ["equal", "OBSERVATION_MODIFIER", 42, 47], ["greater", "OBSERVATION_MODIFIER", 51, 58], ["amounts", "OBSERVATION_MODIFIER", 59, 66], ["subgenomic viral RNA", "OBSERVATION", 82, 102], ["coronavirus replication", "OBSERVATION", 165, 188], ["size", "OBSERVATION_MODIFIER", 246, 250]]], ["Notably, when equal infectivities of two viruses were added to the same flask at a temperature where both viruses could grow normally, several mutants with small DMV and low-DMV phenotypes did not appear to be at a competitive disadvantage compared to wild-type virus (Al-Mulla et al., 2014) .", [["wild-type virus", "ORGANISM", 252, 267], ["two viruses", "PROBLEM", 37, 48], ["small DMV", "PROBLEM", 156, 165], ["low-DMV phenotypes", "PROBLEM", 170, 188], ["a competitive disadvantage", "PROBLEM", 213, 239], ["type virus", "PROBLEM", 257, 267], ["viruses", "OBSERVATION", 106, 113], ["small", "OBSERVATION_MODIFIER", 156, 161]]], ["This result was replicated in several continuous cell lines and primary cells.", [["cell lines", "ANATOMY", 49, 59], ["primary cells", "ANATOMY", 64, 77], ["cell lines", "CELL", 49, 59], ["primary cells", "CELL", 64, 77], ["continuous cell lines", "CELL_LINE", 38, 59], ["primary cells", "CELL_TYPE", 64, 77], ["cell lines", "OBSERVATION", 49, 59], ["primary cells", "OBSERVATION", 64, 77]]], ["Furthermore, a survey of Infectious bronchitis virus revealed that one high-pathogenicity strain produced abnormally low numbers of double-membrane spherules, while still producing an equivalent amount of RNA to a vaccine strain (Maier et al., 2016) .", [["membrane spherules", "ANATOMY", 139, 157], ["Infectious bronchitis virus", "DISEASE", 25, 52], ["Infectious bronchitis virus", "ORGANISM", 25, 52], ["membrane spherules", "CELLULAR_COMPONENT", 139, 157], ["Infectious bronchitis virus", "SPECIES", 25, 52], ["Infectious bronchitis virus", "PROBLEM", 25, 52], ["one high-pathogenicity strain", "PROBLEM", 67, 96], ["abnormally low numbers of double-membrane spherules", "PROBLEM", 106, 157], ["a vaccine strain", "PROBLEM", 212, 228], ["Infectious", "OBSERVATION_MODIFIER", 25, 35], ["abnormally", "OBSERVATION_MODIFIER", 106, 116], ["low", "OBSERVATION_MODIFIER", 117, 120], ["numbers", "OBSERVATION_MODIFIER", 121, 128], ["double-membrane spherules", "OBSERVATION_MODIFIER", 132, 157], ["equivalent", "OBSERVATION_MODIFIER", 184, 194], ["amount", "OBSERVATION_MODIFIER", 195, 201]]], ["These results suggest that whatever their purpose, coronavirus replicative organelles display a surprising degree of structural plasticity without necessarily impairing RNA production, pathogenicity or competitive fitness.", [["organelles", "ANATOMY", 75, 85], ["coronavirus", "ORGANISM", 51, 62], ["organelles", "CELLULAR_COMPONENT", 75, 85], ["coronavirus replicative organelles", "PROBLEM", 51, 85], ["structural plasticity", "PROBLEM", 117, 138], ["impairing RNA production", "PROBLEM", 159, 183], ["structural plasticity", "OBSERVATION", 117, 138], ["without necessarily", "UNCERTAINTY", 139, 158], ["impairing", "OBSERVATION_MODIFIER", 159, 168], ["RNA production", "OBSERVATION", 169, 183]]]], "PMC7194797": [["IntroductionViral diseases continue to pose a serious threat to public health.", [["IntroductionViral diseases", "DISEASE", 0, 26], ["IntroductionViral diseases", "PROBLEM", 0, 26]]], ["The world has witnessed several viral epidemics in past twenty years that include severe acute respiratory syndrome coronavirus (SARS-CoV-1) in 2003, H1N1 influenza in 2009 and the Middle East respiratory syndrome coronavirus (MERS-CoV) in 2012.IntroductionRecently, an outbreak of pneumonia of unknown etiology was detected in Wuhan City, Hubei Province of China and reported to China Country Office of The World Health Organization (WHO) on December 31, 2019.", [["acute respiratory syndrome coronavirus", "DISEASE", 89, 127], ["SARS", "DISEASE", 129, 133], ["H1N1 influenza", "DISEASE", 150, 164], ["respiratory syndrome coronavirus", "DISEASE", 193, 225], ["pneumonia", "DISEASE", 282, 291], ["SARS-CoV-1", "ORGANISM", 129, 139], ["Middle East respiratory syndrome coronavirus", "ORGANISM", 181, 225], ["MERS-CoV", "ORGANISM", 227, 235], ["CoV-1", "SPECIES", 134, 139], ["H1N1 influenza", "SPECIES", 150, 164], ["severe acute respiratory syndrome coronavirus", "SPECIES", 82, 127], ["SARS-CoV-1", "SPECIES", 129, 139], ["Middle East respiratory syndrome coronavirus", "SPECIES", 181, 225], ["MERS-CoV", "SPECIES", 227, 235], ["several viral epidemics", "PROBLEM", 24, 47], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 82, 127], ["CoV", "TEST", 134, 137], ["H1N1 influenza", "PROBLEM", 150, 164], ["the Middle East respiratory syndrome coronavirus", "PROBLEM", 177, 225], ["pneumonia", "PROBLEM", 282, 291], ["viral epidemics", "OBSERVATION", 32, 47], ["severe", "OBSERVATION_MODIFIER", 82, 88], ["acute", "OBSERVATION_MODIFIER", 89, 94], ["respiratory syndrome coronavirus", "OBSERVATION", 95, 127], ["Middle", "ANATOMY_MODIFIER", 181, 187], ["respiratory syndrome", "OBSERVATION", 193, 213], ["outbreak", "OBSERVATION_MODIFIER", 270, 278], ["pneumonia", "OBSERVATION", 282, 291]]], ["The etiological agent of the atypical pneumonia was isolated on January 7, 2020 by the Chinese authorities as novel coronavirus (2019-nCoV).", [["pneumonia", "DISEASE", 38, 47], ["coronavirus", "ORGANISM", 116, 127], ["the atypical pneumonia", "PROBLEM", 25, 47], ["novel coronavirus", "PROBLEM", 110, 127], ["atypical", "OBSERVATION_MODIFIER", 29, 37], ["pneumonia", "OBSERVATION", 38, 47]]], ["The genetic sequence of the novel coronavirus identified was shared to other countries to develop specific diagnostic kits on January 12, 2020.", [["coronavirus", "ORGANISM", 34, 45], ["coronavirus", "SPECIES", 34, 45], ["the novel coronavirus", "PROBLEM", 24, 45]]], ["Subsequently, International Committee on Taxonomy of Viruses termed it SARS-Cov-2, due to similarity of its symptoms to those induced by the SARS.", [["SARS", "DISEASE", 141, 145], ["Viruses", "TREATMENT", 53, 60], ["its symptoms", "PROBLEM", 104, 116]]], ["On February 11, 2020, the WHO announced that the disease caused by this new virus as a \"COVID-19,\" which is the acronym of \"coronavirus disease 2019\".", [["coronavirus disease", "DISEASE", 124, 143], ["the disease", "PROBLEM", 45, 56], ["this new virus", "PROBLEM", 67, 81], ["a \"COVID", "TEST", 85, 93], ["\"coronavirus disease", "PROBLEM", 123, 143], ["disease", "OBSERVATION", 49, 56], ["coronavirus disease", "OBSERVATION", 124, 143]]], ["On March 11, 2020, WHO declared this disease as pandemic.", [["this disease", "PROBLEM", 32, 44], ["pandemic", "PROBLEM", 48, 56]]], ["As of March 30, 2020, WHO has reported 693,224 case and 33,104 death, that has occurred worldwide [1].EtiologyCoronavirus (CoV) belongs to Coronaviridae family of order Nidovirale.", [["death", "DISEASE", 63, 68], ["EtiologyCoronavirus", "GENE_OR_GENE_PRODUCT", 102, 121], ["CoV", "ORGANISM", 123, 126], ["CoV", "SPECIES", 123, 126], ["Nidovirale", "TREATMENT", 169, 179]]], ["CoV are single-stranded RNA viruses (+ssRNA) having a spike glycoprotein on the envelope, giving it a crown-like appearance, when seen on electron microscope.", [["CoV", "ORGANISM", 0, 3], ["spike glycoprotein", "PROTEIN", 54, 72], ["CoV", "SPECIES", 0, 3], ["CoV", "PROBLEM", 0, 3], ["stranded RNA viruses", "PROBLEM", 15, 35], ["ssRNA", "PROBLEM", 38, 43], ["a spike glycoprotein", "PROBLEM", 52, 72], ["electron microscope", "TEST", 138, 157], ["stranded RNA viruses", "OBSERVATION", 15, 35]]], ["The subfamily Orthocoronavirinae has four genera of CoVs: Alpha-coronavirus, Beta-coronavirus, Delta-coronavirus and Gamma-coronavirus.", [["CoVs", "GENE_OR_GENE_PRODUCT", 52, 56], ["Alpha-coronavirus", "ORGANISM", 58, 75], ["Beta-coronavirus", "ORGANISM", 77, 93], ["Delta-coronavirus", "ORGANISM", 95, 112], ["Gamma-coronavirus", "ORGANISM", 117, 134], ["Beta-coronavirus", "SPECIES", 77, 93], ["Delta-coronavirus", "SPECIES", 95, 112], ["Gamma-coronavirus", "SPECIES", 117, 134], ["Alpha-coronavirus", "SPECIES", 58, 75], ["Beta-coronavirus", "SPECIES", 77, 93], ["Delta-coronavirus", "SPECIES", 95, 112], ["Gamma-coronavirus", "SPECIES", 117, 134], ["Alpha", "TEST", 58, 63], ["coronavirus", "PROBLEM", 64, 75], ["Beta-coronavirus", "PROBLEM", 77, 93], ["Delta", "TEST", 95, 100], ["coronavirus", "PROBLEM", 101, 112], ["coronavirus", "PROBLEM", 123, 134], ["Alpha", "ANATOMY", 58, 63]]], ["Furthermore, the genus Beta-coronavirus divides into five sub-genera or lineages.", [["the genus Beta-coronavirus", "TEST", 13, 39], ["genus Beta-coronavirus", "OBSERVATION", 17, 39]]], ["While bats and rodents are considered to be the genetic sources of alpha and beta-coronavirus, avian species represents the genetic sources of delta and gamma-coronavirus [2].EtiologyTo date, seven human coronaviruses (HCov) have been identified.", [["rodents", "ORGANISM", 15, 22], ["alpha", "GENE_OR_GENE_PRODUCT", 67, 72], ["beta-coronavirus", "GENE_OR_GENE_PRODUCT", 77, 93], ["avian species", "ORGANISM", 95, 108], ["human", "ORGANISM", 198, 203], ["coronaviruses", "ORGANISM", 204, 217], ["HCov", "CANCER", 219, 223], ["human", "SPECIES", 198, 203], ["human coronaviruses", "SPECIES", 198, 217], ["alpha and beta-coronavirus", "PROBLEM", 67, 93], ["avian species", "PROBLEM", 95, 108], ["delta and gamma-coronavirus", "PROBLEM", 143, 170], ["seven human coronaviruses", "PROBLEM", 192, 217]]], ["The A lineage of beta-coronavirus (such as HCoV-OC43 and HCoV-HKU1) as well as alpha-coronavirus (such as HCoV-229E and HCoV-NL63), causes common colds and self-limiting respiratory infections.", [["respiratory", "ANATOMY", 170, 181], ["colds", "DISEASE", 146, 151], ["respiratory infections", "DISEASE", 170, 192], ["A lineage", "CELL", 4, 13], ["beta-coronavirus", "GENE_OR_GENE_PRODUCT", 17, 33], ["HCoV-OC43", "GENE_OR_GENE_PRODUCT", 43, 52], ["HCoV-HKU1", "GENE_OR_GENE_PRODUCT", 57, 66], ["alpha-coronavirus", "CANCER", 79, 96], ["HCoV-229E", "GENE_OR_GENE_PRODUCT", 106, 115], ["HCoV-NL63", "CELL", 120, 129], ["HCoV", "SPECIES", 43, 47], ["HCoV-229E", "SPECIES", 106, 115], ["beta-coronavirus", "TEST", 17, 33], ["HCoV", "TEST", 43, 47], ["OC43", "TEST", 48, 52], ["HCoV", "TEST", 57, 61], ["alpha-coronavirus", "TEST", 79, 96], ["HCoV", "TEST", 106, 110], ["HCoV", "TEST", 120, 124], ["common colds", "PROBLEM", 139, 151], ["self-limiting respiratory infections", "PROBLEM", 156, 192], ["lineage", "OBSERVATION_MODIFIER", 6, 13], ["common", "OBSERVATION_MODIFIER", 139, 145], ["colds", "OBSERVATION", 146, 151], ["respiratory", "ANATOMY", 170, 181], ["infections", "OBSERVATION", 182, 192]]], ["In contrast, B lineage of beta-corona virus causes SARS-CoV-1, SARS-CoV-2 (COVID-19), while C lineage of beta-corona virus causes MERS-CoV; both responsible for recent epidemics with a variable clinical severity of pulmonary and extra-pulmonary involvement and associated significant increase in mortality [3].EtiologyCOVID-19 is a single-stranded, positive sense RNA virus, having a diameter of 60\u2013140 nm with a round or elliptic shape, however, it often exists in pleomorphic form.", [["B lineage", "ANATOMY", 13, 22], ["pulmonary", "ANATOMY", 215, 224], ["pulmonary and extra-pulmonary involvement", "DISEASE", 215, 256], ["B lineage", "CELL", 13, 22], ["beta-corona virus", "ORGANISM", 26, 43], ["SARS-CoV-1", "ORGANISM", 51, 61], ["SARS-CoV-2", "ORGANISM", 63, 73], ["COVID-19", "ORGANISM", 75, 83], ["C lineage", "ORGANISM", 92, 101], ["beta-corona virus", "ORGANISM", 105, 122], ["MERS-CoV", "ORGANISM", 130, 138], ["pulmonary", "ORGAN", 215, 224], ["B lineage", "CELL_TYPE", 13, 22], ["EtiologyCOVID-19", "DNA", 310, 326], ["beta-corona virus", "SPECIES", 26, 43], ["SARS-CoV-1", "SPECIES", 51, 61], ["SARS-CoV-2 (COVID-19", "SPECIES", 63, 83], ["beta-corona virus", "SPECIES", 105, 122], ["MERS-CoV", "SPECIES", 130, 138], ["beta-corona virus", "PROBLEM", 26, 43], ["SARS", "PROBLEM", 51, 55], ["CoV", "TEST", 56, 59], ["SARS", "TEST", 63, 67], ["CoV", "TEST", 68, 71], ["COVID", "TEST", 75, 80], ["beta-corona virus", "PROBLEM", 105, 122], ["CoV", "PROBLEM", 135, 138], ["recent epidemics", "PROBLEM", 161, 177], ["pulmonary and extra-pulmonary involvement", "PROBLEM", 215, 256], ["significant increase in mortality", "PROBLEM", 272, 305], ["EtiologyCOVID", "TEST", 310, 323], ["a single-stranded, positive sense RNA virus", "PROBLEM", 330, 373], ["a round or elliptic shape", "PROBLEM", 411, 436], ["pulmonary", "ANATOMY", 215, 224], ["extra-pulmonary", "ANATOMY", 229, 244], ["significant", "OBSERVATION_MODIFIER", 272, 283], ["increase", "OBSERVATION_MODIFIER", 284, 292], ["RNA virus", "OBSERVATION", 364, 373], ["diameter", "OBSERVATION_MODIFIER", 384, 392], ["round", "OBSERVATION_MODIFIER", 413, 418], ["elliptic", "OBSERVATION_MODIFIER", 422, 430], ["shape", "OBSERVATION_MODIFIER", 431, 436]]], ["Its RNA genome contains 29891 nucleotides, encoding for 9860 amino acids and shares 99.9% sequence identity, suggesting a very recent host shift into humans [4,5].", [["amino acids", "CHEMICAL", 61, 72], ["amino acids", "CHEMICAL", 61, 72], ["amino acids", "AMINO_ACID", 61, 72], ["humans", "ORGANISM", 150, 156], ["RNA genome", "DNA", 4, 14], ["humans", "SPECIES", 150, 156], ["humans", "SPECIES", 150, 156], ["nucleotides", "TREATMENT", 30, 41], ["amino acids", "TEST", 61, 72], ["RNA genome", "OBSERVATION", 4, 14]]], ["Like other CoVs, it is sensitive to ultraviolet rays and heat.", [["CoVs", "GENE_OR_GENE_PRODUCT", 11, 15], ["other CoVs", "PROBLEM", 5, 15], ["ultraviolet rays", "TREATMENT", 36, 52], ["CoVs", "OBSERVATION", 11, 15]]], ["Besides, these viruses can be effectively inactivated by lipid solvents including chloroform, ether (75%), ethanol, peroxyacetic acid and chlorine-containing disinfectant.", [["chloroform, ether", "CHEMICAL", 82, 99], ["ethanol", "CHEMICAL", 107, 114], ["peroxyacetic acid", "CHEMICAL", 116, 133], ["chlorine", "CHEMICAL", 138, 146], ["chloroform", "CHEMICAL", 82, 92], ["ether", "CHEMICAL", 94, 99], ["ethanol", "CHEMICAL", 107, 114], ["peroxyacetic acid", "CHEMICAL", 116, 133], ["chlorine", "CHEMICAL", 138, 146], ["lipid solvents", "SIMPLE_CHEMICAL", 57, 71], ["chloroform", "SIMPLE_CHEMICAL", 82, 92], ["ether", "SIMPLE_CHEMICAL", 94, 99], ["ethanol", "SIMPLE_CHEMICAL", 107, 114], ["peroxyacetic acid", "SIMPLE_CHEMICAL", 116, 133], ["chlorine", "SIMPLE_CHEMICAL", 138, 146], ["these viruses", "PROBLEM", 9, 22], ["lipid solvents", "TREATMENT", 57, 71], ["chloroform", "TREATMENT", 82, 92], ["ethanol", "TREATMENT", 107, 114], ["peroxyacetic acid", "TREATMENT", 116, 133], ["chlorine", "TREATMENT", 138, 146], ["viruses", "OBSERVATION", 15, 22]]], ["Chlorhexidine does not inactivate this virus [4], [5].Transmission cycleCoronaviruses are naturally hosted by bats and it is believed that most human coronaviruses are derived from the bat reservoir [5,6].", [["Chlorhexidine", "CHEMICAL", 0, 13], ["Chlorhexidine", "CHEMICAL", 0, 13], ["Chlorhexidine", "SIMPLE_CHEMICAL", 0, 13], ["human", "ORGANISM", 144, 149], ["coronaviruses", "ORGANISM", 150, 163], ["bat", "ORGANISM", 185, 188], ["human", "SPECIES", 144, 149], ["human coronaviruses", "SPECIES", 144, 163], ["Chlorhexidine", "TREATMENT", 0, 13], ["this virus", "PROBLEM", 34, 44], ["most human coronaviruses", "PROBLEM", 139, 163]]], ["Genomic sequence studies of COVID-19 have identified nearly 50%, 79% and 96% similarity to MERS-CoV, SARS-CoV-1 and bat SARS-related coronavirus, respectively [[7], [8], [9]].", [["MERS-CoV", "ORGANISM", 91, 99], ["SARS-CoV-1", "ORGANISM", 101, 111], ["bat SARS-related coronavirus", "ORGANISM", 116, 144], ["COVID-19", "DNA", 28, 36], ["CoV-1", "SPECIES", 106, 111], ["MERS-CoV", "SPECIES", 91, 99], ["SARS-CoV-1", "SPECIES", 101, 111], ["Genomic sequence studies", "TEST", 0, 24], ["COVID", "TEST", 28, 33], ["MERS", "TEST", 91, 95], ["CoV", "TEST", 96, 99], ["SARS", "TEST", 101, 105], ["CoV", "TEST", 106, 109], ["bat SARS", "TEST", 116, 124], ["coronavirus", "PROBLEM", 133, 144]]], ["The specific route of transmission to human from natural reservoirs is still yet to be known, however, some of the studies suggests pangolin could be the intermediate mammalian hosts.", [["pangolin", "CHEMICAL", 132, 140], ["human", "ORGANISM", 38, 43], ["pangolin", "GENE_OR_GENE_PRODUCT", 132, 140], ["human", "SPECIES", 38, 43], ["human", "SPECIES", 38, 43], ["the studies", "TEST", 111, 122], ["intermediate mammalian hosts", "OBSERVATION", 154, 182]]], ["Since spike protein of SAR-CoV-2 are nearly identical to one virus isolated from pangolin, it is believed that pangolins could have provided a partial spike gene to SARS-CoV-2, to infect mammals [10,11].", [["pangolins", "CHEMICAL", 111, 120], ["SAR-CoV-2", "GENE_OR_GENE_PRODUCT", 23, 32], ["pangolin", "GENE_OR_GENE_PRODUCT", 81, 89], ["pangolins", "GENE_OR_GENE_PRODUCT", 111, 120], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 165, 175], ["spike protein", "PROTEIN", 6, 19], ["SAR", "PROTEIN", 23, 26], ["CoV", "PROTEIN", 27, 30], ["partial spike gene", "DNA", 143, 161], ["spike protein of SAR", "PROBLEM", 6, 26], ["CoV", "TEST", 27, 30], ["a partial spike gene to SARS", "PROBLEM", 141, 169], ["CoV", "TEST", 170, 173]]], ["A recent study has also shown a development of new variations at the functional sites in the receptor-binding domain of the spike of SARS-CoV-2 and viruses from pangolin, likely caused due to either a natural selection or mutations or recombination or both [12].Transmission cycleNevertheless, once human is infected, virus could also be transmitted from human-to-human through the respiratory droplets and aerosols from coughing and sneezing, like other respiratory pathogens, including SARS-CoV-2.", [["respiratory droplets", "ANATOMY", 382, 402], ["coughing", "DISEASE", 421, 429], ["sneezing", "DISEASE", 434, 442], ["respiratory pathogens", "DISEASE", 455, 476], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 133, 143], ["pangolin", "GENE_OR_GENE_PRODUCT", 161, 169], ["human", "ORGANISM", 299, 304], ["human", "ORGANISM", 355, 360], ["human", "ORGANISM", 364, 369], ["SARS-CoV-2", "ORGANISM", 488, 498], ["receptor-binding domain", "PROTEIN", 93, 116], ["human", "SPECIES", 299, 304], ["human", "SPECIES", 355, 360], ["human", "SPECIES", 364, 369], ["human", "SPECIES", 299, 304], ["human", "SPECIES", 355, 360], ["human", "SPECIES", 364, 369], ["SARS-CoV", "SPECIES", 488, 496], ["A recent study", "TEST", 0, 14], ["new variations at the functional sites", "PROBLEM", 47, 85], ["SARS", "PROBLEM", 133, 137], ["CoV", "TEST", 138, 141], ["viruses", "PROBLEM", 148, 155], ["pangolin", "TREATMENT", 161, 169], ["a natural selection", "PROBLEM", 199, 218], ["mutations", "PROBLEM", 222, 231], ["infected", "PROBLEM", 308, 316], ["virus", "PROBLEM", 318, 323], ["the respiratory droplets", "TREATMENT", 378, 402], ["coughing", "PROBLEM", 421, 429], ["sneezing", "PROBLEM", 434, 442], ["other respiratory pathogens", "PROBLEM", 449, 476], ["new", "OBSERVATION_MODIFIER", 47, 50], ["variations", "OBSERVATION", 51, 61], ["functional sites", "OBSERVATION", 69, 85], ["spike", "OBSERVATION_MODIFIER", 124, 129], ["likely caused due to", "UNCERTAINTY", 171, 191], ["infected", "OBSERVATION", 308, 316], ["respiratory droplets", "OBSERVATION", 382, 402], ["respiratory", "ANATOMY", 455, 466], ["pathogens", "OBSERVATION", 467, 476]]], ["SARS-CoV-2 also uses the angiotensin converting enzyme II (ACE2) receptors like the SARS-CoV [13].Transmission cycleThe incubation period of COVID-19 could vary from 3 days to 14 days, based on the data from Chinese CDC.", [["SARS", "DISEASE", 0, 4], ["angiotensin", "CHEMICAL", 25, 36], ["COVID-19", "CHEMICAL", 141, 149], ["COVID-19", "CHEMICAL", 141, 149], ["angiotensin converting enzyme II", "GENE_OR_GENE_PRODUCT", 25, 57], ["ACE2", "GENE_OR_GENE_PRODUCT", 59, 63], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 84, 92], ["angiotensin converting enzyme II (ACE2) receptors", "PROTEIN", 25, 74], ["SARS-CoV", "SPECIES", 84, 92], ["the angiotensin converting enzyme II (ACE2) receptors", "TREATMENT", 21, 74], ["the SARS", "TEST", 80, 88], ["COVID", "TEST", 141, 146]]], ["The longest time from infection to symptoms was 12.5 days (95% CI, 9.2\u201318 days).", [["infection", "DISEASE", 22, 31], ["infection to symptoms", "PROBLEM", 22, 43], ["CI", "TEST", 63, 65], ["infection", "OBSERVATION", 22, 31]]], ["The Chinese epidemic also doubled about every seven days and on average, each patient transmits the infection to an additional 2.2 individuals, suggesting the basic reproduction number (R0 or R naught) to be 2.2, which is a bit lesser compared to R0 of the SARS-CoV-1 epidemic of nearly 3.0, in 2002\u20132003 [14,15].", [["infection", "DISEASE", 100, 109], ["SARS", "DISEASE", 257, 261], ["patient", "ORGANISM", 78, 85], ["patient", "SPECIES", 78, 85], ["SARS-CoV-1", "SPECIES", 257, 267], ["the infection", "PROBLEM", 96, 109], ["the SARS", "TEST", 253, 261], ["CoV", "TEST", 262, 265], ["infection", "OBSERVATION", 100, 109]]], ["An epidemiological and transmission difference in characteristics between SARS-CoV1, MERS and Covid-19 has been summarized in Table 1.Transmission cycleA recent study from a genetic analysis of SARS-CoV-2 genomes (n = 103) found this virus to be evolving into two major types (designated as L and S) with two different SNPs.", [["SARS", "DISEASE", 74, 78], ["SARS-CoV-2", "ORGANISM", 194, 204], ["SARS-CoV1, MERS and Covid-19", "DNA", 74, 102], ["SARS-CoV-2 genomes", "DNA", 194, 212], ["SARS-CoV", "SPECIES", 194, 202], ["SARS", "TEST", 74, 78], ["Covid", "TEST", 94, 99], ["recent study", "TEST", 154, 166], ["a genetic analysis", "TEST", 172, 190], ["SARS", "PROBLEM", 194, 198], ["CoV", "TEST", 199, 202], ["this virus", "PROBLEM", 229, 239], ["different SNPs", "OBSERVATION", 309, 323]]], ["While the L type is more prevalent (\u223c70%), aggressive and spread more quickly, as seen in the early stages of the outbreak in Wuhan, the S type (\u223c30%) is an ancestral version, evolutionarily older, and less aggressive.", [["L type", "OBSERVATION_MODIFIER", 10, 16], ["more prevalent", "OBSERVATION_MODIFIER", 20, 34], ["aggressive", "OBSERVATION_MODIFIER", 43, 53], ["less", "OBSERVATION_MODIFIER", 202, 206], ["aggressive", "OBSERVATION_MODIFIER", 207, 217]]], ["It appears that the frequency of the L type has decreased after early January 2020, and it is hypothesized that the change in selective pressure might change the behavior of this virus.", [["the change in selective pressure", "PROBLEM", 112, 144], ["this virus", "PROBLEM", 174, 184], ["L type", "OBSERVATION_MODIFIER", 37, 43], ["decreased", "OBSERVATION_MODIFIER", 48, 57], ["selective", "OBSERVATION_MODIFIER", 126, 135], ["pressure", "OBSERVATION", 136, 144]]], ["It is thought that coercive human interventions may have placed a more severe selective pressure on the L type to mutate to S type.", [["human", "ORGANISM", 28, 33], ["human", "SPECIES", 28, 33], ["human", "SPECIES", 28, 33], ["coercive human interventions", "TREATMENT", 19, 47], ["pressure", "OBSERVATION", 88, 96]]], ["Conversely, the S type might have been increased also due to a relatively weaker selective pressure [13].Transmission cycleThese ultra-rapid development in viral epidemics strongly suggest an urgent need of understanding about these viral dynamics to cope up with this public health emergency of COVID-19.Clinical features of COVID-19There may be a variety of symptoms that a patient with COVID-19 may present with.", [["COVID-19", "CHEMICAL", 326, 334], ["COVID-19", "CHEMICAL", 326, 334], ["patient", "ORGANISM", 376, 383], ["patient", "SPECIES", 376, 383], ["viral epidemics", "PROBLEM", 156, 171], ["COVID", "TEST", 296, 301], ["COVID", "TEST", 326, 331], ["a variety of symptoms", "PROBLEM", 347, 368], ["COVID", "TEST", 389, 394], ["viral epidemics", "OBSERVATION", 156, 171], ["may be", "UNCERTAINTY", 340, 346], ["variety", "OBSERVATION_MODIFIER", 349, 356]]], ["The usual triad to suspect is fever, dry cough and dyspnea.", [["fever", "DISEASE", 30, 35], ["dry cough", "DISEASE", 37, 46], ["dyspnea", "DISEASE", 51, 58], ["fever", "PROBLEM", 30, 35], ["dry cough", "PROBLEM", 37, 46], ["dyspnea", "PROBLEM", 51, 58], ["fever", "OBSERVATION", 30, 35], ["cough", "OBSERVATION", 41, 46], ["dyspnea", "OBSERVATION", 51, 58]]], ["It may be classified as asymptomatic or symptomatic, carrier or infective state, from mild prodrome to profusely symptomatic; depending upon immunity status of patients.", [["patients", "ORGANISM", 160, 168], ["patients", "SPECIES", 160, 168], ["asymptomatic", "PROBLEM", 24, 36], ["symptomatic", "PROBLEM", 40, 51], ["infective state", "PROBLEM", 64, 79], ["mild prodrome", "PROBLEM", 86, 99], ["profusely symptomatic", "PROBLEM", 103, 124], ["symptomatic", "OBSERVATION_MODIFIER", 40, 51], ["mild", "OBSERVATION_MODIFIER", 86, 90]]], ["There are reports of conjunctivitis, gastrointestinal symptoms like diarrhea, vomiting, nausea, abdominal pain.", [["gastrointestinal", "ANATOMY", 37, 53], ["abdominal", "ANATOMY", 96, 105], ["conjunctivitis", "DISEASE", 21, 35], ["gastrointestinal symptoms", "DISEASE", 37, 62], ["diarrhea", "DISEASE", 68, 76], ["vomiting", "DISEASE", 78, 86], ["nausea", "DISEASE", 88, 94], ["abdominal pain", "DISEASE", 96, 110], ["gastrointestinal", "ORGANISM_SUBDIVISION", 37, 53], ["abdominal", "ORGANISM_SUBDIVISION", 96, 105], ["conjunctivitis", "PROBLEM", 21, 35], ["gastrointestinal symptoms", "PROBLEM", 37, 62], ["diarrhea", "PROBLEM", 68, 76], ["vomiting", "PROBLEM", 78, 86], ["nausea", "PROBLEM", 88, 94], ["abdominal pain", "PROBLEM", 96, 110], ["conjunctivitis", "OBSERVATION", 21, 35], ["gastrointestinal", "ANATOMY", 37, 53], ["diarrhea", "OBSERVATION", 68, 76], ["abdominal", "ANATOMY", 96, 105], ["pain", "OBSERVATION", 106, 110]]], ["Some critically ill may present without fever but with abdominal pain, anorexia and dyspnea.", [["abdominal", "ANATOMY", 55, 64], ["critically ill", "DISEASE", 5, 19], ["fever", "DISEASE", 40, 45], ["abdominal pain", "DISEASE", 55, 69], ["anorexia", "DISEASE", 71, 79], ["dyspnea", "DISEASE", 84, 91], ["abdominal", "ORGANISM_SUBDIVISION", 55, 64], ["Some critically ill", "PROBLEM", 0, 19], ["fever", "PROBLEM", 40, 45], ["abdominal pain", "PROBLEM", 55, 69], ["anorexia", "PROBLEM", 71, 79], ["dyspnea", "PROBLEM", 84, 91], ["critically", "OBSERVATION_MODIFIER", 5, 15], ["ill", "OBSERVATION", 16, 19], ["without", "UNCERTAINTY", 32, 39], ["fever", "OBSERVATION", 40, 45], ["abdominal", "ANATOMY", 55, 64], ["pain", "OBSERVATION", 65, 69], ["anorexia", "OBSERVATION", 71, 79], ["dyspnea", "OBSERVATION", 84, 91]]], ["Less common symptoms were gastrointestinal, anosmia, dysgeusia [13].", [["gastrointestinal", "ANATOMY", 26, 42], ["gastrointestinal, anosmia", "DISEASE", 26, 51], ["dysgeusia", "DISEASE", 53, 62], ["gastrointestinal", "ORGANISM_SUBDIVISION", 26, 42], ["Less common symptoms", "PROBLEM", 0, 20], ["anosmia", "PROBLEM", 44, 51], ["dysgeusia", "PROBLEM", 53, 62], ["gastrointestinal", "ANATOMY", 26, 42]]], ["Overall, the case fatality rate was varied between 2.3% and 5% with an average of 3%.", [["the case fatality rate", "TEST", 9, 31]]], ["Poor prognostic epidemiological risk factors include older age, male sex, smokers and associated comorbidities including obesity, hypertension, diabetes, chronic pulmonary diseases, cardiovascular disease and chronic kidney disease.", [["pulmonary", "ANATOMY", 162, 171], ["cardiovascular", "ANATOMY", 182, 196], ["kidney", "ANATOMY", 217, 223], ["obesity", "DISEASE", 121, 128], ["hypertension", "DISEASE", 130, 142], ["diabetes", "DISEASE", 144, 152], ["chronic pulmonary diseases", "DISEASE", 154, 180], ["cardiovascular disease", "DISEASE", 182, 204], ["chronic kidney disease", "DISEASE", 209, 231], ["pulmonary", "ORGAN", 162, 171], ["cardiovascular", "ANATOMICAL_SYSTEM", 182, 196], ["kidney", "ORGAN", 217, 223], ["Poor prognostic epidemiological risk factors", "PROBLEM", 0, 44], ["obesity", "PROBLEM", 121, 128], ["hypertension", "PROBLEM", 130, 142], ["diabetes", "PROBLEM", 144, 152], ["chronic pulmonary diseases", "PROBLEM", 154, 180], ["cardiovascular disease", "PROBLEM", 182, 204], ["chronic kidney disease", "PROBLEM", 209, 231], ["obesity", "OBSERVATION", 121, 128], ["hypertension", "OBSERVATION", 130, 142], ["diabetes", "OBSERVATION", 144, 152], ["chronic", "OBSERVATION_MODIFIER", 154, 161], ["pulmonary", "ANATOMY", 162, 171], ["diseases", "OBSERVATION", 172, 180], ["cardiovascular disease", "OBSERVATION", 182, 204], ["chronic", "OBSERVATION_MODIFIER", 209, 216], ["kidney", "ANATOMY", 217, 223], ["disease", "OBSERVATION", 224, 231]]], ["More the number of risk factors, more is the severity at presentation [18].Clinical features of COVID-19Depending on the clinical features of COVID-19, patients are generally divided as mild, moderate, severe and critical [18].a.Mild COVID-19: low grade fever, cough, malaise, rhinorrhea, sore throat with or without hemoptysis, nausea, vomiting, diarrhea, but without any radiological features of pneumonia and absence of mental changes.b.Moderate COVID-19: fever, respiratory symptoms including dry cough and shortness of breath that may emerge along with the radiological features [15].c.Severe COVID-19: dyspnea, respiratory frequency \u226530/minute, blood oxygen saturation \u226493%, PaO2/FiO2 ratio <300, and/or lung infiltrates >50% of the lung field within 24\u201348 h.d.Critical COVID-19: usually develops after 7 days in patients with mild/moderate/severe COVID-19 with features of Acute respiratory distress syndrome (ARDS) requiring mechanical ventilation along with presence of multiorgan dysfunction failure, metabolic acidosis and coagulation dysfunction.", [["sore throat", "ANATOMY", 289, 300], ["respiratory", "ANATOMY", 466, 477], ["respiratory", "ANATOMY", 617, 628], ["blood", "ANATOMY", 651, 656], ["lung", "ANATOMY", 710, 714], ["lung", "ANATOMY", 739, 743], ["multiorgan", "ANATOMY", 979, 989], ["fever", "DISEASE", 254, 259], ["cough", "DISEASE", 261, 266], ["rhinorrhea", "DISEASE", 277, 287], ["sore throat", "DISEASE", 289, 300], ["hemoptysis", "DISEASE", 317, 327], ["nausea", "DISEASE", 329, 335], ["vomiting", "DISEASE", 337, 345], ["diarrhea", "DISEASE", 347, 355], ["pneumonia", "DISEASE", 398, 407], ["fever", "DISEASE", 459, 464], ["respiratory symptoms", "DISEASE", 466, 486], ["dry cough", "DISEASE", 497, 506], ["shortness of breath", "DISEASE", 511, 530], ["dyspnea", "DISEASE", 608, 615], ["oxygen", "CHEMICAL", 657, 663], ["COVID", "DISEASE", 854, 859], ["Acute respiratory distress syndrome", "DISEASE", 880, 915], ["ARDS", "DISEASE", 917, 921], ["multiorgan dysfunction failure", "DISEASE", 979, 1009], ["metabolic acidosis", "DISEASE", 1011, 1029], ["coagulation dysfunction", "DISEASE", 1034, 1057], ["oxygen", "CHEMICAL", 657, 663], ["patients", "ORGANISM", 152, 160], ["c", "GENE_OR_GENE_PRODUCT", 589, 590], ["blood", "ORGANISM_SUBSTANCE", 651, 656], ["oxygen", "SIMPLE_CHEMICAL", 657, 663], ["lung", "ORGAN", 710, 714], ["lung", "ORGAN", 739, 743], ["patients", "ORGANISM", 819, 827], ["patients", "SPECIES", 152, 160], ["patients", "SPECIES", 819, 827], ["a.", "SPECIES", 227, 229], ["COVID", "TEST", 96, 101], ["COVID", "TEST", 142, 147], ["mild, moderate, severe", "PROBLEM", 186, 208], ["Mild COVID", "PROBLEM", 229, 239], ["low grade fever", "PROBLEM", 244, 259], ["cough", "PROBLEM", 261, 266], ["malaise", "PROBLEM", 268, 275], ["rhinorrhea", "PROBLEM", 277, 287], ["sore throat", "PROBLEM", 289, 300], ["hemoptysis", "PROBLEM", 317, 327], ["nausea", "PROBLEM", 329, 335], ["vomiting", "PROBLEM", 337, 345], ["diarrhea", "PROBLEM", 347, 355], ["pneumonia", "PROBLEM", 398, 407], ["mental changes", "PROBLEM", 423, 437], ["Moderate COVID", "PROBLEM", 440, 454], ["fever", "PROBLEM", 459, 464], ["respiratory symptoms", "PROBLEM", 466, 486], ["dry cough", "PROBLEM", 497, 506], ["shortness of breath", "PROBLEM", 511, 530], ["Severe COVID", "PROBLEM", 591, 603], ["dyspnea", "PROBLEM", 608, 615], ["respiratory frequency", "TEST", 617, 638], ["blood oxygen saturation", "TEST", 651, 674], ["PaO2/FiO2 ratio", "TEST", 681, 696], ["lung infiltrates", "PROBLEM", 710, 726], ["Critical COVID", "TEST", 767, 781], ["mild/moderate/severe COVID", "PROBLEM", 833, 859], ["Acute respiratory distress syndrome", "PROBLEM", 880, 915], ["ARDS", "PROBLEM", 917, 921], ["mechanical ventilation", "TREATMENT", 933, 955], ["multiorgan dysfunction failure", "PROBLEM", 979, 1009], ["metabolic acidosis", "PROBLEM", 1011, 1029], ["coagulation dysfunction", "PROBLEM", 1034, 1057], ["mild", "OBSERVATION_MODIFIER", 186, 190], ["moderate", "OBSERVATION_MODIFIER", 192, 200], ["severe", "OBSERVATION_MODIFIER", 202, 208], ["low grade", "OBSERVATION_MODIFIER", 244, 253], ["fever", "OBSERVATION", 254, 259], ["sore throat", "ANATOMY", 289, 300], ["without", "UNCERTAINTY", 309, 316], ["hemoptysis", "OBSERVATION", 317, 327], ["diarrhea", "OBSERVATION", 347, 355], ["pneumonia", "OBSERVATION", 398, 407], ["fever", "OBSERVATION", 459, 464], ["cough", "OBSERVATION", 501, 506], ["dyspnea", "OBSERVATION", 608, 615], ["respiratory", "ANATOMY", 617, 628], ["lung", "ANATOMY", 710, 714], ["infiltrates", "OBSERVATION", 715, 726], ["lung", "ANATOMY", 739, 743], ["mild", "OBSERVATION_MODIFIER", 833, 837], ["moderate", "OBSERVATION_MODIFIER", 838, 846], ["Acute", "OBSERVATION_MODIFIER", 880, 885], ["respiratory distress", "OBSERVATION", 886, 906], ["ARDS", "OBSERVATION", 917, 921], ["mechanical ventilation", "OBSERVATION", 933, 955], ["multiorgan dysfunction", "OBSERVATION", 979, 1001], ["failure", "OBSERVATION", 1002, 1009], ["metabolic acidosis", "OBSERVATION", 1011, 1029], ["coagulation dysfunction", "OBSERVATION", 1034, 1057]]]], "24e96c4bc16cfcb69cb4d9441c13fbe063c7e854": [["Infective gastroenteritis causes substantial morbidity and mortality worldwide.", [["Infective gastroenteritis", "DISEASE", 0, 25], ["Infective gastroenteritis", "PROBLEM", 0, 25], ["substantial morbidity", "PROBLEM", 33, 54], ["gastroenteritis", "OBSERVATION", 10, 25], ["substantial", "OBSERVATION_MODIFIER", 33, 44], ["morbidity", "OBSERVATION", 45, 54]]], ["Although various bacterial species have long been associated with gastrointestinal disease, 1 specific viral causes of these infections were not delineated until the early 1970s.", [["gastrointestinal", "ANATOMY", 66, 82], ["gastrointestinal disease", "DISEASE", 66, 90], ["infections", "DISEASE", 125, 135], ["gastrointestinal", "ORGAN", 66, 82], ["various bacterial species", "PROBLEM", 9, 34], ["gastrointestinal disease", "PROBLEM", 66, 90], ["these infections", "PROBLEM", 119, 135], ["bacterial species", "OBSERVATION", 17, 34], ["associated with", "UNCERTAINTY", 50, 65], ["gastrointestinal", "ANATOMY", 66, 82], ["disease", "OBSERVATION", 83, 90], ["infections", "OBSERVATION", 125, 135]]], ["However, with the discovery of Norwalk virus in 1972 2 and rotavirus in 1973, 3 the causative agents for most non-bacterial gastroenteritis infections were identified.", [["gastroenteritis infections", "DISEASE", 124, 150], ["Norwalk virus", "ORGANISM", 31, 44], ["Norwalk virus", "SPECIES", 31, 44], ["Norwalk virus", "PROBLEM", 31, 44], ["rotavirus", "PROBLEM", 59, 68], ["most non-bacterial gastroenteritis infections", "PROBLEM", 105, 150], ["infections", "OBSERVATION", 140, 150]]], ["Almost immediately, the spectrum of viruses causing gastrointestinal infection in adults was recognised as differing from that in children.", [["gastrointestinal", "ANATOMY", 52, 68], ["gastrointestinal infection", "DISEASE", 52, 78], ["gastrointestinal", "ORGAN", 52, 68], ["children", "ORGANISM", 130, 138], ["children", "SPECIES", 130, 138], ["viruses", "PROBLEM", 36, 43], ["gastrointestinal infection", "PROBLEM", 52, 78], ["viruses", "OBSERVATION", 36, 43], ["gastrointestinal", "ANATOMY", 52, 68], ["infection", "OBSERVATION", 69, 78]]], ["Among children younger than 2 years, nearly half of all cases of diarrhoea requiring admission to hospital can be attributed to rotavirus infection.", [["diarrhoea", "DISEASE", 65, 74], ["rotavirus infection", "DISEASE", 128, 147], ["children", "ORGANISM", 6, 14], ["rotavirus", "ORGANISM", 128, 137], ["children", "SPECIES", 6, 14], ["rotavirus", "SPECIES", 128, 137], ["diarrhoea", "PROBLEM", 65, 74], ["rotavirus infection", "PROBLEM", 128, 147], ["rotavirus", "OBSERVATION_MODIFIER", 128, 137], ["infection", "OBSERVATION", 138, 147]]], ["4 By contrast, among adults most non-bacterial outbreaks of gastroenteritis can be linked to the Norwalk-like viruses.", [["gastroenteritis", "DISEASE", 60, 75], ["Norwalk-like viruses", "ORGANISM", 97, 117], ["gastroenteritis", "PROBLEM", 60, 75], ["the Norwalk-like viruses", "PROBLEM", 93, 117], ["gastroenteritis", "OBSERVATION", 60, 75], ["viruses", "OBSERVATION", 110, 117]]], ["5 The important part played by viral pathogens besides the Norwalk-like viruses in adults with gastroenteritis is not yet fully appreciated.", [["gastroenteritis", "DISEASE", 95, 110], ["Norwalk-like viruses", "ORGANISM", 59, 79], ["viral pathogens", "PROBLEM", 31, 46], ["the Norwalk-like viruses", "PROBLEM", 55, 79], ["gastroenteritis", "PROBLEM", 95, 110], ["viruses", "OBSERVATION", 72, 79], ["gastroenteritis", "OBSERVATION", 95, 110]]], ["Specifically, the contribution of pathogens that typically affect children is not recognised by most clinicians who take care of adults.", [["children", "ORGANISM", 66, 74], ["adults", "ORGANISM", 129, 135], ["children", "SPECIES", 66, 74], ["pathogens", "PROBLEM", 34, 43], ["pathogens", "OBSERVATION", 34, 43]]], ["Such is the case for adult infections caused by the common paediatric pathogen rotavirus.", [["infections", "DISEASE", 27, 37], ["rotavirus", "DISEASE", 79, 88], ["rotavirus", "ORGANISM", 79, 88], ["adult infections", "PROBLEM", 21, 37], ["the common paediatric pathogen rotavirus", "PROBLEM", 48, 88], ["infections", "OBSERVATION", 27, 37]]], ["Here we review important features of rotavirus microbiology and pathophysiology, along with relevant clinical and epidemiological features of rotavirus infection.StructureIn 1973, Bishop and colleagues 3 described unique viral particles obtained from the duodenal mucosa of children with gastroenteritis.", [["duodenal mucosa", "ANATOMY", 255, 270], ["rotavirus infection", "DISEASE", 142, 161], ["gastroenteritis", "DISEASE", 288, 303], ["rotavirus", "ORGANISM", 37, 46], ["rotavirus", "ORGANISM", 142, 151], ["duodenal mucosa", "MULTI-TISSUE_STRUCTURE", 255, 270], ["children", "ORGANISM", 274, 282], ["children", "SPECIES", 274, 282], ["rotavirus", "SPECIES", 37, 46], ["rotavirus", "SPECIES", 142, 151], ["rotavirus microbiology", "TEST", 37, 59], ["rotavirus infection", "PROBLEM", 142, 161], ["unique viral particles", "PROBLEM", 214, 236], ["gastroenteritis", "PROBLEM", 288, 303], ["rotavirus infection", "OBSERVATION", 142, 161], ["viral particles", "OBSERVATION", 221, 236], ["duodenal mucosa", "ANATOMY", 255, 270], ["gastroenteritis", "OBSERVATION", 288, 303]]], ["Viruses with similar morphological appearance had been seen in 1963 in the intestinal tissue of mice with diarrhoea.", [["intestinal tissue", "ANATOMY", 75, 92], ["diarrhoea", "DISEASE", 106, 115], ["intestinal tissue", "TISSUE", 75, 92], ["mice", "ORGANISM", 96, 100], ["mice", "SPECIES", 96, 100], ["mice", "SPECIES", 96, 100], ["Viruses", "PROBLEM", 0, 7], ["diarrhoea", "PROBLEM", 106, 115], ["intestinal tissue", "ANATOMY", 75, 92], ["diarrhoea", "OBSERVATION", 106, 115]]], ["6 Under the electron microscope, the 70 nm diameter viral particles first described in these reports had a wheel-like appearance, prompting the name rotavirus, from the Latin rota (figure).", [["rotavirus", "ORGANISM", 149, 158], ["the electron microscope", "TEST", 8, 31], ["the 70 nm diameter viral particles", "TREATMENT", 33, 67], ["a wheel-like appearance", "PROBLEM", 105, 128], ["the name rotavirus", "PROBLEM", 140, 158]]], ["7 Rotavirus is a non-enveloped virus now classified within the Reoviridae family.", [["Rotavirus", "DISEASE", 2, 11], ["Reoviridae", "GENE_OR_GENE_PRODUCT", 63, 73], ["Rotavirus", "PROBLEM", 2, 11], ["a non-enveloped virus", "PROBLEM", 15, 36]]], ["11 segments of doublestranded RNA reside within the core.", [["doublestranded RNA", "RNA", 15, 33], ["11 segments of doublestranded RNA", "PROBLEM", 0, 33], ["segments", "OBSERVATION_MODIFIER", 3, 11], ["doublestranded RNA", "OBSERVATION", 15, 33], ["core", "OBSERVATION_MODIFIER", 52, 56]]], ["The RNA encodes six viral proteins (VP) that make up the viral capsid, and six non-structural proteins (NSP).", [["VP", "GENE_OR_GENE_PRODUCT", 36, 38], ["NSP", "GENE_OR_GENE_PRODUCT", 104, 107], ["viral proteins", "PROTEIN", 20, 34], ["VP", "PROTEIN", 36, 38], ["viral capsid", "PROTEIN", 57, 69], ["non-structural proteins", "PROTEIN", 79, 102], ["NSP", "PROTEIN", 104, 107], ["The RNA encodes six viral proteins", "PROBLEM", 0, 34], ["the viral capsid", "PROBLEM", 53, 69], ["viral proteins", "OBSERVATION", 20, 34], ["viral capsid", "OBSERVATION", 57, 69], ["non-structural proteins", "OBSERVATION", 79, 102]]], ["The core is surrounded by an inner capsid, composed mostly of VP6, the primary group antigen, 1, 8 and includes the epitope detected by most common diagnostic assays.", [["inner capsid", "ANATOMY", 29, 41], ["inner capsid", "CELLULAR_COMPONENT", 29, 41], ["VP6", "GENE_OR_GENE_PRODUCT", 62, 65], ["VP6", "PROTEIN", 62, 65], ["primary group antigen, 1, 8", "PROTEIN", 71, 98], ["an inner capsid", "PROBLEM", 26, 41], ["core", "OBSERVATION_MODIFIER", 4, 8], ["inner", "OBSERVATION_MODIFIER", 29, 34], ["capsid", "OBSERVATION", 35, 41]]], ["Other structural proteins also seem to confer some degree of group specificity.", [["structural proteins", "PROTEIN", 6, 25]]], ["9 The outer capsid is primarily composed of VP4 and VP7.", [["VP4", "GENE_OR_GENE_PRODUCT", 44, 47], ["VP7", "GENE_OR_GENE_PRODUCT", 52, 55], ["VP4", "PROTEIN", 44, 47], ["VP7", "PROTEIN", 52, 55], ["The outer capsid", "TREATMENT", 2, 18], ["VP4", "TEST", 44, 47], ["outer", "ANATOMY_MODIFIER", 6, 11], ["capsid", "OBSERVATION", 12, 18]]], ["10 VP4 contributes the spoke-like projections to the wheel-shaped appearance of rotavirus.", [["rotavirus", "DISEASE", 80, 89], ["VP4", "GENE_OR_GENE_PRODUCT", 3, 6], ["rotavirus", "ORGANISM", 80, 89], ["VP4", "PROTEIN", 3, 6], ["rotavirus", "PROBLEM", 80, 89], ["rotavirus", "OBSERVATION", 80, 89]]], ["This VP is cleaved by trypsin in vitro to yield VP5* and VP8Data included when >50% infectious dose ingested (>9 ffu). \u202015 of 38 patients had mild illness (including one patient with no antibody response or shedding). \u2021One of four volunteers experienced illness but no specific symptoms were recorded. \u00a7Summary percentages after rotavirus ingestion calculated only from data from studies in which full clinical syndrome of illness described.", [["VP", "CHEMICAL", 5, 7], ["illness", "DISEASE", 147, 154], ["illness", "DISEASE", 254, 261], ["illness", "DISEASE", 423, 430], ["VP", "GENE_OR_GENE_PRODUCT", 5, 7], ["trypsin", "GENE_OR_GENE_PRODUCT", 22, 29], ["VP5", "GENE_OR_GENE_PRODUCT", 48, 51], ["VP8Data", "GENE_OR_GENE_PRODUCT", 57, 64], ["patients", "ORGANISM", 129, 137], ["patient", "ORGANISM", 170, 177], ["volunteers", "ORGANISM", 231, 241], ["rotavirus", "ORGANISM", 329, 338], ["trypsin", "PROTEIN", 22, 29], ["VP5", "PROTEIN", 48, 51], ["VP8Data", "PROTEIN", 57, 64], ["patients", "SPECIES", 129, 137], ["patient", "SPECIES", 170, 177], ["rotavirus", "SPECIES", 329, 338], ["VP8Data", "TEST", 57, 64], ["mild illness", "PROBLEM", 142, 154], ["antibody response", "PROBLEM", 186, 203], ["illness", "PROBLEM", 254, 261], ["specific symptoms", "PROBLEM", 269, 286], ["rotavirus ingestion", "PROBLEM", 329, 348], ["data from studies", "TEST", 370, 387], ["illness", "PROBLEM", 423, 430], ["mild", "OBSERVATION_MODIFIER", 142, 146], ["illness", "OBSERVATION", 147, 154], ["no", "UNCERTAINTY", 266, 268]]], ["All percentages have been rounded to the nearest whole percentage point.Endemic diseaseadult serum in routine hospital samples are present throughout the year.", [["serum", "ANATOMY", 93, 98], ["samples", "ANATOMY", 119, 126], ["serum", "ORGANISM_SUBSTANCE", 93, 98], ["Endemic diseaseadult serum", "TEST", 72, 98], ["rounded", "OBSERVATION_MODIFIER", 26, 33]]], ["IgM concentrations increased with older age, and antibodies reached 20% in March and fell to 10-11% during the summer months.", [["IgM", "GENE_OR_GENE_PRODUCT", 0, 3], ["IgM", "PROTEIN", 0, 3], ["antibodies", "PROTEIN", 49, 59], ["IgM concentrations", "TEST", 0, 18], ["antibodies", "TEST", 49, 59], ["concentrations", "OBSERVATION_MODIFIER", 4, 18], ["increased", "OBSERVATION_MODIFIER", 19, 28]]], ["Cox and Medley attributed the high rates to IgM persistence, IgM crossreactivity, or possibly to non-seasonal high infection rates in adults.", [["infection", "DISEASE", 115, 124], ["IgM", "GENE_OR_GENE_PRODUCT", 44, 47], ["IgM", "GENE_OR_GENE_PRODUCT", 61, 64], ["IgM", "PROTEIN", 44, 47], ["IgM", "PROTEIN", 61, 64], ["Cox", "TEST", 0, 3], ["the high rates", "PROBLEM", 26, 40], ["IgM persistence", "PROBLEM", 44, 59], ["IgM crossreactivity", "PROBLEM", 61, 80], ["non-seasonal high infection rates", "PROBLEM", 97, 130], ["high", "OBSERVATION_MODIFIER", 110, 114], ["infection", "OBSERVATION", 115, 124]]], ["Other researchers have also found that rates of adult disease do not mirror the winter seasonality of infection in paediatric patients.", [["adult disease", "DISEASE", 48, 61], ["infection", "DISEASE", 102, 111], ["patients", "ORGANISM", 126, 134], ["patients", "SPECIES", 126, 134], ["adult disease", "PROBLEM", 48, 61], ["infection", "PROBLEM", 102, 111], ["infection", "OBSERVATION", 102, 111]]], ["71 These studies suggest that endemic disease in adults may not arise solely from unrecognised transmission of rotavirus from children to adults.Endemic diseaseThe contribution of rotavirus as a cause of endemic gastrointestinal disease varies according to geographic distribution and characteristics of patients.", [["gastrointestinal", "ANATOMY", 212, 228], ["rotavirus", "DISEASE", 111, 120], ["Endemic disease", "DISEASE", 145, 160], ["rotavirus", "DISEASE", 180, 189], ["gastrointestinal disease", "DISEASE", 212, 236], ["adults", "ORGANISM", 49, 55], ["rotavirus", "ORGANISM", 111, 120], ["children", "ORGANISM", 126, 134], ["rotavirus", "ORGANISM", 180, 189], ["gastrointestinal", "ORGAN", 212, 228], ["patients", "ORGANISM", 304, 312], ["children", "SPECIES", 126, 134], ["patients", "SPECIES", 304, 312], ["rotavirus", "SPECIES", 111, 120], ["rotavirus", "SPECIES", 180, 189], ["These studies", "TEST", 3, 16], ["endemic disease", "PROBLEM", 30, 45], ["rotavirus", "PROBLEM", 111, 120], ["Endemic disease", "PROBLEM", 145, 160], ["rotavirus", "PROBLEM", 180, 189], ["endemic gastrointestinal disease", "PROBLEM", 204, 236], ["endemic", "OBSERVATION_MODIFIER", 30, 37], ["disease", "OBSERVATION", 38, 45], ["disease", "OBSERVATION", 153, 160], ["rotavirus", "OBSERVATION", 180, 189], ["endemic", "OBSERVATION_MODIFIER", 204, 211], ["gastrointestinal", "ANATOMY", 212, 228], ["disease", "OBSERVATION", 229, 236]]], ["In a small prospective study in the UK, rotavirus caused 4\u00b71% of acute diarrhoea in adults admitted to hospital.", [["rotavirus", "DISEASE", 40, 49], ["diarrhoea", "DISEASE", 71, 80], ["rotavirus", "ORGANISM", 40, 49], ["rotavirus", "SPECIES", 40, 49], ["a small prospective study", "TEST", 3, 28], ["rotavirus", "PROBLEM", 40, 49], ["acute diarrhoea", "PROBLEM", 65, 80], ["small", "OBSERVATION_MODIFIER", 5, 10], ["acute", "OBSERVATION_MODIFIER", 65, 70], ["diarrhoea", "OBSERVATION", 71, 80]]], ["72 Similarly, 3% of acute diarrhoea in Switzerland, 73 3% of infectious diarrhoea pathogens in a Swedish clinic for infectious diseases, 74 5% of adults with gastroenteritis requiring admission in Thailand, 75 2-4% of adults older than 15 years with gastroenteritis presenting to their family physician in the Netherlands, 76 and nearly 4% of individuals older than 45 years in Michigan 77 were due to rotavirus.Endemic diseaseIn studies in other geographic areas even higher rates of infection have been seen.", [["diarrhoea", "DISEASE", 26, 35], ["diarrhoea", "DISEASE", 72, 81], ["infectious diseases", "DISEASE", 116, 135], ["gastroenteritis", "DISEASE", 158, 173], ["gastroenteritis", "DISEASE", 250, 265], ["rotavirus", "DISEASE", 402, 411], ["infection", "DISEASE", 485, 494], ["rotavirus", "ORGANISM", 402, 411], ["rotavirus", "SPECIES", 402, 411], ["acute diarrhoea", "PROBLEM", 20, 35], ["infectious diarrhoea pathogens", "PROBLEM", 61, 91], ["infectious diseases", "PROBLEM", 116, 135], ["gastroenteritis", "PROBLEM", 158, 173], ["gastroenteritis", "PROBLEM", 250, 265], ["rotavirus", "PROBLEM", 402, 411], ["Endemic diseaseIn studies", "TEST", 412, 437], ["infection", "PROBLEM", 485, 494], ["acute", "OBSERVATION_MODIFIER", 20, 25], ["diarrhoea", "OBSERVATION", 26, 35], ["infectious", "OBSERVATION_MODIFIER", 61, 71], ["gastroenteritis", "OBSERVATION", 158, 173], ["gastroenteritis", "OBSERVATION", 250, 265], ["higher", "OBSERVATION_MODIFIER", 469, 475], ["infection", "OBSERVATION", 485, 494]]], ["In Japan, Nakajima and colleagues 71 reported that group A rotavirus had a role in 14% of patients with diarrhoea.", [["rotavirus", "DISEASE", 59, 68], ["diarrhoea", "DISEASE", 104, 113], ["rotavirus", "ORGANISM", 59, 68], ["patients", "ORGANISM", 90, 98], ["patients", "SPECIES", 90, 98], ["rotavirus", "SPECIES", 59, 68], ["A rotavirus", "PROBLEM", 57, 68], ["diarrhoea", "PROBLEM", 104, 113], ["diarrhoea", "OBSERVATION", 104, 113]]], ["Pryor and colleagues 78 noted that rotavirus was second only to Campylobacter spp as a cause of diarrhoea among Australian adults, accounting for 17% of all cases.", [["Campylobacter spp", "DISEASE", 64, 81], ["diarrhoea", "DISEASE", 96, 105], ["rotavirus", "ORGANISM", 35, 44], ["Campylobacter spp", "ORGANISM", 64, 81], ["rotavirus", "SPECIES", 35, 44], ["rotavirus", "PROBLEM", 35, 44], ["Campylobacter spp", "PROBLEM", 64, 81], ["diarrhoea", "PROBLEM", 96, 105]]], ["In Indonesia, 42% of patients presenting with diarrhoea had rotavirus-positive stools compared with 11% of control samples.", [["samples", "ANATOMY", 115, 122], ["diarrhoea", "DISEASE", 46, 55], ["rotavirus-positive stools", "DISEASE", 60, 85], ["patients", "ORGANISM", 21, 29], ["samples", "CANCER", 115, 122], ["patients", "SPECIES", 21, 29], ["diarrhoea", "PROBLEM", 46, 55], ["rotavirus-positive stools", "PROBLEM", 60, 85]]], ["79 In a study of Mexican adults, 63% of patients presenting with acute gastroenteritis during winter months were positive for rotavirus.", [["gastroenteritis", "DISEASE", 71, 86], ["rotavirus", "DISEASE", 126, 135], ["patients", "ORGANISM", 40, 48], ["patients", "SPECIES", 40, 48], ["rotavirus", "SPECIES", 126, 135], ["acute gastroenteritis", "PROBLEM", 65, 86], ["rotavirus", "PROBLEM", 126, 135], ["acute", "OBSERVATION_MODIFIER", 65, 70], ["gastroenteritis", "OBSERVATION", 71, 86]]], ["80 Even these results might underestimate the true prevalence of endemic rotavirus infection.", [["rotavirus infection", "DISEASE", 73, 92], ["rotavirus", "ORGANISM", 73, 82], ["rotavirus", "SPECIES", 73, 82], ["endemic rotavirus infection", "PROBLEM", 65, 92], ["endemic", "OBSERVATION_MODIFIER", 65, 72], ["rotavirus infection", "OBSERVATION", 73, 92]]], ["Group C rotavirus is not routinely detected by commercial assays but it does contribute to endemic rotavirus infection worldwide.", [["rotavirus infection", "DISEASE", 99, 118], ["Group C rotavirus", "ORGANISM", 0, 17], ["rotavirus", "ORGANISM", 99, 108], ["rotavirus", "SPECIES", 99, 108], ["Group C rotavirus", "PROBLEM", 0, 17], ["endemic rotavirus infection", "PROBLEM", 91, 118], ["rotavirus", "OBSERVATION", 8, 17], ["endemic", "OBSERVATION_MODIFIER", 91, 98], ["rotavirus", "OBSERVATION_MODIFIER", 99, 108], ["infection", "OBSERVATION", 109, 118]]], ["In a study in the UK, 43% of patients were seropositive for group C rotavirus.", [["patients", "ORGANISM", 29, 37], ["C rotavirus", "ORGANISM", 66, 77], ["patients", "SPECIES", 29, 37], ["a study", "TEST", 3, 10], ["group C rotavirus", "PROBLEM", 60, 77]]], ["81Epidemic outbreaksAmong adults, clusters of rotavirus infections most frequently occur in communities that are otherwise sheltered from more routine exposure to rotavirus-infected children.", [["rotavirus infections", "DISEASE", 46, 66], ["rotavirus-infected", "DISEASE", 163, 181], ["rotavirus", "ORGANISM", 46, 55], ["rotavirus", "ORGANISM", 163, 172], ["children", "ORGANISM", 182, 190], ["children", "SPECIES", 182, 190], ["rotavirus", "SPECIES", 46, 55], ["rotavirus", "SPECIES", 163, 172], ["rotavirus infections", "PROBLEM", 46, 66], ["rotavirus infections", "OBSERVATION", 46, 66]]], ["82 One of the largest outbreaks involved nearly 3500 people in 1964, in an isolated area of Micronesia.", [["people", "ORGANISM", 53, 59], ["people", "SPECIES", 53, 59], ["largest", "OBSERVATION_MODIFIER", 14, 21], ["outbreaks", "OBSERVATION", 22, 31], ["isolated", "OBSERVATION_MODIFIER", 75, 83], ["area", "OBSERVATION_MODIFIER", 84, 88], ["Micronesia", "OBSERVATION", 92, 102]]], ["86 Outbreaks of rotavirus infection have also occurred in long-term health-care facilities, particularly those with close living quarters; compromised host immunity and multiple comorbid disorders might help facilitate the spread of infection.", [["rotavirus infection", "DISEASE", 16, 35], ["comorbid disorders", "DISEASE", 178, 196], ["infection", "DISEASE", 233, 242], ["rotavirus", "ORGANISM", 16, 25], ["rotavirus", "SPECIES", 16, 25], ["rotavirus infection", "PROBLEM", 16, 35], ["multiple comorbid disorders", "PROBLEM", 169, 196], ["infection", "PROBLEM", 233, 242], ["rotavirus", "OBSERVATION_MODIFIER", 16, 25], ["infection", "OBSERVATION", 26, 35], ["infection", "OBSERVATION", 233, 242]]], ["87-91 Cubitt and colleagues 88 described an epidemic of rotavirus among staff and patients in an extended-stay geriatric hospital, in which 15 of 39 residents developed symptoms and seven had confirmed rotavirus infection.", [["rotavirus", "DISEASE", 56, 65], ["rotavirus infection", "DISEASE", 202, 221], ["rotavirus", "ORGANISM", 56, 65], ["patients", "ORGANISM", 82, 90], ["rotavirus", "ORGANISM", 202, 211], ["patients", "SPECIES", 82, 90], ["rotavirus", "SPECIES", 56, 65], ["rotavirus", "SPECIES", 202, 211], ["symptoms", "PROBLEM", 169, 177], ["rotavirus infection", "PROBLEM", 202, 221], ["rotavirus", "OBSERVATION_MODIFIER", 202, 211], ["infection", "OBSERVATION", 212, 221]]], ["Halvorsrud and Orstavik 92 described an outbreak of 92 cases of acute gastroenteritis among nursing-home patients with identification of rotavirus by comparing acute and convalescent antibody titres.", [["gastroenteritis", "DISEASE", 70, 85], ["rotavirus", "DISEASE", 137, 146], ["patients", "ORGANISM", 105, 113], ["rotavirus", "ORGANISM", 137, 146], ["patients", "SPECIES", 105, 113], ["rotavirus", "SPECIES", 137, 146], ["Orstavik", "TREATMENT", 15, 23], ["acute gastroenteritis", "PROBLEM", 64, 85], ["rotavirus", "PROBLEM", 137, 146], ["acute and convalescent antibody titres", "PROBLEM", 160, 198], ["acute", "OBSERVATION_MODIFIER", 64, 69], ["gastroenteritis", "OBSERVATION", 70, 85]]], ["Rotavirus has been suggested as the causal pathogen in 5% of diarrhoea outbreaks in a study of institutions caring for elderly residents.", [["Rotavirus", "DISEASE", 0, 9], ["diarrhoea", "DISEASE", 61, 70], ["Rotavirus", "ORGANISM", 0, 9], ["Rotavirus", "PROBLEM", 0, 9], ["diarrhoea", "PROBLEM", 61, 70]]], ["93 Among adults, rotavirus outbreaks are not confined to geriatric populations.", [["rotavirus outbreaks", "DISEASE", 17, 36], ["adults", "ORGANISM", 9, 15], ["rotavirus", "SPECIES", 17, 26], ["rotavirus outbreaks", "PROBLEM", 17, 36]]], ["Group A rotavirus was associated with an outbreak of gastroenteritis among college students in the District of Colombia.", [["gastroenteritis", "DISEASE", 53, 68], ["rotavirus", "ORGANISM", 8, 17], ["rotavirus", "SPECIES", 8, 17], ["A rotavirus", "PROBLEM", 6, 17], ["gastroenteritis", "PROBLEM", 53, 68], ["rotavirus", "OBSERVATION", 8, 17], ["gastroenteritis", "OBSERVATION", 53, 68], ["Colombia", "OBSERVATION", 111, 119]]], ["58 Rotavirus also caused a waterborne outbreak of gastroenteritis in 1981 in Eagle-Vail and Avon, CO, USA in which severity of symptoms correlated with the amount of tap water consumed.", [["Rotavirus", "DISEASE", 3, 12], ["gastroenteritis", "DISEASE", 50, 65], ["Rotavirus", "PROBLEM", 3, 12], ["gastroenteritis", "PROBLEM", 50, 65], ["symptoms", "PROBLEM", 127, 135], ["tap water consumed", "TREATMENT", 166, 184], ["gastroenteritis", "OBSERVATION", 50, 65]]], ["94 Finally, Griffin and colleagues 95 screened 263 outbreaks of gastroenteritis in the USA between 1998 and 2000 and found that rotavirus was implicated in three outbreaks.", [["gastroenteritis", "DISEASE", 64, 79], ["rotavirus", "DISEASE", 128, 137], ["rotavirus", "ORGANISM", 128, 137], ["rotavirus", "SPECIES", 128, 137], ["gastroenteritis", "PROBLEM", 64, 79], ["rotavirus", "PROBLEM", 128, 137], ["gastroenteritis", "OBSERVATION", 64, 79], ["rotavirus", "OBSERVATION", 128, 137]]], ["Uniquely affecting Asia, group B rotavirus has been associated with outbreaks affecting large numbers of adults in broad geographic distributions of China and India.", [["rotavirus", "DISEASE", 33, 42], ["group B rotavirus", "ORGANISM", 25, 42], ["B rotavirus", "SPECIES", 31, 42], ["group B rotavirus", "PROBLEM", 25, 42], ["large", "OBSERVATION_MODIFIER", 88, 93], ["numbers", "OBSERVATION_MODIFIER", 94, 101]]], ["96, 97Travel-related gastroenteritisRotavirus has been implicated as an important contributor to travellers' diarrhoea among adults, especially among those visiting Central America and the Caribbean.", [["gastroenteritis", "DISEASE", 21, 36], ["Rotavirus", "DISEASE", 36, 45], ["diarrhoea", "DISEASE", 109, 118], ["Rotavirus", "ORGANISM", 36, 45], ["Rotavirus", "SPECIES", 36, 45], ["gastroenteritis", "PROBLEM", 21, 36], ["Rotavirus", "PROBLEM", 36, 45], ["gastroenteritis", "OBSERVATION", 21, 36]]], ["In a study of travellers returning from Jamaica, rotavirus was identified in 9% of individuals with diarrhoea, making the virus second only to enterotoxigenic Escherichia coli as a cause.", [["rotavirus", "DISEASE", 49, 58], ["diarrhoea", "DISEASE", 100, 109], ["enterotoxigenic Escherichia coli", "DISEASE", 143, 175], ["travellers", "ORGANISM", 14, 24], ["rotavirus", "ORGANISM", 49, 58], ["Escherichia coli", "ORGANISM", 159, 175], ["Escherichia coli", "SPECIES", 159, 175], ["rotavirus", "SPECIES", 49, 58], ["Escherichia coli", "SPECIES", 159, 175], ["a study", "TEST", 3, 10], ["rotavirus", "PROBLEM", 49, 58], ["diarrhoea", "PROBLEM", 100, 109], ["the virus", "PROBLEM", 118, 127], ["enterotoxigenic Escherichia coli", "PROBLEM", 143, 175], ["diarrhoea", "OBSERVATION", 100, 109], ["Escherichia coli", "OBSERVATION", 159, 175]]], ["98 In two studies of US students travelling in Mexico, electron microscopy identified rotavirus in about 25% of patients who had diarrhoea, compared with 3% and 15%, respectively, of symptom-free patients.", [["rotavirus", "DISEASE", 86, 95], ["diarrhoea", "DISEASE", 129, 138], ["rotavirus", "ORGANISM", 86, 95], ["patients", "ORGANISM", 112, 120], ["patients", "ORGANISM", 196, 204], ["patients", "SPECIES", 112, 120], ["patients", "SPECIES", 196, 204], ["electron microscopy", "TEST", 55, 74], ["rotavirus", "PROBLEM", 86, 95], ["diarrhoea", "PROBLEM", 129, 138], ["symptom", "PROBLEM", 183, 190], ["rotavirus", "OBSERVATION", 86, 95], ["diarrhoea", "OBSERVATION", 129, 138]]], ["99, 100 In a third study, a substantial rise of antibodies to rotavirus was seen in 17% of two student groups travelling to Mexico.", [["rotavirus", "DISEASE", 62, 71], ["rotavirus", "ORGANISM", 62, 71], ["antibodies", "PROTEIN", 48, 58], ["rotavirus", "SPECIES", 62, 71], ["a third study", "TEST", 11, 24], ["a substantial rise of antibodies", "PROBLEM", 26, 58], ["rotavirus", "PROBLEM", 62, 71], ["substantial", "OBSERVATION_MODIFIER", 28, 39], ["rise", "OBSERVATION_MODIFIER", 40, 44]]], ["101 By contrast, only 5-6% seroconverted to Norwalk virus.", [["Norwalk virus", "ORGANISM", 44, 57], ["Norwalk virus", "SPECIES", 44, 57]]], ["101 Ryder and colleagues 102 found rotavirus in 26% of Panamanian travellers to Mexico who had diarrhoea.", [["rotavirus", "DISEASE", 35, 44], ["diarrhoea", "DISEASE", 95, 104], ["rotavirus", "ORGANISM", 35, 44], ["rotavirus", "PROBLEM", 35, 44], ["diarrhoea", "PROBLEM", 95, 104], ["diarrhoea", "OBSERVATION", 95, 104]]], ["Sheridan and colleagues 103 similarly found that 36% of US Peace Corps volunteers and 30% of Panamanian travellers visiting Mexico had at least a four-fold increase in rotavirus antibody titres.", [["rotavirus", "ORGANISM", 168, 177], ["rotavirus antibody", "PROTEIN", 168, 186], ["rotavirus", "SPECIES", 168, 177], ["rotavirus antibody titres", "PROBLEM", 168, 193], ["rotavirus antibody titres", "OBSERVATION", 168, 193]]], ["Adult travellers with rotavirus shed 10-100 times less rotavirus than do paediatric patients.", [["rotavirus", "DISEASE", 55, 64], ["travellers", "ORGANISM", 6, 16], ["rotavirus", "ORGANISM", 22, 31], ["rotavirus", "ORGANISM", 55, 64], ["patients", "ORGANISM", 84, 92], ["patients", "SPECIES", 84, 92], ["rotavirus", "SPECIES", 55, 64], ["rotavirus", "TREATMENT", 22, 31]]], ["99, 100Infection transmitted from children to adultsAlthough rotavirus can be linked to adult gastroenteritis in each of the other settings, adults who are in contact with children are at particularly high risk of infection.", [["rotavirus", "DISEASE", 61, 70], ["gastroenteritis", "DISEASE", 94, 109], ["infection", "DISEASE", 214, 223], ["children", "ORGANISM", 34, 42], ["rotavirus", "ORGANISM", 61, 70], ["adults", "ORGANISM", 141, 147], ["children", "ORGANISM", 172, 180], ["children", "SPECIES", 34, 42], ["children", "SPECIES", 172, 180], ["rotavirus", "SPECIES", 61, 70], ["Infection", "PROBLEM", 7, 16], ["rotavirus", "PROBLEM", 61, 70], ["adult gastroenteritis", "PROBLEM", 88, 109], ["infection", "PROBLEM", 214, 223], ["gastroenteritis", "OBSERVATION", 94, 109], ["infection", "OBSERVATION", 214, 223]]], ["Transmission of rotavirus within families from children to parents seems to be a common event.", [["rotavirus", "ORGANISM", 16, 25], ["children", "ORGANISM", 47, 55], ["children", "SPECIES", 47, 55], ["rotavirus", "SPECIES", 16, 25], ["rotavirus", "PROBLEM", 16, 25], ["rotavirus", "OBSERVATION", 16, 25]]], ["Wenman and colleagues 55 showed prospectively that rotavirus infection occurred in 36 of 102 adults caring for children with rotavirus infection.", [["rotavirus infection", "DISEASE", 51, 70], ["rotavirus infection", "DISEASE", 125, 144], ["rotavirus", "ORGANISM", 51, 60], ["children", "ORGANISM", 111, 119], ["rotavirus", "ORGANISM", 125, 134], ["children", "SPECIES", 111, 119], ["rotavirus", "SPECIES", 51, 60], ["rotavirus", "SPECIES", 125, 134], ["rotavirus infection", "PROBLEM", 51, 70], ["rotavirus infection", "PROBLEM", 125, 144], ["rotavirus", "OBSERVATION_MODIFIER", 51, 60], ["infection", "OBSERVATION", 61, 70], ["infection", "OBSERVATION", 135, 144]]], ["By contrast, only four of 86 adults whose children had no documented rotavirus infection became infected.", [["rotavirus infection", "DISEASE", 69, 88], ["adults", "ORGANISM", 29, 35], ["children", "ORGANISM", 42, 50], ["rotavirus", "ORGANISM", 69, 78], ["children", "SPECIES", 42, 50], ["rotavirus", "SPECIES", 69, 78], ["rotavirus infection", "PROBLEM", 69, 88], ["infected", "PROBLEM", 96, 104], ["rotavirus", "OBSERVATION_MODIFIER", 69, 78], ["infection", "OBSERVATION", 79, 88], ["infected", "OBSERVATION", 96, 104]]], ["55 Grimwood and colleagues 57 confirmed this finding in a report that a third of adult family members in New Zealand developed evidence of rotavirus infection.", [["rotavirus infection", "DISEASE", 139, 158], ["rotavirus", "ORGANISM", 139, 148], ["rotavirus", "SPECIES", 139, 148], ["rotavirus infection", "PROBLEM", 139, 158], ["evidence of", "UNCERTAINTY", 127, 138], ["rotavirus", "OBSERVATION_MODIFIER", 139, 148], ["infection", "OBSERVATION", 149, 158]]], ["The same phenomenon has been seen among parents of more severely ill children.", [["ill", "DISEASE", 65, 68], ["children", "ORGANISM", 69, 77], ["children", "SPECIES", 69, 77]]], ["Kim and colleagues 104 found evidence of rotavirus infection in 55% of adult contacts of children who were admitted to hospital with rotavirus, compared with 17% of adult contacts whose children wereRotavirus infection in adultsnot infected.", [["rotavirus infection", "DISEASE", 41, 60], ["rotavirus", "DISEASE", 133, 142], ["Rotavirus infection", "DISEASE", 199, 218], ["rotavirus", "ORGANISM", 41, 50], ["children", "ORGANISM", 89, 97], ["children", "ORGANISM", 186, 194], ["children", "SPECIES", 89, 97], ["children", "SPECIES", 186, 194], ["rotavirus", "SPECIES", 41, 50], ["rotavirus", "SPECIES", 133, 142], ["rotavirus infection", "PROBLEM", 41, 60], ["rotavirus", "PROBLEM", 133, 142], ["Rotavirus infection", "PROBLEM", 199, 218], ["evidence of", "UNCERTAINTY", 29, 40], ["rotavirus", "OBSERVATION_MODIFIER", 41, 50], ["infection", "OBSERVATION", 51, 60], ["infection", "OBSERVATION", 209, 218], ["infected", "OBSERVATION", 232, 240]]], ["More casual contact might also be sufficient to facilitate rotavirus transmission from children to adults.", [["rotavirus", "ORGANISM", 59, 68], ["children", "ORGANISM", 87, 95], ["children", "SPECIES", 87, 95], ["rotavirus", "SPECIES", 59, 68]]], ["Rodriguez and colleagues 105 reported that nine of 12 adults experienced illness after exposure to children infected with rotavirus in a playgroup.", [["illness", "DISEASE", 73, 80], ["rotavirus", "DISEASE", 122, 131], ["adults", "ORGANISM", 54, 60], ["children", "ORGANISM", 99, 107], ["rotavirus", "ORGANISM", 122, 131], ["children", "SPECIES", 99, 107], ["rotavirus", "SPECIES", 122, 131], ["rotavirus", "PROBLEM", 122, 131], ["rotavirus", "OBSERVATION", 122, 131]]], ["Although substantial evidence is lacking, child-to-adult transmission of rotavirus is accepted to occur with some frequency on paediatric wards.", [["rotavirus", "DISEASE", 73, 82], ["rotavirus", "ORGANISM", 73, 82], ["rotavirus", "SPECIES", 73, 82], ["rotavirus", "PROBLEM", 73, 82], ["rotavirus", "OBSERVATION", 73, 82]]], ["Many paediatric nurses, medical students, and house officers experience symptoms of gastroenteritis during the winter months when most paediatric rotavirus infections are encountered.", [["gastroenteritis", "DISEASE", 84, 99], ["rotavirus infections", "DISEASE", 146, 166], ["rotavirus", "ORGANISM", 146, 155], ["rotavirus", "SPECIES", 146, 155], ["symptoms", "PROBLEM", 72, 80], ["gastroenteritis", "PROBLEM", 84, 99], ["most paediatric rotavirus infections", "PROBLEM", 130, 166], ["gastroenteritis", "OBSERVATION", 84, 99], ["infections", "OBSERVATION", 156, 166]]], ["Von Bonsdorff and colleagues 106 described paediatric nurses at several different locations with acute gastroenteritis caused by rotavirus.", [["gastroenteritis", "DISEASE", 103, 118], ["rotavirus", "DISEASE", 129, 138], ["rotavirus", "ORGANISM", 129, 138], ["rotavirus", "SPECIES", 129, 138], ["acute gastroenteritis", "PROBLEM", 97, 118], ["rotavirus", "PROBLEM", 129, 138], ["acute", "OBSERVATION_MODIFIER", 97, 102], ["gastroenteritis", "OBSERVATION", 103, 118], ["rotavirus", "OBSERVATION", 129, 138]]], ["Among seven hospital staff that developed diarrhoea after direct contact with children with diarrhoea staying in hospital, a rise in antibody titres was detected in three.", [["diarrhoea", "DISEASE", 42, 51], ["diarrhoea", "DISEASE", 92, 101], ["children", "ORGANISM", 78, 86], ["children", "SPECIES", 78, 86], ["diarrhoea", "PROBLEM", 42, 51], ["diarrhoea", "PROBLEM", 92, 101], ["a rise in antibody titres", "PROBLEM", 123, 148], ["antibody titres", "OBSERVATION", 133, 148]]], ["104 Interestingly, in the same study, six of 45 medical students reported gastroenteritis.", [["gastroenteritis", "DISEASE", 74, 89], ["gastroenteritis", "PROBLEM", 74, 89], ["gastroenteritis", "OBSERVATION", 74, 89]]], ["Three of the students had rotavirus particles present on electron microscopy and were noted to be more ill than the parents of the children who were infected.", [["rotavirus", "ORGANISM", 26, 35], ["children", "ORGANISM", 131, 139], ["children", "SPECIES", 131, 139], ["rotavirus", "SPECIES", 26, 35], ["rotavirus particles", "PROBLEM", 26, 45], ["electron microscopy", "TEST", 57, 76], ["infected", "OBSERVATION", 149, 157]]], ["All had diarrhoea for 3-6 days and two of the three had low-grade fever and vomiting.", [["diarrhoea", "DISEASE", 8, 17], ["fever", "DISEASE", 66, 71], ["vomiting", "DISEASE", 76, 84], ["diarrhoea", "PROBLEM", 8, 17], ["low-grade fever", "PROBLEM", 56, 71], ["vomiting", "PROBLEM", 76, 84], ["diarrhoea", "OBSERVATION", 8, 17], ["low-grade", "OBSERVATION_MODIFIER", 56, 65], ["fever", "OBSERVATION", 66, 71]]], ["Another case report supports transmission of rotavirus from children to hospital caretakers.", [["rotavirus", "DISEASE", 45, 54], ["rotavirus", "ORGANISM", 45, 54], ["children", "ORGANISM", 60, 68], ["children", "SPECIES", 60, 68], ["rotavirus", "SPECIES", 45, 54]]], ["107DiagnosisElectron microscopy, which permits visualisation of the pathognomonic wheel-like appearance, was initially used for diagnostic purposes, but ELISA or EIA have become more commonly used.", [["107DiagnosisElectron microscopy", "TEST", 0, 31], ["diagnostic purposes", "TEST", 128, 147], ["ELISA", "TEST", 153, 158], ["EIA", "TEST", 162, 165]]], ["108, 109 The false-positive rate of commercial assays is 3-5%.", [["The false", "TEST", 9, 18], ["commercial assays", "TEST", 36, 53], ["false", "OBSERVATION", 13, 18], ["positive", "OBSERVATION_MODIFIER", 19, 27]]], ["69 One of the biggest limitations of most commercial assays is that they do not detect non-group-A rotavirus.", [["non-group-A rotavirus", "ORGANISM", 87, 108], ["A rotavirus", "PROBLEM", 97, 108], ["biggest", "OBSERVATION_MODIFIER", 14, 21]]], ["68, 110 Other more sensitive and newer methods are being used in research.", [["newer methods", "TREATMENT", 33, 46]]], ["One such method is PCR, which is up to 1000 times more sensitive than immunoassays.", [["PCR", "TEST", 19, 22], ["immunoassays", "TEST", 70, 82]]], ["109 In one study using PCR, 30% of otherwise healthy children shed virus for 25-57 days after symptoms developed.", [["children", "ORGANISM", 53, 61], ["children", "SPECIES", 53, 61], ["one study", "TEST", 7, 16], ["PCR", "TEST", 23, 26], ["symptoms", "PROBLEM", 94, 102]]], ["111 Although stool cultures are routinely tested for bacterial pathogens, the low frequency of detecting a positive result calls the usefulness of this practice into question.", [["stool cultures", "ANATOMY", 13, 27], ["stool cultures", "CELL", 13, 27], ["stool cultures", "TEST", 13, 27], ["bacterial pathogens", "PROBLEM", 53, 72]]], ["Rotavirus infection can occur in a similar number of patients to some bacterial pathogens.", [["Rotavirus infection", "DISEASE", 0, 19], ["Rotavirus", "ORGANISM", 0, 9], ["patients", "ORGANISM", 53, 61], ["patients", "SPECIES", 53, 61], ["Rotavirus infection", "PROBLEM", 0, 19], ["some bacterial pathogens", "PROBLEM", 65, 89], ["infection", "OBSERVATION", 10, 19], ["bacterial", "OBSERVATION_MODIFIER", 70, 79], ["pathogens", "OBSERVATION", 80, 89]]], ["Sending a sample of rotavirus antigen for testing by ELISA or EIA could potentially cut costs if by doing so either hospital stay or procedures could be avoided.", [["rotavirus", "ORGANISM", 20, 29], ["rotavirus antigen", "PROTEIN", 20, 37], ["rotavirus", "SPECIES", 20, 29], ["a sample of rotavirus antigen", "TEST", 8, 37], ["testing", "TEST", 42, 49], ["ELISA", "TEST", 53, 58], ["EIA", "TEST", 62, 65], ["procedures", "TREATMENT", 133, 143]]], ["Such a cost-benefit analysis in adult patients has not been published.", [["patients", "ORGANISM", 38, 46], ["patients", "SPECIES", 38, 46], ["a cost-benefit analysis", "TEST", 5, 28]]], ["One limitation is that adults might shed less rotavirus in faeces than do children, further hampering diagnosis.", [["rotavirus", "DISEASE", 46, 55], ["adults", "ORGANISM", 23, 29], ["rotavirus", "ORGANISM", 46, 55], ["faeces", "ORGANISM_SUBDIVISION", 59, 65], ["children", "ORGANISM", 74, 82], ["children", "SPECIES", 74, 82]]], ["100 We suggest that obtaining rotavirus antigen testing for patients admitted to hospital with risk factors for rotavirus infection will be cost effective if additional inpatient studies can be avoided.", [["rotavirus antigen", "CHEMICAL", 30, 47], ["rotavirus infection", "DISEASE", 112, 131], ["rotavirus", "ORGANISM", 30, 39], ["patients", "ORGANISM", 60, 68], ["rotavirus", "ORGANISM", 112, 121], ["patients", "SPECIES", 60, 68], ["rotavirus", "SPECIES", 30, 39], ["rotavirus", "SPECIES", 112, 121], ["rotavirus antigen testing", "TEST", 30, 55], ["risk factors", "PROBLEM", 95, 107], ["rotavirus infection", "PROBLEM", 112, 131], ["additional inpatient studies", "TEST", 158, 186]]], ["Determination of rotavirus infection may also be beneficial if infectious patients can be isolated to prevent nosocomial spread.", [["rotavirus infection", "DISEASE", 17, 36], ["rotavirus", "ORGANISM", 17, 26], ["patients", "ORGANISM", 74, 82], ["patients", "SPECIES", 74, 82], ["rotavirus", "SPECIES", 17, 26], ["rotavirus infection", "PROBLEM", 17, 36], ["nosocomial spread", "PROBLEM", 110, 127], ["rotavirus", "OBSERVATION_MODIFIER", 17, 26], ["infection", "OBSERVATION", 27, 36]]], ["A positive rotavirus antigen test might also allow physicians to avoid prescribing antibiotics for travel-related rotavirus infections.TreatmentTreatment of rotavirus infections is primarily directed at symptom relief and restoration of normal physiological function.", [["rotavirus infections", "DISEASE", 114, 134], ["rotavirus infections", "DISEASE", 157, 177], ["rotavirus", "ORGANISM", 11, 20], ["rotavirus", "ORGANISM", 114, 123], ["rotavirus", "ORGANISM", 157, 166], ["rotavirus", "SPECIES", 11, 20], ["rotavirus", "SPECIES", 114, 123], ["rotavirus", "SPECIES", 157, 166], ["A positive rotavirus antigen test", "PROBLEM", 0, 33], ["prescribing antibiotics", "TREATMENT", 71, 94], ["rotavirus infections", "PROBLEM", 114, 134], ["Treatment", "TREATMENT", 135, 144], ["rotavirus infections", "PROBLEM", 157, 177], ["symptom relief", "TREATMENT", 203, 217], ["positive", "OBSERVATION_MODIFIER", 2, 10], ["rotavirus", "OBSERVATION", 11, 20], ["rotavirus infections", "OBSERVATION", 114, 134], ["rotavirus infections", "OBSERVATION", 157, 177], ["normal physiological function", "OBSERVATION", 237, 266]]], ["Oral rehydration should be attempted initially.", [["Oral", "ANATOMY", 0, 4], ["Oral", "ORGANISM_SUBDIVISION", 0, 4], ["Oral rehydration", "TREATMENT", 0, 16]]], ["In most developing countries, oral rehydration salt solutions are used extensively in children.", [["oral", "ANATOMY", 30, 34], ["rehydration salt", "CHEMICAL", 35, 51], ["oral", "ORGANISM_SUBDIVISION", 30, 34], ["children", "ORGANISM", 86, 94], ["children", "SPECIES", 86, 94], ["oral rehydration salt solutions", "TREATMENT", 30, 61]]], ["Most adults can be managed by encouraging them to drink fluids.", [["adults", "ORGANISM", 5, 11]]], ["An additional intervention that has been used is administration of Lactobacillus spp bacteria to shorten the duration of diarrhoea.", [["diarrhoea", "DISEASE", 121, 130], ["Lactobacillus spp", "ORGANISM", 67, 84], ["An additional intervention", "TREATMENT", 0, 26], ["Lactobacillus spp bacteria", "PROBLEM", 67, 93], ["diarrhoea", "PROBLEM", 121, 130], ["diarrhoea", "OBSERVATION", 121, 130]]], ["112, 113 Although seldom used in children, codeine, loperamide, and diphenoxylate can help with symptom relief and control of the volume of diarrhoea.", [["codeine", "CHEMICAL", 43, 50], ["loperamide", "CHEMICAL", 52, 62], ["diphenoxylate", "CHEMICAL", 68, 81], ["diarrhoea", "DISEASE", 140, 149], ["codeine", "CHEMICAL", 43, 50], ["loperamide", "CHEMICAL", 52, 62], ["diphenoxylate", "CHEMICAL", 68, 81], ["children", "ORGANISM", 33, 41], ["codeine", "SIMPLE_CHEMICAL", 43, 50], ["loperamide", "SIMPLE_CHEMICAL", 52, 62], ["diphenoxylate", "SIMPLE_CHEMICAL", 68, 81], ["children", "SPECIES", 33, 41], ["codeine", "TREATMENT", 43, 50], ["loperamide", "TREATMENT", 52, 62], ["diphenoxylate", "TREATMENT", 68, 81], ["symptom relief", "PROBLEM", 96, 110], ["diarrhoea", "PROBLEM", 140, 149], ["diarrhoea", "OBSERVATION", 140, 149]]], ["114 Bismuth salicylate, in a placebo-controlled double-blinded trial, was efficacious in treating the symptoms of rotavirus diarrhoea.", [["Bismuth salicylate", "CHEMICAL", 4, 22], ["rotavirus diarrhoea", "DISEASE", 114, 133], ["Bismuth salicylate", "CHEMICAL", 4, 22], ["Bismuth salicylate", "SIMPLE_CHEMICAL", 4, 22], ["rotavirus", "ORGANISM", 114, 123], ["rotavirus", "SPECIES", 114, 123], ["Bismuth salicylate", "TREATMENT", 4, 22], ["a placebo", "TREATMENT", 27, 36], ["double-blinded trial", "TREATMENT", 48, 68], ["the symptoms", "PROBLEM", 98, 110], ["rotavirus diarrhoea", "PROBLEM", 114, 133], ["rotavirus diarrhoea", "OBSERVATION", 114, 133]]], ["115 Trial use of bismuth salicylate can be considered in adults when other coexistent infectious causes have been ruled out.TreatmentIf symptoms cannot be controlled and the patient becomes dehydrated, administration of intravenous fluids and hospital admission might be necessary.", [["intravenous", "ANATOMY", 220, 231], ["bismuth salicylate", "CHEMICAL", 17, 35], ["bismuth salicylate", "CHEMICAL", 17, 35], ["bismuth salicylate", "SIMPLE_CHEMICAL", 17, 35], ["patient", "ORGANISM", 174, 181], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 220, 231], ["patient", "SPECIES", 174, 181], ["bismuth salicylate", "TREATMENT", 17, 35], ["other coexistent infectious causes", "PROBLEM", 69, 103], ["Treatment", "TREATMENT", 124, 133], ["symptoms", "PROBLEM", 136, 144], ["dehydrated", "PROBLEM", 190, 200], ["intravenous fluids", "TREATMENT", 220, 238], ["infectious", "OBSERVATION", 86, 96]]], ["Rarely, extraordinary measures have been attempted to help resolve rotavirus infections.", [["rotavirus infections", "DISEASE", 67, 87], ["rotavirus", "ORGANISM", 67, 76], ["rotavirus", "SPECIES", 67, 76], ["rotavirus infections", "PROBLEM", 67, 87]]], ["For example, human breastmilk has been provided to immunodeficient infected children to help resolve chronic diarrhoea.", [["immunodeficient infected", "DISEASE", 51, 75], ["diarrhoea", "DISEASE", 109, 118], ["human", "ORGANISM", 13, 18], ["children", "ORGANISM", 76, 84], ["human", "SPECIES", 13, 18], ["children", "SPECIES", 76, 84], ["human", "SPECIES", 13, 18], ["immunodeficient infected children", "TREATMENT", 51, 84], ["chronic diarrhoea", "PROBLEM", 101, 118], ["chronic", "OBSERVATION_MODIFIER", 101, 108], ["diarrhoea", "OBSERVATION", 109, 118]]], ["Several groups report oral administration of human serum immunoglobulins possessing antirotavirus activity to bind free rotavirus antigen.", [["oral", "ANATOMY", 22, 26], ["serum", "ANATOMY", 51, 56], ["oral", "ORGANISM_SUBDIVISION", 22, 26], ["human", "ORGANISM", 45, 50], ["serum", "ORGANISM_SUBSTANCE", 51, 56], ["immunoglobulins", "GENE_OR_GENE_PRODUCT", 57, 72], ["antirotavirus", "SIMPLE_CHEMICAL", 84, 97], ["rotavirus antigen", "GENE_OR_GENE_PRODUCT", 120, 137], ["human serum immunoglobulins", "PROTEIN", 45, 72], ["rotavirus antigen", "PROTEIN", 120, 137], ["human", "SPECIES", 45, 50], ["human", "SPECIES", 45, 50], ["oral administration", "TREATMENT", 22, 41], ["human serum immunoglobulins", "TREATMENT", 45, 72], ["antirotavirus activity", "TREATMENT", 84, 106], ["bind free rotavirus antigen", "PROBLEM", 110, 137]]], ["Guarino and colleagues 116 noted a mean duration of diarrhoea of 76 h in children who received one oral dose of 300 mg/kg human serum immunoglobulin, compared with 131 h in children who did not.", [["oral", "ANATOMY", 99, 103], ["serum", "ANATOMY", 128, 133], ["diarrhoea", "DISEASE", 52, 61], ["children", "ORGANISM", 73, 81], ["oral", "ORGANISM_SUBDIVISION", 99, 103], ["human", "ORGANISM", 122, 127], ["serum", "ORGANISM_SUBSTANCE", 128, 133], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 134, 148], ["children", "ORGANISM", 173, 181], ["human serum immunoglobulin", "PROTEIN", 122, 148], ["children", "SPECIES", 73, 81], ["human", "SPECIES", 122, 127], ["children", "SPECIES", 173, 181], ["human", "SPECIES", 122, 127], ["diarrhoea", "PROBLEM", 52, 61], ["human serum immunoglobulin", "TREATMENT", 122, 148]]], ["In a study involving three immunocompromised children with chronic rotavirus diarrhoea, oral administration of human serum immunoglobulins (IgG 150 mg/kg) cleared rotavirus antigen in all three, but rotavirus antigen recurred in two.", [["oral", "ANATOMY", 88, 92], ["serum", "ANATOMY", 117, 122], ["rotavirus diarrhoea", "DISEASE", 67, 86], ["children", "ORGANISM", 45, 53], ["oral", "ORGANISM_SUBDIVISION", 88, 92], ["human", "ORGANISM", 111, 116], ["serum", "ORGANISM_SUBSTANCE", 117, 122], ["immunoglobulins", "GENE_OR_GENE_PRODUCT", 123, 138], ["rotavirus", "ORGANISM", 163, 172], ["human serum immunoglobulins", "PROTEIN", 111, 138], ["IgG", "PROTEIN", 140, 143], ["rotavirus antigen", "PROTEIN", 163, 180], ["rotavirus antigen", "PROTEIN", 199, 216], ["children", "SPECIES", 45, 53], ["rotavirus", "SPECIES", 67, 76], ["human", "SPECIES", 111, 116], ["rotavirus", "SPECIES", 67, 76], ["human", "SPECIES", 111, 116], ["rotavirus", "SPECIES", 163, 172], ["rotavirus", "SPECIES", 199, 208], ["a study", "TEST", 3, 10], ["chronic rotavirus diarrhoea", "PROBLEM", 59, 86], ["oral administration", "TREATMENT", 88, 107], ["human serum immunoglobulins", "TREATMENT", 111, 138], ["IgG", "TREATMENT", 140, 143], ["rotavirus antigen", "PROBLEM", 163, 180], ["rotavirus antigen", "PROBLEM", 199, 216], ["chronic", "OBSERVATION_MODIFIER", 59, 66], ["rotavirus diarrhoea", "OBSERVATION", 67, 86]]], ["117 Among adults, oral immunoglobulin administration of 5-6 g daily for 5 days to bone-marrow-transplant recipients has been successful.", [["oral", "ANATOMY", 18, 22], ["bone", "ANATOMY", 82, 86], ["marrow", "ANATOMY", 87, 93], ["adults", "ORGANISM", 10, 16], ["oral", "ORGANISM_SUBDIVISION", 18, 22], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 23, 37], ["bone-marrow", "MULTI-TISSUE_STRUCTURE", 82, 93], ["recipients", "ORGANISM", 105, 115], ["oral immunoglobulin administration", "TREATMENT", 18, 52], ["transplant recipients", "TREATMENT", 94, 115], ["bone", "ANATOMY", 82, 86], ["marrow", "ANATOMY", 87, 93]]], ["118PreventionPrevention of rotavirus infection can be facilitated by avoiding exposures and faecal-oral spread.", [["oral", "ANATOMY", 99, 103], ["rotavirus infection", "DISEASE", 27, 46], ["rotavirus", "ORGANISM", 27, 36], ["faecal", "ORGANISM_SUBDIVISION", 92, 98], ["oral", "ORGANISM_SUBDIVISION", 99, 103], ["rotavirus", "SPECIES", 27, 36], ["rotavirus infection", "PROBLEM", 27, 46], ["faecal-oral spread", "PROBLEM", 92, 110], ["rotavirus infection", "OBSERVATION", 27, 46]]], ["Contact with sick children and potentially contaminated food and water should be avoided.", [["children", "ORGANISM", 18, 26], ["children", "SPECIES", 18, 26]]], ["Since 43% of rotavirus virions placed on human fingers survive for 60 min, thorough hand washing is critical in prevention.", [["virions", "ANATOMY", 23, 30], ["fingers", "ANATOMY", 47, 54], ["hand", "ANATOMY", 84, 88], ["rotavirus virions", "ORGANISM", 13, 30], ["human", "ORGANISM", 41, 46], ["fingers", "ORGANISM_SUBDIVISION", 47, 54], ["hand", "ORGANISM_SUBDIVISION", 84, 88], ["human", "SPECIES", 41, 46], ["rotavirus", "SPECIES", 13, 22], ["human", "SPECIES", 41, 46], ["rotavirus virions", "TREATMENT", 13, 30], ["thorough hand washing", "TREATMENT", 75, 96]]], ["119 Contact isolation for patients diagnosed with rotavirus infection is necessary, generally for the duration of hospital stay, because of sustained faecal shedding of low concentrations of virus.", [["faecal", "ANATOMY", 150, 156], ["rotavirus infection", "DISEASE", 50, 69], ["patients", "ORGANISM", 26, 34], ["rotavirus", "ORGANISM", 50, 59], ["faecal", "ORGANISM_SUBSTANCE", 150, 156], ["patients", "SPECIES", 26, 34], ["rotavirus", "SPECIES", 50, 59], ["rotavirus infection", "PROBLEM", 50, 69], ["sustained faecal shedding", "PROBLEM", 140, 165], ["low concentrations of virus", "PROBLEM", 169, 196], ["infection", "OBSERVATION", 60, 69], ["low concentrations", "OBSERVATION_MODIFIER", 169, 187]]], ["120 Gloves, gowns, isolation, and rigorous hand washing should be used in the care of individuals infected with rotavirus.", [["hand", "ANATOMY", 43, 47], ["rotavirus", "DISEASE", 112, 121], ["individuals", "ORGANISM", 86, 97], ["rotavirus", "ORGANISM", 112, 121], ["rotavirus", "SPECIES", 112, 121], ["Gloves", "TREATMENT", 4, 10], ["gowns", "TREATMENT", 12, 17], ["isolation", "TREATMENT", 19, 28], ["rigorous hand washing", "TREATMENT", 34, 55], ["rotavirus", "PROBLEM", 112, 121]]], ["121 Sattar and colleagues 122 reported that rotavirus survives best in low humidity on non-porous surfaces at room temperature or cooler.", [["rotavirus", "ORGANISM", 44, 53], ["rotavirus", "SPECIES", 44, 53], ["rotavirus survives", "PROBLEM", 44, 62], ["low humidity", "OBSERVATION_MODIFIER", 71, 83]]], ["Phenolic disinfectants do not inactivate rotavirus; instead hypochlorite or sodium dichloroisocyanurate tablets with a free chlorine concentration of at least 20 000 parts per million are recommended.", [["hypochlorite", "CHEMICAL", 60, 72], ["sodium dichloroisocyanurate", "CHEMICAL", 76, 103], ["chlorine", "CHEMICAL", 124, 132], ["hypochlorite", "CHEMICAL", 60, 72], ["sodium dichloroisocyanurate", "CHEMICAL", 76, 103], ["chlorine", "CHEMICAL", 124, 132], ["rotavirus", "ORGANISM", 41, 50], ["hypochlorite", "SIMPLE_CHEMICAL", 60, 72], ["sodium dichloroisocyanurate tablets", "SIMPLE_CHEMICAL", 76, 111], ["chlorine", "SIMPLE_CHEMICAL", 124, 132], ["rotavirus", "SPECIES", 41, 50], ["Phenolic disinfectants", "TREATMENT", 0, 22], ["rotavirus", "PROBLEM", 41, 50], ["hypochlorite", "TREATMENT", 60, 72], ["sodium dichloroisocyanurate tablets", "TREATMENT", 76, 111], ["a free chlorine concentration", "TREATMENT", 117, 146]]], ["110 A 70% ethanol solution is also effective in inactivation of rotavirus and can help to prevent environmental spread.", [["ethanol", "CHEMICAL", 10, 17], ["rotavirus", "DISEASE", 64, 73], ["ethanol", "CHEMICAL", 10, 17], ["ethanol", "SIMPLE_CHEMICAL", 10, 17], ["rotavirus", "ORGANISM", 64, 73], ["rotavirus", "SPECIES", 64, 73], ["A 70% ethanol solution", "TREATMENT", 4, 26], ["rotavirus", "TREATMENT", 64, 73], ["environmental spread", "PROBLEM", 98, 118]]], ["120 Rotavirus infection in adults has been successfully prevented by use of a commercially available Review disinfectant spray on rotavirus contaminated fomites under experimental conditions.", [["Rotavirus infection", "DISEASE", 4, 23], ["rotavirus contaminated fomites", "DISEASE", 130, 160], ["Rotavirus", "ORGANISM", 4, 13], ["adults", "ORGANISM", 27, 33], ["rotavirus", "ORGANISM", 130, 139], ["rotavirus", "SPECIES", 130, 139], ["Rotavirus infection", "PROBLEM", 4, 23], ["Review disinfectant spray", "TREATMENT", 101, 126], ["rotavirus", "TREATMENT", 130, 139], ["Rotavirus", "OBSERVATION_MODIFIER", 4, 13], ["infection", "OBSERVATION", 14, 23]]], ["123 Given the substantial disease-related morbidity and mortality associated with rotavirus, the development of an effective vaccine is a priority.", [["rotavirus", "DISEASE", 82, 91], ["rotavirus", "SPECIES", 82, 91], ["the substantial disease", "PROBLEM", 10, 33], ["morbidity", "PROBLEM", 42, 51], ["mortality", "PROBLEM", 56, 65], ["rotavirus", "PROBLEM", 82, 91], ["an effective vaccine", "TREATMENT", 112, 132], ["substantial", "OBSERVATION_MODIFIER", 14, 25], ["disease", "OBSERVATION", 26, 33]]], ["Although multiple vaccines were under development, the tetravalent rhesus-human reassortant rotavirus vaccine (RRV-TV) seemed to produce the best results.", [["rhesus-", "ORGANISM", 67, 74], ["human", "ORGANISM", 74, 79], ["reassortant rotavirus", "ORGANISM", 80, 101], ["RRV", "ORGANISM", 111, 114], ["rhesus-", "SPECIES", 67, 74], ["human", "SPECIES", 74, 79], ["reassortant rotavirus vaccine", "SPECIES", 80, 109], ["rhesus-human reassortant rotavirus", "SPECIES", 67, 101], ["RRV", "SPECIES", 111, 114], ["multiple vaccines", "TREATMENT", 9, 26], ["the tetravalent rhesus", "TREATMENT", 51, 73], ["human reassortant rotavirus vaccine", "TREATMENT", 74, 109], ["multiple", "OBSERVATION_MODIFIER", 9, 17], ["vaccines", "OBSERVATION", 18, 26]]], ["The RRV-TV vaccine prevented about half of rotavirus infections, but was much more effective in preventing severe disease.", [["rotavirus infections", "DISEASE", 43, 63], ["RRV", "ORGANISM", 4, 7], ["rotavirus", "ORGANISM", 43, 52], ["RRV", "SPECIES", 4, 7], ["rotavirus", "SPECIES", 43, 52], ["The RRV", "TEST", 0, 7], ["TV vaccine", "TREATMENT", 8, 18], ["rotavirus infections", "PROBLEM", 43, 63], ["severe disease", "PROBLEM", 107, 121], ["rotavirus", "OBSERVATION_MODIFIER", 43, 52], ["infections", "OBSERVATION", 53, 63], ["severe", "OBSERVATION_MODIFIER", 107, 113], ["disease", "OBSERVATION", 114, 121]]], ["124, 125 Shortly after the vaccine was approved, the vaccine adverse-event monitoring system noted by mid-1999 an excess of cases of intussusception among recently vaccinated infants, eventually prompting the vaccine to be withdrawn.", [["intussusception", "DISEASE", 133, 148], ["infants", "ORGANISM", 175, 182], ["infants", "SPECIES", 175, 182], ["the vaccine", "TREATMENT", 23, 34], ["the vaccine", "TREATMENT", 49, 60], ["intussusception", "PROBLEM", 133, 148], ["the vaccine", "TREATMENT", 205, 216], ["intussusception", "OBSERVATION", 133, 148]]], ["Two sharply differing perspectives on the risk and benefits of the RRV-TV vaccine and the Advisory Committee on Immunization Practices' confirmation of its decision to withdraw its recommendation for the vaccine have been put forward.", [["RRV", "ORGANISM", 67, 70], ["RRV", "SPECIES", 67, 70], ["the RRV-TV vaccine", "TREATMENT", 63, 81], ["Immunization Practices", "TREATMENT", 112, 134], ["the vaccine", "TREATMENT", 200, 211], ["sharply", "OBSERVATION_MODIFIER", 4, 11], ["differing", "OBSERVATION_MODIFIER", 12, 21]]], ["126, 127 Other vaccines are under development.PreventionVaccines have been primarily developed to attempt to decrease the severity of rotavirus infections in children.", [["rotavirus infections", "DISEASE", 134, 154], ["rotavirus", "ORGANISM", 134, 143], ["children", "ORGANISM", 158, 166], ["children", "SPECIES", 158, 166], ["rotavirus", "SPECIES", 134, 143], ["Other vaccines", "TREATMENT", 9, 23], ["PreventionVaccines", "TREATMENT", 46, 64], ["rotavirus infections", "PROBLEM", 134, 154], ["rotavirus", "OBSERVATION_MODIFIER", 134, 143], ["infections", "OBSERVATION", 144, 154]]], ["Although vaccines seem to be fairly safe in adults from the vaccine trials, we are unaware of any plan to consider vaccination in adult patients.", [["patients", "ORGANISM", 136, 144], ["patients", "SPECIES", 136, 144], ["vaccines", "TREATMENT", 9, 17], ["the vaccine trials", "TREATMENT", 56, 74], ["vaccination", "TREATMENT", 115, 126]]], ["Vaccination could theoretically be used in adult patients considering travel to Central America or the Caribbean or among immunocompromised patients to prevent or lessen the severity of rotavirus diarrhoea.Salient pointsDespite recognition as an important cause of gastroenteritis in children, rotavirus's role in adult gastroenteritis is underappreciated.", [["rotavirus diarrhoea", "DISEASE", 186, 205], ["gastroenteritis", "DISEASE", 265, 280], ["gastroenteritis", "DISEASE", 320, 335], ["patients", "ORGANISM", 49, 57], ["patients", "ORGANISM", 140, 148], ["rotavirus", "ORGANISM", 186, 195], ["children", "ORGANISM", 284, 292], ["rotavirus", "ORGANISM", 294, 303], ["patients", "SPECIES", 49, 57], ["patients", "SPECIES", 140, 148], ["children", "SPECIES", 284, 292], ["rotavirus", "SPECIES", 186, 195], ["rotavirus", "SPECIES", 294, 303], ["Vaccination", "TREATMENT", 0, 11], ["rotavirus diarrhoea", "PROBLEM", 186, 205], ["gastroenteritis", "PROBLEM", 265, 280], ["rotavirus's role", "PROBLEM", 294, 310], ["adult gastroenteritis", "PROBLEM", 314, 335], ["rotavirus", "OBSERVATION", 186, 195], ["gastroenteritis", "OBSERVATION", 265, 280], ["gastroenteritis", "OBSERVATION", 320, 335]]], ["Immunity to rotavirus is incomplete and most people have multiple infections over their lifetime.", [["rotavirus", "DISEASE", 12, 21], ["infections", "DISEASE", 66, 76], ["rotavirus", "ORGANISM", 12, 21], ["people", "ORGANISM", 45, 51], ["people", "SPECIES", 45, 51], ["rotavirus", "SPECIES", 12, 21], ["rotavirus", "PROBLEM", 12, 21], ["multiple infections", "PROBLEM", 57, 76], ["multiple", "OBSERVATION_MODIFIER", 57, 65], ["infections", "OBSERVATION", 66, 76]]], ["Adults with rotavirus can be asymptomatic, but the most common symptoms are nausea, malaise, headache, abdominal cramping, diarrhoea, and fever.", [["abdominal", "ANATOMY", 103, 112], ["nausea", "DISEASE", 76, 82], ["headache", "DISEASE", 93, 101], ["abdominal cramping", "DISEASE", 103, 121], ["diarrhoea", "DISEASE", 123, 132], ["fever", "DISEASE", 138, 143], ["Adults", "ORGANISM", 0, 6], ["rotavirus", "ORGANISM", 12, 21], ["abdominal", "ORGANISM_SUBDIVISION", 103, 112], ["Adults", "SPECIES", 0, 6], ["rotavirus", "SPECIES", 12, 21], ["rotavirus", "PROBLEM", 12, 21], ["asymptomatic", "PROBLEM", 29, 41], ["the most common symptoms", "PROBLEM", 47, 71], ["nausea", "PROBLEM", 76, 82], ["malaise", "PROBLEM", 84, 91], ["headache", "PROBLEM", 93, 101], ["abdominal cramping", "PROBLEM", 103, 121], ["diarrhoea", "PROBLEM", 123, 132], ["fever", "PROBLEM", 138, 143], ["rotavirus", "OBSERVATION", 12, 21], ["abdominal", "ANATOMY", 103, 112], ["cramping", "OBSERVATION", 113, 121], ["diarrhoea", "OBSERVATION", 123, 132], ["fever", "OBSERVATION", 138, 143]]], ["Adults at particular risk of rotavirus infection are travellers, adults exposed to infected children, and immunocompromised people.", [["rotavirus infection", "DISEASE", 29, 48], ["Adults", "ORGANISM", 0, 6], ["rotavirus", "ORGANISM", 29, 38], ["children", "ORGANISM", 92, 100], ["people", "ORGANISM", 124, 130], ["Adults", "SPECIES", 0, 6], ["children", "SPECIES", 92, 100], ["people", "SPECIES", 124, 130], ["rotavirus", "SPECIES", 29, 38], ["rotavirus infection", "PROBLEM", 29, 48], ["rotavirus", "OBSERVATION_MODIFIER", 29, 38], ["infection", "OBSERVATION", 39, 48]]], ["Group A rotavirus, the most common human pathogen, can be diagnosed with many different commercial assays, but all have limited sensitivity.", [["Group A rotavirus", "ORGANISM", 0, 17], ["human", "ORGANISM", 35, 40], ["human", "SPECIES", 35, 40], ["Group A rotavirus", "SPECIES", 0, 17], ["human", "SPECIES", 35, 40], ["Group A rotavirus", "PROBLEM", 0, 17], ["rotavirus", "OBSERVATION", 8, 17]]], ["Rotavirus testing might be beneficial in certain clinical settings if detecting rotavirus would change management of patients or prevent nosocomial spread.", [["Rotavirus", "DISEASE", 0, 9], ["rotavirus", "ORGANISM", 80, 89], ["patients", "ORGANISM", 117, 125], ["patients", "SPECIES", 117, 125], ["Rotavirus", "SPECIES", 0, 9], ["rotavirus", "SPECIES", 80, 89], ["Rotavirus testing", "TEST", 0, 17], ["rotavirus", "PROBLEM", 80, 89], ["nosocomial spread", "PROBLEM", 137, 154], ["nosocomial spread", "OBSERVATION", 137, 154]]], ["Treatment is primarily symptomatic.", [["symptomatic", "PROBLEM", 23, 34], ["symptomatic", "OBSERVATION_MODIFIER", 23, 34]]], ["Rotavirus should be considered in the differential diagnosis of adult infectious gastroenteritis.Conflicts of interestWe have no conflicts of interest.Search strategy and selection criteriaWe identified sources for this review by searches of Medline with use of the key words \"rotavirus infection\" and \"adult.\"", [["Rotavirus", "DISEASE", 0, 9], ["infectious gastroenteritis", "DISEASE", 70, 96], ["rotavirus infection", "DISEASE", 277, 296], ["Rotavirus", "ORGANISM", 0, 9], ["Rotavirus", "TREATMENT", 0, 9], ["adult infectious gastroenteritis", "PROBLEM", 64, 96], ["rotavirus infection", "PROBLEM", 277, 296], ["infectious", "OBSERVATION_MODIFIER", 70, 80], ["gastroenteritis", "OBSERVATION", 81, 96], ["no", "UNCERTAINTY", 126, 128], ["conflicts", "OBSERVATION", 129, 138]]], ["The search strategy and selection criteria included all English and human studies from the year 1970 until the present.", [["human", "ORGANISM", 68, 73], ["human", "SPECIES", 68, 73], ["human", "SPECIES", 68, 73], ["human studies", "TEST", 68, 81]]], ["Review of the references of the papers retrieved by the initial search allowed for additional studies to be identified and considered for inclusion.", [["additional studies", "TEST", 83, 101]]]], "PMC7127734": [["IntroductionIn April 2009, a novel influenza A virus (H1N1) of swine origin emerged in the United States [1] and triggered alarm about its pandemic potential [2] across the world.", [["influenza A virus", "DISEASE", 35, 52], ["influenza A virus", "ORGANISM", 35, 52], ["swine", "ORGANISM", 63, 68], ["influenza A virus (H1N1", "SPECIES", 35, 58], ["swine", "SPECIES", 63, 68], ["influenza A virus", "SPECIES", 35, 52], ["swine", "SPECIES", 63, 68], ["a novel influenza A virus", "PROBLEM", 27, 52]]], ["On June 11, 2009, the World Health Organisation announced that the virus had become pandemic and is now referred to as the pandemic (H1N1) 2009 virus [3].IntroductionTropical countries experience influenza year round, with 2 peaks corresponding to the rainy seasons [4].", [["pandemic", "DISEASE", 123, 131], ["influenza", "DISEASE", 196, 205], ["pandemic (H1N1) 2009 virus", "ORGANISM", 123, 149], ["the virus", "PROBLEM", 63, 72], ["pandemic", "PROBLEM", 84, 92], ["influenza", "PROBLEM", 196, 205]]], ["Singapore is a tropical island city, and as such, influenza activity is seen all year-round and usually peaks in June and December [5].", [["influenza", "DISEASE", 50, 59], ["influenza activity", "PROBLEM", 50, 68], ["tropical", "OBSERVATION_MODIFIER", 15, 23], ["island", "OBSERVATION", 24, 30]]], ["The high prevalence of seasonal influenza during peak times in Singapore is comparable to that during typical influenza seasons in temperate countries in the Southern Hemisphere and underscores the need for not neglecting seasonal influenza in Singapore [6].", [["influenza", "DISEASE", 32, 41], ["influenza", "DISEASE", 110, 119], ["influenza", "DISEASE", 231, 240], ["seasonal influenza", "PROBLEM", 23, 41], ["typical influenza seasons", "PROBLEM", 102, 127], ["seasonal influenza", "PROBLEM", 222, 240], ["high prevalence", "OBSERVATION_MODIFIER", 4, 19], ["seasonal", "OBSERVATION_MODIFIER", 23, 31], ["influenza", "OBSERVATION", 32, 41]]], ["Chow et al. reported in 2006 that the annual all-cause death rate from seasonal influenza in Singapore has been estimated at 14.8/100,000 person-years and the proportion of deaths among persons \u226565 years of age is 11.3 times higher than that among the general population [7].", [["death", "DISEASE", 55, 60], ["influenza", "DISEASE", 80, 89], ["deaths", "DISEASE", 173, 179], ["persons", "ORGANISM", 186, 193], ["persons", "SPECIES", 186, 193], ["death rate", "PROBLEM", 55, 65], ["seasonal influenza", "PROBLEM", 71, 89]]], ["It was also found that the previous pandemic influenza-related excess deaths in Singapore were comparable to those in temperate countries [8].IntroductionSince Severe Acute Respiratory Syndrome (SARS) in 2003, Singapore has been on the alert for pandemic influenza.", [["influenza", "DISEASE", 45, 54], ["deaths", "DISEASE", 70, 76], ["Acute Respiratory Syndrome", "DISEASE", 167, 193], ["SARS", "DISEASE", 195, 199], ["influenza", "DISEASE", 255, 264], ["the previous pandemic influenza", "PROBLEM", 23, 54], ["excess deaths", "PROBLEM", 63, 76], ["Severe Acute Respiratory Syndrome", "PROBLEM", 160, 193], ["pandemic influenza", "PROBLEM", 246, 264], ["Severe", "OBSERVATION_MODIFIER", 160, 166], ["Acute", "OBSERVATION_MODIFIER", 167, 172], ["Respiratory Syndrome", "OBSERVATION", 173, 193]]], ["With the world-wide announcement of the new H1N1 influenza strain, Singapore implemented strict containment measures for pandemic (H1N1) 2009 with enhanced surveillance and hospital isolation since April 25, 2009.", [["influenza", "DISEASE", 49, 58], ["pandemic", "DISEASE", 121, 129], ["H1N1 influenza", "SPECIES", 44, 58], ["the new H1N1 influenza strain", "PROBLEM", 36, 65], ["strict containment measures", "TREATMENT", 89, 116], ["pandemic", "PROBLEM", 121, 129], ["new", "OBSERVATION_MODIFIER", 40, 43], ["H1N1", "OBSERVATION", 44, 48]]], ["Pandemic (H1N1) 2009 was first detected in Singapore during the week beginning June 14, and the weekly incidence rapidly increased until the week ending July 25, when all influenza cases were caused by pandemic (H1N1) 2009 virus [6].", [["Pandemic", "DISEASE", 0, 8], ["influenza", "DISEASE", 171, 180], ["pandemic", "DISEASE", 202, 210], ["pandemic (H1N1) 2009 virus", "ORGANISM", 202, 228], ["pandemic (H1N1) 2009 virus", "SPECIES", 202, 228], ["Pandemic", "PROBLEM", 0, 8], ["all influenza cases", "PROBLEM", 167, 186], ["pandemic (H1N1)", "PROBLEM", 202, 217], ["increased", "OBSERVATION_MODIFIER", 121, 130]]], ["Meanwhile, the primary healthcare workers (HCWs) at both private and public clinics were at the frontline, managing patients with acute respiratory illness and influenza-like illness.", [["respiratory", "ANATOMY", 136, 147], ["acute respiratory illness", "DISEASE", 130, 155], ["influenza-like illness", "DISEASE", 160, 182], ["patients", "ORGANISM", 116, 124], ["patients", "SPECIES", 116, 124], ["acute respiratory illness", "PROBLEM", 130, 155], ["influenza", "PROBLEM", 160, 169], ["illness", "PROBLEM", 175, 182], ["acute", "OBSERVATION_MODIFIER", 130, 135], ["respiratory", "ANATOMY", 136, 147], ["illness", "OBSERVATION", 148, 155]]], ["All HCWs were at risk of contracting the H1N1 virus from their patients.IntroductionAnnual seasonal influenza vaccination has been found to be effective for preventing influenza virus infection and its complications.", [["influenza virus infection", "DISEASE", 168, 193], ["patients", "ORGANISM", 63, 71], ["influenza virus", "ORGANISM", 168, 183], ["patients", "SPECIES", 63, 71], ["influenza virus", "SPECIES", 168, 183], ["H1N1 virus", "SPECIES", 41, 51], ["influenza virus", "SPECIES", 168, 183], ["the H1N1 virus", "PROBLEM", 37, 51], ["Annual seasonal influenza vaccination", "TREATMENT", 84, 121], ["influenza virus infection", "PROBLEM", 168, 193], ["its complications", "PROBLEM", 198, 215], ["H1N1", "OBSERVATION", 41, 45]]], ["A recent study by Kheok et al. described the benefits in the reduction of morbidity with influenza vaccination of HCWs in Singapore [9].", [["A recent study", "TEST", 0, 14], ["influenza vaccination", "TREATMENT", 89, 110]]], ["The Singapore Ministry of Health (MOH) recommends that elderly persons aged 65 years or above, young children aged six months to five years, those with chronic heart and lung diseases and persons with diabetes mellitus or renal diseases, who are at a higher risk of developing complications from influenza [10], to undergo routine annual flu vaccination [11].", [["heart", "ANATOMY", 160, 165], ["lung", "ANATOMY", 170, 174], ["renal", "ANATOMY", 222, 227], ["chronic heart and lung diseases", "DISEASE", 152, 183], ["diabetes mellitus", "DISEASE", 201, 218], ["renal diseases", "DISEASE", 222, 236], ["influenza", "DISEASE", 296, 305], ["persons", "ORGANISM", 63, 70], ["children", "ORGANISM", 101, 109], ["heart", "ORGAN", 160, 165], ["lung", "ORGAN", 170, 174], ["renal", "ORGAN", 222, 227], ["persons", "SPECIES", 63, 70], ["children", "SPECIES", 101, 109], ["persons", "SPECIES", 188, 195], ["chronic heart and lung diseases", "PROBLEM", 152, 183], ["diabetes mellitus", "PROBLEM", 201, 218], ["renal diseases", "PROBLEM", 222, 236], ["developing complications", "PROBLEM", 266, 290], ["influenza", "PROBLEM", 296, 305], ["routine annual flu vaccination", "TREATMENT", 323, 353], ["heart", "ANATOMY", 160, 165], ["lung", "ANATOMY", 170, 174], ["diseases", "OBSERVATION", 175, 183], ["renal", "ANATOMY", 222, 227], ["diseases", "OBSERVATION", 228, 236], ["complications", "OBSERVATION", 277, 290]]], ["Seasonal influenza vaccination has also been shown to reduce infection and absenteeism among HCWs [9].", [["infection", "DISEASE", 61, 70], ["Seasonal influenza vaccination", "TREATMENT", 0, 30], ["infection", "PROBLEM", 61, 70]]], ["Despite this recommendation, and free vaccine offered by healthcare organisations, the vaccination rates among HCWs have remained low in many countries [12], [13], [14], [15], [16], [17], [18].IntroductionThe same recommendations for vaccination were given with priority for vaccinating individuals at the highest risk of complications of influenza and to HCWs who are most at risk of transmitting the infection through their occupations [11].", [["influenza", "DISEASE", 339, 348], ["infection", "DISEASE", 402, 411], ["[13]", "SIMPLE_CHEMICAL", 158, 162], ["[14]", "SIMPLE_CHEMICAL", 164, 168], ["[15]", "SIMPLE_CHEMICAL", 170, 174], ["[16]", "SIMPLE_CHEMICAL", 176, 180], ["[17]", "SIMPLE_CHEMICAL", 182, 186], ["free vaccine", "TREATMENT", 33, 45], ["the vaccination rates", "TREATMENT", 83, 104], ["vaccination", "TREATMENT", 234, 245], ["vaccinating individuals", "TREATMENT", 275, 298], ["influenza", "PROBLEM", 339, 348], ["the infection", "PROBLEM", 398, 411], ["infection", "OBSERVATION", 402, 411]]], ["HCWs, as described by the Association of National Health Occupational Physicians (ANHOPS), include (1) clinical staff who have regular, clinical contact with patients grouped conveniently as doctors, dentists, nurses and dental assistants, pharmacists, physiotherapists, dieticians, medical social workers, psychologists and radiographers; (2) laboratory personnel who may have direct contact with potentially infectious clinical specimens and may additionally be exposed to pathogens in the laboratory; and (3) non-clinical ancillary staff who may have social contact with patients, including receptionists, health attendants and maintenance personnel such as cleaners.IntroductionIt is not known how many HCWs are willing to accept the new H1N1 vaccine and whether the individuals with chronic pulmonary or cardiovascular system disorders who are at higher risk of developing influenza-related complications are more willing to receive the vaccination.", [["specimens", "ANATOMY", 430, 439], ["pulmonary", "ANATOMY", 796, 805], ["cardiovascular system", "ANATOMY", 809, 830], ["chronic pulmonary or cardiovascular system disorders", "DISEASE", 788, 840], ["influenza", "DISEASE", 878, 887], ["patients", "ORGANISM", 158, 166], ["patients", "ORGANISM", 574, 582], ["HCWs", "ORGANISM", 707, 711], ["pulmonary", "ORGAN", 796, 805], ["patients", "SPECIES", 158, 166], ["patients", "SPECIES", 574, 582], ["the new H1N1 vaccine", "TREATMENT", 734, 754], ["chronic pulmonary or cardiovascular system disorders", "PROBLEM", 788, 840], ["influenza", "PROBLEM", 878, 887], ["related complications", "PROBLEM", 888, 909], ["the vaccination", "TREATMENT", 938, 953], ["chronic", "OBSERVATION_MODIFIER", 788, 795], ["pulmonary", "ANATOMY", 796, 805], ["cardiovascular system", "ANATOMY", 809, 830], ["influenza", "OBSERVATION", 878, 887]]], ["This study aims to compare the willingness to accept the novel H1N1 vaccination among HCWs in a primary healthcare clinic with and without chronic medical conditions and describes their reasons for choosing not to be vaccinated and whether they needed additional information to make an informed decision to accept the vaccination.Materials and methodsAn anonymous, self-administered survey was conducted in November 2009 over 1 month.", [["This study", "TEST", 0, 10], ["chronic medical conditions", "PROBLEM", 139, 165], ["the vaccination", "TREATMENT", 314, 329]]], ["Participants were asked to complete the questionnaire anonymously and drop them in the box provided in their respective clinics.", [["Participants", "SPECIES", 0, 12]]], ["The ICNs collected the completed questionnaires and returned to the research team for data entry and analysis.Materials and methodsThe research team developed the questionnaire and pilot tested among ten colleagues.", [["data entry and analysis", "TEST", 86, 109]]], ["In addition to demographic characteristics, participants were asked if they have any of the following chronic conditions (asthma, hypertension, diabetes mellitus, high cholesterol/lipids, stroke, heart disease, cancer and chronic renal disease).Materials and methodsParticipants were also asked their perceptions towards pandemic H1N1 and seasonal influenza vaccines and willingness to accept these vaccines if both were readily available.", [["heart", "ANATOMY", 196, 201], ["cancer", "ANATOMY", 211, 217], ["renal", "ANATOMY", 230, 235], ["asthma", "DISEASE", 122, 128], ["hypertension", "DISEASE", 130, 142], ["diabetes mellitus", "DISEASE", 144, 161], ["cholesterol", "CHEMICAL", 168, 179], ["stroke", "DISEASE", 188, 194], ["heart disease", "DISEASE", 196, 209], ["cancer", "DISEASE", 211, 217], ["chronic renal disease", "DISEASE", 222, 243], ["H1N1", "DISEASE", 330, 334], ["influenza", "DISEASE", 348, 357], ["cholesterol", "CHEMICAL", 168, 179], ["cholesterol", "SIMPLE_CHEMICAL", 168, 179], ["heart", "ORGAN", 196, 201], ["cancer", "CANCER", 211, 217], ["renal", "ORGAN", 230, 235], ["H1N1", "ORGANISM", 330, 334], ["participants", "SPECIES", 44, 56], ["Participants", "SPECIES", 266, 278], ["chronic conditions", "PROBLEM", 102, 120], ["asthma", "PROBLEM", 122, 128], ["hypertension", "PROBLEM", 130, 142], ["diabetes mellitus", "PROBLEM", 144, 161], ["high cholesterol/lipids", "PROBLEM", 163, 186], ["stroke", "PROBLEM", 188, 194], ["heart disease", "PROBLEM", 196, 209], ["cancer", "PROBLEM", 211, 217], ["chronic renal disease)", "PROBLEM", 222, 244], ["pandemic H1N1", "PROBLEM", 321, 334], ["seasonal influenza vaccines", "TREATMENT", 339, 366], ["these vaccines", "TREATMENT", 393, 407], ["heart", "ANATOMY", 196, 201], ["disease", "OBSERVATION", 202, 209], ["cancer", "OBSERVATION", 211, 217], ["chronic", "OBSERVATION_MODIFIER", 222, 229], ["renal", "ANATOMY", 230, 235], ["disease", "OBSERVATION", 236, 243]]], ["They were asked to indicate reasons if they did not receive the seasonal influenza vaccination in the last 2 years or chose not to be vaccinated against H1N1.", [["influenza", "DISEASE", 73, 82], ["H1N1", "DISEASE", 153, 157], ["the seasonal influenza vaccination", "TREATMENT", 60, 94], ["H1N1", "PROBLEM", 153, 157]]], ["All participants were asked if they needed additional information to make a decision to accept H1N1 vaccination.Materials and methodsIncomplete questionnaires (<90% complete) and those without any response to the designation and chronic medical history sections were excluded from this analysis.", [["sections", "ANATOMY", 253, 261], ["H1N1", "DISEASE", 95, 99], ["participants", "SPECIES", 4, 16], ["H1N1 vaccination", "TREATMENT", 95, 111], ["this analysis", "TEST", 281, 294], ["chronic", "OBSERVATION_MODIFIER", 229, 236]]], ["We also excluded the respondents who did not answer these 3 questions: (1) Did you receive the influenza vaccination in the last 2 years? (2) Would you be going for the influenza vaccination this year? and (3) If vaccination against H1N1 is made available, would you go for it?Materials and methodsThe respondents were divided into 4 groups of HCWs.", [["influenza", "DISEASE", 95, 104], ["influenza", "DISEASE", 169, 178], ["H1N1", "DISEASE", 233, 237], ["H1N1", "ORGANISM", 233, 237], ["HCWs", "ORGANISM", 344, 348], ["H1N1", "SPECIES", 233, 237], ["the influenza vaccination", "TREATMENT", 91, 116], ["the influenza vaccination", "TREATMENT", 165, 190], ["vaccination", "TREATMENT", 213, 224], ["H1N1", "PROBLEM", 233, 237]]], ["Doctors and dentists were grouped under \u201cMedical\u201d; nurses and dental assistants under \u201cNursing\u201d; dieticians, pharmacists, radiographers, laboratory technicians, psychologists and social workers under \u201cAllied Health\u201d; clinic support and operations workers including the outsourced contract workers were under \u201cOperations\u201d.Materials and methodsWe compared willingness to accept the H1N1 vaccination among respondents with and without chronic conditions.", [["the H1N1 vaccination", "TREATMENT", 376, 396], ["chronic conditions", "PROBLEM", 432, 450]]], ["Among those who refused to accept vaccination, we analysed their reasons for refusal to be vaccinated by the 4 groups.Materials and methodsData was analysed using PASW (version 18.0).", [["vaccination", "TREATMENT", 34, 45], ["methodsData", "TEST", 132, 143], ["PASW", "TEST", 163, 167]]], ["Significance testing of proportions was carried out using Chi-square test, where a probability (p) of less than 0.05 was considered significant.", [["Chi-square test", "TEST", 58, 73]]], ["Multivariate logistic regression was used to study the factors predicting the \u201cwillingness to receive the H1N1 vaccine\u201d.Materials and methodsThis study was approved by the Institution Ethics Review Board and granted a waiver of informed consent.Demographic characteristics of respondents (Table 1tbl0005table) ::: ResultsThe sample consisted of 14.6% \u201cMedical\u201d, 25.7% \u201cNursing\u201d, 21.5% \u201cAllied Health\u201d and 38.1% \u201cOperations\u201d HCWs.", [["Multivariate logistic regression", "PROBLEM", 0, 32], ["the H1N1 vaccine", "TREATMENT", 102, 118], ["This study", "TEST", 141, 151], ["The sample", "TEST", 321, 331]]], ["Among the 711 respondents, 16.6% reported having at least 1 chronic condition.", [["chronic", "OBSERVATION_MODIFIER", 60, 67], ["condition", "OBSERVATION", 68, 77]]], ["Only 1.0% had 2 or more chronic conditions.", [["more chronic conditions", "PROBLEM", 19, 42], ["chronic", "OBSERVATION_MODIFIER", 24, 31], ["conditions", "OBSERVATION", 32, 42]]], ["Asthma (10.8%), hypertension (10.4%) and dyslipidaemia (9.8%) were the top 3 conditions.", [["Asthma", "DISEASE", 0, 6], ["hypertension", "DISEASE", 16, 28], ["dyslipidaemia", "DISEASE", 41, 54], ["Asthma", "PROBLEM", 0, 6], ["hypertension", "PROBLEM", 16, 28], ["dyslipidaemia", "PROBLEM", 41, 54], ["hypertension", "OBSERVATION", 16, 28]]]], "02a7cb632180f53394b196ec9327445bf1ac730b": [["we would like to contribute to the oral manifestations of SARS-CoV-2 infection due to the small number of case reports described and confusing data from the available literature.", [["oral", "ANATOMY", 35, 39], ["SARS-CoV-2 infection", "DISEASE", 58, 78], ["oral", "ORGANISM_SUBDIVISION", 35, 39], ["SARS-CoV-2", "ORGANISM", 58, 68], ["SARS-CoV-2", "SPECIES", 58, 68], ["SARS", "PROBLEM", 58, 62], ["CoV-2 infection", "PROBLEM", 63, 78], ["small", "OBSERVATION_MODIFIER", 90, 95]]]], "82cbd1ae14d9f2b48754823adcbbbc106ea551f5": [["IntroductionCoronavirus is one of the major viruses which primarily affecting the respiratory system in human (1) .", [["respiratory system", "ANATOMY", 82, 100], ["human", "ORGANISM", 104, 109], ["human", "SPECIES", 104, 109], ["human", "SPECIES", 104, 109], ["IntroductionCoronavirus", "PROBLEM", 0, 23], ["the major viruses", "PROBLEM", 34, 51], ["Coronavirus", "OBSERVATION", 12, 23], ["viruses", "OBSERVATION", 44, 51], ["respiratory system", "ANATOMY", 82, 100]]], ["However, Coronaviruses have been also diagnosed in animals and can cause a range of severe diseases such as gastroenteritis and pneumonia (2, 3) .", [["gastroenteritis", "DISEASE", 108, 123], ["pneumonia", "DISEASE", 128, 137], ["Coronaviruses", "GENE_OR_GENE_PRODUCT", 9, 22], ["Coronaviruses", "PROBLEM", 9, 22], ["severe diseases", "PROBLEM", 84, 99], ["gastroenteritis", "PROBLEM", 108, 123], ["pneumonia", "PROBLEM", 128, 137], ["severe", "OBSERVATION_MODIFIER", 84, 90], ["diseases", "OBSERVATION", 91, 99], ["gastroenteritis", "OBSERVATION", 108, 123], ["pneumonia", "OBSERVATION", 128, 137]]], ["Previous coronavirus outbreaks have been reported, including severe acute respiratory syndrome (SARS-CoV) and Middle East respiratory syndrome (MERS-CoV), which is described as a significant public health threat (4).IntroductionIn 2002, coronavirus infections (SARS-CoVs) spread in Guangdong, south China, causing high fever, breathlessness and pneumonia, and rapidly spread to various regions around the world.IntroductionThe infection has spread in 26 countries, resulting about 8096 cases and 774 deaths (5, 6) .IntroductionWhereas MERS-CoV was first detected in Saudi Arabia in 2012.", [["coronavirus outbreaks", "DISEASE", 9, 30], ["acute respiratory syndrome", "DISEASE", 68, 94], ["SARS-CoV)", "DISEASE", 96, 105], ["Middle East respiratory syndrome (MERS-CoV)", "DISEASE", 110, 153], ["coronavirus infections", "DISEASE", 237, 259], ["SARS-CoVs", "DISEASE", 261, 270], ["fever", "DISEASE", 319, 324], ["breathlessness", "DISEASE", 326, 340], ["pneumonia", "DISEASE", 345, 354], ["infection", "DISEASE", 427, 436], ["deaths", "DISEASE", 500, 506], ["coronavirus", "ORGANISM", 9, 20], ["MERS-CoV", "ORGANISM", 144, 152], ["coronavirus", "ORGANISM", 237, 248], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 535, 543], ["SARS-CoV", "SPECIES", 96, 104], ["Middle East respiratory syndrome (MERS-CoV", "SPECIES", 110, 152], ["MERS-CoV", "SPECIES", 535, 543], ["Previous coronavirus outbreaks", "PROBLEM", 0, 30], ["severe acute respiratory syndrome", "PROBLEM", 61, 94], ["SARS-CoV)", "PROBLEM", 96, 105], ["Middle East respiratory syndrome", "PROBLEM", 110, 142], ["IntroductionIn", "TREATMENT", 216, 230], ["coronavirus infections", "PROBLEM", 237, 259], ["SARS", "PROBLEM", 261, 265], ["high fever", "PROBLEM", 314, 324], ["breathlessness", "PROBLEM", 326, 340], ["pneumonia", "PROBLEM", 345, 354], ["The infection", "PROBLEM", 423, 436], ["coronavirus", "OBSERVATION", 9, 20], ["severe", "OBSERVATION_MODIFIER", 61, 67], ["acute", "OBSERVATION_MODIFIER", 68, 73], ["respiratory syndrome", "OBSERVATION", 74, 94], ["Middle", "ANATOMY_MODIFIER", 110, 116], ["respiratory syndrome", "OBSERVATION", 122, 142], ["significant", "OBSERVATION_MODIFIER", 179, 190], ["coronavirus infections", "OBSERVATION", 237, 259], ["high", "OBSERVATION_MODIFIER", 314, 318], ["fever", "OBSERVATION", 319, 324], ["pneumonia", "OBSERVATION", 345, 354], ["infection", "OBSERVATION", 427, 436], ["spread", "OBSERVATION_MODIFIER", 441, 447]]], ["The disease has mild respiratory symptoms that can lead to acute respiratory syndrome and death.", [["respiratory", "ANATOMY", 21, 32], ["respiratory", "ANATOMY", 65, 76], ["respiratory symptoms", "DISEASE", 21, 41], ["acute respiratory syndrome", "DISEASE", 59, 85], ["death", "DISEASE", 90, 95], ["The disease", "PROBLEM", 0, 11], ["mild respiratory symptoms", "PROBLEM", 16, 41], ["acute respiratory syndrome", "PROBLEM", 59, 85], ["death", "PROBLEM", 90, 95], ["disease", "OBSERVATION", 4, 11], ["mild", "OBSERVATION_MODIFIER", 16, 20], ["respiratory symptoms", "OBSERVATION", 21, 41], ["acute", "OBSERVATION_MODIFIER", 59, 64], ["respiratory syndrome", "OBSERVATION", 65, 85]]], ["On December 2019, Atypical unkown pneumonia was first recorded in Wuhan city, Hubei province.", [["pneumonia", "DISEASE", 34, 43], ["Atypical unkown pneumonia", "PROBLEM", 18, 43], ["pneumonia", "OBSERVATION", 34, 43]]], ["Patients have showed high fever (more than 38 C\u00b0), dry cough, malaise, and breath difficulties.", [["fever", "DISEASE", 26, 31], ["dry cough", "DISEASE", 51, 60], ["breath difficulties", "DISEASE", 75, 94], ["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["high fever", "PROBLEM", 21, 31], ["dry cough", "PROBLEM", 51, 60], ["malaise", "PROBLEM", 62, 69], ["breath difficulties", "PROBLEM", 75, 94], ["high", "OBSERVATION_MODIFIER", 21, 25], ["fever", "OBSERVATION", 26, 31], ["cough", "OBSERVATION", 55, 60], ["malaise", "OBSERVATION", 62, 69]]], ["The infection has been linked to the seafood market of Wuhan, China and named COVID-19 (10) (11) (12) .", [["infection", "DISEASE", 4, 13], ["COVID-19", "CHEMICAL", 78, 86], ["The infection", "PROBLEM", 0, 13], ["infection", "OBSERVATION", 4, 13]]], ["It spread rapidly to other Far East Asian nations, then to the Middle East and Europe.", [["Middle", "ANATOMY_MODIFIER", 63, 69]]], ["In severe cases the disease causes pneumonia, septic shock, metabolic acidosis and bleeding (13) .", [["pneumonia", "DISEASE", 35, 44], ["septic shock", "DISEASE", 46, 58], ["metabolic acidosis", "DISEASE", 60, 78], ["bleeding", "DISEASE", 83, 91], ["the disease", "PROBLEM", 16, 27], ["pneumonia", "PROBLEM", 35, 44], ["septic shock", "PROBLEM", 46, 58], ["metabolic acidosis", "PROBLEM", 60, 78], ["bleeding", "PROBLEM", 83, 91], ["severe", "OBSERVATION_MODIFIER", 3, 9], ["disease", "OBSERVATION", 20, 27], ["pneumonia", "OBSERVATION", 35, 44], ["septic shock", "OBSERVATION", 46, 58], ["metabolic acidosis", "OBSERVATION", 60, 78], ["bleeding", "OBSERVATION", 83, 91]]], ["The incubation period has been estimated from 5 -14 days and may vary from patient to patient according to age and infection history (14) .IntroductionSeveral studies have revealed that COVID-19 can be transmitted between humans via nasal droplets and direct contact in both symptomatic and asymptomatic patients (15) (16) (17) .", [["nasal droplets", "ANATOMY", 233, 247], ["infection", "DISEASE", 115, 124], ["COVID-19", "CHEMICAL", 186, 194], ["patient", "ORGANISM", 75, 82], ["patient", "ORGANISM", 86, 93], ["COVID-19", "GENE_OR_GENE_PRODUCT", 186, 194], ["humans", "ORGANISM", 222, 228], ["patients", "ORGANISM", 304, 312], ["COVID-19", "DNA", 186, 194], ["patient", "SPECIES", 75, 82], ["patient", "SPECIES", 86, 93], ["humans", "SPECIES", 222, 228], ["patients", "SPECIES", 304, 312], ["humans", "SPECIES", 222, 228], ["Several studies", "TEST", 151, 166], ["COVID", "TEST", 186, 191], ["humans via nasal droplets", "TREATMENT", 222, 247], ["infection", "OBSERVATION", 115, 124], ["nasal", "ANATOMY", 233, 238]]], ["No vaccine or effective medication currently available to prevent or cure COVID-19 infections; however, some preventive health measures can help to resolve primary complications in patients (18).", [["infections", "DISEASE", 83, 93], ["patients", "ORGANISM", 181, 189], ["patients", "SPECIES", 181, 189], ["COVID-19", "SPECIES", 74, 82], ["vaccine", "TREATMENT", 3, 10], ["effective medication", "TREATMENT", 14, 34], ["cure COVID-19 infections", "PROBLEM", 69, 93], ["primary complications", "PROBLEM", 156, 177]]], ["On 16 March 2020, the disease affected more than 150 countries and territories around the world.IntroductionOver the past few months there has been a significant increase in COVID-19 cases.", [["the disease", "PROBLEM", 18, 29], ["COVID", "TEST", 174, 179], ["disease", "OBSERVATION", 22, 29], ["significant", "OBSERVATION_MODIFIER", 150, 161], ["increase", "OBSERVATION_MODIFIER", 162, 170]]], ["In Iraq, the first confirmed case of COVID-19 has been reported in Najaf province for the Iranian student came from Iran on 24 February 2020, followed by 4 cases from one family in Kirkuk province on 25 February, they have also a travel history to Iran.", [["COVID-19", "DNA", 37, 45]]], ["An additional case was recorded on 27 February in Baghdad, for a patient who recently visited Iran.", [["patient", "ORGANISM", 65, 72], ["patient", "SPECIES", 65, 72]]], ["The confirmed cases jumped to 1415 on 16 April 2020, with 78 fatalities were recorded (21) .", [["fatalities", "DISEASE", 61, 71]]], ["By 24 May 2020, the confirmed cases of COVID-19 reached 4469 and reported 160 deaths, while 2738 patients recovered from the infection (22) .", [["deaths", "DISEASE", 78, 84], ["infection", "DISEASE", 125, 134], ["patients", "ORGANISM", 97, 105], ["patients", "SPECIES", 97, 105], ["COVID", "TEST", 39, 44], ["the infection", "PROBLEM", 121, 134], ["infection", "OBSERVATION", 125, 134]]], ["Here, we aim to describe a comprehensive, epidemiological study of all cases diagnosed in Iraq by 24 May 2020.", [["epidemiological study", "TEST", 42, 63]]], ["We hope our study will alert the community to the risk of this novel coronavirus, in order to prevent a second wave of the virus infections.MethodsThis study was an exploratory and descriptive analysis of all COVID-19 confirmed cases, diagnosed in Iraq as of 24 May 2020.", [["coronavirus", "DISEASE", 69, 80], ["infections", "DISEASE", 129, 139], ["coronavirus", "ORGANISM", 69, 80], ["our study", "TEST", 8, 17], ["this novel coronavirus", "PROBLEM", 58, 80], ["the virus infections", "PROBLEM", 119, 139], ["This study", "TEST", 147, 157], ["an exploratory", "TEST", 162, 176], ["descriptive analysis", "TEST", 181, 201], ["all COVID", "TEST", 205, 214], ["virus infections", "OBSERVATION", 123, 139]]], ["We obtained epidemiological and demographic data for all COVID-19 cases that were reported from 24 February 2020 to 24 May 2020 by the Iraqi Ministry of Health, Directorate of Public Health.", [["demographic data", "TEST", 32, 48], ["all COVID", "TEST", 53, 62]]], ["Sex-disaggregated data about COVID-19 was obtained from Global Health 50/50.", [["COVID", "TEST", 29, 34]]], ["We collected data for global COVID-19 cases from ProMED, WHO, and CDC reports.MethodsCase fatality rates (CFR) were calculated as the total number of deaths (td) divided by the total number of cases (tc), represented as a percentage (23, 24) .MethodsWhile the incidence rates (IR) were calculated as the total number of COVID-19 confirmed cases (tc) divided by the population (p) of each province times 100,000 (25) .MethodsThis study was evaluated according to the reporting guidelines for Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) (26) .Demographics and the distribution of COVID-19Overall, 4469 cases were confirmed with COVID 19 infection and showed a substantial cumulative rise since the first case was confirmed on 24 Feb 2020 until 24 May 2020. ( Figure 1A and B).", [["deaths", "DISEASE", 150, 156], ["infection", "DISEASE", 669, 678], ["global COVID", "TEST", 22, 34], ["COVID", "TEST", 320, 325], ["This study", "TEST", 424, 434], ["Observational Studies", "TEST", 522, 543], ["COVID", "TEST", 612, 617], ["COVID 19 infection", "PROBLEM", 660, 678], ["a substantial cumulative rise", "PROBLEM", 690, 719], ["infection", "OBSERVATION", 669, 678], ["substantial", "OBSERVATION_MODIFIER", 692, 703], ["cumulative", "OBSERVATION_MODIFIER", 704, 714], ["rise", "OBSERVATION_MODIFIER", 715, 719]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)Demographics and the distribution of COVID-19The copyright holder for this preprint this version posted June 26, 2020. . https://doi.org/10.1101/2020.06.23.20138370 doi: medRxiv preprint cities, the fatalities of COVID-19 infection in Baghdad was high (97 deaths), followed by Basra (18 deaths) and Kerbala with 8 deaths ( Figure 1C ).", [["CC", "CHEMICAL", 0, 2], ["COVID-19", "CHEMICAL", 415, 423], ["infection", "DISEASE", 424, 433], ["deaths", "DISEASE", 458, 464], ["deaths", "DISEASE", 489, 495], ["deaths", "DISEASE", 516, 522], ["ND", "PROBLEM", 9, 11], ["COVID", "TEST", 239, 244], ["The copyright holder", "TREATMENT", 247, 267], ["COVID", "TEST", 415, 420], ["infection", "PROBLEM", 424, 433], ["med", "ANATOMY", 105, 108], ["infection", "OBSERVATION", 424, 433]]], ["On the other hand, Erbil (Kurdistan region, north Iraq) registered only one death for 242 confirmed cases.", [["death", "DISEASE", 76, 81], ["hand", "ANATOMY", 13, 17]]], ["In addition, Figure 1D shows the breakdown of confirmed cases and deaths by gender across all cities.", [["deaths", "DISEASE", 66, 72]]], ["Approximately 45% of patients were female and 55% were male.", [["patients", "ORGANISM", 21, 29], ["patients", "SPECIES", 21, 29]]], ["While the death rates were 68% for males and 31% for females.COVID-19 cases and indicators by province and ageData revealed that most cases are between the ages of 20-59, with those aged 30-39 years being the most affected range (19 %).", [["death", "DISEASE", 10, 15], ["the death rates", "TEST", 6, 21], ["COVID", "TEST", 61, 66]]], ["Data have also shown that around 8% of overall confirmed cases are children under 10 years old ( Figure 2A ).", [["children", "ORGANISM", 67, 75], ["children", "SPECIES", 67, 75]]], ["As can be seen from the Figure 2A , there is a clear trend of increasing in the fatality rate with ages between 60-80 years old reaching the max in patients with above 80 years old (24%).COVID-19 cases and indicators by province and ageThe provinces are widely varied in their incidence and case fatality rates (CFR) ( Figure 2B ).", [["patients", "ORGANISM", 148, 156], ["patients", "SPECIES", 148, 156], ["COVID", "TEST", 187, 192], ["clear", "OBSERVATION_MODIFIER", 47, 52], ["trend", "OBSERVATION_MODIFIER", 53, 58], ["increasing", "OBSERVATION_MODIFIER", 62, 72]]], ["The incidence rate, which is the number of new cases in the population over a given period, has been calculated in all provinces.", [["new", "OBSERVATION_MODIFIER", 43, 46]]], ["A higher incidence rate can be seen in Baghdad (26.09) followed by Basra with (24.39) and Najaf with (20.52) ( Figure 2B ).", [["A higher incidence rate", "PROBLEM", 0, 23], ["higher", "OBSERVATION_MODIFIER", 2, 8]]], ["The high incidence rate in those large cities could be explained by the high number of confirmed cases.", [["The high incidence rate", "PROBLEM", 0, 23], ["high", "OBSERVATION_MODIFIER", 4, 8], ["incidence", "OBSERVATION_MODIFIER", 9, 18]]], ["On the other hand, despite these findings on incidence rates, the case fatality rates were higher in Diyala (11%) and Babylon (10%), followed by Diwaniya (7%) ( Figure 2B ).COVID-19 cases and indicators by province and ageAmong the confirmed cases of COVID 19, cure rates have shown a promising trend in some cities ( Figure 3 ).", [["the case fatality rates", "TEST", 62, 85], ["Babylon", "TREATMENT", 118, 125], ["COVID", "TEST", 173, 178], ["COVID", "TEST", 251, 256], ["cure rates", "TEST", 261, 271]]], ["For example, Najaf showed (94%) cure rate of the 318 confirmed cases.", [["Najaf", "TEST", 13, 18], ["cure rate", "TEST", 32, 41]]], ["Erbil and Missan showed a cure rate of (87%).", [["a cure rate", "TEST", 24, 35]]], ["Despite this, Baghdad represented the lowest cure rate with (42%).Healthcare workersBy 24 May 2020, a total of 207 healthcare workers had been infected with COVID-19 ( Figure 4 ).", [["COVID", "TEST", 157, 162]]], ["The most interesting aspect of this data is that around (80%) of these infections were located in Baghdad, Najaf, Basra and .", [["infections", "DISEASE", 71, 81], ["these infections", "PROBLEM", 65, 81], ["most interesting", "OBSERVATION_MODIFIER", 4, 20], ["infections", "OBSERVATION", 71, 81]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted June 26, 2020. . https://doi.org/10.1101/2020.06.23.20138370 doi: medRxiv preprint Sulaymaniya.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["medRxiv preprint Sulaymaniya", "TREATMENT", 326, 354], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["The majority of the infected health workers were nursing staff (60%), followed by physicians (30%) (Figure 4 ).", [["majority", "OBSERVATION_MODIFIER", 4, 12], ["infected", "OBSERVATION_MODIFIER", 20, 28]]], ["These two groups have a greater chance of being in contact with infected patients.COVID-19 cure and fatality rate in Iraq and neighboring countriesIraq has shown a (61%) cure rate lower than those reported by Iran, Turkey and Jordan ( Figure 5A ).", [["patients", "ORGANISM", 73, 81], ["patients", "SPECIES", 73, 81], ["COVID", "TEST", 82, 87], ["fatality rate", "TEST", 100, 113], ["cure rate", "TEST", 170, 179], ["greater", "OBSERVATION_MODIFIER", 24, 31]]], ["This figure is, however, higher than the reported cure rate for other neighboring countries.COVID-19 cure and fatality rate in Iraq and neighboring countriesOn the other hand, Iraq's fatality rate was (4%) lower than Iran, which is indicated the high rate of fatality (5%).", [["COVID", "TEST", 92, 97], ["fatality rate", "TEST", 110, 123], ["Iraq's fatality rate", "TEST", 176, 196], ["higher", "OBSERVATION_MODIFIER", 25, 31]]], ["Saudi Arabia, by contrast, showed the lowest fatality rate (0.5%) ( Figure 5B ).DiscussionThe recent COVID-19 is a continuing pandemic that creates confusion and panic around the world.", [["confusion", "DISEASE", 148, 157], ["panic", "DISEASE", 162, 167], ["the lowest fatality rate", "TEST", 34, 58], ["confusion", "PROBLEM", 148, 157], ["panic", "PROBLEM", 162, 167]]], ["According to the genomic studies, the virus is considered to originate from infected bats, and can be transmitted to humans and animals, as well as to humans (27) .", [["bats", "ORGANISM", 85, 89], ["humans", "ORGANISM", 117, 123], ["humans", "ORGANISM", 151, 157], ["humans", "SPECIES", 117, 123], ["humans", "SPECIES", 151, 157], ["humans", "SPECIES", 117, 123], ["humans", "SPECIES", 151, 157], ["the genomic studies", "TEST", 13, 32], ["the virus", "PROBLEM", 34, 43], ["virus", "OBSERVATION", 38, 43], ["infected", "OBSERVATION", 76, 84]]], ["It was found to have a positive-sensed, single-strand beta-coronavirus RNA virus similar to Bat Coronavirus (BatCoV RaTG13) with 88% identity (27, 28) .", [["Bat Coronavirus", "ORGANISM", 92, 107], ["Bat Coronavirus", "PROTEIN", 92, 107], ["Bat Coronavirus (BatCoV RaTG13)", "SPECIES", 92, 123], ["a positive-sensed, single-strand beta-coronavirus RNA virus", "PROBLEM", 21, 80], ["Bat Coronavirus", "TEST", 92, 107], ["positive", "OBSERVATION", 23, 31]]], ["By 24 May 2020, an astounding 5,230,755 confirmed COVID-19 cases were reported worldwide, with 339,588 fatalities.DiscussionIn Iraq, as of 24 May, 4469 COVID 19 confirmed cases, 160 deaths and 2738 patients who have recovered from the virus and discharged from hospitals.", [["fatalities", "DISEASE", 103, 113], ["deaths", "DISEASE", 182, 188], ["patients", "ORGANISM", 198, 206], ["patients", "SPECIES", 198, 206], ["an astounding", "TEST", 16, 29], ["COVID", "TEST", 50, 55], ["the virus", "PROBLEM", 231, 240]]], ["Unfortunately, while we were writing this manuscript, the number of confirmed cases increased dramatically from 4469 on 24 May to 15,414 on 10 June with 426 deaths.", [["deaths", "DISEASE", 157, 163]]], ["One possible explanation for this increase could be that during this period (24 May-10 June) people celebrated Eid Al-Fitr after fasting in the holly Ramadan, which exhibited many gatherings for all family members and friends.", [["Al", "CHEMICAL", 115, 117], ["people", "ORGANISM", 93, 99], ["people", "SPECIES", 93, 99], ["possible explanation for", "UNCERTAINTY", 4, 28]]], ["Another possible explanation is that authorities has generally relaxed enforcement of the stringent curfews and movement restrictions which have been in place for the past several weeks.", [["possible explanation is", "UNCERTAINTY", 8, 31]]], ["Partial lockdowns are currently in force in order to limit the spreading of the virus.", [["Partial lockdowns", "TREATMENT", 0, 17], ["the virus", "PROBLEM", 76, 85]]], ["It's worth notice that the total cumulative number of COVID-19 cases increasing significantly, so this is could be a sign that a country will faces a second wave of virus infections.", [["infections", "DISEASE", 171, 181], ["COVID", "TEST", 54, 59], ["virus infections", "PROBLEM", 165, 181], ["virus infections", "OBSERVATION", 165, 181]]], ["The highest .", [["highest", "OBSERVATION_MODIFIER", 4, 11]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted June 26, 2020. . https://doi.org/10.1101/2020.06.23.20138370 doi: medRxiv preprint number of cases were recorded in Baghdad and Basra compared to other cities due to the fact that these provinces have a large population with many factories and shopping malls that could not follow the instructions of the health authorities to contain the spread of the virus.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["the virus", "PROBLEM", 609, 618], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108], ["large", "OBSERVATION_MODIFIER", 463, 468], ["population", "OBSERVATION", 469, 479]]], ["The current study also found 54% of confirmed cases were males, and 45% were females (male: female ratio = 1.2:1).", [["The current study", "TEST", 0, 17], ["female ratio", "TEST", 92, 104]]], ["In addition, the fatality rates were higher in male (68%) than female (31%).", [["the fatality rates", "TEST", 13, 31], ["higher", "OBSERVATION_MODIFIER", 37, 43]]], ["These data seem to be consistent with other studies which found that men with COVID-19 infection are more likely to have serious consequences and death (29, 30) .", [["infection", "DISEASE", 87, 96], ["death", "DISEASE", 146, 151], ["men", "ORGANISM", 69, 72], ["COVID-19", "ORGANISM", 78, 86], ["men", "SPECIES", 69, 72], ["other studies", "TEST", 38, 51], ["COVID-19 infection", "PROBLEM", 78, 96], ["infection", "OBSERVATION", 87, 96]]], ["Differences between males and females in getting infection with COVID-19 remain unclear.", [["infection", "DISEASE", 49, 58], ["COVID-19", "CHEMICAL", 64, 72], ["COVID-19", "CHEMICAL", 64, 72], ["infection", "PROBLEM", 49, 58], ["COVID", "TEST", 64, 69], ["infection", "OBSERVATION", 49, 58]]], ["Countries like Italy, Scotland, Switzerland, Sweden and Belgium have reported a higher percentage of cases among women according to Global Health 50/50 (31) .", [["women", "ORGANISM", 113, 118], ["women", "SPECIES", 113, 118]]], ["While the rates of infection among men appear to be much higher in Iran, Costa Rica, Thailand, Greece, Pakistan and Mexico.(which was not certified by peer review)In our study, data showed all ages are susceptible to infected with COVID-19 and the highest range was between 30-39 years old.", [["infection", "DISEASE", 19, 28], ["men", "ORGANISM", 35, 38], ["men", "SPECIES", 35, 38], ["infection", "PROBLEM", 19, 28], ["our study", "TEST", 166, 175], ["COVID", "TEST", 231, 236], ["infection", "OBSERVATION", 19, 28], ["infected", "OBSERVATION_MODIFIER", 217, 225]]], ["Consistent with other studies (32) (33) (34) , this research found that fatality rates were higher in patients with \u2265 60 years old.", [["patients", "ORGANISM", 102, 110], ["patients", "SPECIES", 102, 110], ["other studies", "TEST", 16, 29], ["fatality rates", "TEST", 72, 86]]], ["COVID-19 negative outcomes tend to be related to comorbidity including diabetes, obesity, cardiovascular and lung diseases.", [["cardiovascular", "ANATOMY", 90, 104], ["lung", "ANATOMY", 109, 113], ["diabetes", "DISEASE", 71, 79], ["obesity", "DISEASE", 81, 88], ["cardiovascular and lung diseases", "DISEASE", 90, 122], ["cardiovascular", "ANATOMICAL_SYSTEM", 90, 104], ["lung", "ORGAN", 109, 113], ["COVID", "TEST", 0, 5], ["comorbidity", "PROBLEM", 49, 60], ["diabetes", "PROBLEM", 71, 79], ["obesity", "PROBLEM", 81, 88], ["cardiovascular and lung diseases", "PROBLEM", 90, 122], ["diabetes", "OBSERVATION", 71, 79], ["obesity", "OBSERVATION", 81, 88], ["cardiovascular", "ANATOMY", 90, 104], ["lung", "ANATOMY", 109, 113], ["diseases", "OBSERVATION", 114, 122]]], ["These factors may account for high death rates in older patients.", [["death", "DISEASE", 35, 40], ["patients", "ORGANISM", 56, 64], ["patients", "SPECIES", 56, 64], ["high death rates", "PROBLEM", 30, 46], ["may account for", "UNCERTAINTY", 14, 29]]], ["Despite this, the majority of provinces, apart from Baghdad, showed promising cure rates.(which was not certified by peer review)As our healthcare workers continue to fight COVID-19, they get infected with the virus.", [["promising cure rates", "PROBLEM", 68, 88], ["the virus", "PROBLEM", 206, 215], ["virus", "OBSERVATION", 210, 215]]], ["Overall, 207 Healthcare workers were tested positive for COVID-19 representing (5%) of the total confirmed cases in Iraq.", [["COVID", "TEST", 57, 62]]], ["What stands out in the data is that (78%) of these cases were in Baghdad, Najaf and Basra.", [["Najaf", "TREATMENT", 74, 79], ["Basra", "TREATMENT", 84, 89]]], ["Cure and fatality rates have shown variation when comparing Iraq with neighboring countries.", [["fatality rates", "TEST", 9, 23]]], ["This inconsistency may be due to the fact that each country has different management protocols, case reporting and the number of tests carried out on each day.", [["different management protocols", "TREATMENT", 64, 94], ["tests", "TEST", 129, 134]]], ["Some countries may not report mild cases if they do not need treatment or if they have been treated at home.", [["treatment", "TREATMENT", 61, 70]]], ["There are some limitations to this study.", [["this study", "TEST", 30, 40]]], ["First, We were unable to evaluate the clinical characteristics of confirmed cases since these data were not accessible at the moment of analysis.", [["these data", "TEST", 88, 98], ["analysis", "TEST", 136, 144]]], ["Second, we did not have any information as to whether or not these patients, especially elderly patients, have comorbidities.", [["patients", "ORGANISM", 67, 75], ["patients", "ORGANISM", 96, 104], ["patients", "SPECIES", 67, 75], ["patients", "SPECIES", 96, 104], ["comorbidities", "PROBLEM", 111, 124]]], ["A further study with more focus on the comorbidities and the severity of COVID-19 in elderly is therefore suggested.", [["A further study", "TEST", 0, 15], ["the comorbidities", "PROBLEM", 35, 52], ["COVID", "TEST", 73, 78]]], ["Taken together, these findings contribute to our understanding of the epidemiology and prevalence of COVID-19 in Iraq, in several ways, which may be useful and provide a basis for future studies.(which was not certified by peer review).", [["COVID", "TEST", 101, 106], ["future studies", "TEST", 180, 194]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted June 26, 2020. .", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.Age (Years)M u t h a n n a M i s s a n K e r b a l a D i w a n i y a D a h u k W a s s i t N a j a f S a l a -A l d i n K i r k u k D i y a l a A n b a r E r b i l B a b y l o n T h i -Q a r S u l a y m a n i y a B a s r a N i n e w a B a g h d a d M u t h a n n a M i s s a n K e r b a l a D i w a n i y a", [["CC", "CHEMICAL", 0, 2], ["ND", "PROBLEM", 9, 11], ["med", "ANATOMY", 105, 108]]]], "PMC4968982": [["The current study ::: IntroductionWe extend research in this area by using a discrete choice conjoint experiment (DCE) to engage a large sample of patients, or those acting on their behalf, in the design of an approach to hospital safety partnerships.27 Although DCEs have been applied to the design of other risk reduction strategies,28 this is, to our knowledge, the first application of these methods to the study of hospital safety partnerships.", [["patients", "ORGANISM", 147, 155], ["patients", "SPECIES", 147, 155], ["The current study", "TEST", 0, 17], ["other risk reduction strategies", "TREATMENT", 303, 334], ["the study", "TEST", 407, 416], ["large", "OBSERVATION_MODIFIER", 131, 136]]], ["DCEs make a methodological contribution to safety research by engaging the multistage decision strategies likely to influence the intent to participate in real-world safety initiatives,29 reducing the influence of social desirability biases,30 and improving the estimates of the relative value of the individual components of complex safety initiatives.31The current study ::: IntroductionWe explored four general research questions (RQs) and examined six more specific hypotheses (HYPs).RQ 1: What features of safety partnerships are most important?", [["The current study", "TEST", 355, 372]]], ["In addition to hand hygiene campaigns that have been the focus of considerable research,12 we examined relative preferences for partnerships that might include medication and identity double checks or membership on hospital safety committees.", [["hand", "ANATOMY", 15, 19], ["medication", "TREATMENT", 160, 170], ["double checks", "TEST", 184, 197]]], ["Previous studies suggest that, while patients respond positively to safety partnerships focusing on strategies to ensure the accuracy of medication administration,6 they are uncomfortable in addressing staff compliance with hand hygiene protocols.6 We predicted, therefore, that:HYP 1.", [["hand", "ANATOMY", 224, 228], ["patients", "ORGANISM", 37, 45], ["hand", "ORGANISM_SUBDIVISION", 224, 228], ["HYP 1", "GENE_OR_GENE_PRODUCT", 279, 284], ["patients", "SPECIES", 37, 45], ["Previous studies", "TEST", 0, 16], ["strategies", "TREATMENT", 100, 110], ["medication administration", "TREATMENT", 137, 162], ["uncomfortable", "PROBLEM", 174, 187], ["hand hygiene protocols", "TREATMENT", 224, 246]]], ["Patients would show a stronger preference for partnerships involving medication double checks than for those asking staff to clean their hands.The current study ::: IntroductionAlthough patients recognize the value of hand hygiene,24 they are hesitant to participate in safety partnerships that involve questioning staff.8,21 We predicted that:HYP 2.", [["hand", "ANATOMY", 218, 222], ["Patients", "ORGANISM", 0, 8], ["patients", "ORGANISM", 186, 194], ["hand", "ORGANISM_SUBDIVISION", 218, 222], ["HYP 2", "GENE_OR_GENE_PRODUCT", 344, 349], ["Patients", "SPECIES", 0, 8], ["patients", "SPECIES", 186, 194], ["medication double checks", "TREATMENT", 69, 93], ["The current study", "TEST", 143, 160], ["hands", "ANATOMY", 137, 142], ["HYP", "OBSERVATION", 344, 347]]], ["Participants would prefer partnerships focusing on hand hygiene for patients rather than an approach encouraging patients to remind staff to clean their hands.The current study ::: IntroductionAlthough previous studies do not provide a basis for specific HYPs, we extend research in this area by exploring a set of partnership features that might influence the decision to participate.", [["hand", "ANATOMY", 51, 55], ["hand", "ORGANISM_SUBDIVISION", 51, 55], ["patients", "ORGANISM", 68, 76], ["patients", "ORGANISM", 113, 121], ["hands", "ORGANISM_SUBDIVISION", 153, 158], ["Participants", "SPECIES", 0, 12], ["patients", "SPECIES", 68, 76], ["patients", "SPECIES", 113, 121], ["The current study", "TEST", 159, 176], ["previous studies", "TEST", 202, 218], ["hands", "ANATOMY", 153, 158]]], ["These included the way in which risk information is communicated to patients, sources of evidence regarding the benefits of safety partnerships, the process via which patients are engaged in safety partnerships, strategies for providing the training needed to participate, processes for reporting errors, and organizational responses to safety concerns.RQ 2: Are there segments preferring different safety partnerships?", [["patients", "ORGANISM", 68, 76], ["patients", "ORGANISM", 167, 175], ["patients", "SPECIES", 68, 76], ["patients", "SPECIES", 167, 175], ["the training", "TREATMENT", 237, 249]]], ["Patients hold different attitudes regarding their role in their health32 and safety.6,20,33,34 A patient-centered approach to safety partnerships needs to reflect these differences.", [["6,20,33,34", "CHEMICAL", 84, 94], ["Patients", "ORGANISM", 0, 8], ["patient", "ORGANISM", 97, 104], ["Patients", "SPECIES", 0, 8], ["patient", "SPECIES", 97, 104]]], ["Using latent class analysis,35 we identified segments of participants with different safety partnership preferences and examined factors linked to segment membership.HYP 3.", [["HYP 3", "GENE_OR_GENE_PRODUCT", 166, 171], ["participants", "SPECIES", 57, 69], ["latent class analysis", "TEST", 6, 27]]], ["Given previous studies,32,36 we hypothesized a segment of participants preferring a more active approach to safety partnerships and a segment preferring a less active role in safety.The current study ::: IntroductionConsistent with the Theory of Planned Behavior,3,11 we postulated that:HYP 4.", [["participants", "SPECIES", 58, 70], ["previous studies", "TEST", 6, 22], ["The current study", "TEST", 182, 199], ["HYP", "OBSERVATION", 287, 290]]], ["Those preferring a more active role in safety partnerships would anticipate greater benefit, expect more encouragement to participate, and express more confidence in their ability to contribute.RQ 3: To what extent do patients prefer a collaborative approach to safety?", [["patients", "ORGANISM", 218, 226], ["patients", "SPECIES", 218, 226]]], ["Although the role of patients in hospital safety has been questioned,37,38 patients believe they can contribute to the safety of the care they receive and are willing to consider participating in some safety initiatives.6,11,19,21 HYP 5, therefore, postulated that:HYP 5.", [["patients", "ORGANISM", 21, 29], ["patients", "ORGANISM", 75, 83], ["HYP 5", "ORGANISM", 265, 270], ["patients", "SPECIES", 21, 29], ["patients", "SPECIES", 75, 83], ["HYP", "OBSERVATION", 265, 268]]], ["Participants would prefer an approach in which patients and staff collaborate to improve safety rather than a model relying solely on staff to ensure safe care.RQ 4: What type of engagement strategy do patients prefer?", [["patients", "ORGANISM", 47, 55], ["patients", "ORGANISM", 202, 210], ["Participants", "SPECIES", 0, 12], ["patients", "SPECIES", 47, 55], ["patients", "SPECIES", 202, 210]]], ["RQ 4 addressed a gap in the literature regarding the type of engagement strategies patients prefer.", [["patients", "ORGANISM", 83, 91], ["patients", "SPECIES", 83, 91], ["engagement strategies", "TREATMENT", 61, 82]]], ["Although signs and posters are an integral component of many hospital safety campaigns,39,40 surveys suggest that an invitation from health care workers would be more likely to motivate participation in safety campaigns.9,12 HYP 6 predicted that:HYP 6.", [["integral", "OBSERVATION_MODIFIER", 34, 42], ["component", "OBSERVATION_MODIFIER", 43, 52]]], ["Patients would prefer that staff, rather than posters or signage, encourage participation in hospital safety partnerships.Participants ::: MethodsThis study was approved by the Hamilton Integrated Research Ethics Board.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["Participants", "SPECIES", 122, 134]]], ["In outpatient waiting areas and inpatient rooms, a hospital staff member asked patients or those acting on their behalf (eg, parents of children, partners, or friends) if they would consider participating.", [["patients", "ORGANISM", 79, 87], ["children", "ORGANISM", 136, 144], ["patients", "SPECIES", 79, 87], ["children", "SPECIES", 136, 144]]], ["If they agreed, a research team member explained the study, obtained electronic consent, and administered the survey on a laptop computer.", [["the study", "TEST", 49, 58]]], ["A member of the research team presented the study to 1,567 potential participants (42 of 1,609 were called for an appointment before the study was presented).", [["participants", "SPECIES", 69, 81], ["the study", "TEST", 40, 49], ["the study", "TEST", 133, 142]]], ["Overall, 1,084 completed the DCE.", [["DCE", "CHEMICAL", 29, 32], ["the DCE", "TEST", 25, 32]]], ["Our sample size is consistent with the recommendation of 200 participants per segment.31 Demographics are summarized in Table 1.DCE development ::: MethodsWe developed safety partnership attributes in several steps.41 Focus groups or individual interviews were conducted with patients (n=18), family members or support persons (n=6), a Family Advisory Council (n=6), staff (n=18), and physicians (n=1).", [["patients", "ORGANISM", 276, 284], ["participants", "SPECIES", 61, 73], ["patients", "SPECIES", 276, 284], ["persons", "SPECIES", 319, 326], ["Our sample size", "TEST", 0, 15], ["size", "OBSERVATION_MODIFIER", 11, 15], ["consistent with", "UNCERTAINTY", 19, 34]]], ["Staff participating in focus groups or interviews included registered nurses, physiotherapists, occupational therapists, imaging technologists, clinical managers, and environmental aides.", [["imaging technologists", "TEST", 121, 142]]], ["Recordings were transcribed and summarized thematically.", [["Recordings", "TEST", 0, 10]]], ["Next, we identified widely disseminated safety partnerships and attributes of the implementation process that might influence patient decisions (eg, safety partnership decision making or training).", [["patient", "ORGANISM", 126, 133], ["patient", "SPECIES", 126, 133], ["widely", "OBSERVATION_MODIFIER", 20, 26], ["disseminated", "OBSERVATION_MODIFIER", 27, 39]]], ["Attributes ranged from the point of care (eg, medication and identity double checks) to policy and governance (safety committee membership).26 Each attribute included four levels42 selected to combine logically with the levels of other attributes.31,41 We included a level depicting the absence of most attributes.31Experimental design and procedure ::: MethodsEach participant completed 17 choice sets.", [["participant", "SPECIES", 366, 377], ["care (eg", "TREATMENT", 36, 44], ["medication", "TREATMENT", 46, 56], ["identity double checks)", "TREATMENT", 61, 84]]], ["Participants were instructed that \u201cBelow are three ways to make health care safer.", [["Participants", "SPECIES", 0, 12]]], ["We used a partial profile design to simplify choices and improve the performance of participants.43,44 Each profile included the levels of two attributes.", [["participants", "SPECIES", 84, 96], ["a partial profile design", "TREATMENT", 8, 32], ["Each profile", "TEST", 103, 115], ["the levels", "TEST", 125, 135]]], ["Sawtooth Software\u2019s experimental design algorithm created the attribute combinations appearing in each choice set.44 Given a main effects design, the attribute levels in each profile did not overlap.", [["experimental design algorithm", "PROBLEM", 20, 49]]], ["The term \u201cpatients\u201d was defined as patients or their family members.41 Participants completed one warm-up task, 17 choice sets, the Safety Partnership Attitudes Questionnaire described in Figure S1, and demographic questions (a median completion time of 13.4 minutes).Other measures ::: MethodsTo explore attitudes that might influence safety partnership preferences, we developed a Safety Partnership Attitudes Questionnaire reflecting the components of the Theory of Planned Behavior, a model linked to participation in safety initiatives.45 We composed 33 Likert-type scale questions (strongly disagree to strongly agree) reflecting the Theory of Planned Behavior\u2019s five subscales.", [["patients", "ORGANISM", 10, 18], ["patients", "ORGANISM", 35, 43], ["patients", "SPECIES", 10, 18], ["patients", "SPECIES", 35, 43], ["Participants", "SPECIES", 71, 83], ["Methods", "TREATMENT", 287, 294]]], ["Attitudes measured the anticipated benefits of patient safety behaviors.", [["patient", "ORGANISM", 47, 54], ["patient", "SPECIES", 47, 54]]], ["Questions from the Safety Partnership Attitudes Questionnaire and internal consistency scores from this study appear in the Supplementary material.Data analysis ::: MethodsAs described elsewhere,46 we used a latent class program (Latent Gold Choice 4.5) to group participants with similar safety partnership preferences into classes.", [["participants", "SPECIES", 263, 275], ["internal consistency scores", "TEST", 66, 93], ["this study", "TEST", 99, 109], ["Data analysis", "TEST", 147, 160]]], ["Utility coefficients, reflecting preference for the levels of each safety partnership attribute, were estimated for each class.47 Three covariates were included in the latent class model:35,47 intent to participate in safety partnerships (from the Safety Partnership Questionnaire), education (high school or less versus some college or higher), and status as a patient versus parent or person acting on behalf of a patient.", [["patient", "ORGANISM", 362, 369], ["patient", "ORGANISM", 416, 423], ["patient", "SPECIES", 362, 369], ["person", "SPECIES", 387, 393], ["patient", "SPECIES", 416, 423], ["Utility coefficients", "TEST", 0, 20]]], ["A maximum likelihood solution with 1, 2, 3, 4, and 5 classes was estimated.", [["A maximum likelihood solution", "TREATMENT", 0, 29], ["maximum", "OBSERVATION_MODIFIER", 2, 9]]], ["To avoid an unrepresentative model, each solution was computed ten times from different starting points.35,47 Using Latent Gold\u2019s individual utility coefficients, importance scores were derived by converting the range of the utility coefficients of each attribute to a percentage of the total range across attributes.47 Importance scores reflect the relative influence of variation in the levels of each safety partnership attribute on choices.Data analysis ::: MethodsAs described elsewhere,46 HYPs 5 and 6 were examined by entering Latent Gold Choice 4.5\u2019s individual utility coefficients into Sawtooth Software\u2019s Randomized First Choice simulator.48,49 Simulations predict each participant\u2019s response to hypothetical safety partnerships created by combining the levels of several attributes.", [["participant", "SPECIES", 681, 692], ["an unrepresentative model, each solution", "TREATMENT", 9, 49], ["Data analysis", "TEST", 444, 457]]], ["Across 200,000 iterations estimating two sources of error, the simulator assumes that participants would choose a safety partnership with a combination of attribute levels yielding the greatest utility.48,50Reliability and validity ::: MethodsWe included identical \u201chold-out\u201d choice sets at positions 7 and 13 in the 17 set sequences.31,41 These choices were not used to compute utility coefficients.31 Reliability analysis showed that 96% of participants made identical choices to the two hold-out sets.", [["17 set sequences", "DNA", 317, 333], ["participants", "SPECIES", 86, 98], ["participants", "SPECIES", 443, 455], ["Reliability analysis", "TEST", 403, 423]]], ["Simulations based on the remaining choice data predicted the percentage of participants choosing each option.", [["participants", "SPECIES", 75, 87]]], ["This measure, mean absolute error, shows high predictive validity.31Safety partnership options ::: RQ 1: What features of safety partnerships are most important? ::: ResultsImportance scores (Table 2) show the relative influence of variations in the levels of each attribute on partnership choices.", [["mean absolute error", "TEST", 14, 33], ["high predictive validity", "PROBLEM", 41, 65], ["ResultsImportance scores", "TEST", 166, 190], ["absolute error", "OBSERVATION", 19, 33], ["high", "OBSERVATION_MODIFIER", 41, 45], ["predictive validity", "OBSERVATION", 46, 65]]], ["Patient\u2019s identity and medication double checks exerted an especially strong influence on choices.", [["Patient", "SPECIES", 0, 7], ["medication double checks", "TREATMENT", 23, 47]]], ["Consistent with HYP 1, the opportunity to participate in medication double checks was more important to participants than hand hygiene campaigns (Table 2).", [["hand", "ANATOMY", 122, 126], ["HYP 1", "GENE_OR_GENE_PRODUCT", 16, 21], ["hand", "ORGANISM_SUBDIVISION", 122, 126], ["participants", "SPECIES", 104, 116], ["medication double checks", "TEST", 57, 81]]], ["Utility coefficients show the strength of preference for the levels of each attribute (Table 3).", [["Utility coefficients", "TEST", 0, 20]]], ["Both segments preferred that patients and staff double check patient\u2019s identity and medication accuracy.", [["patients", "ORGANISM", 29, 37], ["patient", "ORGANISM", 61, 68], ["patients", "SPECIES", 29, 37], ["patient", "SPECIES", 61, 68], ["medication accuracy", "TEST", 84, 103], ["segments", "ANATOMY_MODIFIER", 5, 13]]], ["Consistent with HYP 2, an initiative encouraging patients to clean their hands was more important than asking patients to remind staff to clean their hands.", [["HYP 2", "GENE_OR_GENE_PRODUCT", 16, 21], ["patients", "ORGANISM", 49, 57], ["patients", "ORGANISM", 110, 118], ["patients", "SPECIES", 49, 57], ["patients", "SPECIES", 110, 118], ["HYP 2", "PROBLEM", 16, 21], ["hands", "ANATOMY", 150, 155]]], ["Both segments preferred signs (versus staff or volunteers) reminding patients to wash their hands and to ask staff if they had washed their hands (Table 3).Communicating risk and safety information to patients ::: RQ 1: What features of safety partnerships are most important? ::: ResultsDisclosure of risks exerted an important influence on choices (Table 2).", [["patients", "ORGANISM", 69, 77], ["patients", "ORGANISM", 201, 209], ["patients", "SPECIES", 69, 77], ["patients", "SPECIES", 201, 209], ["segments", "ANATOMY_MODIFIER", 5, 13]]], ["Both segments preferred that all patients were informed of risks and that staff encourage patients to ask about safety (Table 3).Safety partnership process ::: RQ 1: What features of safety partnerships are most important? ::: ResultsThe safety reporting process and the hospital\u2019s response to safety questions exerted a moderate influence on choices (Table 2).", [["patients", "ORGANISM", 33, 41], ["patients", "ORGANISM", 90, 98], ["patients", "SPECIES", 33, 41], ["patients", "SPECIES", 90, 98], ["segments", "ANATOMY_MODIFIER", 5, 13]]], ["Both segments preferred that patients report safety concerns directly to staff and that those reporting concerns were thanked and informed about the hospital\u2019s response (Table 3).", [["patients", "ORGANISM", 29, 37], ["patients", "SPECIES", 29, 37], ["segments", "ANATOMY_MODIFIER", 5, 13]]], ["Although both segments preferred that patients decide whether to give their names when reporting safety concerns (Table 3), variations in the anonymity afforded patients reporting concerns exerted little influence on choices (Table 2).", [["patients", "ORGANISM", 38, 46], ["patients", "ORGANISM", 161, 169], ["patients", "SPECIES", 38, 46], ["patients", "SPECIES", 161, 169]]], ["Although utility values suggest that a collaborative approach to safety partnership decisions was preferred (Table 3), variations in the levels of this attribute exerted a limited influence on choices (Table 2).Actively engaged ::: RQ 2: Are there segments preferring different safety partnerships? ::: ResultsCovariate analysis suggests that membership in the actively engaged segment was linked to higher education, P<0.001, and a greater intent to participate in safety partnerships, P<0.01.", [["utility values", "TEST", 9, 23], ["ResultsCovariate analysis", "TEST", 303, 328]]], ["The status of informants as patients versus those acting on behalf of patients was not associated with segment membership, P=0.09.", [["patients", "ORGANISM", 28, 36], ["patients", "ORGANISM", 70, 78], ["patients", "SPECIES", 28, 36], ["patients", "SPECIES", 70, 78]]], ["The actively engaged segment was likely to be younger, outpatients, born in Canada (Table 1).", [["likely to be", "UNCERTAINTY", 33, 45]]], ["Scores from the Safety Partnership Attitudes scale (Table 4) address HYP 4.", [["Scores", "TEST", 0, 6]]], ["As predicted, actively engaged participants anticipated greater benefits to partnerships, reported more confidence in their ability to contribute, and expressed a stronger intent to participate.", [["participants", "SPECIES", 31, 43]]], ["The actively engaged segment preferred that staff, rather than signs, encourage patients to report safety concerns and that staff disclose all mistakes.Passively engaged ::: RQ 2: Are there segments preferring different safety partnerships? ::: ResultsMembership in the passively engaged segment was associated with lower education and a lower intent to participate in safety partnerships.", [["patients", "ORGANISM", 80, 88], ["patients", "SPECIES", 80, 88]]], ["Participants who were immigrants were more likely to reside in this segment (Table 1).", [["Participants", "SPECIES", 0, 12]]], ["The utility values show that they preferred staff to decide whether patients were informed of mistakes (Table 3).", [["patients", "ORGANISM", 68, 76], ["patients", "SPECIES", 68, 76], ["The utility values", "TEST", 0, 18]]], ["In contrast to the evidence-informed approach preferred by the actively engaged segment, passively engaged participants preferred that staff explain why they (rather than research) felt patients should participate in safety partnerships.", [["patients", "ORGANISM", 186, 194], ["participants", "SPECIES", 107, 119], ["patients", "SPECIES", 186, 194]]], ["Patient representation on hospital safety committees was more important to the passively engaged segment than to the actively engaged segment; they preferred that patients were represented on all safety committees.RQ 3: To what extent do patients prefer a collaborative approach to safety? ::: ResultsTo explore this question, we simulated each participant\u2019s response to three approaches to safety.", [["patients", "ORGANISM", 163, 171], ["patients", "ORGANISM", 238, 246], ["Patient", "SPECIES", 0, 7], ["patients", "SPECIES", 163, 171], ["patients", "SPECIES", 238, 246], ["participant", "SPECIES", 345, 356]]], ["According to the safety partnership model, patients received safety training that 1) included readings, videos, and checklists.", [["patients", "ORGANISM", 43, 51], ["patients", "SPECIES", 43, 51], ["safety training", "TREATMENT", 61, 76]]], ["Both patients and staff double checked that 2) staff helped the right patient and 3) medications were correct.", [["patients", "ORGANISM", 5, 13], ["patient", "ORGANISM", 70, 77], ["patients", "SPECIES", 5, 13], ["patient", "SPECIES", 70, 77], ["medications", "TREATMENT", 85, 96]]], ["According to the staff safety model: 1) patients did not learn to make care safer.", [["patients", "ORGANISM", 40, 48], ["patients", "SPECIES", 40, 48]]], ["Staff double checked that 2) they were helping the right patient and 3) medications were correct.", [["patient", "ORGANISM", 57, 64], ["patient", "SPECIES", 57, 64], ["medications", "TREATMENT", 72, 83]]], ["In the control condition, 1) patients did not learn to make care safer, and no one double checked that 2) staff were helping the right patient, and 3) medications were correct.", [["patients", "ORGANISM", 29, 37], ["patient", "ORGANISM", 135, 142], ["patients", "SPECIES", 29, 37], ["patient", "SPECIES", 135, 142], ["medications", "TREATMENT", 151, 162]]], ["Consistent with HYP 5 simulations predicted that both actively (100%) and passively engaged (91%) participants would prefer partnerships with staff rather than a model delegating safety to staff alone (Table 5).RQ 4: What type of engagement strategy do patients prefer? ::: ResultsWe used Randomized First Choice simulations to address this question and to examine HYP 6\u2019s prediction that patients would prefer that staff personally engage them in safety partnerships.", [["patients", "ORGANISM", 253, 261], ["patients", "ORGANISM", 389, 397], ["participants", "SPECIES", 98, 110], ["patients", "SPECIES", 253, 261], ["patients", "SPECIES", 389, 397], ["HYP 5 simulations", "PROBLEM", 16, 33]]], ["According to the personal engagement model, staff encouraged patients to 1) ask about safety, 2) report concerns, 3) clean their hands, and 4) remind staff to wash their hands.", [["patients", "ORGANISM", 61, 69], ["hands", "ORGANISM_SUBDIVISION", 170, 175], ["patients", "SPECIES", 61, 69], ["hands", "ANATOMY", 170, 175]]], ["According to the visual engagement model, signs encouraged patients to 1) ask about safety, 2) report concerns, 3) clean their hands, and 4) remind staff to clean their hands.", [["patients", "ORGANISM", 59, 67], ["patients", "SPECIES", 59, 67], ["hands", "ANATOMY", 169, 174]]], ["In the control condition, patients were not encouraged to 1) ask about safety, 2) report concerns, 3) clean their hands, or 4) tell staff to clean their hands.", [["patients", "ORGANISM", 26, 34], ["hands", "ORGANISM_SUBDIVISION", 153, 158], ["patients", "SPECIES", 26, 34], ["hands", "ANATOMY", 153, 158]]], ["Simulations predicted that 57.5% of participants would prefer personal engagement, while 42.4% would prefer visual engagement (Table 5).", [["participants", "ORGANISM", 36, 48], ["participants", "SPECIES", 36, 48]]], ["The actively engaged segment was more likely to prefer personal engagement (63.9%), while passively engaged participants would be more likely to choose visual engagement (59.7%).RQ 1: What features of safety partnerships are most important to each segment? ::: DiscussionAs predicted, participants preferred point of care initiatives such as medication and identity double checks that might contribute to an immediate reduction in personal risk.", [["participants", "ORGANISM", 108, 120], ["participants", "SPECIES", 108, 120], ["participants", "SPECIES", 285, 297], ["care initiatives", "TREATMENT", 317, 333], ["medication", "TREATMENT", 342, 352], ["identity double checks", "TEST", 357, 379], ["an immediate reduction in personal risk", "PROBLEM", 405, 444], ["more likely", "UNCERTAINTY", 33, 44], ["reduction", "OBSERVATION_MODIFIER", 418, 427]]], ["The administration of medications, for example, represents a significant source of error.52 Double-checking medications exerted a stronger influence on choices than any other attribute.", [["medications", "TREATMENT", 22, 33], ["Double-checking medications", "TREATMENT", 92, 119], ["significant", "OBSERVATION_MODIFIER", 61, 72]]], ["This is consistent with studies suggesting that patients rate double checks, and related approaches to the prevention of medication errors, very positively.19,21RQ 1: What features of safety partnerships are most important to each segment? ::: DiscussionHand hygiene campaigns, in contrast, exerted a limited influence on safety partnership choices.", [["19,21RQ", "CHEMICAL", 156, 163], ["19,21RQ", "CHEMICAL", 156, 163], ["patients", "ORGANISM", 48, 56], ["patients", "SPECIES", 48, 56], ["studies", "TEST", 24, 31], ["patients rate double checks", "TEST", 48, 75], ["medication errors", "PROBLEM", 121, 138], ["consistent with", "UNCERTAINTY", 8, 23]]], ["Consistent with HYP 2, participants were more likely to choose partnerships prompting patients to wash their hands than those encouraging patients to remind staff to wash their hands.", [["HYP 2", "GENE_OR_GENE_PRODUCT", 16, 21], ["patients", "ORGANISM", 86, 94], ["patients", "ORGANISM", 138, 146], ["hands", "ORGANISM_SUBDIVISION", 177, 182], ["participants", "SPECIES", 23, 35], ["patients", "SPECIES", 86, 94], ["patients", "SPECIES", 138, 146]]], ["This finding is consistent with research suggesting that patients consider asking staff whether they have cleaned their hands to be less effective than other strategies and themselves to be less likely to participate in these programs than in other risk reduction initiatives.21,53 Waterman et al19 reported that only 5% of 2,078 post-discharge inpatients asked nurses or doctors whether they had cleaned their hands.", [["patients", "ORGANISM", 57, 65], ["inpatients", "ORGANISM", 345, 355], ["patients", "SPECIES", 57, 65], ["consistent with", "UNCERTAINTY", 16, 31], ["hands", "ANATOMY", 411, 416]]], ["This is consistent with evidence that patients are reluctant to engage in partnerships that might be perceived to challenge the competence of service providers.8RQ 2: Are there segments with different safety partnership preferences? ::: DiscussionConsistent with HYP 3, latent class analysis revealed two segments that might be expected to respond to different safety partnerships.", [["patients", "ORGANISM", 38, 46], ["HYP 3", "GENE_OR_GENE_PRODUCT", 263, 268], ["patients", "SPECIES", 38, 46], ["latent class analysis", "TEST", 270, 291], ["consistent with", "UNCERTAINTY", 8, 23]]], ["Younger outpatients with higher education were more likely to be members of an actively engaged segment that valued scientific evidence that patients could improve safety.", [["outpatients", "ORGANISM", 8, 19], ["patients", "ORGANISM", 141, 149], ["outpatients", "SPECIES", 8, 19], ["patients", "SPECIES", 141, 149]]], ["In previous studies, patients with higher activation scores engage in more preventive activities, are more likely to follow treatment protocols, evidence better health outcomes, incur fewer costs, and evaluate care experiences more positively.32RQ 2: Are there segments with different safety partnership preferences? ::: DiscussionPassively engaged participants anticipated fewer benefits to safety partnerships, were less confident in their ability to contribute, and less intent on participating.", [["patients", "ORGANISM", 21, 29], ["patients", "SPECIES", 21, 29], ["participants", "SPECIES", 349, 361], ["previous studies", "TEST", 3, 19], ["higher activation scores", "PROBLEM", 35, 59], ["treatment protocols", "TREATMENT", 124, 143]]], ["They preferred that staff give a rationale for safety partnerships and decide whether patients were informed of errors.", [["patients", "ORGANISM", 86, 94], ["patients", "SPECIES", 86, 94]]], ["In comparison to the actively engaged segment, patient representation on safety committees was more important to the passively engaged segment.", [["patient", "ORGANISM", 47, 54], ["patient", "SPECIES", 47, 54]]], ["Passively engaged participants, who may be less comfortable expressing their concerns, may value patient representatives who can speak on their behalf.", [["participants", "ORGANISM", 18, 30], ["patient", "ORGANISM", 97, 104], ["participants", "SPECIES", 18, 30], ["patient", "SPECIES", 97, 104]]], ["Participants with immigrant backgrounds, less education, and receiving services as inpatients were more likely to be members of the passively engaged segment.", [["Participants", "SPECIES", 0, 12]]], ["These findings are consistent with studies linking limited education and lower levels of health literacy54 to a preference for a less active role in health32,36 and safety.3,8,19,55RQ 2: Are there segments with different safety partnership preferences? ::: DiscussionThe Theory of Planned Behavior predicts that enhancing self-efficacy should increase the intent to participate.11 Although utility values showed that actively engaged participants preferred to read how to make care safer, they also responded positively to a more comprehensive multimodal approach to safety education utilizing readings, videos, and checklists.", [["3,8,19,55RQ", "CHEMICAL", 172, 183], ["3,8,19,55RQ", "CHEMICAL", 172, 183], ["participants", "ORGANISM", 434, 446], ["participants", "SPECIES", 434, 446], ["utility values", "TEST", 390, 404], ["consistent with", "UNCERTAINTY", 19, 34]]], ["Passively engaged participants, in contrast, preferred to simply read about safety strategies.", [["participants", "SPECIES", 18, 30]]], ["However, when the medication and identity double-checks participants valued were included in a multicomponent (readings, videos, and checklists) educational strategy, simulations predicted that 91% of the passively engaged segment would choose an approach including this active learning option.", [["participants", "SPECIES", 56, 68], ["the medication", "TREATMENT", 14, 28], ["an approach", "TREATMENT", 244, 255], ["this active learning option", "TREATMENT", 266, 293]]], ["The results of simulations reveal attitudinal processes via which highly valued attributes (medication and identity double checks) compensate for the inclusion of features such as active learning that, while less preferred, may enhance the success of safety partnerships.RQ 3: To what extent do patients prefer a collaborative approach to safety? ::: DiscussionConsistent with HYP 5, simulations predicted that, rather than delegating responsibility for safety to hospital staff, 97.6% of our study participants would prefer partnerships between staff and patients.", [["patients", "ORGANISM", 295, 303], ["patients", "ORGANISM", 556, 564], ["patients", "SPECIES", 295, 303], ["participants", "SPECIES", 499, 511], ["patients", "SPECIES", 556, 564], ["attitudinal processes", "PROBLEM", 34, 55], ["medication", "TREATMENT", 92, 102], ["identity double checks", "TEST", 107, 129], ["active", "OBSERVATION_MODIFIER", 180, 186]]], ["The strength of this finding is consistent with a study reporting that 91% of a sample of discharged inpatients agreed that patients could contribute to the prevention of health service errors.19RQ 4: What type of engagement strategy do patients prefer? ::: DiscussionHYP 6 postulated that patients would prefer a personal engagement strategy rather than visual safety prompts.", [["patients", "ORGANISM", 124, 132], ["patients", "ORGANISM", 237, 245], ["patients", "ORGANISM", 290, 298], ["patients", "SPECIES", 124, 132], ["patients", "SPECIES", 237, 245], ["patients", "SPECIES", 290, 298], ["a study", "TEST", 48, 55], ["a personal engagement strategy", "TREATMENT", 312, 342], ["consistent with", "UNCERTAINTY", 32, 47]]], ["Simulations predicted that 57.5% of the study participants would prefer a personal strategy in which staff engaged patients in safety partnerships.", [["patients", "ORGANISM", 115, 123], ["participants", "SPECIES", 46, 58], ["patients", "SPECIES", 115, 123], ["the study", "TEST", 36, 45]]], ["This is consistent with evidence that encouragement by doctors and nurses may increase participation.12 In contrast, 42.4% would prefer an approach with signage reminding patients to ask about safety, report safety concerns, and wash their hands.", [["patients", "ORGANISM", 171, 179], ["patients", "SPECIES", 171, 179], ["consistent with", "UNCERTAINTY", 8, 23]]], ["Preference for a visual communication strategy was strongest in the passively engaged segment.", [["a visual communication strategy", "TREATMENT", 15, 46]]], ["We were surprised by the number of participants predicted to choose a visual strategy.", [["participants", "SPECIES", 35, 47]]], ["There may be several explanations for this finding.", [["may be", "UNCERTAINTY", 6, 12]]], ["Patients, for example, may perceive signs to be less of a burden to staff than a personal discussion.3 In a sample of 277 health care workers, 26% felt there was insufficient time to encourage patients to ask about hand washing.22 Signs may also put less pressure on those who find safety partnerships inconsistent with their perception of the patient\u2019s role.", [["hand", "ANATOMY", 215, 219], ["Patients", "ORGANISM", 0, 8], ["patients", "ORGANISM", 193, 201], ["hand", "ORGANISM_SUBDIVISION", 215, 219], ["patient", "ORGANISM", 344, 351], ["Patients", "SPECIES", 0, 8], ["patients", "SPECIES", 193, 201], ["patient", "SPECIES", 344, 351], ["hand washing", "TREATMENT", 215, 227], ["less pressure", "OBSERVATION_MODIFIER", 250, 263]]], ["In addition to their alignment with the preferences of a significant number of participants, the signage and visual prompts included in a range of health, safety, and infection control initiatives56,57 can simultaneously inform patients, family members, staff, and the administrators who are critical to the success of large-scale safety initiatives.39,58 Signs can be prepared in multiple languages, use an array of interactive strategies, allow patients to review safety recommendations, and facilitate the positioning of reminders at key points along the health service pathway.59 Despite these advantages, effective signage requires careful attention to visual appeal, content, health literacy, and culture;39,60,61 evidence regarding its unique contribution to hospital safety is lacking.39RQ 4: What type of engagement strategy do patients prefer? ::: DiscussionAlthough decision-making processes exerted less influence than many other partnership design attributes, both segments preferred an approach to safety based on shared decisions.", [["infection", "DISEASE", 167, 176], ["patients", "ORGANISM", 228, 236], ["patients", "ORGANISM", 447, 455], ["patients", "ORGANISM", 837, 845], ["participants", "SPECIES", 79, 91], ["patients", "SPECIES", 228, 236], ["patients", "SPECIES", 447, 455], ["patients", "SPECIES", 837, 845], ["the signage", "TEST", 93, 104], ["large-scale safety initiatives", "TREATMENT", 319, 349], ["interactive strategies", "TREATMENT", 417, 439], ["effective signage", "TREATMENT", 610, 627], ["culture", "TEST", 703, 710]]], ["Systematic reviews show that patients are more likely to adhere to health services that are consistent with their preferences.62,63 Collaborative decisions, therefore, are more likely to promote the engagement that enhances the patient experience and improves outcome.32 Informed decisions require an awareness of the risks safety partnerships might reduce.", [["patients", "ORGANISM", 29, 37], ["patient", "ORGANISM", 228, 235], ["patients", "SPECIES", 29, 37], ["patient", "SPECIES", 228, 235], ["Systematic reviews", "TEST", 0, 18]]], ["Both segments preferred that all patients were informed about risks to safety.", [["patients", "ORGANISM", 33, 41], ["patients", "SPECIES", 33, 41], ["segments", "ANATOMY_MODIFIER", 5, 13]]], ["Awareness of risks is associated with greater confidence in one\u2019s ability to prevent medical errors.21 Confidence in one\u2019s ability to prevent medical errors (self-efficacy), in turn, predicts the intent to act preventively.21RQ 4: What type of engagement strategy do patients prefer? ::: DiscussionBoth segments preferred that patients report safety concerns directly to staff and that those conveying safety concerns were thanked and told how the hospital will respond.", [["patients", "ORGANISM", 267, 275], ["patients", "ORGANISM", 327, 335], ["patients", "SPECIES", 267, 275], ["patients", "SPECIES", 327, 335], ["medical errors", "PROBLEM", 85, 99], ["medical errors", "PROBLEM", 142, 156]]], ["Although both segments preferred that patients decide whether to give their names when reporting safety concerns, variations in the anonymity afforded those reporting safety concerns exerted relatively little influence on choices.Limitations ::: DiscussionThis study was conducted in Ontario, Canada, a province in which local media coverage of issues such as SARS (severe acute respiratory syndrome) and Avian flu might have altered public perceptions of the risks of hospital-acquired infection and the importance of participation in infection control strategies.64,65 Results require replication.Limitations ::: DiscussionWe defined the term staff as doctors, nurses, health care providers, and administrative personnel.", [["SARS", "DISEASE", 360, 364], ["acute respiratory syndrome", "DISEASE", 373, 399], ["Avian flu", "DISEASE", 405, 414], ["infection", "DISEASE", 487, 496], ["infection", "DISEASE", 536, 545], ["patients", "ORGANISM", 38, 46], ["patients", "SPECIES", 38, 46], ["Avian flu", "SPECIES", 405, 414], ["This study", "TEST", 256, 266], ["local media coverage", "TREATMENT", 321, 341], ["SARS (severe acute respiratory syndrome", "PROBLEM", 360, 399], ["Avian flu", "PROBLEM", 405, 414], ["acquired infection", "PROBLEM", 478, 496], ["infection control strategies", "TREATMENT", 536, 564], ["replication", "TREATMENT", 587, 598], ["severe", "OBSERVATION_MODIFIER", 366, 372], ["acute", "OBSERVATION_MODIFIER", 373, 378], ["respiratory syndrome", "OBSERVATION", 379, 399], ["infection", "OBSERVATION", 487, 496]]], ["The finding that patients are more likely to engage in safety partnerships that may challenge nurses rather than doctors66 suggests that future studies should examine preferences for partnerships with different health service providers.Limitations ::: DiscussionAlthough the waiting areas in which most surveys were completed may have increased the survey\u2019s contextual validity, return rates were reduced: 26% of those prepared to consider participation were called for appointments before completing the survey.", [["patients", "ORGANISM", 17, 25], ["patients", "SPECIES", 17, 25], ["future studies", "TEST", 137, 151], ["more likely", "UNCERTAINTY", 30, 41]]], ["Because this sample loss was related to organizational factors beyond patient control, it did not, in all probability, represent a systematic enrollment bias.Limitations ::: DiscussionFinally, DCEs have limitations.", [["patient", "ORGANISM", 70, 77], ["patient", "SPECIES", 70, 77], ["this sample loss", "PROBLEM", 8, 24], ["organizational factors", "PROBLEM", 40, 62], ["enrollment bias", "OBSERVATION", 142, 157]]], ["Study design and analysis are complex, the tradeoffs presented in choice tasks are challenging for informants, and the validity of models may be compromised if key attributes are excluded.67ConclusionParticipants preferred point of contact safety partnerships that might afford an immediate reduction in risk.", [["Study design", "TEST", 0, 12], ["analysis", "TEST", 17, 25]]], ["Health service providers need to ask patients about their goals and preferences, ensure the safety partnerships available reflect the views of different segments, teach the skills needed to participate, enhance self efficacy, and ensure a receptive response when patients participate or raise safety concerns.", [["patients", "ORGANISM", 37, 45], ["patients", "ORGANISM", 263, 271], ["patients", "SPECIES", 37, 45], ["patients", "SPECIES", 263, 271]]], ["Respecting individual differences in safety partnership preferences should enhance engagement, improve health outcomes, and contribute to a more positive patient experience.32", [["patient", "ORGANISM", 154, 161], ["patient", "SPECIES", 154, 161]]]], "PMC7129220": [["Case presentationThe patient was a 3-year-old girl born at term.", [["patient", "ORGANISM", 21, 28], ["girl", "ORGANISM", 46, 50], ["patient", "SPECIES", 21, 28], ["girl", "SPECIES", 46, 50]]], ["Autism spectrum disorder (ASD) had recently been diagnosed.", [["Autism spectrum disorder", "DISEASE", 0, 24], ["ASD", "DISEASE", 26, 29], ["Autism spectrum disorder", "PROBLEM", 0, 24], ["ASD", "PROBLEM", 26, 29]]], ["The child was in a day-care centre where no case of gastroenteritis had been reported in the previous days or in her family.", [["gastroenteritis", "DISEASE", 52, 67], ["child", "ORGANISM", 4, 9], ["child", "SPECIES", 4, 9], ["gastroenteritis", "PROBLEM", 52, 67], ["gastroenteritis", "OBSERVATION", 52, 67]]], ["She had not been vaccinated against measles, mumps and rubella.", [["measles, mumps and rubella", "DISEASE", 36, 62], ["She", "ORGANISM", 0, 3], ["measles", "PROBLEM", 36, 43], ["mumps", "PROBLEM", 45, 50], ["rubella", "PROBLEM", 55, 62]]], ["No food allergies had been suspected in the child during her first years.", [["food allergies", "DISEASE", 3, 17], ["child", "ORGANISM", 44, 49], ["food allergies", "PROBLEM", 3, 17], ["food allergies", "OBSERVATION", 3, 17]]], ["At home, her parents noted diarrhoea, but no bloody stools, and found their daughter warm.", [["diarrhoea", "DISEASE", 27, 36], ["diarrhoea", "PROBLEM", 27, 36], ["bloody stools", "PROBLEM", 45, 58], ["diarrhoea", "OBSERVATION", 27, 36]]], ["No rash was observed.", [["rash", "DISEASE", 3, 7], ["rash", "PROBLEM", 3, 7], ["rash", "OBSERVATION", 3, 7]]], ["At 6 pm, her condition had not improved but oral rehydration solution was given successfully.", [["oral", "ANATOMY", 44, 48], ["oral", "ORGANISM_SUBDIVISION", 44, 48], ["oral rehydration solution", "TREATMENT", 44, 69]]], ["At 8 pm, the parents noted mottling on her face and thighs.", [["face", "ANATOMY", 43, 47], ["thighs", "ANATOMY", 52, 58], ["face", "ORGANISM_SUBDIVISION", 43, 47], ["thighs", "ORGANISM_SUBDIVISION", 52, 58], ["mottling on her face and thighs", "PROBLEM", 27, 58], ["mottling", "OBSERVATION", 27, 35], ["face", "ANATOMY", 43, 47], ["thighs", "ANATOMY", 52, 58]]], ["Her condition deteriorated with persistence of abundant and watery stools, a decreased heart rate and then loss of consciousness.", [["watery stools", "ANATOMY", 60, 73], ["heart", "ANATOMY", 87, 92], ["loss of consciousness", "DISEASE", 107, 128], ["heart", "ORGAN", 87, 92], ["watery stools", "PROBLEM", 60, 73], ["a decreased heart rate", "PROBLEM", 75, 97], ["loss of consciousness", "PROBLEM", 107, 128], ["abundant", "OBSERVATION_MODIFIER", 47, 55], ["watery stools", "OBSERVATION", 60, 73], ["heart", "ANATOMY", 87, 92]]], ["At 10 pm, the parents contacted emergency services but, despite resuscitation attempts, the child died of cardiac arrest a few minutes after their arrival.", [["cardiac", "ANATOMY", 106, 113], ["cardiac arrest", "DISEASE", 106, 120], ["cardiac", "ORGAN", 106, 113], ["resuscitation attempts", "TREATMENT", 64, 86], ["cardiac arrest", "PROBLEM", 106, 120], ["cardiac", "ANATOMY", 106, 113], ["arrest", "OBSERVATION", 114, 120]]], ["Postmortem microbiological investigations and autopsy were conducted with the parents\u2019 consent.", [["Postmortem microbiological investigations", "TEST", 0, 41], ["autopsy", "TEST", 46, 53]]], ["The autopsy revealed significant abnormalities only in the intestine with inflammation and adenopathies visible in the colon.", [["intestine", "ANATOMY", 59, 68], ["colon", "ANATOMY", 119, 124], ["inflammation", "DISEASE", 74, 86], ["adenopathies", "DISEASE", 91, 103], ["intestine", "ORGAN", 59, 68], ["colon", "ORGAN", 119, 124], ["The autopsy", "TEST", 0, 11], ["significant abnormalities", "PROBLEM", 21, 46], ["inflammation", "PROBLEM", 74, 86], ["adenopathies visible in the colon", "PROBLEM", 91, 124], ["significant", "OBSERVATION_MODIFIER", 21, 32], ["abnormalities", "OBSERVATION", 33, 46], ["intestine", "ANATOMY", 59, 68], ["inflammation", "OBSERVATION", 74, 86], ["adenopathies", "OBSERVATION", 91, 103], ["colon", "ANATOMY", 119, 124]]], ["The histopathology showed inflammation characterized by significant infiltration of lymphocytes in the intestinal mucosa.", [["lymphocytes", "ANATOMY", 84, 95], ["intestinal mucosa", "ANATOMY", 103, 120], ["inflammation", "DISEASE", 26, 38], ["lymphocytes", "CELL", 84, 95], ["intestinal mucosa", "MULTI-TISSUE_STRUCTURE", 103, 120], ["lymphocytes", "CELL_TYPE", 84, 95], ["The histopathology", "TEST", 0, 18], ["inflammation", "PROBLEM", 26, 38], ["significant infiltration of lymphocytes in the intestinal mucosa", "PROBLEM", 56, 120], ["inflammation", "OBSERVATION", 26, 38], ["significant", "OBSERVATION_MODIFIER", 56, 67], ["infiltration", "OBSERVATION", 68, 80], ["lymphocytes", "OBSERVATION", 84, 95], ["intestinal mucosa", "ANATOMY", 103, 120]]], ["These observations were compatible with the diagnosis of acute gastroenteritis (AGE).", [["acute gastroenteritis", "DISEASE", 57, 78], ["AGE", "DISEASE", 80, 83], ["acute gastroenteritis", "PROBLEM", 57, 78], ["acute", "OBSERVATION_MODIFIER", 57, 62], ["gastroenteritis", "OBSERVATION", 63, 78]]], ["No signs of myocarditis were observed.", [["myocarditis", "DISEASE", 12, 23], ["myocarditis", "PROBLEM", 12, 23], ["signs of", "UNCERTAINTY", 3, 11], ["myocarditis", "OBSERVATION", 12, 23]]], ["None of the microbiological cultures yielded any pathogenic bacteria in the patient\u2019s cerebrospinal fluid (CSF), blood and lung specimens.", [["cerebrospinal fluid", "ANATOMY", 86, 105], ["CSF", "ANATOMY", 107, 110], ["blood", "ANATOMY", 113, 118], ["lung specimens", "ANATOMY", 123, 137], ["patient", "ORGANISM", 76, 83], ["cerebrospinal fluid", "ORGANISM_SUBSTANCE", 86, 105], ["CSF", "ORGANISM_SUBSTANCE", 107, 110], ["blood", "ORGANISM_SUBSTANCE", 113, 118], ["lung specimens", "CANCER", 123, 137], ["patient", "SPECIES", 76, 83], ["the microbiological cultures", "TEST", 8, 36], ["any pathogenic bacteria", "PROBLEM", 45, 68], ["cerebrospinal fluid (CSF", "TEST", 86, 110], ["blood and lung specimens", "TEST", 113, 137], ["pathogenic", "OBSERVATION_MODIFIER", 49, 59], ["bacteria", "OBSERVATION", 60, 68], ["cerebrospinal", "ANATOMY", 86, 99], ["fluid", "OBSERVATION", 100, 105], ["lung", "ANATOMY", 123, 127], ["specimens", "OBSERVATION", 128, 137]]], ["Cultures for Salmonella, Shigella, Campylobacter jejuni, Campylobacter coli, Clostridium difficile and Yersinia were negative in stool and intestine biopsy specimens.", [["stool", "ANATOMY", 129, 134], ["intestine biopsy specimens", "ANATOMY", 139, 165], ["Campylobacter jejuni", "DISEASE", 35, 55], ["Campylobacter coli", "DISEASE", 57, 75], ["Clostridium difficile", "DISEASE", 77, 98], ["Salmonella", "ORGANISM", 13, 23], ["Shigella,", "ORGANISM", 25, 34], ["Campylobacter jejuni", "ORGANISM", 35, 55], ["Campylobacter coli", "ORGANISM", 57, 75], ["Clostridium difficile", "ORGANISM", 77, 98], ["Yersinia", "ORGANISM", 103, 111], ["stool", "ORGANISM_SUBSTANCE", 129, 134], ["intestine biopsy specimens", "MULTI-TISSUE_STRUCTURE", 139, 165], ["Shigella", "SPECIES", 25, 33], ["Campylobacter jejuni", "SPECIES", 35, 55], ["Campylobacter coli", "SPECIES", 57, 75], ["Clostridium difficile", "SPECIES", 77, 98], ["Salmonella", "SPECIES", 13, 23], ["Campylobacter jejuni", "SPECIES", 35, 55], ["Campylobacter coli", "SPECIES", 57, 75], ["Clostridium difficile", "SPECIES", 77, 98], ["Cultures", "TEST", 0, 8], ["Salmonella", "PROBLEM", 13, 23], ["Shigella", "PROBLEM", 25, 33], ["Campylobacter jejuni", "PROBLEM", 35, 55], ["Campylobacter coli", "PROBLEM", 57, 75], ["Clostridium difficile", "PROBLEM", 77, 98], ["Yersinia", "PROBLEM", 103, 111], ["intestine biopsy specimens", "TEST", 139, 165], ["Campylobacter jejuni", "ANATOMY", 35, 55], ["Campylobacter coli", "OBSERVATION", 57, 75], ["Clostridium difficile", "OBSERVATION", 77, 98], ["intestine", "ANATOMY", 139, 148]]], ["Rapid tests for rotavirus, adenovirus 40\u201341 and norovirus were negative in the stool specimen.", [["stool specimen", "ANATOMY", 79, 93], ["rotavirus", "ORGANISM", 16, 25], ["adenovirus 40\u201341", "ORGANISM", 27, 43], ["norovirus", "ORGANISM", 48, 57], ["stool specimen", "MULTI-TISSUE_STRUCTURE", 79, 93], ["rotavirus", "SPECIES", 16, 25], ["adenovirus", "SPECIES", 27, 37], ["norovirus", "SPECIES", 48, 57], ["Rapid tests", "TEST", 0, 11], ["rotavirus", "PROBLEM", 16, 25], ["adenovirus", "PROBLEM", 27, 37], ["norovirus", "PROBLEM", 48, 57], ["the stool specimen", "TEST", 75, 93]]], ["Serological findings showed a recent cytomegalovirus (CMV) primary infection with presence of CMV IgM (index 6, CMV-IgM-ELA test PKS, medac) and IgG-specific antibodies (OD 0.584, Enzygnost\u00ae assay) combined with a low IgG avidity test (avidity 30%, VIDAS\u00ae assay).", [["cytomegalovirus (CMV) primary infection", "DISEASE", 37, 76], ["cytomegalovirus", "ORGANISM", 37, 52], ["CMV", "ORGANISM", 54, 57], ["CMV", "ORGANISM", 94, 97], ["CMV", "ORGANISM", 112, 115], ["CMV IgM", "PROTEIN", 94, 101], ["IgM", "PROTEIN", 116, 119], ["ELA", "PROTEIN", 120, 123], ["PKS", "PROTEIN", 129, 132], ["medac", "PROTEIN", 134, 139], ["IgG", "PROTEIN", 145, 148], ["specific antibodies", "PROTEIN", 149, 168], ["IgG", "PROTEIN", 218, 221], ["CMV", "SPECIES", 54, 57], ["CMV", "SPECIES", 94, 97], ["Serological findings", "TEST", 0, 20], ["a recent cytomegalovirus (CMV) primary infection", "PROBLEM", 28, 76], ["CMV IgM", "TEST", 94, 101], ["index", "TEST", 103, 108], ["CMV", "TEST", 112, 115], ["IgM", "TEST", 116, 119], ["ELA test PKS", "TEST", 120, 132], ["medac", "TEST", 134, 139], ["IgG", "TEST", 145, 148], ["specific antibodies", "TEST", 149, 168], ["OD", "TEST", 170, 172], ["Enzygnost\u00ae assay", "TEST", 180, 196], ["a low IgG avidity test", "PROBLEM", 212, 234], ["avidity", "TEST", 236, 243], ["VIDAS", "TEST", 249, 254], ["cytomegalovirus", "OBSERVATION", 37, 52], ["CMV IgM", "OBSERVATION", 94, 101]]], ["Serology was negative for Epstein-Barr virus, HIV, measles, parvovirus B19, Mycoplasma pneumoniae and herpes simplex virus, but a high level of enterovirus IgG antibodies was found (index 207, SERION ELISA Classic assay).", [["measles", "DISEASE", 51, 58], ["parvovirus B19", "DISEASE", 60, 74], ["Mycoplasma pneumoniae and herpes simplex virus", "DISEASE", 76, 122], ["Epstein-Barr virus", "ORGANISM", 26, 44], ["HIV", "ORGANISM", 46, 49], ["measles", "ORGANISM", 51, 58], ["parvovirus B19", "ORGANISM", 60, 74], ["Mycoplasma pneumoniae", "ORGANISM", 76, 97], ["herpes simplex virus", "ORGANISM", 102, 122], ["enterovirus", "ORGANISM", 144, 155], ["IgG antibodies", "GENE_OR_GENE_PRODUCT", 156, 170], ["enterovirus IgG antibodies", "PROTEIN", 144, 170], ["HIV", "SPECIES", 46, 49], ["parvovirus B19", "SPECIES", 60, 74], ["Mycoplasma pneumoniae", "SPECIES", 76, 97], ["herpes simplex virus", "SPECIES", 102, 122], ["Epstein-Barr virus", "SPECIES", 26, 44], ["HIV", "SPECIES", 46, 49], ["parvovirus B19", "SPECIES", 60, 74], ["Mycoplasma pneumoniae", "SPECIES", 76, 97], ["herpes simplex virus", "SPECIES", 102, 122], ["enterovirus", "SPECIES", 144, 155], ["Serology", "TEST", 0, 8], ["Epstein", "TEST", 26, 33], ["Barr virus", "PROBLEM", 34, 44], ["HIV", "PROBLEM", 46, 49], ["measles", "PROBLEM", 51, 58], ["parvovirus B19", "PROBLEM", 60, 74], ["Mycoplasma pneumoniae", "PROBLEM", 76, 97], ["herpes simplex virus", "PROBLEM", 102, 122], ["enterovirus IgG antibodies", "TEST", 144, 170], ["index", "TEST", 182, 187], ["negative for", "UNCERTAINTY", 13, 25], ["Barr virus", "OBSERVATION", 34, 44], ["Mycoplasma pneumoniae", "OBSERVATION", 76, 97]]], ["PCR for herpes simplex virus, varicella zona virus and enterovirus were negative in CSF.", [["herpes simplex virus", "DISEASE", 8, 28], ["varicella zona virus", "DISEASE", 30, 50], ["herpes simplex virus", "ORGANISM", 8, 28], ["varicella zona virus", "ORGANISM", 30, 50], ["enterovirus", "ORGANISM", 55, 66], ["CSF", "ORGANISM_SUBSTANCE", 84, 87], ["herpes simplex virus", "SPECIES", 8, 28], ["varicella zona virus", "SPECIES", 30, 50], ["herpes simplex virus", "SPECIES", 8, 28], ["varicella zona virus", "SPECIES", 30, 50], ["PCR", "TEST", 0, 3], ["herpes simplex virus", "PROBLEM", 8, 28], ["varicella zona virus", "PROBLEM", 30, 50], ["enterovirus", "PROBLEM", 55, 66], ["herpes simplex virus", "OBSERVATION", 8, 28]]], ["Respiratory multiplex PCR detected M. pneumoniae and coronavirus 229E in the tracheal aspirate and lung biopsy.", [["tracheal aspirate", "ANATOMY", 77, 94], ["lung", "ANATOMY", 99, 103], ["M. pneumoniae", "ORGANISM", 35, 48], ["coronavirus 229E", "ORGANISM", 53, 69], ["tracheal aspirate", "MULTI-TISSUE_STRUCTURE", 77, 94], ["lung biopsy", "MULTI-TISSUE_STRUCTURE", 99, 110], ["M. pneumoniae", "SPECIES", 35, 48], ["coronavirus", "SPECIES", 53, 64], ["M. pneumoniae", "SPECIES", 35, 48], ["coronavirus 229E", "SPECIES", 53, 69], ["Respiratory multiplex PCR", "TEST", 0, 25], ["pneumoniae", "PROBLEM", 38, 48], ["coronavirus", "PROBLEM", 53, 64], ["the tracheal aspirate", "TEST", 73, 94], ["lung biopsy", "TEST", 99, 110], ["pneumoniae", "OBSERVATION", 38, 48], ["coronavirus 229E", "OBSERVATION", 53, 69], ["tracheal", "ANATOMY", 77, 85], ["aspirate", "OBSERVATION", 86, 94], ["lung", "ANATOMY", 99, 103], ["biopsy", "OBSERVATION", 104, 110]]], ["In this AGE context, the patient\u2019s frozen specimens were sent to the French National Reference Centre for enteric viruses.", [["specimens", "ANATOMY", 42, 51], ["enteric viruses", "DISEASE", 106, 121], ["patient", "ORGANISM", 25, 32], ["patient", "SPECIES", 25, 32], ["the patient\u2019s frozen specimens", "TEST", 21, 51], ["enteric viruses", "PROBLEM", 106, 121], ["enteric", "ANATOMY", 106, 113], ["viruses", "OBSERVATION", 114, 121]]], ["Mixed infections were detected by PCR analysis.", [["infections", "DISEASE", 6, 16], ["Mixed infections", "PROBLEM", 0, 16], ["PCR analysis", "TEST", 34, 46], ["infections", "OBSERVATION", 6, 16]]], ["Semi-quantitative results estimated by the cycle threshold (Ct) values showed presence of adenovirus (genotyped as A-31), bocavirus, norovirus (genotyped as GII.e/II.2), sapovirus, CMV and enterovirus (genotyped as enterovirus A-5) in the patient's stool and/or digestive biopsy specimens.", [["stool", "ANATOMY", 249, 254], ["digestive biopsy specimens", "ANATOMY", 262, 288], ["CMV and enterovirus", "DISEASE", 181, 200], ["enterovirus A-5", "CHEMICAL", 215, 230], ["adenovirus", "ORGANISM", 90, 100], ["A-31", "GENE_OR_GENE_PRODUCT", 115, 119], ["bocavirus", "GENE_OR_GENE_PRODUCT", 122, 131], ["norovirus", "ORGANISM", 133, 142], ["sapovirus", "GENE_OR_GENE_PRODUCT", 170, 179], ["CMV", "ORGANISM", 181, 184], ["enterovirus", "ORGANISM", 189, 200], ["enterovirus A-5", "ORGANISM", 215, 230], ["patient", "ORGANISM", 239, 246], ["stool", "ORGANISM_SUBSTANCE", 249, 254], ["digestive biopsy specimens", "CANCER", 262, 288], ["patient", "SPECIES", 239, 246], ["CMV", "SPECIES", 181, 184], ["the cycle threshold", "TEST", 39, 58], ["Ct) values", "TEST", 60, 70], ["adenovirus", "PROBLEM", 90, 100], ["bocavirus", "PROBLEM", 122, 131], ["norovirus", "PROBLEM", 133, 142], ["GII", "TEST", 157, 160], ["sapovirus", "PROBLEM", 170, 179], ["CMV", "PROBLEM", 181, 184], ["enterovirus", "PROBLEM", 189, 200], ["enterovirus A", "TEST", 215, 228], ["the patient's stool", "TEST", 235, 254], ["digestive biopsy specimens", "TEST", 262, 288], ["adenovirus", "OBSERVATION", 90, 100], ["norovirus", "OBSERVATION", 133, 142], ["sapovirus", "OBSERVATION", 170, 179], ["CMV", "OBSERVATION", 181, 184]]], ["Only CMV DNA was detected in whole blood (Fig. 1).What is your interpretation of laboratory results?", [["whole blood", "ANATOMY", 29, 40], ["CMV", "ORGANISM", 5, 8], ["DNA", "CELLULAR_COMPONENT", 9, 12], ["blood", "ORGANISM_SUBSTANCE", 35, 40], ["CMV DNA", "DNA", 5, 12], ["CMV", "SPECIES", 5, 8], ["CMV DNA", "PROBLEM", 5, 12], ["CMV DNA", "OBSERVATION", 5, 12]]], ["Which virus(es) could be the causative agent(s) of this fatal case of AGE? ::: Evidence-based opinionViruses such as rotavirus, norovirus, enteric adenovirus, human astrovirus and sapovirus are the major etiological agents of AGE in children under 5 years of age.", [["AGE", "DISEASE", 70, 73], ["rotavirus, norovirus", "DISEASE", 117, 137], ["enteric adenovirus", "DISEASE", 139, 157], ["human astrovirus and sapovirus", "DISEASE", 159, 189], ["AGE", "DISEASE", 226, 229], ["AGE", "SIMPLE_CHEMICAL", 70, 73], ["rotavirus", "ORGANISM", 117, 126], ["norovirus", "ORGANISM", 128, 137], ["enteric adenovirus", "ORGANISM", 139, 157], ["human", "ORGANISM", 159, 164], ["astrovirus", "ORGANISM", 165, 175], ["sapovirus", "GENE_OR_GENE_PRODUCT", 180, 189], ["AGE", "SIMPLE_CHEMICAL", 226, 229], ["children", "ORGANISM", 233, 241], ["human", "SPECIES", 159, 164], ["astrovirus", "SPECIES", 165, 175], ["children", "SPECIES", 233, 241], ["human astrovirus", "SPECIES", 159, 175], ["based opinionViruses", "PROBLEM", 88, 108], ["rotavirus", "PROBLEM", 117, 126], ["norovirus", "PROBLEM", 128, 137], ["enteric adenovirus", "PROBLEM", 139, 157], ["human astrovirus", "PROBLEM", 159, 175], ["sapovirus", "PROBLEM", 180, 189], ["rotavirus", "OBSERVATION", 117, 126], ["enteric adenovirus", "ANATOMY", 139, 157]]], ["Our investigations also included other viruses with digestive tropism such as aichivirus, human parechovirus, human bocavirus, CMV and enterovirus, but their association with AGE is less documented [1], [2].", [["digestive", "ANATOMY", 52, 61], ["AGE", "DISEASE", 175, 178], ["digestive", "ORGAN", 52, 61], ["aichivirus", "GENE_OR_GENE_PRODUCT", 78, 88], ["human", "ORGANISM", 90, 95], ["parechovirus", "GENE_OR_GENE_PRODUCT", 96, 108], ["human", "ORGANISM", 110, 115], ["bocavirus", "ORGANISM", 116, 125], ["CMV", "ORGANISM", 127, 130], ["enterovirus", "ORGANISM", 135, 146], ["AGE", "SIMPLE_CHEMICAL", 175, 178], ["human", "SPECIES", 90, 95], ["human", "SPECIES", 110, 115], ["human", "SPECIES", 90, 95], ["human", "SPECIES", 110, 115], ["CMV", "SPECIES", 127, 130], ["Our investigations", "TEST", 0, 18], ["other viruses", "PROBLEM", 33, 46], ["digestive tropism", "PROBLEM", 52, 69], ["aichivirus", "PROBLEM", 78, 88], ["human parechovirus", "PROBLEM", 90, 108], ["human bocavirus", "PROBLEM", 110, 125], ["CMV", "PROBLEM", 127, 130], ["enterovirus", "PROBLEM", 135, 146]]], ["This case was unusual because an extraordinary number of pathogens were found in the patient\u2019s specimens by PCR analysis (Fig. 1).", [["specimens", "ANATOMY", 95, 104], ["patient", "ORGANISM", 85, 92], ["patient", "SPECIES", 85, 92], ["pathogens", "PROBLEM", 57, 66], ["PCR analysis", "TEST", 108, 120]]], ["New molecular PCR methods can detect diarrheal pathogens with better specificity and sensitivity than rapid antigen tests [3].", [["New molecular PCR methods", "TEST", 0, 25], ["diarrheal pathogens", "PROBLEM", 37, 56], ["rapid antigen tests", "TEST", 102, 121]]], ["However, the presence of a pathogen in a fecal sample is not necessarily associated with a gastrointestinal disease, since high detection rates have also been reported for asymptomatic individuals [1], [4], [5], [6], [7].", [["fecal sample", "ANATOMY", 41, 53], ["gastrointestinal", "ANATOMY", 91, 107], ["gastrointestinal disease", "DISEASE", 91, 115], ["gastrointestinal", "ORGAN", 91, 107], ["[4]", "SIMPLE_CHEMICAL", 202, 205], ["[5]", "SIMPLE_CHEMICAL", 207, 210], ["[6]", "SIMPLE_CHEMICAL", 212, 215], ["a pathogen in a fecal sample", "PROBLEM", 25, 53], ["a gastrointestinal disease", "PROBLEM", 89, 115], ["high detection rates", "PROBLEM", 123, 143], ["asymptomatic individuals", "PROBLEM", 172, 196], ["pathogen", "OBSERVATION", 27, 35], ["fecal", "ANATOMY", 41, 46], ["not necessarily associated with", "UNCERTAINTY", 57, 88], ["gastrointestinal", "ANATOMY", 91, 107], ["disease", "OBSERVATION", 108, 115]]], ["Many studies have also reported mixed infections in children with AGE or in asymptomatic cases making the interpretation of PCR results very difficult [1], [4], [8], [9].", [["infections", "DISEASE", 38, 48], ["AGE", "DISEASE", 66, 69], ["children", "ORGANISM", 52, 60], ["children", "SPECIES", 52, 60], ["Many studies", "TEST", 0, 12], ["mixed infections", "PROBLEM", 32, 48], ["PCR", "TEST", 124, 127], ["mixed", "OBSERVATION_MODIFIER", 32, 37], ["infections", "OBSERVATION", 38, 48]]], ["Indeed, it is not possible to determine which pathogen is related to the disease at the time the sample is analyzed.", [["pathogen", "PROBLEM", 46, 54], ["the disease", "PROBLEM", 69, 80], ["not possible", "UNCERTAINTY", 14, 26], ["disease", "OBSERVATION", 73, 80]]], ["Previous studies have assessed the usefulness of a semi-quantitative approach using the PCR Ct values to establish a causality link between a pathogen and the clinical manifestation, even if Ct cutoff values for a specific pathogen differ between laboratories [5], [7], [8], [10], [11], [12].", [["[7]", "SIMPLE_CHEMICAL", 265, 268], ["[8]", "SIMPLE_CHEMICAL", 270, 273], ["[10]", "SIMPLE_CHEMICAL", 275, 279], ["[11]", "SIMPLE_CHEMICAL", 281, 285], ["Previous studies", "TEST", 0, 16], ["a semi-quantitative approach", "TEST", 49, 77], ["the PCR Ct values", "TEST", 84, 101], ["a pathogen", "PROBLEM", 140, 150], ["Ct cutoff values", "TEST", 191, 207], ["a specific pathogen", "TEST", 212, 231]]], ["For example, Phillips et al. proposed a Ct value cutoff of 31 in fecal specimens for attributing AGE to norovirus [10].", [["fecal specimens", "ANATOMY", 65, 80], ["AGE", "CHEMICAL", 97, 100], ["norovirus", "DISEASE", 104, 113], ["fecal specimens", "ORGANISM_SUBSTANCE", 65, 80], ["AGE", "SIMPLE_CHEMICAL", 97, 100], ["a Ct value cutoff", "TEST", 38, 55], ["fecal specimens", "TEST", 65, 80], ["norovirus", "PROBLEM", 104, 113]]], ["In our patient, the more abundant viruses were norovirus and adenovirus detected in biopsy and stool specimens with a Ct value less than 30.", [["biopsy", "ANATOMY", 84, 90], ["stool specimens", "ANATOMY", 95, 110], ["norovirus", "DISEASE", 47, 56], ["patient", "ORGANISM", 7, 14], ["norovirus", "ORGANISM", 47, 56], ["adenovirus", "ORGANISM", 61, 71], ["biopsy", "TISSUE", 84, 90], ["stool specimens", "ORGANISM_SUBSTANCE", 95, 110], ["patient", "SPECIES", 7, 14], ["adenovirus", "SPECIES", 61, 71], ["norovirus", "PROBLEM", 47, 56], ["adenovirus", "PROBLEM", 61, 71], ["biopsy", "TEST", 84, 90], ["stool specimens", "TEST", 95, 110], ["a Ct value", "TEST", 116, 126], ["abundant", "OBSERVATION_MODIFIER", 25, 33], ["viruses", "OBSERVATION", 34, 41]]], ["Sapovirus was detected with a low Ct value only in the small intestine biopsy (Fig. 1).", [["intestine", "ANATOMY", 61, 70], ["intestine biopsy", "MULTI-TISSUE_STRUCTURE", 61, 77], ["Sapovirus", "SPECIES", 0, 9], ["Sapovirus", "PROBLEM", 0, 9], ["a low Ct value", "TEST", 28, 42], ["the small intestine biopsy", "TEST", 51, 77], ["small intestine", "ANATOMY", 55, 70]]], ["To our knowledge, few studies have reported analysis of Ct values in specimens other than stools.What is your interpretation of laboratory results?", [["specimens", "ANATOMY", 69, 78], ["stools", "ANATOMY", 90, 96], ["specimens", "CANCER", 69, 78], ["few studies", "TEST", 18, 29], ["Ct values in specimens", "TEST", 56, 78]]], ["Which virus(es) could be the causative agent(s) of this fatal case of AGE? ::: Evidence-based opinionOther pathogens were detected in the patient\u2019s specimens.", [["specimens", "ANATOMY", 148, 157], ["AGE", "DISEASE", 70, 73], ["AGE", "SIMPLE_CHEMICAL", 70, 73], ["patient", "ORGANISM", 138, 145], ["patient", "SPECIES", 138, 145], ["based opinionOther pathogens", "PROBLEM", 88, 116], ["the patient\u2019s specimens", "TEST", 134, 157], ["pathogens", "OBSERVATION", 107, 116]]], ["A recent infection with enterovirus was suspected by serology findings and positive PCR results (Fig. 1).", [["infection", "DISEASE", 9, 18], ["enterovirus", "DISEASE", 24, 35], ["enterovirus", "ORGANISM", 24, 35], ["A recent infection", "PROBLEM", 0, 18], ["enterovirus", "PROBLEM", 24, 35], ["serology findings", "TEST", 53, 70], ["positive PCR results", "PROBLEM", 75, 95], ["infection", "OBSERVATION", 9, 18], ["enterovirus", "OBSERVATION", 24, 35]]], ["Note that PCR for enterovirus was negative in CSF and serum samples.", [["serum samples", "ANATOMY", 54, 67], ["enterovirus", "ORGANISM", 18, 29], ["CSF", "ORGANISM_SUBSTANCE", 46, 49], ["serum samples", "ORGANISM_SUBSTANCE", 54, 67], ["enterovirus", "SPECIES", 18, 29], ["PCR", "TEST", 10, 13], ["enterovirus", "PROBLEM", 18, 29], ["CSF and serum samples", "TEST", 46, 67]]], ["Since asymptomatic infections are frequent, it is difficult to ascertain a pathogenic role of enterovirus in our patient.", [["infections", "DISEASE", 19, 29], ["enterovirus", "DISEASE", 94, 105], ["enterovirus", "ORGANISM", 94, 105], ["patient", "ORGANISM", 113, 120], ["patient", "SPECIES", 113, 120], ["asymptomatic infections", "PROBLEM", 6, 29], ["enterovirus", "PROBLEM", 94, 105], ["asymptomatic", "OBSERVATION_MODIFIER", 6, 18], ["infections", "OBSERVATION", 19, 29], ["enterovirus", "OBSERVATION", 94, 105]]], ["Colitis caused by CMV is unusual in immunocompetent children, but the virus was detected in blood and colon biopsy specimens with a low viral load, making a direct role of CMV in the pathogenesis of the gastrointestinal disease unlikely.", [["blood", "ANATOMY", 92, 97], ["colon biopsy specimens", "ANATOMY", 102, 124], ["gastrointestinal", "ANATOMY", 203, 219], ["Colitis", "DISEASE", 0, 7], ["gastrointestinal disease", "DISEASE", 203, 227], ["CMV", "ORGANISM", 18, 21], ["children", "ORGANISM", 52, 60], ["blood", "ORGANISM_SUBSTANCE", 92, 97], ["colon biopsy specimens", "CANCER", 102, 124], ["CMV", "ORGANISM", 172, 175], ["gastrointestinal", "ORGAN", 203, 219], ["children", "SPECIES", 52, 60], ["CMV", "SPECIES", 18, 21], ["CMV", "SPECIES", 172, 175], ["Colitis", "PROBLEM", 0, 7], ["CMV", "PROBLEM", 18, 21], ["the virus", "PROBLEM", 66, 75], ["blood and colon biopsy specimens", "TEST", 92, 124], ["a low viral load", "PROBLEM", 130, 146], ["CMV", "PROBLEM", 172, 175], ["the gastrointestinal disease", "PROBLEM", 199, 227], ["CMV", "OBSERVATION", 18, 21], ["colon", "ANATOMY", 102, 107], ["CMV", "OBSERVATION", 172, 175], ["gastrointestinal", "ANATOMY", 203, 219], ["disease", "OBSERVATION", 220, 227]]], ["M. pneumoniae and coronavirus 229E were found in the patient's respiratory specimens, but this finding should be interpreted with caution considering the clinical context and the possibility of also detecting these pathogens in asymptomatic cases [13], [14], [15].Which viral and host factors could be associated with severe outcome in gastroenteritis cases? ::: Evidence-based opinionAGE occurring at extreme ages (>85 and <2 years of age) and in immunocompromised hosts are associated with more severe outcomes [16].", [["respiratory specimens", "ANATOMY", 63, 84], ["gastroenteritis", "DISEASE", 336, 351], ["M. pneumoniae", "ORGANISM", 0, 13], ["coronavirus 229E", "ORGANISM", 18, 34], ["patient", "ORGANISM", 53, 60], ["[14]", "SIMPLE_CHEMICAL", 253, 257], ["M. pneumoniae", "SPECIES", 0, 13], ["coronavirus", "SPECIES", 18, 29], ["patient", "SPECIES", 53, 60], ["M. pneumoniae", "SPECIES", 0, 13], ["coronavirus 229E", "SPECIES", 18, 34], ["M. pneumoniae", "PROBLEM", 0, 13], ["coronavirus 229E", "PROBLEM", 18, 34], ["the patient's respiratory specimens", "TEST", 49, 84], ["these pathogens in asymptomatic cases", "PROBLEM", 209, 246], ["based opinionAGE", "PROBLEM", 372, 388], ["immunocompromised hosts", "PROBLEM", 448, 471], ["pneumoniae", "OBSERVATION", 3, 13], ["coronavirus 229E", "OBSERVATION", 18, 34], ["gastroenteritis", "OBSERVATION", 336, 351], ["opinionAGE", "OBSERVATION_MODIFIER", 378, 388], ["immunocompromised hosts", "OBSERVATION", 448, 471]]], ["Our patient was affected by ASD and many studies support the possibility that this disease can be associated with immune dysregulation [17], [18].", [["ASD", "DISEASE", 28, 31], ["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11], ["ASD", "PROBLEM", 28, 31], ["many studies", "TEST", 36, 48], ["this disease", "PROBLEM", 78, 90], ["immune dysregulation", "PROBLEM", 114, 134]]], ["However, little is known about the increased risk of these patients for severe gastrointestinal diseases.", [["gastrointestinal", "ANATOMY", 79, 95], ["gastrointestinal diseases", "DISEASE", 79, 104], ["patients", "ORGANISM", 59, 67], ["gastrointestinal", "ORGAN", 79, 95], ["patients", "SPECIES", 59, 67], ["severe gastrointestinal diseases", "PROBLEM", 72, 104], ["severe", "OBSERVATION_MODIFIER", 72, 78], ["gastrointestinal", "ANATOMY", 79, 95], ["diseases", "OBSERVATION", 96, 104]]], ["Viral factors could contribute to the severity of AGE.", [["AGE", "DISEASE", 50, 53], ["AGE", "SIMPLE_CHEMICAL", 50, 53], ["Viral factors", "PROTEIN", 0, 13], ["Viral factors", "PROBLEM", 0, 13]]], ["Severe outcomes are associated with norovirus genotype II.4 outbreaks occurring in healthcare facilities [19].", [["Severe outcomes", "PROBLEM", 0, 15], ["norovirus genotype II", "PROBLEM", 36, 57], ["norovirus", "OBSERVATION", 36, 45]]], ["Mixed infections raise the question as to whether a single pathogen is responsible for the illness or whether several pathogens act in synergy and may predict a more severe outcome in children [20].", [["infections", "DISEASE", 6, 16], ["illness", "DISEASE", 91, 98], ["children", "ORGANISM", 184, 192], ["children", "SPECIES", 184, 192], ["Mixed infections", "PROBLEM", 0, 16], ["a single pathogen", "PROBLEM", 50, 67], ["the illness", "PROBLEM", 87, 98], ["infections", "OBSERVATION", 6, 16]]], ["Gonzales et al. showed no differences between severity or clinical presentation when comparing single to multiple infections [9], but further studies are needed to better assess this controversial point.", [["infections", "DISEASE", 114, 124], ["differences between severity", "PROBLEM", 26, 54], ["multiple infections", "PROBLEM", 105, 124], ["further studies", "TEST", 134, 149], ["no", "UNCERTAINTY", 23, 25], ["infections", "OBSERVATION", 114, 124]]], ["Even if Ct values can be useful to discriminate AGE and asymptomatic cases, Gonzales et al. showed no correlation between viral load and severity of disease [9].", [["AGE", "DISEASE", 48, 51], ["AGE", "SIMPLE_CHEMICAL", 48, 51], ["Ct values", "TEST", 8, 17], ["viral load and severity of disease", "PROBLEM", 122, 156]]], ["Given that viremia with enteric virus has been described and may be associated with more severe disease [21], PCR for enteric virus was made in the patient\u2019s blood specimen, but only CMV was detected, which was compatible with a recent infection (Fig. 1).", [["blood specimen", "ANATOMY", 158, 172], ["viremia", "DISEASE", 11, 18], ["enteric virus", "DISEASE", 24, 37], ["infection", "DISEASE", 236, 245], ["enteric virus", "ORGANISM", 24, 37], ["patient", "ORGANISM", 148, 155], ["blood specimen", "ORGANISM_SUBSTANCE", 158, 172], ["CMV", "ORGANISM", 183, 186], ["patient", "SPECIES", 148, 155], ["CMV", "SPECIES", 183, 186], ["viremia", "PROBLEM", 11, 18], ["enteric virus", "PROBLEM", 24, 37], ["more severe disease", "PROBLEM", 84, 103], ["PCR", "TEST", 110, 113], ["enteric virus", "PROBLEM", 118, 131], ["blood specimen", "TEST", 158, 172], ["CMV", "PROBLEM", 183, 186], ["a recent infection", "PROBLEM", 227, 245], ["viremia", "OBSERVATION", 11, 18], ["enteric virus", "OBSERVATION", 24, 37], ["may be associated with", "UNCERTAINTY", 61, 83], ["severe", "OBSERVATION_MODIFIER", 89, 95], ["disease", "OBSERVATION", 96, 103], ["compatible with", "UNCERTAINTY", 211, 226], ["infection", "OBSERVATION", 236, 245]]], ["During primary infection, CMV leads to transitory immunosuppression, which could inhibit the immune response against other pathogens such as enteric viruses [22].ConclusionIn developed countries, AGE-associated death is uncommon in immunocompetent children [23], [24].", [["primary infection", "DISEASE", 7, 24], ["enteric viruses", "DISEASE", 141, 156], ["AGE", "CHEMICAL", 196, 199], ["death", "DISEASE", 211, 216], ["CMV", "ORGANISM", 26, 29], ["AGE", "SIMPLE_CHEMICAL", 196, 199], ["children", "ORGANISM", 248, 256], ["children", "SPECIES", 248, 256], ["CMV", "SPECIES", 26, 29], ["primary infection", "PROBLEM", 7, 24], ["CMV", "PROBLEM", 26, 29], ["transitory immunosuppression", "TREATMENT", 39, 67], ["other pathogens", "PROBLEM", 117, 132], ["enteric viruses", "PROBLEM", 141, 156], ["infection", "OBSERVATION", 15, 24], ["CMV", "OBSERVATION", 26, 29]]], ["This report describes a fatal case of AGE in a 3-year-old girl with a medical history of ASD.", [["AGE", "DISEASE", 38, 41], ["ASD", "DISEASE", 89, 92], ["AGE", "SIMPLE_CHEMICAL", 38, 41], ["girl", "ORGANISM", 58, 62], ["girl", "SPECIES", 58, 62], ["ASD", "PROBLEM", 89, 92], ["ASD", "OBSERVATION", 89, 92]]], ["We cannot rule out that this patient had an underlying immune disorder, but we could not explore this possibility.", [["immune disorder", "DISEASE", 55, 70], ["patient", "ORGANISM", 29, 36], ["patient", "SPECIES", 29, 36], ["an underlying immune disorder", "PROBLEM", 41, 70], ["immune disorder", "OBSERVATION", 55, 70]]], ["Extensive investigations showed multiple viral infections in the patient\u2019s specimens.", [["specimens", "ANATOMY", 75, 84], ["viral infections", "DISEASE", 41, 57], ["patient", "ORGANISM", 65, 72], ["patient", "SPECIES", 65, 72], ["Extensive investigations", "TEST", 0, 24], ["multiple viral infections", "PROBLEM", 32, 57], ["the patient\u2019s specimens", "TEST", 61, 84], ["multiple", "OBSERVATION_MODIFIER", 32, 40], ["viral", "OBSERVATION_MODIFIER", 41, 46], ["infections", "OBSERVATION", 47, 57]]], ["Using PCR cycle threshold values, viral load for each enteric virus was estimated.", [["PCR cycle threshold values", "TEST", 6, 32], ["viral load", "TEST", 34, 44], ["each enteric virus", "PROBLEM", 49, 67], ["viral load", "OBSERVATION", 34, 44]]], ["Until now, few studies have focused on the clinical interpretation of PCR results, but high viral load seems to correlate with symptomatic cases.", [["few studies", "TEST", 11, 22], ["PCR results", "TEST", 70, 81], ["high viral load", "PROBLEM", 87, 102], ["symptomatic cases", "PROBLEM", 127, 144]]], ["In the case presented herein, a strict comparison of our results with Ct values from other studies should be interpreted with caution since the patient's underlying medical condition may interfere with the quantification of enteric pathogens.", [["patient", "ORGANISM", 144, 151], ["patient", "SPECIES", 144, 151], ["Ct values", "TEST", 70, 79], ["other studies", "TEST", 85, 98], ["the patient's underlying medical condition", "PROBLEM", 140, 182], ["enteric pathogens", "PROBLEM", 224, 241], ["enteric", "ANATOMY", 224, 231], ["pathogens", "OBSERVATION", 232, 241]]], ["Recent studies suggest that enteric viruses are not only pathogens, but could also be symbiotic modulators of host physiology [25].", [["enteric viruses", "DISEASE", 28, 43], ["enteric viruses", "ORGANISM", 28, 43], ["Recent studies", "TEST", 0, 14], ["enteric viruses", "PROBLEM", 28, 43], ["pathogens", "PROBLEM", 57, 66], ["enteric", "OBSERVATION_MODIFIER", 28, 35], ["viruses", "OBSERVATION", 36, 43]]], ["Considering the emerging view of enteric virome, it is possible that our clinical interpretation of enteric infections will change in the future.Competing interestsNone declared.FundingNone.Ethics approvalNot required.", [["enteric infections", "DISEASE", 100, 118], ["enteric virome", "PROBLEM", 33, 47], ["enteric infections", "PROBLEM", 100, 118], ["enteric virome", "OBSERVATION", 33, 47], ["enteric", "OBSERVATION_MODIFIER", 100, 107], ["infections", "OBSERVATION", 108, 118]]]], "PMC7266437": [], "3301a21965d77cb118b0540783328ca1a4ed6cc5": [["IntroductionCoronaviruses (CoVs) are enveloped, single-stranded, positivesense RNA viruses that can be divided into four genera: Alphacoronavirus, Betacoronavirus, Gammacoronavirus, and the newly identified Deltacoronavirus.", [["IntroductionCoronaviruses", "GENE_OR_GENE_PRODUCT", 0, 25], ["CoVs", "GENE_OR_GENE_PRODUCT", 27, 31], ["Alphacoronavirus", "GENE_OR_GENE_PRODUCT", 129, 145], ["Betacoronavirus", "GENE_OR_GENE_PRODUCT", 147, 162], ["Gammacoronavirus", "GENE_OR_GENE_PRODUCT", 164, 180], ["CoVs", "PROTEIN", 27, 31], ["IntroductionCoronaviruses (CoVs)", "PROBLEM", 0, 32], ["positivesense RNA viruses", "PROBLEM", 65, 90], ["Alphacoronavirus", "PROBLEM", 129, 145], ["Betacoronavirus", "TREATMENT", 147, 162], ["Gammacoronavirus", "TREATMENT", 164, 180], ["the newly identified Deltacoronavirus", "PROBLEM", 186, 223]]], ["Alphacoronavirus and Betacoronavirus mainly infect mammals and Gammacoronavirus generally infects birds (Chan et al., 2013) , while Deltacoronavirus can be detected in both mammals and birds.", [["Alphacoronavirus", "CHEMICAL", 0, 16], ["Betacoronavirus", "CHEMICAL", 21, 36], ["Alphacoronavirus", "GENE_OR_GENE_PRODUCT", 0, 16], ["Betacoronavirus", "GENE_OR_GENE_PRODUCT", 21, 36], ["Gammacoronavirus", "GENE_OR_GENE_PRODUCT", 63, 79], ["birds", "ORGANISM", 98, 103], ["Deltacoronavirus", "GENE_OR_GENE_PRODUCT", 132, 148], ["birds", "ORGANISM", 185, 190], ["Alphacoronavirus", "SPECIES", 0, 16], ["Alphacoronavirus", "PROBLEM", 0, 16], ["Betacoronavirus", "TREATMENT", 21, 36]]], ["Porcine deltacoronavirus (PDCoV) was first described in 2012 during a study to identify new coronaviruses in mammals and birds in Hong Kong, China (Woo et al., 2009; Woo et al., 2012) .", [["Porcine deltacoronavirus", "ORGANISM", 0, 24], ["PDCoV", "CANCER", 26, 31], ["coronaviruses", "ORGANISM", 92, 105], ["birds", "ORGANISM", 121, 126], ["Porcine", "SPECIES", 0, 7], ["Porcine deltacoronavirus", "SPECIES", 0, 24], ["PDCoV", "SPECIES", 26, 31], ["Porcine deltacoronavirus (PDCoV", "TREATMENT", 0, 31], ["a study", "TEST", 68, 75], ["new", "OBSERVATION_MODIFIER", 88, 91], ["coronaviruses", "OBSERVATION", 92, 105]]], ["In early 2014, an outbreak of PDCoV was announced in some pig farms in the United States , and this novel porcine coronavirus has been demonstrated in at least 18 U. S. states (Marthaler et al., 2014a; Marthaler et al., 2014b; Thachil et al., 2015) .", [["PDCoV", "DISEASE", 30, 35], ["porcine coronavirus", "DISEASE", 106, 125], ["PDCoV", "CANCER", 30, 35], ["pig", "ORGANISM", 58, 61], ["porcine coronavirus", "ORGANISM", 106, 125], ["pig", "SPECIES", 58, 61], ["porcine coronavirus", "SPECIES", 106, 125], ["PDCoV", "SPECIES", 30, 35], ["pig", "SPECIES", 58, 61], ["porcine coronavirus", "SPECIES", 106, 125], ["PDCoV", "TREATMENT", 30, 35], ["this novel porcine coronavirus", "PROBLEM", 95, 125]]], ["Subsequently, the detection of PDCoV was also reported in fecal samples from piglets with diarrhea in Korea, Canada, and mainland China (Dong et al., 2015; Lee and Lee, 2014; Song et al., 2015) .", [["fecal samples", "ANATOMY", 58, 71], ["diarrhea", "DISEASE", 90, 98], ["PDCoV", "GENE_OR_GENE_PRODUCT", 31, 36], ["fecal samples", "ORGANISM_SUBSTANCE", 58, 71], ["piglets", "ORGANISM", 77, 84], ["PDCoV", "PROTEIN", 31, 36], ["piglets", "SPECIES", 77, 84], ["PDCoV", "SPECIES", 31, 36], ["PDCoV", "PROBLEM", 31, 36], ["diarrhea", "PROBLEM", 90, 98], ["diarrhea", "OBSERVATION", 90, 98]]], ["More recently, several groups have demonstrated that PDCoV can cause severe clinical diarrhea and intestinal pathological damage in roughly 10-day-old gnotobiotic and conventional piglets Jung et al., 2015; Ma et al., 2015) adding to the increasing concern regarding the epidemiology, evolution, pathogenesis, and immunology of this emerging coronavirus.IntroductionInterferon (IFN) and the IFN-induced cellular antiviral response are the primary defense mechanisms against viral infection.", [["intestinal", "ANATOMY", 98, 108], ["cellular", "ANATOMY", 403, 411], ["PDCoV", "CHEMICAL", 53, 58], ["diarrhea", "DISEASE", 85, 93], ["coronavirus", "DISEASE", 342, 353], ["IFN", "CHEMICAL", 391, 394], ["viral infection", "DISEASE", 474, 489], ["PDCoV", "SIMPLE_CHEMICAL", 53, 58], ["intestinal", "ORGAN", 98, 108], ["coronavirus", "ORGANISM", 342, 353], ["Interferon", "GENE_OR_GENE_PRODUCT", 366, 376], ["IFN", "GENE_OR_GENE_PRODUCT", 378, 381], ["IFN", "GENE_OR_GENE_PRODUCT", 391, 394], ["cellular", "CELL", 403, 411], ["Interferon", "PROTEIN", 366, 376], ["IFN", "PROTEIN", 378, 381], ["IFN", "PROTEIN", 391, 394], ["severe clinical diarrhea", "PROBLEM", 69, 93], ["intestinal pathological damage", "PROBLEM", 98, 128], ["pathogenesis", "PROBLEM", 296, 308], ["this emerging coronavirus", "PROBLEM", 328, 353], ["IntroductionInterferon (IFN)", "TREATMENT", 354, 382], ["the IFN", "TREATMENT", 387, 394], ["cellular antiviral response", "PROBLEM", 403, 430], ["viral infection", "PROBLEM", 474, 489], ["severe", "OBSERVATION_MODIFIER", 69, 75], ["intestinal", "ANATOMY", 98, 108], ["cellular antiviral response", "OBSERVATION", 403, 430], ["viral", "OBSERVATION_MODIFIER", 474, 479], ["infection", "OBSERVATION", 480, 489]]], ["In virusinfected cells, viral components or replication intermediates known as the pathogen-associated molecular patterns (PAMPs), can be recognized by host pattern-recognition receptors (PRRs), such as the cytoplasmic retinoic acid-inducible gene I (RIG-I) and melanoma differentiation gene 5 (MDA5).", [["virusinfected cells", "ANATOMY", 3, 22], ["cytoplasmic", "ANATOMY", 207, 218], ["virusinfected cells", "CELL", 3, 22], ["pathogen-associated molecular patterns", "GENE_OR_GENE_PRODUCT", 83, 121], ["PAMPs", "GENE_OR_GENE_PRODUCT", 123, 128], ["pattern-recognition receptors", "GENE_OR_GENE_PRODUCT", 157, 186], ["PRRs", "GENE_OR_GENE_PRODUCT", 188, 192], ["cytoplasmic", "ORGANISM_SUBSTANCE", 207, 218], ["retinoic acid-inducible gene I", "GENE_OR_GENE_PRODUCT", 219, 249], ["RIG-I", "GENE_OR_GENE_PRODUCT", 251, 256], ["melanoma differentiation gene 5", "GENE_OR_GENE_PRODUCT", 262, 293], ["MDA5", "GENE_OR_GENE_PRODUCT", 295, 299], ["virusinfected cells", "CELL_TYPE", 3, 22], ["pathogen-associated molecular patterns", "PROTEIN", 83, 121], ["PAMPs", "PROTEIN", 123, 128], ["host pattern-recognition receptors", "PROTEIN", 152, 186], ["PRRs", "PROTEIN", 188, 192], ["cytoplasmic retinoic acid-inducible gene I", "DNA", 207, 249], ["RIG-I", "DNA", 251, 256], ["melanoma differentiation gene 5", "DNA", 262, 293], ["MDA5", "DNA", 295, 299], ["virusinfected cells", "PROBLEM", 3, 22], ["viral components", "PROBLEM", 24, 40], ["replication intermediates", "PROBLEM", 44, 69], ["the pathogen", "PROBLEM", 79, 91], ["the cytoplasmic retinoic acid-inducible gene I (RIG-I) and melanoma differentiation gene", "PROBLEM", 203, 291], ["virusinfected cells", "OBSERVATION", 3, 22], ["viral components", "OBSERVATION", 24, 40], ["melanoma", "OBSERVATION", 262, 270]]], ["After recognition, RIG-I and/or MDA5 interact with the IFN-\u03b2 promoter stimulator 1 (IPS-1, also known as MAVS/VISA/Cardif) via the caspase-recruiting domain (CARD)-like domain to activate the downstream \u03baB kinase (IKK)-related kinases, such as TANK-binding kinase 1 and IKK\u03b5, leading to the activation of interferon regulation factor 3 (IRF3) and nuclear factor \u03baB (NF-\u03baB).IntroductionPhosphorylated IRF3 and NF-\u03baB translocate to nucleus and coordinately activate the type I IFN promoter (Hiscott et al., 2006; Ramos and Gale, 2011; Seth et al., 2005) .IntroductionTo combat the antiviral effects of IFN, viruses have evolved various mechanisms to antagonize the host IFN responses.", [["nucleus", "ANATOMY", 430, 437], ["IFN", "CHEMICAL", 600, 603], ["RIG-I", "GENE_OR_GENE_PRODUCT", 19, 24], ["MDA5", "GENE_OR_GENE_PRODUCT", 32, 36], ["IFN-\u03b2 promoter stimulator 1", "GENE_OR_GENE_PRODUCT", 55, 82], ["IPS-1", "GENE_OR_GENE_PRODUCT", 84, 89], ["MAVS", "GENE_OR_GENE_PRODUCT", 105, 109], ["VISA", "GENE_OR_GENE_PRODUCT", 110, 114], ["Cardif", "GENE_OR_GENE_PRODUCT", 115, 121], ["caspase", "GENE_OR_GENE_PRODUCT", 131, 138], ["CARD", "GENE_OR_GENE_PRODUCT", 158, 162], ["\u03baB kinase", "GENE_OR_GENE_PRODUCT", 203, 212], ["IKK", "GENE_OR_GENE_PRODUCT", 214, 217], ["TANK-binding kinase 1", "GENE_OR_GENE_PRODUCT", 244, 265], ["IKK\u03b5", "GENE_OR_GENE_PRODUCT", 270, 274], ["interferon regulation factor 3", "GENE_OR_GENE_PRODUCT", 305, 335], ["IRF3", "GENE_OR_GENE_PRODUCT", 337, 341], ["nuclear factor \u03baB", "GENE_OR_GENE_PRODUCT", 347, 364], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 366, 371], ["IRF3", "GENE_OR_GENE_PRODUCT", 400, 404], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 409, 414], ["nucleus", "CELLULAR_COMPONENT", 430, 437], ["type I IFN", "GENE_OR_GENE_PRODUCT", 468, 478], ["IFN", "GENE_OR_GENE_PRODUCT", 600, 603], ["IFN", "GENE_OR_GENE_PRODUCT", 668, 671], ["RIG", "PROTEIN", 19, 22], ["MDA5", "PROTEIN", 32, 36], ["IFN-\u03b2 promoter stimulator 1", "DNA", 55, 82], ["IPS-1", "DNA", 84, 89], ["MAVS", "PROTEIN", 105, 109], ["VISA", "PROTEIN", 110, 114], ["Cardif", "DNA", 115, 121], ["caspase-recruiting domain (CARD)-like domain", "PROTEIN", 131, 175], ["\u03baB kinase", "PROTEIN", 203, 212], ["IKK", "PROTEIN", 214, 217], ["TANK-binding kinase 1", "PROTEIN", 244, 265], ["IKK\u03b5", "PROTEIN", 270, 274], ["interferon regulation factor 3", "PROTEIN", 305, 335], ["IRF3", "PROTEIN", 337, 341], ["nuclear factor \u03baB", "PROTEIN", 347, 364], ["NF-\u03baB", "PROTEIN", 366, 371], ["IRF3", "PROTEIN", 400, 404], ["NF-\u03baB", "PROTEIN", 409, 414], ["type I IFN promoter", "DNA", 468, 487], ["IFN", "PROTEIN", 600, 603], ["IFN", "PROTEIN", 668, 671], ["the IFN-\u03b2 promoter stimulator", "TREATMENT", 51, 80], ["VISA/Cardif", "TREATMENT", 110, 121], ["the caspase", "TREATMENT", 127, 138], ["the downstream \u03baB kinase", "TEST", 188, 212], ["kinases", "TEST", 227, 234], ["TANK-binding kinase", "TEST", 244, 263], ["IKK\u03b5", "PROBLEM", 270, 274], ["interferon regulation factor", "TREATMENT", 305, 333], ["nuclear factor \u03baB", "TEST", 347, 364], ["IntroductionPhosphorylated IRF3", "TREATMENT", 373, 404], ["Introduction", "TREATMENT", 553, 565], ["the antiviral effects", "TREATMENT", 575, 596], ["IFN", "TREATMENT", 600, 603], ["viruses", "TREATMENT", 605, 612]]], ["The molecular mechanisms of IFN antagonism have been extensively studied for alphacoronaviruses, betacoronaviruses, and gammacoronaviruses (Perlman and Netland, 2009) .", [["IFN", "GENE_OR_GENE_PRODUCT", 28, 31], ["alphacoronaviruses", "GENE_OR_GENE_PRODUCT", 77, 95], ["betacoronaviruses", "GENE_OR_GENE_PRODUCT", 97, 114], ["IFN", "PROTEIN", 28, 31], ["IFN antagonism", "PROBLEM", 28, 42], ["alphacoronaviruses", "PROBLEM", 77, 95], ["betacoronaviruses", "PROBLEM", 97, 114], ["IFN antagonism", "OBSERVATION", 28, 42]]], ["For example, porcine epidemic diarrhea virus (PEDV), a member of the Alphacoronavirus genus, inhibits dsRNA-induced IFN-\u03b2 production by blockading the RIG-I-mediated pathway (Cao et al., 2015; Ding et al., 2014; Wang et al., 2016) .", [["porcine epidemic diarrhea virus", "DISEASE", 13, 44], ["porcine epidemic diarrhea virus", "ORGANISM", 13, 44], ["PEDV", "ORGANISM", 46, 50], ["Alphacoronavirus genus", "ORGANISM", 69, 91], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 116, 121], ["RIG-I", "GENE_OR_GENE_PRODUCT", 151, 156], ["IFN", "PROTEIN", 116, 119], ["\u03b2", "PROTEIN", 120, 121], ["RIG-I", "PROTEIN", 151, 156], ["porcine epidemic diarrhea virus", "SPECIES", 13, 44], ["porcine epidemic diarrhea virus", "SPECIES", 13, 44], ["PEDV", "SPECIES", 46, 50], ["porcine epidemic diarrhea virus", "PROBLEM", 13, 44], ["PEDV", "PROBLEM", 46, 50], ["the Alphacoronavirus genus", "PROBLEM", 65, 91], ["dsRNA", "PROBLEM", 102, 107], ["porcine", "OBSERVATION_MODIFIER", 13, 20], ["epidemic", "OBSERVATION_MODIFIER", 21, 29], ["Alphacoronavirus genus", "ANATOMY", 69, 91]]], ["Additionally, mouse hepatitis virus (MHV) and severe acute respiratory syndrome coronavirus (SARS-CoV), two representative members of the Betacoronavirus genus, interfere with the IFN response in various ways (Roth-Cross et al., 2007; Totura and Baric, 2012; Zhou and Perlman, 2007) , and at least eight proteins encoded by SARS-CoV have been identified as IFN antagonists (Devaraj et al., 2007; Kopecky-Bromberg et al., 2007; Siu et al., 2009; Wathelet et al., 2007) .", [["mouse hepatitis virus", "DISEASE", 14, 35], ["acute respiratory syndrome coronavirus", "DISEASE", 53, 91], ["SARS-CoV)", "DISEASE", 93, 102], ["mouse hepatitis virus (MHV)", "ORGANISM", 14, 41], ["severe acute respiratory syndrome coronavirus", "ORGANISM", 46, 91], ["SARS-CoV", "ORGANISM", 93, 101], ["Betacoronavirus genus", "ORGANISM", 138, 159], ["IFN", "GENE_OR_GENE_PRODUCT", 180, 183], ["SARS-CoV", "ORGANISM", 324, 332], ["IFN", "PROTEIN", 180, 183], ["IFN", "PROTEIN", 357, 360], ["mouse", "SPECIES", 14, 19], ["hepatitis virus", "SPECIES", 20, 35], ["mouse hepatitis virus", "SPECIES", 14, 35], ["MHV", "SPECIES", 37, 40], ["severe acute respiratory syndrome coronavirus", "SPECIES", 46, 91], ["SARS-CoV", "SPECIES", 93, 101], ["SARS-CoV", "SPECIES", 324, 332], ["mouse hepatitis virus", "PROBLEM", 14, 35], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 46, 91], ["the Betacoronavirus genus", "PROBLEM", 134, 159], ["IFN antagonists", "TREATMENT", 357, 372], ["hepatitis virus", "OBSERVATION", 20, 35], ["severe", "OBSERVATION_MODIFIER", 46, 52], ["acute", "OBSERVATION_MODIFIER", 53, 58], ["respiratory syndrome coronavirus", "OBSERVATION", 59, 91]]], ["The infectious bronchitis virus, a member of the Gammacoronavirus genus, induces a delayed activation of the IFN response (Kint et al., 2015) .", [["infectious bronchitis virus", "DISEASE", 4, 31], ["infectious bronchitis virus", "ORGANISM", 4, 31], ["Gammacoronavirus genus", "ORGANISM", 49, 71], ["IFN", "GENE_OR_GENE_PRODUCT", 109, 112], ["IFN", "PROTEIN", 109, 112], ["infectious bronchitis virus", "SPECIES", 4, 31], ["infectious bronchitis virus", "SPECIES", 4, 31], ["The infectious bronchitis virus", "PROBLEM", 0, 31], ["infectious", "OBSERVATION_MODIFIER", 4, 14], ["bronchitis virus", "OBSERVATION", 15, 31]]], ["As a new member of coronavirus family, however, whether or not deltacoronaviruses antagonize IFN responses and, if they do, the details of this process are unclear.IntroductionCurrently, PDCoV is the sole deltacoronavirus that has been successfully isolated in cell culture.", [["cell culture", "ANATOMY", 261, 273], ["PDCoV", "CHEMICAL", 187, 192], ["coronavirus", "ORGANISM", 19, 30], ["deltacoronaviruses", "GENE_OR_GENE_PRODUCT", 63, 81], ["IFN", "GENE_OR_GENE_PRODUCT", 93, 96], ["PDCoV", "GENE_OR_GENE_PRODUCT", 187, 192], ["deltacoronavirus", "CANCER", 205, 221], ["cell culture", "CELL", 261, 273], ["IFN", "PROTEIN", 93, 96], ["PDCoV", "DNA", 187, 192], ["IntroductionCurrently", "TREATMENT", 164, 185], ["PDCoV", "TREATMENT", 187, 192], ["the sole deltacoronavirus", "PROBLEM", 196, 221], ["cell culture", "TEST", 261, 273]]], ["In this study, we investigated the IFN responses after PDCoV infection of LLC-PK1 cells, a porcine kidney cell line.", [["LLC-PK1 cells", "ANATOMY", 74, 87], ["kidney cell line", "ANATOMY", 99, 115], ["infection", "DISEASE", 61, 70], ["IFN", "GENE_OR_GENE_PRODUCT", 35, 38], ["PDCoV", "SIMPLE_CHEMICAL", 55, 60], ["LLC-PK1 cells", "CELL", 74, 87], ["porcine", "ORGANISM", 91, 98], ["kidney cell line", "CELL", 99, 115], ["IFN", "PROTEIN", 35, 38], ["LLC-PK1 cells", "CELL_LINE", 74, 87], ["porcine kidney cell line", "CELL_LINE", 91, 115], ["porcine", "SPECIES", 91, 98], ["PDCoV", "SPECIES", 55, 60], ["this study", "TEST", 3, 13], ["PDCoV infection of LLC", "PROBLEM", 55, 77], ["PK1 cells", "PROBLEM", 78, 87], ["a porcine kidney cell line", "TREATMENT", 89, 115], ["LLC", "ANATOMY", 74, 77], ["PK1 cells", "OBSERVATION", 78, 87], ["kidney", "ANATOMY", 99, 105], ["cell line", "OBSERVATION", 106, 115]]], ["Our results show that PDCoV infection not only fails to activate IFN-\u03b2 production, but it also inhibits Sendai virus (SeV)-or poly(I:C)-induced IFN-\u03b2 production.", [["PDCoV", "CHEMICAL", 22, 27], ["infection", "DISEASE", 28, 37], ["poly(I:C", "CHEMICAL", 126, 134], ["PDCoV", "SIMPLE_CHEMICAL", 22, 27], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 65, 70], ["Sendai virus", "ORGANISM", 104, 116], ["SeV", "ORGANISM", 118, 121], ["poly(I:C", "SIMPLE_CHEMICAL", 126, 134], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 144, 149], ["IFN", "PROTEIN", 65, 68], ["\u03b2", "PROTEIN", 69, 70], ["IFN", "PROTEIN", 144, 147], ["\u03b2", "PROTEIN", 148, 149], ["Sendai virus", "SPECIES", 104, 116], ["PDCoV", "SPECIES", 22, 27], ["Sendai virus", "SPECIES", 104, 116], ["SeV", "SPECIES", 118, 121], ["PDCoV infection", "PROBLEM", 22, 37], ["IFN", "TEST", 65, 68], ["Sendai virus", "PROBLEM", 104, 116], ["IFN", "PROBLEM", 144, 147], ["infection", "OBSERVATION", 28, 37], ["Sendai virus", "OBSERVATION", 104, 116]]], ["We also demonstrate that PDCoV infection interrupts the RIG-I signaling pathway and impedes the activation of the critical transcription factors IRF3 and NF-\u03baB.PDCoV proliferation characteristics in LLC-PK1 cellsTo determine the kinetics of PDCoV propagation in LLC-PK1 cells, the cytopathic effects (CPEs) were examined and the virus titers were determined at different time points after PDCoV infection.", [["LLC-PK1 cells", "ANATOMY", 199, 212], ["LLC-PK1 cells", "ANATOMY", 262, 275], ["PDCoV", "CHEMICAL", 25, 30], ["infection", "DISEASE", 31, 40], ["infection", "DISEASE", 395, 404], ["PDCoV", "GENE_OR_GENE_PRODUCT", 25, 30], ["RIG-I", "GENE_OR_GENE_PRODUCT", 56, 61], ["IRF3", "GENE_OR_GENE_PRODUCT", 145, 149], ["NF-\u03baB.PDCoV", "GENE_OR_GENE_PRODUCT", 154, 165], ["LLC-PK1 cells", "CELL", 199, 212], ["PDCoV", "SIMPLE_CHEMICAL", 241, 246], ["LLC-PK1 cells", "CELL", 262, 275], ["RIG-I", "PROTEIN", 56, 61], ["transcription factors", "PROTEIN", 123, 144], ["IRF3", "PROTEIN", 145, 149], ["NF-\u03baB.PDCoV", "PROTEIN", 154, 165], ["LLC-PK1 cells", "CELL_LINE", 199, 212], ["PDCoV", "PROTEIN", 241, 246], ["LLC-PK1 cells", "CELL_LINE", 262, 275], ["PDCoV", "SPECIES", 389, 394], ["PDCoV infection", "PROBLEM", 25, 40], ["IRF3", "TEST", 145, 149], ["NF", "TEST", 154, 156], ["PK1 cells", "PROBLEM", 203, 212], ["PDCoV propagation", "PROBLEM", 241, 258], ["PK1 cells", "PROBLEM", 266, 275], ["the cytopathic effects (CPEs", "PROBLEM", 277, 305], ["the virus titers", "TEST", 325, 341], ["PDCoV infection", "PROBLEM", 389, 404], ["PDCoV", "OBSERVATION_MODIFIER", 25, 30], ["infection", "OBSERVATION", 31, 40], ["LLC", "ANATOMY", 199, 202], ["PK1 cells", "OBSERVATION", 203, 212], ["LLC", "ANATOMY", 262, 265], ["PK1 cells", "OBSERVATION", 266, 275], ["cytopathic", "OBSERVATION_MODIFIER", 281, 291], ["infection", "OBSERVATION", 395, 404]]], ["To this end, LLC-PK1 cells were infected with PDCoV strain CHN-HN-2014 at a multiplicity of infection (MOI) of 0.01 and the CPEs were examined daily for up to three days.", [["LLC-PK1 cells", "ANATOMY", 13, 26], ["multiplicity of infection", "DISEASE", 76, 101], ["LLC-PK1 cells", "CELL", 13, 26], ["CHN-HN-2014", "CELL", 59, 70], ["LLC-PK1 cells", "CELL_LINE", 13, 26], ["PK1 cells", "PROBLEM", 17, 26], ["PDCoV strain CHN", "PROBLEM", 46, 62], ["infection", "PROBLEM", 92, 101], ["the CPEs", "TEST", 120, 128], ["LLC", "ANATOMY", 13, 16], ["infection", "OBSERVATION", 92, 101]]], ["The infected cells were monitored by indirect immunofluorescence assays (IFAs) using a monoclonal antibody against PDCoV N protein at 6, 12, 18, 24, 30, and 36 h post-infection (hpi).", [["cells", "ANATOMY", 13, 18], ["cells", "CELL", 13, 18], ["PDCoV N protein", "GENE_OR_GENE_PRODUCT", 115, 130], ["infected cells", "CELL_TYPE", 4, 18], ["monoclonal antibody", "PROTEIN", 87, 106], ["PDCoV N protein", "PROTEIN", 115, 130], ["The infected cells", "PROBLEM", 0, 18], ["indirect immunofluorescence assays", "TEST", 37, 71], ["a monoclonal antibody", "TEST", 85, 106], ["PDCoV N protein", "TEST", 115, 130], ["infection", "PROBLEM", 167, 176], ["infected cells", "OBSERVATION", 4, 18], ["infection", "OBSERVATION", 167, 176]]], ["As shown in Fig. 1A , only a small portion of cells were infected by 12 hpi, nearly all of the cells were PDCoV-positive at 18 hpi, and no cell detachment was observed at 24 hpi.", [["cells", "ANATOMY", 46, 51], ["cells", "ANATOMY", 95, 100], ["cell", "ANATOMY", 139, 143], ["cells", "CELL", 46, 51], ["cells", "CELL", 95, 100], ["PDCoV", "GENE_OR_GENE_PRODUCT", 106, 111], ["cell", "CELL", 139, 143], ["PDCoV", "PROTEIN", 106, 111], ["a small portion of cells", "PROBLEM", 27, 51], ["PDCoV", "TEST", 106, 111], ["cell detachment", "PROBLEM", 139, 154], ["Fig", "OBSERVATION", 12, 15], ["small", "OBSERVATION_MODIFIER", 29, 34], ["no", "UNCERTAINTY", 136, 138], ["cell detachment", "OBSERVATION", 139, 154]]], ["The number of infected cells deceased rapidly up to 30 hpi, and obvious CPEs were observed along with serious cytopathy and a large number of detached cells at 36 hpi.", [["cells", "ANATOMY", 23, 28], ["cells", "ANATOMY", 151, 156], ["cytopathy", "DISEASE", 110, 119], ["cells", "CELL", 23, 28], ["CPEs", "PATHOLOGICAL_FORMATION", 72, 76], ["cells", "CELL", 151, 156], ["infected cells", "CELL_TYPE", 14, 28], ["detached cells", "CELL_TYPE", 142, 156], ["infected cells", "PROBLEM", 14, 28], ["obvious CPEs", "PROBLEM", 64, 76], ["serious cytopathy", "PROBLEM", 102, 119], ["detached cells", "PROBLEM", 142, 156], ["infected cells", "OBSERVATION", 14, 28], ["obvious", "OBSERVATION_MODIFIER", 64, 71], ["CPEs", "OBSERVATION", 72, 76], ["serious", "OBSERVATION_MODIFIER", 102, 109], ["cytopathy", "OBSERVATION", 110, 119], ["large", "OBSERVATION_MODIFIER", 126, 131], ["number", "OBSERVATION_MODIFIER", 132, 138], ["detached cells", "OBSERVATION", 142, 156]]], ["A onestep growth curve for PDCoV strain CHN-HN-2014 in LLC-PK1 cells was also generated using TCID 50 assays.", [["LLC-PK1 cells", "ANATOMY", 55, 68], ["CHN-HN-2014", "CHEMICAL", 40, 51], ["LLC-PK1 cells", "CELL", 55, 68], ["LLC-PK1 cells", "CELL_LINE", 55, 68], ["A onestep growth curve", "TEST", 0, 22], ["PDCoV strain CHN", "TEST", 27, 43], ["PK1 cells", "TEST", 59, 68], ["LLC", "ANATOMY", 55, 58]]], ["As shown in Fig. 1B , virus titers presented a gradually upward tendency as the infection progressed, and at 24 hpi they reached a titer of 10 7.2 TCID 50 /mL.", [["infection", "DISEASE", 80, 89], ["1B", "GENE_OR_GENE_PRODUCT", 17, 19], ["virus titers", "TEST", 22, 34], ["a gradually upward tendency", "PROBLEM", 45, 72], ["the infection", "PROBLEM", 76, 89], ["a titer", "TEST", 129, 136], ["Fig", "OBSERVATION", 12, 15], ["virus titers", "OBSERVATION", 22, 34], ["gradually", "OBSERVATION_MODIFIER", 47, 56], ["upward", "OBSERVATION_MODIFIER", 57, 63], ["tendency", "OBSERVATION_MODIFIER", 64, 72], ["infection", "OBSERVATION", 80, 89]]], ["Together, these results show that PDCoV infection in LLC-PK1 cells achieves a high infection rate and titer without cell exfoliation at 24 hpi; thus, this time point was selected as the optimal time point for subsequent immunological studies.PDCoV infection fails to activate IFN-\u03b2 and interrupts SeV-or poly(I:C)-mediated IFN-\u03b2 inductionPrevious studies have demonstrated that Alphacoronavirus, Betacoronavirus, and Gammacoronavirus have evolved diverse mechanisms to evade or suppress the host's antiviral innate immunity, the most important of which are the IFN responses (Perlman and Netland, 2009 ).", [["LLC-PK1 cells", "ANATOMY", 53, 66], ["cell", "ANATOMY", 116, 120], ["PDCoV", "CHEMICAL", 34, 39], ["infection", "DISEASE", 40, 49], ["infection", "DISEASE", 83, 92], ["PDCoV", "CHEMICAL", 242, 247], ["infection", "DISEASE", 248, 257], ["poly(I:C", "CHEMICAL", 304, 312], ["Gammacoronavirus", "CHEMICAL", 417, 433], ["PDCoV", "SIMPLE_CHEMICAL", 34, 39], ["LLC-PK1 cells", "CELL", 53, 66], ["cell", "CELL", 116, 120], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 276, 281], ["SeV", "ORGANISM", 297, 300], ["poly(I:C", "GENE_OR_GENE_PRODUCT", 304, 312], ["IFN", "GENE_OR_GENE_PRODUCT", 323, 326], ["Alphacoronavirus", "GENE_OR_GENE_PRODUCT", 378, 394], ["Betacoronavirus", "GENE_OR_GENE_PRODUCT", 396, 411], ["Gammacoronavirus", "GENE_OR_GENE_PRODUCT", 417, 433], ["LLC-PK1 cells", "CELL_LINE", 53, 66], ["IFN", "PROTEIN", 276, 279], ["\u03b2", "PROTEIN", 280, 281], ["IFN", "PROTEIN", 323, 326], ["IFN", "PROTEIN", 561, 564], ["PDCoV", "SPECIES", 242, 247], ["Alphacoronavirus", "SPECIES", 378, 394], ["PDCoV infection in LLC", "PROBLEM", 34, 56], ["PK1 cells", "PROBLEM", 57, 66], ["a high infection rate", "PROBLEM", 76, 97], ["cell exfoliation", "PROBLEM", 116, 132], ["subsequent immunological studies", "TEST", 209, 241], ["PDCoV infection", "PROBLEM", 242, 257], ["IFN", "TEST", 276, 279], ["inductionPrevious studies", "TEST", 329, 354], ["Alphacoronavirus", "PROBLEM", 378, 394], ["Betacoronavirus", "PROBLEM", 396, 411], ["Gammacoronavirus", "PROBLEM", 417, 433], ["PDCoV", "OBSERVATION_MODIFIER", 34, 39], ["infection", "OBSERVATION", 40, 49], ["LLC", "ANATOMY", 53, 56], ["high", "OBSERVATION_MODIFIER", 78, 82], ["infection", "OBSERVATION", 83, 92], ["infection", "OBSERVATION", 248, 257]]], ["However, the evasion methods used by the deltacoronaviruses remain unclear.", [["deltacoronaviruses", "GENE_OR_GENE_PRODUCT", 41, 59], ["the evasion methods", "TREATMENT", 9, 28]]], ["To explore if PDCoV antagonizes IFN-\u03b2 production, the IFN-\u03b2 promoter luciferase reporter system was used to analyze IFN-\u03b2 expression after PDCoV infection.", [["PDCoV", "CHEMICAL", 14, 19], ["PDCoV infection", "DISEASE", 139, 154], ["PDCoV", "SIMPLE_CHEMICAL", 14, 19], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 32, 37], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 54, 59], ["luciferase", "GENE_OR_GENE_PRODUCT", 69, 79], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 116, 121], ["PDCoV", "SIMPLE_CHEMICAL", 139, 144], ["IFN", "PROTEIN", 32, 35], ["\u03b2", "PROTEIN", 36, 37], ["IFN-\u03b2 promoter luciferase reporter system", "DNA", 54, 95], ["IFN", "PROTEIN", 116, 119], ["\u03b2", "PROTEIN", 120, 121], ["PDCoV", "SPECIES", 139, 144], ["PDCoV antagonizes IFN", "TREATMENT", 14, 35], ["the IFN-\u03b2 promoter luciferase reporter system", "TREATMENT", 50, 95], ["PDCoV infection", "PROBLEM", 139, 154], ["infection", "OBSERVATION", 145, 154]]], ["To this end, LLC-PK1 cells were co-transfected with the luciferase reporter plasmids IFN-\u03b2-Luc and the internal control plasmid pRL-TK, followed by mock-infection or infection with PDCoV at a MOI of 0.01.", [["LLC-PK1 cells", "ANATOMY", 13, 26], ["plasmid", "ANATOMY", 120, 127], ["mock-infection", "DISEASE", 148, 162], ["infection", "DISEASE", 166, 175], ["LLC-PK1 cells", "CELL", 13, 26], ["luciferase", "GENE_OR_GENE_PRODUCT", 56, 66], ["IFN-\u03b2-Luc", "GENE_OR_GENE_PRODUCT", 85, 94], ["pRL", "GENE_OR_GENE_PRODUCT", 128, 131], ["LLC-PK1 cells", "CELL_LINE", 13, 26], ["luciferase reporter plasmids IFN-\u03b2-Luc", "DNA", 56, 94], ["internal control plasmid pRL-TK", "DNA", 103, 134], ["PK1 cells", "PROBLEM", 17, 26], ["the luciferase", "TEST", 52, 66], ["the internal control plasmid pRL", "TEST", 99, 131], ["infection", "PROBLEM", 153, 162], ["infection", "PROBLEM", 166, 175], ["PDCoV", "TREATMENT", 181, 186], ["LLC", "ANATOMY", 13, 16], ["TK", "ANATOMY", 132, 134], ["infection", "OBSERVATION", 153, 162], ["infection", "OBSERVATION", 166, 175]]], ["After 24 h of PDCoV infection, the cell lysates were harvested and the IFN-\u03b2 promoter-driven luciferase activity was measured.", [["cell lysates", "ANATOMY", 35, 47], ["infection", "DISEASE", 20, 29], ["PDCoV", "SIMPLE_CHEMICAL", 14, 19], ["cell lysates", "CELL", 35, 47], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 71, 76], ["luciferase", "GENE_OR_GENE_PRODUCT", 93, 103], ["IFN-\u03b2 promoter", "DNA", 71, 85], ["luciferase", "PROTEIN", 93, 103], ["PDCoV", "SPECIES", 14, 19], ["PDCoV infection", "PROBLEM", 14, 29], ["the cell lysates", "TREATMENT", 31, 47], ["the IFN-\u03b2 promoter", "TREATMENT", 67, 85], ["infection", "OBSERVATION", 20, 29], ["cell lysates", "OBSERVATION", 35, 47]]], ["The mock-infected cells were stimulated with 20 hemagglutinating activity units/well of SeV or 0.5 \u03bcg/well of poly(I:C), respectively, as positive controls to test whether or not LLC-PK1 cells are able to recognize SeV or poly(I:C) and activate IFN-\u03b2 promoter activity in response.", [["cells", "ANATOMY", 18, 23], ["LLC-PK1 cells", "ANATOMY", 179, 192], ["poly(I:C", "CHEMICAL", 110, 118], ["poly(I:C", "CHEMICAL", 110, 118], ["cells", "CELL", 18, 23], ["SeV", "ORGANISM", 88, 91], ["poly(I:C", "SIMPLE_CHEMICAL", 110, 118], ["LLC-PK1 cells", "CELL", 179, 192], ["SeV", "ORGANISM", 215, 218], ["poly(I:C", "GENE_OR_GENE_PRODUCT", 222, 230], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 245, 250], ["mock-infected cells", "CELL_LINE", 4, 23], ["LLC-PK1 cells", "CELL_LINE", 179, 192], ["poly(I:C", "PROTEIN", 222, 230], ["IFN", "PROTEIN", 245, 248], ["\u03b2 promoter", "DNA", 249, 259], ["infected cells", "PROBLEM", 9, 23], ["SeV", "TREATMENT", 88, 91], ["PK1 cells", "PROBLEM", 183, 192], ["IFN", "TEST", 245, 248], ["infected cells", "OBSERVATION", 9, 23], ["LLC", "ANATOMY", 179, 182]]], ["As shown in Fig. 2A and B, IFN-\u03b2 promoter-driven luciferase activity was barely detectable in PDCoV-infected cells compared with the strong reporter signal in SeV-infected or poly(I:C)-transfected cells, indicating that PDCoV infection failed to activate IFN-\u03b2 promoter activity.PDCoV infection fails to activate IFN-\u03b2 and interrupts SeV-or poly(I:C)-mediated IFN-\u03b2 inductionTo further investigate if PDCoV inhibits SeV-or poly(I:C)-induced IFN-\u03b2 promoter activity, LLC-PK1 cells were co-transfected with IFN-\u03b2-Luc and pRL-TK and then mock-infected or infected with PDCoV at different MOIs of 1, 0.1, or 0.01.", [["cells", "ANATOMY", 109, 114], ["cells", "ANATOMY", 197, 202], ["LLC-PK1 cells", "ANATOMY", 466, 479], ["poly(I:C", "CHEMICAL", 175, 183], ["PDCoV", "CHEMICAL", 220, 225], ["infection", "DISEASE", 226, 235], ["PDCoV", "CHEMICAL", 279, 284], ["infection", "DISEASE", 285, 294], ["PDCoV", "CHEMICAL", 401, 406], ["poly(I:C", "CHEMICAL", 423, 431], ["PDCoV", "CHEMICAL", 401, 406], ["2A", "GENE_OR_GENE_PRODUCT", 17, 19], ["B", "GENE_OR_GENE_PRODUCT", 24, 25], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 27, 32], ["luciferase", "GENE_OR_GENE_PRODUCT", 49, 59], ["PDCoV", "CELL", 94, 99], ["cells", "CELL", 109, 114], ["SeV", "ORGANISM", 159, 162], ["poly(I:C", "GENE_OR_GENE_PRODUCT", 175, 183], ["cells", "CELL", 197, 202], ["PDCoV", "GENE_OR_GENE_PRODUCT", 220, 225], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 255, 260], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 313, 318], ["SeV", "ORGANISM", 334, 337], ["poly(I:C", "GENE_OR_GENE_PRODUCT", 341, 349], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 360, 365], ["PDCoV", "SIMPLE_CHEMICAL", 401, 406], ["SeV", "ORGANISM", 416, 419], ["poly(I:C", "SIMPLE_CHEMICAL", 423, 431], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 441, 446], ["LLC-PK1 cells", "CELL", 466, 479], ["IFN-\u03b2-Luc", "GENE_OR_GENE_PRODUCT", 505, 514], ["pRL-TK", "GENE_OR_GENE_PRODUCT", 519, 525], ["2A and B, IFN-\u03b2 promoter", "DNA", 17, 41], ["luciferase", "PROTEIN", 49, 59], ["PDCoV-infected cells", "CELL_LINE", 94, 114], ["SeV-infected or poly(I:C)-transfected cells", "CELL_LINE", 159, 202], ["IFN", "PROTEIN", 255, 258], ["\u03b2 promoter", "DNA", 259, 269], ["IFN", "PROTEIN", 313, 316], ["\u03b2", "PROTEIN", 317, 318], ["IFN", "PROTEIN", 360, 363], ["\u03b2", "PROTEIN", 364, 365], ["IFN", "PROTEIN", 441, 444], ["LLC-PK1 cells", "CELL_LINE", 466, 479], ["IFN", "PROTEIN", 505, 508], ["pRL", "PROTEIN", 519, 522], ["SeV", "SPECIES", 159, 162], ["PDCoV", "SPECIES", 220, 225], ["PDCoV", "SPECIES", 279, 284], ["SeV", "SPECIES", 416, 419], ["IFN-\u03b2 promoter", "TREATMENT", 27, 41], ["infected cells", "PROBLEM", 100, 114], ["transfected cells", "PROBLEM", 185, 202], ["PDCoV infection", "PROBLEM", 220, 235], ["PDCoV infection", "PROBLEM", 279, 294], ["IFN", "TEST", 313, 316], ["PDCoV", "TEST", 401, 406], ["SeV", "TEST", 416, 419], ["IFN", "TEST", 441, 444], ["PK1 cells", "TEST", 470, 479], ["IFN", "TEST", 505, 508], ["Luc", "TEST", 511, 514], ["pRL", "TEST", 519, 522], ["TK", "TEST", 523, 525], ["PDCoV", "TREATMENT", 566, 571], ["Fig", "OBSERVATION", 12, 15], ["infected cells", "OBSERVATION", 100, 114], ["infection", "OBSERVATION", 226, 235], ["infection", "OBSERVATION", 285, 294], ["LLC", "ANATOMY", 466, 469], ["infected", "OBSERVATION", 552, 560]]], ["At 12 h post-PDCoV infection, the infected cells were mock-infected or infected with SeV or transfected with or without poly(I:C), respectively.", [["cells", "ANATOMY", 43, 48], ["infection", "DISEASE", 19, 28], ["cells", "CELL", 43, 48], ["SeV", "ORGANISM", 85, 88], ["infected cells", "CELL_TYPE", 34, 48], ["PDCoV", "SPECIES", 13, 18], ["SeV", "SPECIES", 85, 88], ["PDCoV infection", "PROBLEM", 13, 28], ["the infected cells", "PROBLEM", 30, 48], ["infection", "OBSERVATION", 19, 28], ["infected cells", "OBSERVATION", 34, 48]]], ["The cells were harvested and subjected to a dual-luciferase assay at 12 h after SeV inoculation or at 24 h after poly(I:C) transfection.", [["cells", "ANATOMY", 4, 9], ["poly(I:C", "CHEMICAL", 113, 121], ["cells", "CELL", 4, 9], ["luciferase", "GENE_OR_GENE_PRODUCT", 49, 59], ["SeV", "ORGANISM", 80, 83], ["poly(I:C", "SIMPLE_CHEMICAL", 113, 121], ["luciferase", "PROTEIN", 49, 59], ["SeV", "SPECIES", 80, 83], ["a dual-luciferase assay", "TEST", 42, 65]]], ["As shown in Fig. 2 (C), the IFN-\u03b2 promoter was activated 80-to 100fold when the PDCoV-mock-infected cells were stimulated with SeV, whereas this activation was significantly inhibited by PDCoV infection in a dose-dependent manner.", [["cells", "ANATOMY", 100, 105], ["PDCoV", "CHEMICAL", 187, 192], ["infection", "DISEASE", 193, 202], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 28, 33], ["PDCoV", "GENE_OR_GENE_PRODUCT", 80, 85], ["cells", "CELL", 100, 105], ["SeV", "ORGANISM", 127, 130], ["PDCoV", "SIMPLE_CHEMICAL", 187, 192], ["IFN-\u03b2 promoter", "DNA", 28, 42], ["PDCoV-mock-infected cells", "CELL_LINE", 80, 105], ["PDCoV", "SPECIES", 187, 192], ["the IFN-\u03b2 promoter", "TREATMENT", 24, 42], ["the PDCoV-mock", "TREATMENT", 76, 90], ["infected cells", "PROBLEM", 91, 105], ["SeV", "TREATMENT", 127, 130], ["PDCoV infection", "PROBLEM", 187, 202], ["Fig", "OBSERVATION", 12, 15], ["infection", "OBSERVATION", 193, 202]]], ["Also, PDCoV infection significantly inhibited poly(I:C)-induced IFN-\u03b2 promoter activity (Fig. 2D ).", [["PDCoV", "CHEMICAL", 6, 11], ["infection", "DISEASE", 12, 21], ["poly(I:C", "CHEMICAL", 46, 54], ["poly(I:C", "CHEMICAL", 46, 54], ["PDCoV", "SIMPLE_CHEMICAL", 6, 11], ["poly(I:C", "SIMPLE_CHEMICAL", 46, 54], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 64, 69], ["IFN", "PROTEIN", 64, 67], ["\u03b2 promoter", "DNA", 68, 78], ["PDCoV", "SPECIES", 6, 11], ["PDCoV infection", "PROBLEM", 6, 21], ["infection", "OBSERVATION", 12, 21]]], ["These results suggest that PDCoV infection interrupts SeV-or poly(I:C)-mediated IFN-\u03b2 production.PDCoV impedes SeV-or poly(I:C)-mediated activation of NF-\u03baB and IRF3To investigate whether or not PDCoV impairs the activation of NF-\u03baB and IRF3, LLC-PK1 cells were co-transfected with the luciferase reporter plasmids NF-\u03baB-Luc or IRF3-Luc together with the internal control plasmid pRL-TK and, 12 h later, they were mockinfected or infected with PDCoV at a MOI of 0.01 for 12 h.", [["LLC-PK1 cells", "ANATOMY", 243, 256], ["PDCoV", "CHEMICAL", 27, 32], ["infection", "DISEASE", 33, 42], ["poly(I:C", "CHEMICAL", 61, 69], ["poly(I:C", "CHEMICAL", 118, 126], ["PDCoV", "CHEMICAL", 444, 449], ["PDCoV", "GENE_OR_GENE_PRODUCT", 27, 32], ["SeV", "ORGANISM", 54, 57], ["poly(I:C", "GENE_OR_GENE_PRODUCT", 61, 69], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 80, 85], ["PDCoV", "SIMPLE_CHEMICAL", 97, 102], ["SeV", "ORGANISM", 111, 114], ["poly(I:C", "SIMPLE_CHEMICAL", 118, 126], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 151, 156], ["IRF3To", "GENE_OR_GENE_PRODUCT", 161, 167], ["PDCoV", "GENE_OR_GENE_PRODUCT", 195, 200], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 227, 232], ["IRF3", "GENE_OR_GENE_PRODUCT", 237, 241], ["LLC-PK1 cells", "CELL", 243, 256], ["luciferase", "GENE_OR_GENE_PRODUCT", 286, 296], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 315, 320], ["Luc", "GENE_OR_GENE_PRODUCT", 321, 324], ["IRF3", "GENE_OR_GENE_PRODUCT", 328, 332], ["Luc", "GENE_OR_GENE_PRODUCT", 333, 336], ["IFN", "PROTEIN", 80, 83], ["\u03b2", "PROTEIN", 84, 85], ["NF-\u03baB", "PROTEIN", 151, 156], ["IRF3To", "PROTEIN", 161, 167], ["PDCoV", "PROTEIN", 195, 200], ["NF-\u03baB", "PROTEIN", 227, 232], ["IRF3", "PROTEIN", 237, 241], ["LLC-PK1 cells", "CELL_LINE", 243, 256], ["luciferase reporter plasmids NF-\u03baB-Luc or IRF3-Luc", "DNA", 286, 336], ["internal control plasmid pRL", "DNA", 355, 383], ["PDCoV", "SPECIES", 27, 32], ["PDCoV infection", "PROBLEM", 27, 42], ["NF", "PROBLEM", 151, 153], ["NF", "TEST", 227, 229], ["IRF3", "PROBLEM", 237, 241], ["PK1 cells", "PROBLEM", 247, 256], ["the luciferase reporter plasmids", "TEST", 282, 314], ["NF", "TEST", 315, 317], ["\u03baB", "TEST", 318, 320], ["the internal control plasmid pRL", "TEST", 351, 383], ["PDCoV", "TREATMENT", 444, 449], ["PDCoV", "OBSERVATION_MODIFIER", 27, 32], ["infection", "OBSERVATION", 33, 42], ["LLC", "ANATOMY", 243, 246], ["infected", "OBSERVATION", 430, 438]]], ["The cells were then mock-infected or infected with SeV or transfected with or without poly(I:C), respectively.", [["cells", "ANATOMY", 4, 9], ["cells", "CELL", 4, 9], ["SeV", "ORGANISM", 51, 54], ["SeV", "SPECIES", 51, 54]]], ["Cells were harvested 12 h after SeV infection or 24 h after poly(I:C) transfection and subjected to a dual-luciferase assay.", [["Cells", "ANATOMY", 0, 5], ["infection", "DISEASE", 36, 45], ["poly(I:C", "CHEMICAL", 60, 68], ["Cells", "CELL", 0, 5], ["SeV", "ORGANISM", 32, 35], ["poly(I:C", "SIMPLE_CHEMICAL", 60, 68], ["luciferase", "GENE_OR_GENE_PRODUCT", 107, 117], ["luciferase", "PROTEIN", 107, 117], ["SeV", "SPECIES", 32, 35], ["SeV infection", "PROBLEM", 32, 45], ["transfection", "PROBLEM", 70, 82], ["a dual-luciferase assay", "TEST", 100, 123]]], ["As shown in Fig. 3 , PDCoV infection failed to activate NF-\u03baB promoter activity and significantly blocked the SeV-induced promoter activity of NF-\u03baB (Fig. 3A) or partially blocked the poly(I:C)-induced promoter activity of NF-\u03baB (Fig. 3B ).", [["infection", "DISEASE", 27, 36], ["poly(I:C", "CHEMICAL", 184, 192], ["PDCoV", "SIMPLE_CHEMICAL", 21, 26], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 56, 61], ["SeV", "ORGANISM", 110, 113], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 143, 148], ["Fig. 3A", "GENE_OR_GENE_PRODUCT", 150, 157], ["poly(I:C", "GENE_OR_GENE_PRODUCT", 184, 192], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 223, 228], ["Fig. 3B", "GENE_OR_GENE_PRODUCT", 230, 237], ["NF-\u03baB promoter", "DNA", 56, 70], ["NF-\u03baB", "PROTEIN", 143, 148], ["Fig. 3A", "PROTEIN", 150, 157], ["poly(I:C", "PROTEIN", 184, 192], ["NF-\u03baB", "PROTEIN", 223, 228], ["Fig. 3B", "PROTEIN", 230, 237], ["PDCoV infection", "PROBLEM", 21, 36], ["B promoter activity", "TREATMENT", 60, 79], ["infection", "OBSERVATION", 27, 36]]], ["PDCoV infection also failed to activate IRF3 promoter activity and partially blocked the SeV-induced promoter activity of IRF3 ( Fig. 3B ) or significantly blocked poly(I:C)-induced promoter activity of IRF3 (Fig. 3D) .", [["PDCoV", "CHEMICAL", 0, 5], ["infection", "DISEASE", 6, 15], ["poly(I:C", "CHEMICAL", 164, 172], ["PDCoV", "GENE_OR_GENE_PRODUCT", 0, 5], ["IRF3", "GENE_OR_GENE_PRODUCT", 40, 44], ["SeV", "GENE_OR_GENE_PRODUCT", 89, 92], ["IRF3", "GENE_OR_GENE_PRODUCT", 122, 126], ["Fig. 3B", "GENE_OR_GENE_PRODUCT", 129, 136], ["poly(I:C", "GENE_OR_GENE_PRODUCT", 164, 172], ["IRF3", "GENE_OR_GENE_PRODUCT", 203, 207], ["IRF3 promoter", "DNA", 40, 53], ["IRF3", "PROTEIN", 122, 126], ["Fig. 3B", "PROTEIN", 129, 136], ["IRF3", "PROTEIN", 203, 207], ["PDCoV", "SPECIES", 0, 5], ["PDCoV infection", "PROBLEM", 0, 15], ["IRF3 ( Fig. 3B", "TREATMENT", 122, 136], ["infection", "OBSERVATION", 6, 15]]], ["These results indicate that PDCoV impedes SeV-or poly(I:C)-mediated activation of the transcription factors NF-\u03baB and IRF3, which are associated with the suppression of the IFN-\u03b2 promoter after PDCoV infection.PDCoV interrupts the RIG-I signaling pathwayBoth SeV and dsRNA are critical inducer of the RIG-I-like receptor (RLR)-mediated IFN-\u03b2 signaling pathway (Meylan et al., 2005; Pythoud et al., 2012) .", [["PDCoV", "CHEMICAL", 28, 33], ["poly(I:C", "CHEMICAL", 49, 57], ["infection", "DISEASE", 200, 209], ["PDCoV", "SIMPLE_CHEMICAL", 28, 33], ["SeV", "GENE_OR_GENE_PRODUCT", 42, 45], ["poly(I:C", "GENE_OR_GENE_PRODUCT", 49, 57], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 108, 113], ["IRF3", "GENE_OR_GENE_PRODUCT", 118, 122], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 173, 178], ["PDCoV", "SIMPLE_CHEMICAL", 194, 199], ["PDCoV", "SIMPLE_CHEMICAL", 210, 215], ["RIG-I", "GENE_OR_GENE_PRODUCT", 231, 236], ["SeV", "GENE_OR_GENE_PRODUCT", 259, 262], ["RIG-I-like receptor", "GENE_OR_GENE_PRODUCT", 301, 320], ["RLR", "GENE_OR_GENE_PRODUCT", 322, 325], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 336, 341], ["PDCoV", "PROTEIN", 28, 33], ["transcription factors", "PROTEIN", 86, 107], ["NF-\u03baB", "PROTEIN", 108, 113], ["IRF3", "PROTEIN", 118, 122], ["IFN-\u03b2 promoter", "DNA", 173, 187], ["RIG-I-like receptor", "PROTEIN", 301, 320], ["RLR", "PROTEIN", 322, 325], ["IFN", "PROTEIN", 336, 339], ["\u03b2", "PROTEIN", 340, 341], ["PDCoV", "SPECIES", 194, 199], ["the transcription factors NF", "TEST", 82, 110], ["IRF3", "PROBLEM", 118, 122], ["the IFN-\u03b2 promoter", "TREATMENT", 169, 187], ["PDCoV infection", "PROBLEM", 194, 209], ["PDCoV", "TREATMENT", 210, 215], ["infection", "OBSERVATION", 200, 209]]], ["It is possible that PDCoV interrupts SeV-or ploy(I: C)-mediated IFN-\u03b2 production by blocking some of the individual members of the RIG-I signaling pathway.", [["PDCoV", "SIMPLE_CHEMICAL", 20, 25], ["SeV", "ORGANISM", 37, 40], ["ploy(I: C", "GENE_OR_GENE_PRODUCT", 44, 53], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 64, 69], ["RIG-I", "GENE_OR_GENE_PRODUCT", 131, 136], ["IFN", "PROTEIN", 64, 67], ["RIG-I", "PROTEIN", 131, 136], ["possible", "UNCERTAINTY", 6, 14]]], ["To test this possibility and to identify potential target molecules, we investigated the effect of PDCoV infection on the activity of a series of molecules in the RIG-I signaling pathway: RIG-I, MDA5, IPS-1, TBK1, IKK\u03b5, and IRF3.", [["PDCoV", "CHEMICAL", 99, 104], ["infection", "DISEASE", 105, 114], ["PDCoV", "SIMPLE_CHEMICAL", 99, 104], ["RIG-I", "GENE_OR_GENE_PRODUCT", 163, 168], ["RIG-I", "GENE_OR_GENE_PRODUCT", 188, 193], ["MDA5", "GENE_OR_GENE_PRODUCT", 195, 199], ["IPS-1", "GENE_OR_GENE_PRODUCT", 201, 206], ["TBK1", "GENE_OR_GENE_PRODUCT", 208, 212], ["IKK\u03b5", "GENE_OR_GENE_PRODUCT", 214, 218], ["IRF3", "GENE_OR_GENE_PRODUCT", 224, 228], ["RIG-I", "PROTEIN", 163, 168], ["RIG-I", "PROTEIN", 188, 193], ["MDA5", "PROTEIN", 195, 199], ["IPS", "PROTEIN", 201, 204], ["TBK1", "PROTEIN", 208, 212], ["IKK\u03b5", "PROTEIN", 214, 218], ["IRF3", "PROTEIN", 224, 228], ["potential target molecules", "PROBLEM", 41, 67], ["PDCoV infection", "PROBLEM", 99, 114], ["MDA5", "TEST", 195, 199], ["IPS", "TEST", 201, 204], ["TBK1", "PROBLEM", 208, 212], ["IKK\u03b5", "TEST", 214, 218], ["IRF3", "PROBLEM", 224, 228], ["infection", "OBSERVATION", 105, 114], ["MDA5", "ANATOMY", 195, 199], ["IRF3", "OBSERVATION", 224, 228]]], ["To this end, LLC-PK1 cells were mock-infected or infected with PDCoV at a MOI of 0.01 for 6 h, followed by co-transfection with a series of expression constructs encoding RIG-I, RIG-IN (a constitutively active mutant of RIG-I), MDA5, IPS-1, TBK1, IKK\u03b5, IRF3, and IRF3(5D) (a constitutively active mutant of IRF3) together with the luciferase reporter plasmids IFN-\u03b2-Luc and the internal control plasmid pRL-TK.", [["LLC-PK1 cells", "ANATOMY", 13, 26], ["plasmid", "ANATOMY", 395, 402], ["PDCoV", "CHEMICAL", 63, 68], ["LLC-PK1 cells", "CELL", 13, 26], ["RIG-I", "GENE_OR_GENE_PRODUCT", 171, 176], ["RIG-IN", "GENE_OR_GENE_PRODUCT", 178, 184], ["RIG-I", "GENE_OR_GENE_PRODUCT", 220, 225], ["MDA5", "GENE_OR_GENE_PRODUCT", 228, 232], ["IPS-1", "GENE_OR_GENE_PRODUCT", 234, 239], ["TBK1", "GENE_OR_GENE_PRODUCT", 241, 245], ["IKK\u03b5", "GENE_OR_GENE_PRODUCT", 247, 251], ["IRF3", "GENE_OR_GENE_PRODUCT", 253, 257], ["IRF3(5D)", "GENE_OR_GENE_PRODUCT", 263, 271], ["IRF3", "GENE_OR_GENE_PRODUCT", 307, 311], ["luciferase", "GENE_OR_GENE_PRODUCT", 331, 341], ["IFN-\u03b2-Luc", "GENE_OR_GENE_PRODUCT", 360, 369], ["pRL-TK", "GENE_OR_GENE_PRODUCT", 403, 409], ["LLC-PK1 cells", "CELL_LINE", 13, 26], ["expression constructs", "DNA", 140, 161], ["RIG-I", "PROTEIN", 171, 176], ["RIG", "PROTEIN", 178, 181], ["IN", "PROTEIN", 182, 184], ["RIG-I", "PROTEIN", 220, 225], ["MDA5", "PROTEIN", 228, 232], ["IPS", "PROTEIN", 234, 237], ["TBK1", "PROTEIN", 241, 245], ["IKK\u03b5", "PROTEIN", 247, 251], ["IRF3", "PROTEIN", 253, 257], ["IRF3", "PROTEIN", 263, 267], ["5D", "PROTEIN", 268, 270], ["IRF3", "PROTEIN", 307, 311], ["luciferase reporter plasmids IFN-\u03b2-Luc", "DNA", 331, 369], ["internal control plasmid pRL-TK", "DNA", 378, 409], ["LLC", "TEST", 13, 16], ["PK1 cells", "TEST", 17, 26], ["infected", "PROBLEM", 49, 57], ["PDCoV", "TREATMENT", 63, 68], ["RIG", "TEST", 178, 181], ["MDA5", "TEST", 228, 232], ["IPS", "TEST", 234, 237], ["TBK1", "PROBLEM", 241, 245], ["IKK\u03b5", "TEST", 247, 251], ["IRF3", "TEST", 253, 257], ["IRF3", "PROBLEM", 263, 267], ["the luciferase reporter plasmids", "TREATMENT", 327, 359], ["the internal control plasmid pRL", "TEST", 374, 406], ["LLC", "ANATOMY", 13, 16], ["IRF3", "ANATOMY", 253, 257], ["TK", "ANATOMY", 407, 409]]], ["At 28 h post-transfection, the cell lysates were harvested and IFN-\u03b2 promoter-driven luciferase activities were measured.", [["cell lysates", "ANATOMY", 31, 43], ["cell lysates", "CELL", 31, 43], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 63, 68], ["luciferase", "GENE_OR_GENE_PRODUCT", 85, 95], ["IFN-\u03b2 promoter", "DNA", 63, 77], ["luciferase", "PROTEIN", 85, 95], ["the cell lysates", "TREATMENT", 27, 43], ["IFN-\u03b2 promoter", "TREATMENT", 63, 77]]], ["In contrast, the activation of the IFN-\u03b2 promoter induced by IRF3(5D) was not affected by PDCoV infection (Fig. 4C) .", [["infection", "DISEASE", 96, 105], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 35, 40], ["IRF3", "GENE_OR_GENE_PRODUCT", 61, 65], ["IFN-\u03b2 promoter", "DNA", 35, 49], ["IRF3", "PROTEIN", 61, 65], ["the IFN-\u03b2 promoter", "TREATMENT", 31, 49], ["PDCoV infection", "PROBLEM", 90, 105], ["infection", "OBSERVATION", 96, 105]]], ["These results provided evidence supporting the hypothesis that PDCoV interrupts SeV-or poly(I:C)-mediated IFN-\u03b2 induction by blocking the activity of molecules in the RIG-I signaling pathway.", [["PDCoV", "CHEMICAL", 63, 68], ["poly(I:C", "CHEMICAL", 87, 95], ["PDCoV", "SIMPLE_CHEMICAL", 63, 68], ["SeV", "ORGANISM", 80, 83], ["poly(I:C", "GENE_OR_GENE_PRODUCT", 87, 95], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 106, 111], ["RIG-I", "GENE_OR_GENE_PRODUCT", 167, 172], ["IFN", "PROTEIN", 106, 109], ["\u03b2", "PROTEIN", 110, 111], ["RIG", "PROTEIN", 167, 170], ["the hypothesis", "PROBLEM", 43, 57], ["IFN-\u03b2 induction", "TREATMENT", 106, 121]]], ["Signaling components downstream of IRF3 remained intact in the PDCoV-infected cells.", [["cells", "ANATOMY", 78, 83], ["IRF3", "GENE_OR_GENE_PRODUCT", 35, 39], ["PDCoV", "GENE_OR_GENE_PRODUCT", 63, 68], ["cells", "CELL", 78, 83], ["IRF3", "PROTEIN", 35, 39], ["PDCoV-infected cells", "CELL_LINE", 63, 83], ["Signaling components downstream of IRF3", "PROBLEM", 0, 39], ["components", "OBSERVATION_MODIFIER", 10, 20], ["downstream", "OBSERVATION_MODIFIER", 21, 31], ["IRF3", "OBSERVATION_MODIFIER", 35, 39], ["intact", "OBSERVATION", 49, 55], ["infected cells", "OBSERVATION", 69, 83]]], ["Based on these results, IRF3 appears to be the target protein of PDCoV suppression.PDCoV blocks SeV-induced phosphorylation and nuclear translocation of IRF3 and p65Because our initial results showed that PDCoV blocked SeV-induced IRF3-dependent promoter activity, we further investigated the possible mechanism(s) for this inhibition.", [["nuclear", "ANATOMY", 128, 135], ["PDCoV", "CHEMICAL", 83, 88], ["PDCoV", "CHEMICAL", 205, 210], ["PDCoV", "CHEMICAL", 83, 88], ["PDCoV", "CHEMICAL", 205, 210], ["IRF3", "GENE_OR_GENE_PRODUCT", 24, 28], ["PDCoV", "GENE_OR_GENE_PRODUCT", 65, 70], ["PDCoV", "SIMPLE_CHEMICAL", 83, 88], ["SeV", "ORGANISM", 96, 99], ["nuclear", "CELLULAR_COMPONENT", 128, 135], ["IRF3", "GENE_OR_GENE_PRODUCT", 153, 157], ["p65Because", "GENE_OR_GENE_PRODUCT", 162, 172], ["PDCoV", "SIMPLE_CHEMICAL", 205, 210], ["SeV", "ORGANISM", 219, 222], ["IRF3", "GENE_OR_GENE_PRODUCT", 231, 235], ["IRF3", "PROTEIN", 24, 28], ["PDCoV", "PROTEIN", 65, 70], ["IRF3", "PROTEIN", 153, 157], ["p65Because", "PROTEIN", 162, 172], ["PDCoV", "PROTEIN", 205, 210], ["IRF3", "PROTEIN", 231, 235], ["PDCoV suppression", "TREATMENT", 65, 82], ["PDCoV blocks", "TREATMENT", 83, 95], ["PDCoV", "TREATMENT", 205, 210], ["this inhibition", "TREATMENT", 319, 334], ["PDCoV suppression", "OBSERVATION", 65, 82]]], ["IRF3 and NF-\u03baB are considered to be essential transcription factors for IFN-\u03b2 production, and phosphorylation is a key step during their activation that in turn leads to nuclear translocation.", [["nuclear", "ANATOMY", 170, 177], ["IRF3", "GENE_OR_GENE_PRODUCT", 0, 4], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 9, 14], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 72, 77], ["nuclear", "CELLULAR_COMPONENT", 170, 177], ["IRF3", "PROTEIN", 0, 4], ["NF-\u03baB", "PROTEIN", 9, 14], ["transcription factors", "PROTEIN", 46, 67], ["IFN", "PROTEIN", 72, 75], ["\u03b2", "PROTEIN", 76, 77], ["IRF3", "PROBLEM", 0, 4], ["IFN", "PROBLEM", 72, 75], ["phosphorylation", "TREATMENT", 94, 109]]], ["Together, phosphorylation and nuclear translocation are the hallmarks of IRF3 and NF-\u03baB activation (Ramos and Gale, 2011) .", [["nuclear", "ANATOMY", 30, 37], ["nuclear", "CELLULAR_COMPONENT", 30, 37], ["IRF3", "GENE_OR_GENE_PRODUCT", 73, 77], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 82, 87], ["IRF3", "PROTEIN", 73, 77], ["NF-\u03baB", "PROTEIN", 82, 87], ["IRF3", "TEST", 73, 77], ["nuclear translocation", "OBSERVATION", 30, 51], ["IRF3", "OBSERVATION", 73, 77]]], ["Therefore, we explored the effect of PDCoV infection on the phosphorylation and nuclear translocation of IRF3 and NF-\u03baB.PDCoV blocks SeV-induced phosphorylation and nuclear translocation of IRF3 and p65LLC-PK1 cells were mock-infected or infected with PDCoV at a MOI of 0.01 for 12 h followed by mock-infection or infection with SeV.", [["nuclear", "ANATOMY", 80, 87], ["nuclear", "ANATOMY", 165, 172], ["p65LLC-PK1 cells", "ANATOMY", 199, 215], ["PDCoV", "CHEMICAL", 37, 42], ["infection", "DISEASE", 43, 52], ["PDCoV", "CHEMICAL", 252, 257], ["infection", "DISEASE", 301, 310], ["infection", "DISEASE", 314, 323], ["PDCoV", "SIMPLE_CHEMICAL", 37, 42], ["nuclear", "CELLULAR_COMPONENT", 80, 87], ["IRF3", "GENE_OR_GENE_PRODUCT", 105, 109], ["NF-\u03baB.PDCoV", "GENE_OR_GENE_PRODUCT", 114, 125], ["SeV", "ORGANISM", 133, 136], ["nuclear", "CELLULAR_COMPONENT", 165, 172], ["IRF3", "GENE_OR_GENE_PRODUCT", 190, 194], ["p65LLC-PK1", "GENE_OR_GENE_PRODUCT", 199, 209], ["IRF3", "PROTEIN", 105, 109], ["NF-\u03baB.PDCoV", "PROTEIN", 114, 125], ["IRF3", "PROTEIN", 190, 194], ["p65LLC", "PROTEIN", 199, 205], ["PK1 cells", "CELL_LINE", 206, 215], ["SeV.", "SPECIES", 329, 333], ["PDCoV infection", "PROBLEM", 37, 52], ["the phosphorylation", "TREATMENT", 56, 75], ["IRF3", "PROBLEM", 105, 109], ["NF", "TEST", 114, 116], ["IRF3", "TEST", 190, 194], ["p65LLC", "TEST", 199, 205], ["PK1 cells", "PROBLEM", 206, 215], ["PDCoV", "TREATMENT", 252, 257], ["infection", "PROBLEM", 301, 310], ["infection", "PROBLEM", 314, 323], ["infection", "OBSERVATION", 43, 52], ["infection", "OBSERVATION", 301, 310], ["infection", "OBSERVATION", 314, 323]]], ["At 12 h post-SeV infection, cells were harvested, and their phosphorylation levels of IRF3 and the NF-\u03baB p65 subunit were examined.", [["cells", "ANATOMY", 28, 33], ["SeV", "ORGANISM", 13, 16], ["cells", "CELL", 28, 33], ["IRF3", "GENE_OR_GENE_PRODUCT", 86, 90], ["NF-\u03baB p65", "GENE_OR_GENE_PRODUCT", 99, 108], ["IRF3", "PROTEIN", 86, 90], ["NF-\u03baB p65 subunit", "PROTEIN", 99, 116], ["SeV", "SPECIES", 13, 16], ["SeV infection", "PROBLEM", 13, 26], ["their phosphorylation levels", "TEST", 54, 82], ["IRF3", "TEST", 86, 90], ["the NF", "TEST", 95, 101], ["infection", "OBSERVATION", 17, 26]]], ["As shown in Fig. 5A , the total protein levels of IRF3 and p65 were almost equal between the mock-infected and PDCoVinfected cells.", [["cells", "ANATOMY", 125, 130], ["IRF3", "GENE_OR_GENE_PRODUCT", 50, 54], ["p65", "GENE_OR_GENE_PRODUCT", 59, 62], ["PDCoVinfected cells", "CELL", 111, 130], ["IRF3", "PROTEIN", 50, 54], ["p65", "PROTEIN", 59, 62], ["PDCoVinfected cells", "CELL_LINE", 111, 130], ["the total protein levels", "TEST", 22, 46], ["IRF3", "TEST", 50, 54], ["p65", "TEST", 59, 62], ["infected and PDCoVinfected cells", "PROBLEM", 98, 130], ["Fig", "OBSERVATION", 12, 15], ["infected", "OBSERVATION", 98, 106], ["PDCoVinfected cells", "OBSERVATION", 111, 130]]], ["SeV infection markedly enhanced the IRF3 phosphorylation (p-IRF3) and p65 phosphorylation (p-p65) levels in comparison with the amounts in unstimulated cells.", [["cells", "ANATOMY", 152, 157], ["infection", "DISEASE", 4, 13], ["SeV", "ORGANISM", 0, 3], ["IRF3", "GENE_OR_GENE_PRODUCT", 36, 40], ["IRF3", "GENE_OR_GENE_PRODUCT", 60, 64], ["p65", "GENE_OR_GENE_PRODUCT", 70, 73], ["p-p65", "GENE_OR_GENE_PRODUCT", 91, 96], ["cells", "CELL", 152, 157], ["IRF3", "PROTEIN", 36, 40], ["IRF3", "PROTEIN", 60, 64], ["p65", "PROTEIN", 70, 73], ["p65", "PROTEIN", 93, 96], ["unstimulated cells", "CELL_TYPE", 139, 157], ["SeV", "SPECIES", 0, 3], ["SeV infection", "PROBLEM", 0, 13], ["the IRF3 phosphorylation", "TEST", 32, 56], ["p65 phosphorylation (p-p65) levels", "TEST", 70, 104], ["infection", "OBSERVATION", 4, 13], ["IRF3 phosphorylation", "OBSERVATION", 36, 56], ["unstimulated cells", "OBSERVATION", 139, 157]]], ["As expected, the SeV-mediated increase was significantly reduced in the PDCoV-infected cells.", [["cells", "ANATOMY", 87, 92], ["SeV", "ORGANISM", 17, 20], ["PDCoV", "GENE_OR_GENE_PRODUCT", 72, 77], ["cells", "CELL", 87, 92], ["PDCoV-infected cells", "CELL_LINE", 72, 92], ["the SeV-mediated increase", "PROBLEM", 13, 38], ["increase", "OBSERVATION_MODIFIER", 30, 38], ["significantly", "OBSERVATION_MODIFIER", 43, 56], ["reduced", "OBSERVATION_MODIFIER", 57, 64], ["infected cells", "OBSERVATION", 78, 92]]], ["We also used IFA and confocal microscopy to analyze the translocation of IRF3 and p65 after PDCoV infection.", [["infection", "DISEASE", 98, 107], ["IRF3", "GENE_OR_GENE_PRODUCT", 73, 77], ["p65", "GENE_OR_GENE_PRODUCT", 82, 85], ["PDCoV", "GENE_OR_GENE_PRODUCT", 92, 97], ["IRF3", "PROTEIN", 73, 77], ["p65", "PROTEIN", 82, 85], ["IFA", "TEST", 13, 16], ["confocal microscopy", "TEST", 21, 40], ["IRF3", "PROBLEM", 73, 77], ["PDCoV infection", "PROBLEM", 92, 107], ["infection", "OBSERVATION", 98, 107]]], ["As shown in Fig. 5B and C, consistent with our observations from western blot analyses, IRF3 and p65 were located exclusively in the cytoplasm in unstimulated LLC-PK1 cells, but they rapidly translocated to the nucleus after the cells were infected with SeV.", [["cytoplasm", "ANATOMY", 133, 142], ["LLC-PK1 cells", "ANATOMY", 159, 172], ["nucleus", "ANATOMY", 211, 218], ["cells", "ANATOMY", 229, 234], ["C", "CELL", 24, 25], ["IRF3", "GENE_OR_GENE_PRODUCT", 88, 92], ["p65", "GENE_OR_GENE_PRODUCT", 97, 100], ["cytoplasm", "ORGANISM_SUBSTANCE", 133, 142], ["LLC-PK1 cells", "CELL", 159, 172], ["nucleus", "CELLULAR_COMPONENT", 211, 218], ["cells", "CELL", 229, 234], ["IRF3", "PROTEIN", 88, 92], ["p65", "PROTEIN", 97, 100], ["unstimulated LLC-PK1 cells", "CELL_LINE", 146, 172], ["western blot analyses", "TEST", 65, 86], ["IRF3 and p65", "TREATMENT", 88, 100], ["PK1 cells", "PROBLEM", 163, 172], ["consistent with", "UNCERTAINTY", 27, 42], ["cytoplasm", "OBSERVATION_MODIFIER", 133, 142], ["unstimulated LLC", "OBSERVATION", 146, 162], ["nucleus", "ANATOMY", 211, 218]]], ["In contrast, nuclear IRF3 and p65 translocation did not occur in PDCoV-infected cells.", [["nuclear", "ANATOMY", 13, 20], ["cells", "ANATOMY", 80, 85], ["nuclear", "CELLULAR_COMPONENT", 13, 20], ["IRF3", "GENE_OR_GENE_PRODUCT", 21, 25], ["p65", "GENE_OR_GENE_PRODUCT", 30, 33], ["PDCoV", "SIMPLE_CHEMICAL", 65, 70], ["cells", "CELL", 80, 85], ["IRF3", "PROTEIN", 21, 25], ["p65", "PROTEIN", 30, 33], ["PDCoV-infected cells", "CELL_LINE", 65, 85], ["nuclear IRF3", "TEST", 13, 25], ["p65 translocation", "TEST", 30, 47], ["IRF3", "OBSERVATION", 21, 25], ["infected cells", "OBSERVATION", 71, 85]]], ["Moreover, PDCoV infection blocked the nuclear translocation of IRF3 and p65 otherwise induced by SeV infection.", [["nuclear", "ANATOMY", 38, 45], ["PDCoV", "CHEMICAL", 10, 15], ["infection", "DISEASE", 16, 25], ["SeV infection", "DISEASE", 97, 110], ["PDCoV", "SIMPLE_CHEMICAL", 10, 15], ["nuclear", "CELLULAR_COMPONENT", 38, 45], ["IRF3", "GENE_OR_GENE_PRODUCT", 63, 67], ["p65", "GENE_OR_GENE_PRODUCT", 72, 75], ["SeV", "ORGANISM", 97, 100], ["IRF3", "PROTEIN", 63, 67], ["p65", "PROTEIN", 72, 75], ["PDCoV", "SPECIES", 10, 15], ["SeV", "SPECIES", 97, 100], ["PDCoV infection", "PROBLEM", 10, 25], ["IRF3", "PROBLEM", 63, 67], ["SeV infection", "PROBLEM", 97, 110], ["infection", "OBSERVATION", 16, 25], ["IRF3", "OBSERVATION", 63, 67], ["SeV", "OBSERVATION_MODIFIER", 97, 100], ["infection", "OBSERVATION", 101, 110]]], ["Collectively, our data clearly support the hypothesis that PDCoV inhibits SeV-induced IRF3-dependent promoter activity by blocking the phosphorylation and nuclear translocation of IRF3 and p65.PDCoV blocks SeV-induced phosphorylation and nuclear translocation of IRF3 and p65As a newly identified coronavirus, the immune evasion strategy utilized by PDCoV remains largerly unclear.", [["nuclear", "ANATOMY", 155, 162], ["nuclear", "ANATOMY", 238, 245], ["PDCoV", "CHEMICAL", 59, 64], ["PDCoV", "CHEMICAL", 193, 198], ["PDCoV", "CHEMICAL", 59, 64], ["PDCoV", "CHEMICAL", 193, 198], ["PDCoV", "SIMPLE_CHEMICAL", 59, 64], ["SeV", "ORGANISM", 74, 77], ["IRF3", "GENE_OR_GENE_PRODUCT", 86, 90], ["nuclear", "CELLULAR_COMPONENT", 155, 162], ["IRF3", "GENE_OR_GENE_PRODUCT", 180, 184], ["p65", "GENE_OR_GENE_PRODUCT", 189, 192], ["PDCoV", "SIMPLE_CHEMICAL", 193, 198], ["SeV", "ORGANISM", 206, 209], ["nuclear", "CELLULAR_COMPONENT", 238, 245], ["IRF3", "GENE_OR_GENE_PRODUCT", 263, 267], ["p65As", "GENE_OR_GENE_PRODUCT", 272, 277], ["coronavirus", "ORGANISM", 297, 308], ["PDCoV", "SIMPLE_CHEMICAL", 350, 355], ["IRF3", "PROTEIN", 86, 90], ["IRF3", "PROTEIN", 180, 184], ["p65", "PROTEIN", 189, 192], ["IRF3", "PROTEIN", 263, 267], ["p65As", "PROTEIN", 272, 277], ["the hypothesis", "PROBLEM", 39, 53], ["dependent promoter activity", "PROBLEM", 91, 118], ["blocking the phosphorylation", "TREATMENT", 122, 150], ["PDCoV blocks", "TREATMENT", 193, 205], ["IRF3", "PROBLEM", 263, 267], ["a newly identified coronavirus", "PROBLEM", 278, 308], ["the immune evasion strategy", "TREATMENT", 310, 337]]], ["Previous studies have shown that other coronaviruses, including alphacoronaviruses, betacoronaviruses, and gammacoronaviruses, can suppresses IFN\u03b2 production by blocking the activation of transcription factor IRF3 (Perlman and Netland, 2009) .", [["coronaviruses", "ORGANISM", 39, 52], ["alphacoronaviruses", "GENE_OR_GENE_PRODUCT", 64, 82], ["betacoronaviruses", "GENE_OR_GENE_PRODUCT", 84, 101], ["gammacoronaviruses", "GENE_OR_GENE_PRODUCT", 107, 125], ["IFN\u03b2", "GENE_OR_GENE_PRODUCT", 142, 146], ["IRF3", "GENE_OR_GENE_PRODUCT", 209, 213], ["IFN\u03b2", "PROTEIN", 142, 146], ["transcription factor", "PROTEIN", 188, 208], ["IRF3", "PROTEIN", 209, 213], ["Previous studies", "TEST", 0, 16], ["other coronaviruses", "PROBLEM", 33, 52], ["alphacoronaviruses", "PROBLEM", 64, 82], ["betacoronaviruses", "PROBLEM", 84, 101], ["gammacoronaviruses", "PROBLEM", 107, 125], ["coronaviruses", "OBSERVATION", 39, 52]]], ["In this study, we demonstarted that PDCoV infection also blocks IRF3 activation.", [["PDCoV", "CHEMICAL", 36, 41], ["infection", "DISEASE", 42, 51], ["PDCoV", "GENE_OR_GENE_PRODUCT", 36, 41], ["IRF3", "GENE_OR_GENE_PRODUCT", 64, 68], ["IRF3", "PROTEIN", 64, 68], ["PDCoV", "SPECIES", 36, 41], ["this study", "TEST", 3, 13], ["PDCoV infection", "PROBLEM", 36, 51], ["IRF3 activation", "PROBLEM", 64, 79], ["infection", "OBSERVATION", 42, 51], ["IRF3 activation", "OBSERVATION", 64, 79]]], ["It is possible that blockade of IRF3 activation is a common strategey utilized by coronaviruses to antagonize IFN-\u03b2 production.", [["IRF3", "GENE_OR_GENE_PRODUCT", 32, 36], ["coronaviruses", "ORGANISM", 82, 95], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 110, 115], ["IRF3", "PROTEIN", 32, 36], ["IFN", "PROTEIN", 110, 113], ["\u03b2", "PROTEIN", 114, 115], ["IRF3 activation", "PROBLEM", 32, 47], ["coronaviruses", "PROBLEM", 82, 95], ["IRF3 activation", "OBSERVATION", 32, 47]]], ["In addition, multiple proteins encoded by coronaviruses have been identified as IFN antagonists (Roth-Cross et al., 2007; Totura and Baric, 2012) .", [["coronaviruses", "ORGANISM", 42, 55], ["IFN antagonists", "GENE_OR_GENE_PRODUCT", 80, 95], ["IFN", "PROTEIN", 80, 83], ["multiple proteins", "PROBLEM", 13, 30], ["coronaviruses", "PROBLEM", 42, 55], ["IFN antagonists", "TREATMENT", 80, 95], ["multiple", "OBSERVATION_MODIFIER", 13, 21], ["proteins", "OBSERVATION", 22, 30]]], ["Interestingly, different mechanisms are used by some homologous proteins of different coronaviruses.", [["coronaviruses", "ORGANISM", 86, 99], ["homologous proteins", "PROTEIN", 53, 72], ["different coronaviruses", "PROBLEM", 76, 99], ["different coronaviruses", "OBSERVATION", 76, 99]]], ["For example, the nucleocapsid (N) protein of PEDV antagonizes IFN production by sequestering the interaction between IRF3 and TBK1 (Ding et al., 2014) ; MHV A59 N protein antagonizes IFN activity by interfering with the RNase L activity associated with the induction of 2\u2032 \u00c05\u2032-oligoadenylate synthetase (Ye et al., 2007) ; SARS-CoV N protein blocks a very early step in IFN production, probably at the RNA-sensor recognition step (Lu et al., 2011) .", [["PEDV", "CHEMICAL", 45, 49], ["\u00c05\u2032-oligoadenylate", "CHEMICAL", 273, 291], ["PEDV", "GENE_OR_GENE_PRODUCT", 45, 49], ["IFN", "GENE_OR_GENE_PRODUCT", 62, 65], ["IRF3", "GENE_OR_GENE_PRODUCT", 117, 121], ["TBK1", "GENE_OR_GENE_PRODUCT", 126, 130], ["MHV", "ORGANISM", 153, 156], ["A59 N protein", "GENE_OR_GENE_PRODUCT", 157, 170], ["IFN", "GENE_OR_GENE_PRODUCT", 183, 186], ["RNase L", "GENE_OR_GENE_PRODUCT", 220, 227], ["\u00c05\u2032-oligoadenylate synthetase", "GENE_OR_GENE_PRODUCT", 273, 302], ["SARS-CoV N protein", "GENE_OR_GENE_PRODUCT", 323, 341], ["IFN", "GENE_OR_GENE_PRODUCT", 370, 373], ["nucleocapsid (N) protein", "PROTEIN", 17, 41], ["PEDV", "PROTEIN", 45, 49], ["IFN", "PROTEIN", 62, 65], ["IRF3", "PROTEIN", 117, 121], ["TBK1", "PROTEIN", 126, 130], ["MHV A59 N protein", "PROTEIN", 153, 170], ["IFN", "PROTEIN", 183, 186], ["RNase L", "PROTEIN", 220, 227], ["oligoadenylate synthetase", "PROTEIN", 277, 302], ["SARS-CoV N protein", "PROTEIN", 323, 341], ["IFN", "PROTEIN", 370, 373], ["MHV", "SPECIES", 153, 156], ["the nucleocapsid (N) protein", "PROBLEM", 13, 41], ["PEDV", "PROBLEM", 45, 49], ["MHV A59 N protein antagonizes IFN activity", "TREATMENT", 153, 195], ["the RNase L activity", "TREATMENT", 216, 236], ["oligoadenylate synthetase", "TEST", 277, 302], ["SARS-CoV N protein blocks", "PROBLEM", 323, 348], ["a very early step in IFN production", "PROBLEM", 349, 384]]], ["PDCoV also encodes the nucleocapsid protein, and whether PDCoV N protein antagonize IFN activity and what mechanisms are used by PDCoV N protein are very interesting and these issues are currently under investigation in Fig. 3 .", [["PDCoV", "GENE_OR_GENE_PRODUCT", 0, 5], ["PDCoV N protein", "GENE_OR_GENE_PRODUCT", 57, 72], ["IFN", "GENE_OR_GENE_PRODUCT", 84, 87], ["PDCoV N protein", "GENE_OR_GENE_PRODUCT", 129, 144], ["PDCoV", "PROTEIN", 0, 5], ["nucleocapsid protein", "PROTEIN", 23, 43], ["PDCoV N protein", "PROTEIN", 57, 72], ["IFN", "PROTEIN", 84, 87], ["PDCoV N protein", "PROTEIN", 129, 144], ["PDCoV", "TREATMENT", 0, 5], ["the nucleocapsid protein", "TEST", 19, 43], ["PDCoV N protein antagonize IFN activity", "TREATMENT", 57, 96], ["nucleocapsid protein", "OBSERVATION", 23, 43]]], ["The effect of PDCoV infection on the SeV-or poly(I:C)-mediated activation of NF-\u03baB and IRF3.", [["PDCoV", "CHEMICAL", 14, 19], ["infection", "DISEASE", 20, 29], ["poly(I:C", "CHEMICAL", 44, 52], ["PDCoV", "SIMPLE_CHEMICAL", 14, 19], ["SeV", "ORGANISM", 37, 40], ["poly(I:C", "GENE_OR_GENE_PRODUCT", 44, 52], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 77, 82], ["IRF3", "GENE_OR_GENE_PRODUCT", 87, 91], ["NF-\u03baB", "PROTEIN", 77, 82], ["IRF3", "PROTEIN", 87, 91], ["PDCoV infection", "PROBLEM", 14, 29], ["IRF3", "PROBLEM", 87, 91], ["PDCoV", "OBSERVATION_MODIFIER", 14, 19], ["infection", "OBSERVATION", 20, 29]]], ["LLC-PK1 cells were first co-transfected NF-\u03baB-Luc (A, B) or IRF3-Luc (C, D) together with pRL-TK for 12 h and then mock-infected or infected with PDCoV at a MOI of 0.01.", [["LLC-PK1 cells", "ANATOMY", 0, 13], ["LLC-PK1 cells", "CELL", 0, 13], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 40, 45], ["IRF3", "GENE_OR_GENE_PRODUCT", 60, 64], ["C, D", "SIMPLE_CHEMICAL", 70, 74], ["pRL-TK", "GENE_OR_GENE_PRODUCT", 90, 96], ["LLC-PK1 cells", "CELL_LINE", 0, 13], ["NF-\u03baB", "PROTEIN", 40, 45], ["Luc", "PROTEIN", 46, 49], ["IRF3", "PROTEIN", 60, 64], ["Luc", "PROTEIN", 65, 68], ["pRL", "PROTEIN", 90, 93], ["LLC", "TEST", 0, 3], ["PK1 cells", "TEST", 4, 13], ["NF", "TEST", 40, 42], ["IRF3", "PROBLEM", 60, 64], ["pRL", "TEST", 90, 93], ["PDCoV", "TREATMENT", 146, 151], ["infected", "OBSERVATION", 132, 140]]], ["At 12 hpi, the cells were mock-infected or infected with SeV for an additional 12 h or transfected with or without poly (I:C) for an additional 24 h.", [["cells", "ANATOMY", 15, 20], ["poly (I:C", "CHEMICAL", 115, 124], ["cells", "CELL", 15, 20], ["SeV", "ORGANISM", 57, 60], ["SeV", "SPECIES", 57, 60]]], ["The cells were then harvested and subjected to a dual-luciferase assay, and the results are shown here as the fold induction of the NF-\u03baB (A, B) or IRF3 (C, D) promoter activity.", [["cells", "ANATOMY", 4, 9], ["cells", "CELL", 4, 9], ["luciferase", "GENE_OR_GENE_PRODUCT", 54, 64], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 132, 137], ["A", "GENE_OR_GENE_PRODUCT", 139, 140], ["B", "GENE_OR_GENE_PRODUCT", 142, 143], ["IRF3", "GENE_OR_GENE_PRODUCT", 148, 152], ["C, D", "GENE_OR_GENE_PRODUCT", 154, 158], ["luciferase", "PROTEIN", 54, 64], ["NF-\u03baB", "PROTEIN", 132, 137], ["IRF3 (C, D) promoter", "DNA", 148, 168], ["a dual-luciferase assay", "TEST", 47, 70], ["IRF3 (C, D) promoter activity", "PROBLEM", 148, 177]]], ["All data are presented as means 7 SD of three independent experiments (*p o0.05 and **p o 0.01). our laboratory.ConclusionsIn summary, we showed that PDCoV infection fails to induce IFN-\u03b2 production in LLC-PK1 cells.", [["LLC-PK1 cells", "ANATOMY", 202, 215], ["PDCoV", "CHEMICAL", 150, 155], ["infection", "DISEASE", 156, 165], ["PDCoV", "SIMPLE_CHEMICAL", 150, 155], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 182, 187], ["LLC-PK1 cells", "CELL", 202, 215], ["IFN", "PROTEIN", 182, 185], ["LLC-PK1 cells", "CELL_LINE", 202, 215], ["PDCoV", "SPECIES", 150, 155], ["PDCoV infection", "PROBLEM", 150, 165], ["IFN", "TEST", 182, 185], ["PK1 cells", "PROBLEM", 206, 215], ["infection", "OBSERVATION", 156, 165], ["LLC", "ANATOMY", 202, 205], ["PK1 cells", "OBSERVATION", 206, 215]]], ["Furthermore, PDCoV can interfere with the RIG-I-mediated signaling pathway.", [["PDCoV", "CHEMICAL", 13, 18], ["PDCoV", "SIMPLE_CHEMICAL", 13, 18], ["RIG-I", "GENE_OR_GENE_PRODUCT", 42, 47], ["PDCoV", "PROTEIN", 13, 18], ["RIG-I", "PROTEIN", 42, 47], ["PDCoV", "TREATMENT", 13, 18]]], ["Mechanistically, PDCoV infection suppresses IFN-\u03b2 production by blocking the activation of transcription factors IRF3 and NK-\u03baB.", [["NK", "ANATOMY", 122, 124], ["PDCoV", "CHEMICAL", 17, 22], ["infection", "DISEASE", 23, 32], ["PDCoV", "SIMPLE_CHEMICAL", 17, 22], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 44, 49], ["IRF3", "GENE_OR_GENE_PRODUCT", 113, 117], ["IFN", "PROTEIN", 44, 47], ["\u03b2", "PROTEIN", 48, 49], ["transcription factors", "PROTEIN", 91, 112], ["IRF3", "PROTEIN", 113, 117], ["NK-\u03ba", "PROTEIN", 122, 126], ["PDCoV infection", "PROBLEM", 17, 32], ["infection", "OBSERVATION", 23, 32]]], ["To our knowledge, PDCoV is currently the only isolated deltacoronavirus able to be propagated in a cell culture system; thus, it is an important model for studying the interaction between deltacoronaviruses and the innate immune system.", [["cell culture system", "ANATOMY", 99, 118], ["PDCoV", "CHEMICAL", 18, 23], ["PDCoV", "GENE_OR_GENE_PRODUCT", 18, 23], ["cell", "CELL", 99, 103], ["deltacoronaviruses", "GENE_OR_GENE_PRODUCT", 188, 206], ["a cell culture system", "TEST", 97, 118], ["deltacoronaviruses", "TREATMENT", 188, 206]]], ["Our data provide a novel insight into the immune evasion strategy of PDCoV.", [["PDCoV", "CHEMICAL", 69, 74], ["PDCoV", "CANCER", 69, 74], ["PDCoV", "SPECIES", 69, 74], ["the immune evasion strategy", "TREATMENT", 38, 65], ["PDCoV", "TREATMENT", 69, 74]]], ["Future studies to further identify the PDCoV-encoded IFN antagonists and to understand the mechanism of action of each antagonist could yield novel therapeutic targets and more effective vaccines.Viruses, cells, and reagentsPDCoV strain CHN-HN-2014 (GenBank accession number KT336560), which was isolated from a suckling piglet with acute diarrhea in China in 2014, was used in this study.", [["cells", "ANATOMY", 205, 210], ["piglet", "ANATOMY", 321, 327], ["CHN-HN-2014", "CHEMICAL", 237, 248], ["acute diarrhea", "DISEASE", 333, 347], ["PDCoV", "GENE_OR_GENE_PRODUCT", 39, 44], ["IFN antagonists", "GENE_OR_GENE_PRODUCT", 53, 68], ["cells", "CELL", 205, 210], ["piglet", "ORGANISM_SUBDIVISION", 321, 327], ["PDCoV", "PROTEIN", 39, 44], ["IFN", "PROTEIN", 53, 56], ["piglet", "SPECIES", 321, 327], ["Future studies", "TEST", 0, 14], ["IFN antagonists", "TREATMENT", 53, 68], ["novel therapeutic targets", "TREATMENT", 142, 167], ["Viruses", "PROBLEM", 196, 203], ["acute diarrhea", "PROBLEM", 333, 347], ["this study", "TEST", 378, 388], ["acute", "OBSERVATION_MODIFIER", 333, 338], ["diarrhea", "OBSERVATION", 339, 347]]], ["SeV was acquired from the Centre of Virus Resource and Information at the Wuhan Institute of Virology.", [["SeV", "ORGANISM", 0, 3], ["SeV", "SPECIES", 0, 3]]], ["LLC-PK1 cells, purchased from ATCC, were cultured at 37\u00b0C in 5% CO 2 in Dulbecco's modified Eagle's medium (Invitrogen) supplemented with 10% heat-inactivated fetal bovine serum, and these cells were used to amplify PDCoV.", [["LLC-PK1 cells", "ANATOMY", 0, 13], ["ATCC", "ANATOMY", 30, 34], ["fetal bovine serum", "ANATOMY", 159, 177], ["cells", "ANATOMY", 189, 194], ["CO 2", "CHEMICAL", 64, 68], ["LLC-PK1 cells", "CELL", 0, 13], ["ATCC", "CELL", 30, 34], ["bovine", "ORGANISM", 165, 171], ["serum", "ORGANISM_SUBSTANCE", 172, 177], ["cells", "CELL", 189, 194], ["LLC-PK1 cells", "CELL_LINE", 0, 13], ["ATCC", "CELL_LINE", 30, 34], ["PDCoV", "PROTEIN", 216, 221], ["bovine", "SPECIES", 165, 171], ["ATCC", "SPECIES", 30, 34], ["bovine", "SPECIES", 165, 171], ["PK1 cells", "PROBLEM", 4, 13], ["ATCC", "TEST", 30, 34], ["Dulbecco", "TEST", 72, 80], ["fetal bovine serum", "TEST", 159, 177], ["these cells", "PROBLEM", 183, 194], ["PK1 cells", "OBSERVATION", 4, 13]]], ["Poly(I:C) was purchased from Sigma-Aldrich as a sodium salt and dissolved in water to obtain a stock solution of 1 mg/mL.", [["Poly", "CHEMICAL", 0, 4], ["I:C", "CHEMICAL", 5, 8], ["sodium salt", "CHEMICAL", 48, 59], ["Poly(I:C)", "CHEMICAL", 0, 9], ["sodium salt", "CHEMICAL", 48, 59], ["Poly(I:C)", "SIMPLE_CHEMICAL", 0, 9], ["Sigma-Aldrich", "SIMPLE_CHEMICAL", 29, 42], ["sodium salt", "SIMPLE_CHEMICAL", 48, 59], ["a sodium salt", "TREATMENT", 46, 59], ["a stock solution", "TREATMENT", 93, 109]]], ["Rabbit polyclonal antibodies against NF-\u03baB p65, phosphorylated NF-\u03baB p65 (p-p65), IRF3, and phosphorylated IRF3 (p-IRF3) were purchased from ABclone (China).", [["Rabbit", "ORGANISM", 0, 6], ["NF-\u03baB p65", "GENE_OR_GENE_PRODUCT", 37, 46], ["NF-\u03baB p65", "GENE_OR_GENE_PRODUCT", 63, 72], ["p-p65", "GENE_OR_GENE_PRODUCT", 74, 79], ["IRF3", "GENE_OR_GENE_PRODUCT", 82, 86], ["IRF3", "GENE_OR_GENE_PRODUCT", 107, 111], ["p-IRF3", "GENE_OR_GENE_PRODUCT", 113, 119], ["Rabbit polyclonal antibodies", "PROTEIN", 0, 28], ["NF-\u03baB p65", "PROTEIN", 37, 46], ["phosphorylated NF-\u03baB p65", "PROTEIN", 48, 72], ["p", "PROTEIN", 74, 75], ["p65", "PROTEIN", 76, 79], ["IRF3", "PROTEIN", 82, 86], ["phosphorylated IRF3", "PROTEIN", 92, 111], ["p", "PROTEIN", 113, 114], ["IRF3", "PROTEIN", 115, 119], ["Rabbit", "SPECIES", 0, 6], ["Rabbit", "SPECIES", 0, 6], ["Rabbit polyclonal antibodies", "TEST", 0, 28], ["NF", "TEST", 37, 39], ["phosphorylated NF", "TEST", 48, 65], ["IRF3", "TEST", 82, 86], ["phosphorylated IRF3", "PROBLEM", 92, 111]]], ["Mouse monoclonal antibodies (mAbs) against \u03b2actin were purchased from Medical and Biological Laboratories (Japan).", [["Mouse", "ORGANISM", 0, 5], ["\u03b2actin", "GENE_OR_GENE_PRODUCT", 43, 49], ["Mouse monoclonal antibodies", "PROTEIN", 0, 27], ["mAbs", "PROTEIN", 29, 33], ["\u03b2actin", "PROTEIN", 43, 49], ["Mouse", "SPECIES", 0, 5], ["Mouse", "SPECIES", 0, 5], ["Mouse monoclonal antibodies", "TEST", 0, 27]]], ["The monoclonal antibody used for the detection of PDCoV N protein was produced from hybridoma cells derived from Sp2/0 myeloma cells and the spleen cells of BALB/c mice immunized with the recombinant N protein from PDCoV strain CHN-HN-2014.PlasmidsThe generation of the luciferase reporter plasmids IFN-\u03b2-Luc, 4 \u00c2 PRDII-Luc (referred to as NF-\u03baB-Luc), and 4 \u00c2 PRDIII/I-Luc (referred to as IRF3-Luc) have been described previously (Wang et al., 2008; Wang et al., 2010) .", [["hybridoma cells", "ANATOMY", 84, 99], ["Sp2/0 myeloma cells", "ANATOMY", 113, 132], ["spleen cells", "ANATOMY", 141, 153], ["PDCoV N", "GENE_OR_GENE_PRODUCT", 50, 57], ["hybridoma cells", "CELL", 84, 99], ["Sp2/0 myeloma cells", "CELL", 113, 132], ["spleen cells", "CELL", 141, 153], ["BALB/c mice", "ORGANISM", 157, 168], ["luciferase", "GENE_OR_GENE_PRODUCT", 270, 280], ["IFN-\u03b2-Luc", "GENE_OR_GENE_PRODUCT", 299, 308], ["PRDII", "GENE_OR_GENE_PRODUCT", 314, 319], ["Luc", "GENE_OR_GENE_PRODUCT", 320, 323], ["NF-\u03baB-Luc", "GENE_OR_GENE_PRODUCT", 340, 349], ["PRDIII", "GENE_OR_GENE_PRODUCT", 360, 366], ["I-Luc", "GENE_OR_GENE_PRODUCT", 367, 372], ["IRF3", "GENE_OR_GENE_PRODUCT", 389, 393], ["Luc", "GENE_OR_GENE_PRODUCT", 394, 397], ["monoclonal antibody", "PROTEIN", 4, 23], ["PDCoV N protein", "PROTEIN", 50, 65], ["hybridoma cells", "CELL_LINE", 84, 99], ["Sp2/0 myeloma cells", "CELL_LINE", 113, 132], ["spleen cells", "CELL_TYPE", 141, 153], ["recombinant N protein", "PROTEIN", 188, 209], ["luciferase reporter plasmids IFN-\u03b2-Luc, 4 \u00c2 PRDII", "DNA", 270, 319], ["Luc", "DNA", 320, 323], ["NF", "DNA", 340, 342], ["\u03baB", "DNA", 343, 345], ["Luc", "DNA", 346, 349], ["PRDIII", "DNA", 360, 366], ["I", "DNA", 367, 368], ["Luc", "DNA", 369, 372], ["IRF3", "DNA", 389, 393], ["Luc", "DNA", 394, 397], ["mice", "SPECIES", 164, 168], ["PDCoV", "SPECIES", 50, 55], ["mice", "SPECIES", 164, 168], ["The monoclonal antibody", "TEST", 0, 23], ["the detection", "TEST", 33, 46], ["PDCoV N protein", "PROBLEM", 50, 65], ["hybridoma cells", "PROBLEM", 84, 99], ["Sp2", "TEST", 113, 116], ["myeloma cells", "PROBLEM", 119, 132], ["the spleen cells", "TEST", 137, 153], ["BALB", "TEST", 157, 161], ["Plasmids", "TREATMENT", 240, 248], ["Luc", "TEST", 305, 308], ["NF", "TEST", 340, 342], ["hybridoma cells", "OBSERVATION", 84, 99], ["myeloma cells", "OBSERVATION", 119, 132], ["spleen", "ANATOMY", 141, 147]]], ["The luciferase reporter plasmids 4 \u00c2 PRDII-Luc and 4 \u00c2 PRDIII/I-Luc contain four copies of the NF-\u03baBor IRF-binding motif, respectively, of the porcine IFN-\u03b2 promoter that are upstream of the firefly luciferase reporter gene.", [["luciferase", "GENE_OR_GENE_PRODUCT", 4, 14], ["PRDII", "GENE_OR_GENE_PRODUCT", 37, 42], ["Luc", "GENE_OR_GENE_PRODUCT", 43, 46], ["I-Luc", "GENE_OR_GENE_PRODUCT", 62, 67], ["NF-\u03ba", "GENE_OR_GENE_PRODUCT", 95, 99], ["porcine", "ORGANISM", 143, 150], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 151, 156], ["luciferase", "GENE_OR_GENE_PRODUCT", 199, 209], ["luciferase reporter plasmids 4 \u00c2 PRDII-Luc and 4 \u00c2 PRDIII", "DNA", 4, 61], ["I", "DNA", 62, 63], ["Luc", "DNA", 64, 67], ["NF-\u03baBor IRF-binding motif", "DNA", 95, 120], ["porcine IFN-\u03b2 promoter", "DNA", 143, 165], ["firefly luciferase reporter gene", "DNA", 191, 223], ["The luciferase reporter plasmids", "TEST", 0, 32], ["the porcine IFN-\u03b2 promoter", "TREATMENT", 139, 165]]], ["The generation of the cDNA expression constructs encoding porcine RIG-I and its constitutively active mutant (RIG-IN), MDA5, IPS-1, TBK1, IKK\u03b5, IRF3, and IRF3-5D have also been described previously (Wang et al., 2008; Wang et al., 2011; Wang et al., 2010) .Virus titrations by TCID 50 assayTo determine viral one-step growth curves, LLC-PK1 cells in 24well plates were inoculated with PDCoV (MOI \u00bc0.01).", [["LLC-PK1 cells", "ANATOMY", 333, 346], ["RIG-I", "GENE_OR_GENE_PRODUCT", 66, 71], ["RIG-IN", "GENE_OR_GENE_PRODUCT", 110, 116], ["MDA5", "GENE_OR_GENE_PRODUCT", 119, 123], ["IPS-1", "GENE_OR_GENE_PRODUCT", 125, 130], ["TBK1", "GENE_OR_GENE_PRODUCT", 132, 136], ["IKK\u03b5", "GENE_OR_GENE_PRODUCT", 138, 142], ["IRF3", "GENE_OR_GENE_PRODUCT", 144, 148], ["IRF3-5D", "GENE_OR_GENE_PRODUCT", 154, 161], ["Virus", "ORGANISM", 257, 262], ["LLC-PK1 cells", "CELL", 333, 346], ["cDNA expression constructs", "DNA", 22, 48], ["porcine RIG-I", "PROTEIN", 58, 71], ["constitutively active mutant", "PROTEIN", 80, 108], ["RIG", "PROTEIN", 110, 113], ["IN", "PROTEIN", 114, 116], ["MDA5", "PROTEIN", 119, 123], ["IPS", "PROTEIN", 125, 128], ["TBK1", "PROTEIN", 132, 136], ["IKK\u03b5", "PROTEIN", 138, 142], ["IRF3", "PROTEIN", 144, 148], ["IRF3", "PROTEIN", 154, 158], ["5D", "PROTEIN", 159, 161], ["LLC-PK1 cells", "CELL_LINE", 333, 346], ["porcine", "SPECIES", 58, 65], ["the cDNA expression constructs", "TREATMENT", 18, 48], ["MDA5", "TEST", 119, 123], ["IPS", "TEST", 125, 128], ["TBK1", "TEST", 132, 136], ["IKK\u03b5", "TEST", 138, 142], ["IRF3", "TEST", 144, 148], ["IRF3", "TEST", 154, 158], ["Virus titrations", "TREATMENT", 257, 273], ["viral one-step growth curves", "TEST", 303, 331], ["LLC", "TEST", 333, 336], ["PK1 cells", "TEST", 337, 346], ["24well plates", "TEST", 350, 363], ["PDCoV", "TEST", 385, 390], ["MOI", "TEST", 392, 395], ["IRF3", "ANATOMY", 144, 148], ["LLC", "ANATOMY", 333, 336]]], ["The whole cell samples were collected at 6, 12, 18, 24, 30, or 36 post-infection (hpi) by freezing and thawing three times, followed by centrifugation at 2500 r/min for 10 min to collect the supernatant, and the samples were stored at \u00c0 80\u00b0C until virus titrations were performed.", [["whole cell samples", "ANATOMY", 4, 22], ["supernatant", "ANATOMY", 191, 202], ["samples", "ANATOMY", 212, 219], ["infection", "DISEASE", 71, 80], ["cell samples", "CELL", 10, 22], ["C", "GENE_OR_GENE_PRODUCT", 240, 241], ["The whole cell samples", "TEST", 0, 22], ["the samples", "TEST", 208, 219], ["virus titrations", "TEST", 248, 264], ["whole cell", "OBSERVATION_MODIFIER", 4, 14], ["infection", "OBSERVATION", 71, 80]]], ["The virus titers for each time point were determined by performing TCID 50 assays in LLC-PK1 cells as described previously .", [["LLC-PK1 cells", "ANATOMY", 85, 98], ["LLC-PK1 cells", "CELL", 85, 98], ["LLC-PK1 cells", "CELL_LINE", 85, 98], ["The virus titers", "TEST", 0, 16], ["LLC", "ANATOMY", 85, 88], ["PK1 cells", "OBSERVATION", 89, 98]]], ["Virus titers were calculated using the Reed-Muench method from the results of three independent experiments.Luciferase reporter gene assayLLC-PK1 cells grown in 24-well plates were transfected with a reporter plasmid (IFN-\u03b2-Luc, NK-\u03baB-Luc, or IRF3-Luc) and pRL-TK (an internal control for normalization of the transfection efficiency) using Lipofectamine 2000, and the cells were also mock-infected or infected with PDCoV and/or SeV (20 hemagglutinating activity units/well) or transfected with or without poly (I:C) (0.5 \u03bcg/well).", [["assayLLC-PK1 cells", "ANATOMY", 133, 151], ["NK", "ANATOMY", 229, 231], ["cells", "ANATOMY", 369, 374], ["Lipofectamine 2000", "CHEMICAL", 341, 359], ["I:C", "CHEMICAL", 512, 515], ["poly (I:C)", "CHEMICAL", 506, 516], ["Virus", "ORGANISM", 0, 5], ["NK-\u03baB-Luc", "GENE_OR_GENE_PRODUCT", 229, 238], ["IRF3", "GENE_OR_GENE_PRODUCT", 243, 247], ["Luc", "GENE_OR_GENE_PRODUCT", 248, 251], ["pRL-TK", "GENE_OR_GENE_PRODUCT", 257, 263], ["cells", "CELL", 369, 374], ["PDCoV", "GENE_OR_GENE_PRODUCT", 416, 421], ["SeV", "ORGANISM", 429, 432], ["Luciferase reporter gene assayLLC", "DNA", 108, 141], ["PK1 cells", "CELL_LINE", 142, 151], ["reporter plasmid", "DNA", 200, 216], ["IFN", "PROTEIN", 218, 221], ["NK-\u03baB", "DNA", 229, 234], ["Luc", "DNA", 235, 238], ["IRF3", "DNA", 243, 247], ["Luc", "DNA", 248, 251], ["pRL-TK", "DNA", 257, 263], ["PDCoV", "SPECIES", 416, 421], ["SeV", "SPECIES", 429, 432], ["Virus titers", "TEST", 0, 12], ["the Reed-Muench method", "TREATMENT", 35, 57], ["Luciferase reporter gene assayLLC", "TEST", 108, 141], ["PK1 cells", "TEST", 142, 151], ["a reporter plasmid", "TEST", 198, 216], ["IFN", "TEST", 218, 221], ["Luc", "TEST", 224, 227], ["NK", "TEST", 229, 231], ["B", "TEST", 233, 234], ["Luc", "TEST", 235, 238], ["IRF3", "TEST", 243, 247], ["pRL", "TEST", 257, 260], ["the transfection efficiency", "TREATMENT", 306, 333], ["Lipofectamine", "TREATMENT", 341, 354], ["the cells", "TREATMENT", 365, 374], ["PDCoV", "TREATMENT", 416, 421], ["SeV (20 hemagglutinating activity units", "TREATMENT", 429, 468], ["poly (I:C)", "TREATMENT", 506, 516]]], ["In selected experiments, cells were also transfected with an expression plasmid (RIG-I, RIG-IN, MDA5, IPS-1, TBK1 , IKK\u03b5, IRF3, or IRF3-5D) or an empty control plasmid.", [["cells", "ANATOMY", 25, 30], ["plasmid", "ANATOMY", 160, 167], ["cells", "CELL", 25, 30], ["RIG-I", "GENE_OR_GENE_PRODUCT", 81, 86], ["RIG-IN", "GENE_OR_GENE_PRODUCT", 88, 94], ["MDA5", "GENE_OR_GENE_PRODUCT", 96, 100], ["IPS-1", "GENE_OR_GENE_PRODUCT", 102, 107], ["TBK1", "GENE_OR_GENE_PRODUCT", 109, 113], ["IKK\u03b5", "GENE_OR_GENE_PRODUCT", 116, 120], ["IRF3", "GENE_OR_GENE_PRODUCT", 122, 126], ["IRF3-5D", "GENE_OR_GENE_PRODUCT", 131, 138], ["expression plasmid", "DNA", 61, 79], ["RIG-I", "DNA", 81, 86], ["RIG", "DNA", 88, 91], ["IN", "DNA", 92, 94], ["MDA5", "DNA", 96, 100], ["IPS", "DNA", 102, 105], ["TBK1", "DNA", 109, 113], ["IKK\u03b5", "DNA", 116, 120], ["IRF3", "DNA", 122, 126], ["IRF3", "DNA", 131, 135], ["5D", "DNA", 136, 138], ["empty control plasmid", "DNA", 146, 167], ["an expression plasmid", "TEST", 58, 79], ["RIG", "TEST", 81, 84], ["RIG", "TEST", 88, 91], ["MDA5", "TEST", 96, 100], ["IPS", "TEST", 102, 105], ["TBK1", "TEST", 109, 113], ["IKK\u03b5", "TEST", 116, 120], ["IRF3", "TEST", 122, 126], ["IRF3", "TEST", 131, 135], ["an empty control plasmid", "TREATMENT", 143, 167], ["MDA5", "ANATOMY", 96, 100]]], ["The cells were then lysed, and the firefly luciferase and Renilla luciferase activities were measured using the Dual-Luciferase reporter assay system (Promega).", [["cells", "ANATOMY", 4, 9], ["cells", "CELL", 4, 9], ["luciferase", "GENE_OR_GENE_PRODUCT", 43, 53], ["Renilla", "GENE_OR_GENE_PRODUCT", 58, 65], ["luciferase", "GENE_OR_GENE_PRODUCT", 66, 76], ["luciferase", "PROTEIN", 43, 53], ["luciferase", "PROTEIN", 66, 76], ["the firefly luciferase", "TEST", 31, 53], ["Renilla luciferase activities", "TEST", 58, 87]]], ["Data are shown as the relative firefly luciferase activities normalized to the Renilla luciferase activities from three independently conducted experiments.Western blottingLLC-PK1 cells were cultured in 60-mm dishes and mock-infected or infected with PDCoV and/or SeV.", [["blottingLLC-PK1 cells", "ANATOMY", 164, 185], ["luciferase", "GENE_OR_GENE_PRODUCT", 39, 49], ["luciferase", "GENE_OR_GENE_PRODUCT", 87, 97], ["blottingLLC-PK1 cells", "CELL", 164, 185], ["luciferase", "PROTEIN", 39, 49], ["luciferase", "PROTEIN", 87, 97], ["PK1 cells", "CELL_LINE", 176, 185], ["PDCoV", "SPECIES", 251, 256], ["the relative firefly luciferase activities", "PROBLEM", 18, 60], ["the Renilla luciferase activities", "PROBLEM", 75, 108], ["PK1 cells", "PROBLEM", 176, 185], ["mock", "TEST", 220, 224], ["infected", "PROBLEM", 225, 233], ["PDCoV", "TREATMENT", 251, 256], ["PK1 cells", "OBSERVATION", 176, 185], ["infected", "OBSERVATION", 237, 245]]], ["At 24 hpi, the cells were harvested by adding lysis buffer (4% SDS, 3% DTT, 0.065 mM Tris-HCl [pH 6.8], and 30% glycerin) supplemented with a protease inhibitor cocktail, phenylmethylsulfonyl fluoride (PMSF), and a phosphatase inhibitor cocktail.", [["cells", "ANATOMY", 15, 20], ["Tris-HCl", "CHEMICAL", 85, 93], ["glycerin", "CHEMICAL", 112, 120], ["phenylmethylsulfonyl fluoride", "CHEMICAL", 171, 200], ["PMSF", "CHEMICAL", 202, 206], ["DTT", "CHEMICAL", 71, 74], ["Tris-HCl", "CHEMICAL", 85, 93], ["glycerin", "CHEMICAL", 112, 120], ["phenylmethylsulfonyl fluoride", "CHEMICAL", 171, 200], ["PMSF", "CHEMICAL", 202, 206], ["cells", "CELL", 15, 20], ["DTT", "SIMPLE_CHEMICAL", 71, 74], ["Tris-HCl", "SIMPLE_CHEMICAL", 85, 93], ["glycerin", "SIMPLE_CHEMICAL", 112, 120], ["phenylmethylsulfonyl fluoride", "SIMPLE_CHEMICAL", 171, 200], ["PMSF", "SIMPLE_CHEMICAL", 202, 206], ["lysis buffer", "TREATMENT", 46, 58], ["pH", "TEST", 95, 97], ["a protease inhibitor cocktail", "TREATMENT", 140, 169], ["phenylmethylsulfonyl fluoride (PMSF", "TREATMENT", 171, 206], ["a phosphatase inhibitor cocktail", "TREATMENT", 213, 245]]], ["The lysates were subjected to SDS-PAGE and electroblotted onto a polyvinylidene difluoride membrane (Bio-Rad).", [["lysates", "ANATOMY", 4, 11], ["polyvinylidene", "CHEMICAL", 65, 79], ["difluoride", "CHEMICAL", 80, 90], ["lysates", "ORGANISM_SUBSTANCE", 4, 11], ["membrane", "CELLULAR_COMPONENT", 91, 99], ["The lysates", "TREATMENT", 0, 11], ["SDS", "TEST", 30, 33], ["a polyvinylidene difluoride membrane", "TREATMENT", 63, 99]]], ["The membranes were then analyzed for the expression of p65, p-p65, IRF3, and p-IRF3 proteins by immunoblotting using rabbit anti-p65, anti-p-p65, anti-IRF3, and anti-p-IRF3 antibodies, respectively.", [["membranes", "ANATOMY", 4, 13], ["membranes", "CELLULAR_COMPONENT", 4, 13], ["p65", "GENE_OR_GENE_PRODUCT", 55, 58], ["p-p65", "GENE_OR_GENE_PRODUCT", 60, 65], ["IRF3", "GENE_OR_GENE_PRODUCT", 67, 71], ["p-IRF3", "GENE_OR_GENE_PRODUCT", 77, 83], ["rabbit", "ORGANISM", 117, 123], ["anti-p65", "GENE_OR_GENE_PRODUCT", 124, 132], ["anti-p-p65", "GENE_OR_GENE_PRODUCT", 134, 144], ["anti-IRF3", "GENE_OR_GENE_PRODUCT", 146, 155], ["anti-p-IRF3", "GENE_OR_GENE_PRODUCT", 161, 172], ["p65", "PROTEIN", 55, 58], ["p", "PROTEIN", 60, 61], ["p65", "PROTEIN", 62, 65], ["IRF3", "PROTEIN", 67, 71], ["p", "PROTEIN", 77, 78], ["IRF3 proteins", "PROTEIN", 79, 92], ["anti-p65", "PROTEIN", 124, 132], ["anti-p", "PROTEIN", 134, 140], ["p65", "PROTEIN", 141, 144], ["anti-IRF3", "PROTEIN", 146, 155], ["anti-p", "PROTEIN", 161, 167], ["IRF3 antibodies", "PROTEIN", 168, 183], ["rabbit", "SPECIES", 117, 123], ["rabbit", "SPECIES", 117, 123], ["IRF3", "TEST", 67, 71], ["immunoblotting", "TEST", 96, 110], ["rabbit anti-p65", "TREATMENT", 117, 132], ["anti-p", "TEST", 134, 140], ["anti-IRF3", "TREATMENT", 146, 155], ["anti-p-IRF3 antibodies", "TREATMENT", 161, 183]]], ["An anti-PDCoV N protein monoclonal antibody was used for immunoblotting to confirm the expression levels of the PDCoV N protein.", [["PDCoV N protein", "GENE_OR_GENE_PRODUCT", 112, 127], ["N protein monoclonal antibody", "PROTEIN", 14, 43], ["PDCoV N protein", "PROTEIN", 112, 127], ["An anti-PDCoV", "TREATMENT", 0, 13], ["N protein monoclonal antibody", "TEST", 14, 43], ["immunoblotting", "TEST", 57, 71], ["monoclonal antibody", "OBSERVATION", 24, 43]]], ["An anti-\u03b2-actin monoclonal antibody was used to detect the expression of \u03b2-actin to confirm equal protein sample loading.Indirect immunofluorescence assay (IFA)IFAs were performed to examine the subcellular localization of IRF3 and p65 in LLC-PK1 cells.", [["sample", "ANATOMY", 106, 112], ["subcellular", "ANATOMY", 195, 206], ["LLC-PK1 cells", "ANATOMY", 239, 252], ["\u03b2-actin", "GENE_OR_GENE_PRODUCT", 73, 80], ["IRF3", "GENE_OR_GENE_PRODUCT", 223, 227], ["p65", "GENE_OR_GENE_PRODUCT", 232, 235], ["LLC-PK1 cells", "CELL", 239, 252], ["anti-\u03b2-actin monoclonal antibody", "PROTEIN", 3, 35], ["\u03b2-actin", "PROTEIN", 73, 80], ["IRF3", "PROTEIN", 223, 227], ["p65", "PROTEIN", 232, 235], ["LLC-PK1 cells", "CELL_LINE", 239, 252], ["An anti-\u03b2-actin monoclonal antibody", "TEST", 0, 35], ["\u03b2-actin", "TREATMENT", 73, 80], ["Indirect immunofluorescence assay", "TEST", 121, 154], ["IRF3", "TEST", 223, 227], ["LLC", "ANATOMY", 239, 242], ["PK1 cells", "OBSERVATION", 243, 252]]], ["LLC-PK1 cells were seeded onto microscope coverslips, placed into 24-well dishes, and allowed to reach approximately 80% confluence.", [["LLC-PK1 cells", "ANATOMY", 0, 13], ["LLC-PK1 cells", "CELL", 0, 13], ["LLC-PK1 cells", "CELL_LINE", 0, 13], ["PK1 cells", "PROBLEM", 4, 13], ["microscope coverslips", "TEST", 31, 52], ["PK1 cells", "OBSERVATION", 4, 13], ["confluence", "OBSERVATION_MODIFIER", 121, 131]]], ["The cells were then mockinfected or infected with PDCoV and/or SeV.", [["cells", "ANATOMY", 4, 9], ["cells", "CELL", 4, 9], ["PDCoV", "TREATMENT", 50, 55]]], ["At 24 hpi, the cells were fixed with 4% paraformaldehyde for 15 min and then permeabilized with methyl alcohol for 10 min at room temperature.", [["cells", "ANATOMY", 15, 20], ["methyl alcohol", "CHEMICAL", 96, 110], ["paraformaldehyde", "CHEMICAL", 40, 56], ["methyl alcohol", "CHEMICAL", 96, 110], ["cells", "CELL", 15, 20], ["paraformaldehyde", "SIMPLE_CHEMICAL", 40, 56], ["methyl alcohol", "SIMPLE_CHEMICAL", 96, 110], ["the cells", "TREATMENT", 11, 20], ["4% paraformaldehyde", "TREATMENT", 37, 56]]], ["After three washes with TBST, the cells were blocked with TBST containing 5% bovine serum albumin (BSA) for 1 h and then incubated separately with a rabbit polyclonal antibody against p65 (1:100) or against IRF3 (1:100) or a mouse monoclonal antibody against the PDCoV N protein (1:100) for 1 h.", [["cells", "ANATOMY", 34, 39], ["serum", "ANATOMY", 84, 89], ["cells", "CELL", 34, 39], ["bovine", "ORGANISM", 77, 83], ["serum", "ORGANISM_SUBSTANCE", 84, 89], ["albumin", "SIMPLE_CHEMICAL", 90, 97], ["BSA", "SIMPLE_CHEMICAL", 99, 102], ["rabbit", "ORGANISM", 149, 155], ["p65", "GENE_OR_GENE_PRODUCT", 184, 187], ["IRF3", "GENE_OR_GENE_PRODUCT", 207, 211], ["mouse", "ORGANISM", 225, 230], ["rabbit polyclonal antibody", "PROTEIN", 149, 175], ["p65 (1:100)", "PROTEIN", 184, 195], ["IRF3", "PROTEIN", 207, 211], ["1:100", "PROTEIN", 213, 218], ["mouse monoclonal antibody", "PROTEIN", 225, 250], ["PDCoV N protein", "PROTEIN", 263, 278], ["bovine", "SPECIES", 77, 83], ["rabbit", "SPECIES", 149, 155], ["mouse", "SPECIES", 225, 230], ["rabbit", "SPECIES", 149, 155], ["mouse", "SPECIES", 225, 230], ["TBST", "TREATMENT", 24, 28], ["the cells", "TREATMENT", 30, 39], ["TBST", "TREATMENT", 58, 62], ["5% bovine serum albumin", "TREATMENT", 74, 97], ["BSA", "TEST", 99, 102], ["a rabbit polyclonal antibody", "TEST", 147, 175], ["IRF3", "TEST", 207, 211], ["a mouse monoclonal antibody", "TEST", 223, 250]]], ["The cells were then treated with Alexa Fluor 488-labeled anti-mouse secondary antibody or Alexa Fluor 594-labeled anti-rabbit secondary antibody for 1 h at room temperature and subsequently treated with 4\u02b9,6-diamidino-2-phenylindole (DAPI) for 15 min at room temperature.", [["cells", "ANATOMY", 4, 9], ["Alexa Fluor 594", "CHEMICAL", 90, 105], ["4\u02b9,6-diamidino-2-phenylindole", "CHEMICAL", 203, 232], ["DAPI", "CHEMICAL", 234, 238], ["Alexa Fluor 488", "CHEMICAL", 33, 48], ["Alexa Fluor 594", "CHEMICAL", 90, 105], ["4\u02b9,6-diamidino-2-phenylindole", "CHEMICAL", 203, 232], ["DAPI", "CHEMICAL", 234, 238], ["cells", "CELL", 4, 9], ["Alexa Fluor 488", "SIMPLE_CHEMICAL", 33, 48], ["Alexa Fluor 594", "SIMPLE_CHEMICAL", 90, 105], ["4\u02b9,6-diamidino-2-phenylindole", "SIMPLE_CHEMICAL", 203, 232], ["DAPI", "SIMPLE_CHEMICAL", 234, 238], ["Alexa Fluor 488-labeled anti-mouse secondary antibody", "PROTEIN", 33, 86], ["Alexa Fluor 594-labeled anti-rabbit secondary antibody", "PROTEIN", 90, 144], ["anti-rabbit", "SPECIES", 114, 125], ["Alexa Fluor 594", "SPECIES", 90, 105], ["Alexa Fluor", "TREATMENT", 33, 44], ["Alexa Fluor", "TEST", 90, 101], ["diamidino", "TREATMENT", 208, 217], ["phenylindole (DAPI", "TREATMENT", 220, 238]]], ["Fluorescent images were visualized and examined by using a confocal laser scanning microscope (Fluoview ver.", [["Fluorescent images", "TEST", 0, 18], ["a confocal laser scanning microscope", "TEST", 57, 93]]], ["3.1; Olympus, Japan). infected with PDCoV at a MOI of 0.01 for 12 h and then mock-infected or infected with SeV.", [["PDCoV", "CHEMICAL", 36, 41], ["SeV.", "SPECIES", 108, 112], ["Olympus", "TEST", 5, 12], ["PDCoV", "TREATMENT", 36, 41], ["a MOI", "TREATMENT", 45, 50], ["infected", "OBSERVATION", 82, 90], ["infected", "OBSERVATION", 94, 102]]], ["After 12 h of SeV infection, the cells were collected for western blot analyses with specific antibodies against IRF3, p-IRF3, p65, p-p65, or PDCoV N protein.", [["cells", "ANATOMY", 33, 38], ["SeV", "ORGANISM", 14, 17], ["cells", "CELL", 33, 38], ["IRF3", "GENE_OR_GENE_PRODUCT", 113, 117], ["p-IRF3", "GENE_OR_GENE_PRODUCT", 119, 125], ["p65", "GENE_OR_GENE_PRODUCT", 127, 130], ["p-p65", "GENE_OR_GENE_PRODUCT", 132, 137], ["PDCoV N protein", "GENE_OR_GENE_PRODUCT", 142, 157], ["IRF3", "PROTEIN", 113, 117], ["p", "PROTEIN", 119, 120], ["IRF3", "PROTEIN", 121, 125], ["p65", "PROTEIN", 127, 130], ["p", "PROTEIN", 132, 133], ["p65", "PROTEIN", 134, 137], ["PDCoV N protein", "PROTEIN", 142, 157], ["SeV", "SPECIES", 14, 17], ["SeV infection", "PROBLEM", 14, 27], ["western blot analyses", "TEST", 58, 79], ["specific antibodies", "TEST", 85, 104], ["IRF3", "TEST", 113, 117], ["IRF3", "TEST", 121, 125], ["p65", "TEST", 127, 130], ["p", "TEST", 132, 133], ["infection", "OBSERVATION", 18, 27]]], ["An anti-\u03b2-actin antibody was used as a control for sample loading.", [["sample", "ANATOMY", 51, 57], ["anti-\u03b2-actin antibody", "PROTEIN", 3, 24], ["An anti-\u03b2-actin antibody", "TREATMENT", 0, 24], ["sample loading", "PROBLEM", 51, 65]]], ["(B, C) LLC-PK1 cells were mock-infected or infected with PDCoV at a MOI of 0.01 for 12 h and then mock-infected or infected with SeV.", [["LLC-PK1 cells", "ANATOMY", 7, 20], ["PDCoV", "CHEMICAL", 57, 62], ["B, C) LLC-PK1 cells", "CELL", 1, 20], ["B, C) LLC-PK1 cells", "CELL_LINE", 1, 20], ["PDCoV", "SPECIES", 57, 62], ["SeV.", "SPECIES", 129, 133], ["B, C) LLC-PK1 cells", "TEST", 1, 20], ["PDCoV", "TREATMENT", 57, 62], ["LLC", "ANATOMY", 7, 10], ["infected", "OBSERVATION", 115, 123]]], ["After 12 h of SeV infection, the cells were fixed for indirect immunofluorescence assays with the following antibodies: mouse anti-PDCoV N (green) and rabbit anti-IRF3 (red) (B) or rabbit anti-p65 (red) (C).", [["cells", "ANATOMY", 33, 38], ["infection", "DISEASE", 18, 27], ["SeV", "ORGANISM", 14, 17], ["cells", "CELL", 33, 38], ["mouse", "ORGANISM", 120, 125], ["anti-PDCoV N (green)", "ORGANISM", 126, 146], ["rabbit", "ORGANISM", 151, 157], ["anti-IRF3 (red) (B)", "GENE_OR_GENE_PRODUCT", 158, 177], ["rabbit", "ORGANISM", 181, 187], ["anti-p65", "GENE_OR_GENE_PRODUCT", 188, 196], ["red) (C", "ORGANISM", 198, 205], ["antibodies", "PROTEIN", 108, 118], ["mouse anti-PDCoV N", "PROTEIN", 120, 138], ["anti-IRF3", "PROTEIN", 158, 167], ["red", "PROTEIN", 169, 172], ["B", "PROTEIN", 175, 176], ["rabbit anti-p65 (red) (C)", "PROTEIN", 181, 206], ["mouse", "SPECIES", 120, 125], ["rabbit", "SPECIES", 151, 157], ["rabbit", "SPECIES", 181, 187], ["SeV", "SPECIES", 14, 17], ["mouse", "SPECIES", 120, 125], ["rabbit", "SPECIES", 151, 157], ["rabbit", "SPECIES", 181, 187], ["SeV infection", "PROBLEM", 14, 27], ["the cells", "PROBLEM", 29, 38], ["indirect immunofluorescence assays", "TEST", 54, 88], ["mouse anti-PDCoV N", "TREATMENT", 120, 138], ["infection", "OBSERVATION", 18, 27]]], ["Cellular nuclei (blue) were counterstained with 1 \u03bcg/mL of DAPI.", [["Cellular nuclei", "ANATOMY", 0, 15], ["DAPI", "CHEMICAL", 59, 63], ["Cellular nuclei", "CELLULAR_COMPONENT", 0, 15], ["DAPI", "SIMPLE_CHEMICAL", 59, 63], ["DAPI", "TREATMENT", 59, 63], ["nuclei", "ANATOMY", 9, 15]]], ["3.1 confocal fluorescence microscope (Olympus) and representative images are shown.", [["confocal fluorescence microscope", "TEST", 4, 36], ["representative images", "TEST", 51, 72]]], ["Student's t-tests were performed, and p-values of o0.05 were considered statistically significant.", [["Student's t-tests", "TEST", 0, 17], ["p-values", "TEST", 38, 46]]]]}